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Development	of	 coronary	 artery	 stents	have	 revolutionised	 the	 treatment	of	 coronary	 artery	disease.	
However,	the	currently	available	stents	have	several	limitations	and	side	effects,	which	still	need	to	be	
addressed.	 Within	 this	 group	 of	 biomaterials	 Polyhydroxyalkanoates	 (PHAs),	 which	 are	 biopolyesters	
produced	by	bacteria,	have	a	great	potential	 in	 coronary	 stent	development.	They	are	biodegradable,	
non-toxic	and	biocompatible.	PHAs	have	a	broad	range	of	properties,	which	can	be	tailored	based	on	the	
requirements	 of	 the	 application	 by	 an	 appropriate	 bacterial	 strain,	 carbon	 source	 or	 fermentation	
conditions.		
The	main	aim	of	this	study	was	the	production	of	PHAs	and	their	application	as	a	platform	material	for	
coronary	stent.	Poly(3-hydroxybutyrate),	P(3HB),	short	chain	length	PHA	(scl-PHA),	was	obtained	from	B.	
subtilis	 OK2	 using	 glucose	 as	 the	 sole	 carbon	 source.	 P.	mendocina	 was	 selected	 for	 the	 economical	
production	of	medium	chain	length	PHA	(mcl-PHAs)	using	waste	frying	oil	as	the	carbon	source.	Produced	
mcl-PHA	copolymer	was	hydrolysed	 in	order	to	obtain	 lower	molecular	weight	PHA	(oligo-PHA),	which	
was	used	as	the	plasticising	agent	for	P(3HB)	in	order	to	alter	material	properties	of	the	scl-PHA	polymer.	
Novel	P(3HB)/oligo-PHA	blends,	using	different	ratios	of	P(3HB)	and	oligo-PHA,	which	were	100:0	(P(3HB),	
95:5	(P(3HB):	oligo-PHA),	90:10	(P(3HB):	oligo-PHA)	and	80:20	(P(3HB):	oligo-PHA)	have	been	developed.	
Addition	of	oligo-PHA	to	P(3HB)	resulted	not	only	in	the	enhancement	of	mechanical	properties	of	the	
material,	but	also	 improved	 surface	 topography	and	 increased	 the	biocompatibility	of	 the	 scaffolds	 in	
comparison	to	neat	P(3HB).		
The	 P(3HB)/oligo-PHA	 90/10	 blend	 was	 selected	 for	 the	 fabrication	 of	 radiopaque	 composites	 using	
addition	of	1%,	3%	and	5%	wt	barium	sulphate.	BaSO4	is	well-known	contrast	agent,	commonly	used	in	
biomedical	 applications.	 The	 composites	were	 fully	 characterised	with	 respect	 to	material	 properties,	
surface	 topography	 and	 biocompatibility.	 Preliminary	 studies,	 performed	 by	 MicroCT	 confirmed	 the	
radiopacity	of	the	composite	material.	The	composites	exhibited	an	increased	surface	roughness,	lower	
contact	 angle	 values	 and	 higher	 protein	 adsorption	 in	 comparison	 to	 the	 neat	 blend	without	 barium	
sulphate.	 The	 observed	 cell	 viability	was	 significantly	better	 in	 comparison	 to	 standard	 Tissue	 Culture	
Plastic	(TCP).		
The	P(3HB)/oligo-PHA	90:10	blend	was	selected	as	a	base	material	 for	 tube	manufacturing	by	 the	dip	
moulding	 technique.	Mechanical	properties	of	 the	blend	 tubes	were	similar	 to	 those	obtained	 for	 flat	
films,	except	 for	 tensile	strength,	which	was	slightly	higher	 in	 tubes.	An	 incubation	of	 tubes	 in	DMEM	
media	at	37°C	for	7	weeks	resulted	in	the	decrease	values	of	tensile	strength,	Young’s	Modulus	values	and	
elongation	 at	 break	 in	 comparison	 to	 the	 tubes	 stored	 at	 room	 temperature	 without	 any	 media.	
Additionally,	In	vitro	degradation	study	was	carried	out	on	the	tubes.	After	6	months	of	incubation	in	PBS,	
The	 P(3HB)/oligo-PHA	 90/10	 tubes	 underwent	 a	 30%	 weight	 loss.	 pH	 of	 the	 media	 has	 dropped	
insignificantly,	due	to	release	of	slightly	acidic	degradation	products.	Scanning	Electron	Microscope	(SEM)	
images	confirmed	an	enlarged	porosity	in	the	tube	wall	with	an	increased	time	of	incubation.		
Furthermore,	 an	 investigation	 of	 the	 P(3HB)/oligo-PHA	 90/10	 tubes	 coated	 with	 PCL-PEG550	 with	
incorporated	 drugs:	 rapamycin	 or	 tacrolimus	 was	 carried	 out	 for	 the	 development	 of	 a	 drug	 eluting	
biodegradable	stent.	The	percentage	viability	of	the	HMEC-1	cells	was	significantly	higher	on	the	tubes	
with	tacrolimus	compared	to	the	tubes	with	rapamycin.	Controlled	release	of	both	drugs	was	observed	
within	90	days,	which	is	an	encouraging	result	for	the	development	of	biodegradable	drug	eluting	stents.	
There	was	a	clear	cytotoxic	effect	of	rapamycin	on	the	HMEC-1	cells,	whereas,	presence	of	tacrolimus	did	
not	exhibit	similar	effect	on	cell	attachment	and	viability.		
Haemocompatiblity	studies	were	performed	in	order	to	investigate	the	reaction	of	blood	cells	after	direct	
contact	with	PHAs	polymer	samples.	Obtained	results	confirmed	the	non-haemolytic	effect	of	PHAs	on	
erythrocytes	 and	 low	 risk	 of	 thrombogenicity.	 Although	 all	 tested	 materials	 demonstrated	 slightly	
elevated	 levels	of	monocytes	and	neutrophil	 activation	 in	 comparison	 to	 fresh	whole	blood,	obtained	
values	were	much	lower	in	comparison	to	poly(L-lactic	acid)	(PL38),	a	well-established	medical	polymer	
currently	used	for	coronary	stent	application.		
In	conclusion,	the	results	obtained	in	this	work	confirmed	that	PHAs	have	an	excellent	potential	as	suitable	
platform	matrices	for	coronary	stent	application.	
TABLE	OF	CONTENTS	
	
	 iv	
Chapter	1	Introduction	..............................................................................................	1	
1.1.	Coronary	artery	disease	........................................................................................	2	
1.2.	Coronary	stents	.....................................................................................................	3	
1.2.1.	Bare	metallic	stents	........................................................................................	4	
1.2.2.	Drug-eluting	stents	(DES)	...............................................................................	6	
1.2.3.	Biodegradable	stents	......................................................................................	7	
1.2.3.1.	Absorb	Bioresorbable	Vascular	Scaffold	(BVS)	......................................	10	
1.3.	 Drugs	used	in	drug	eluting	stents	...................................................................	11	
1.3.1.	 Rapamycin	and	its	analogues	.................................................................	12	
1.3.2.	 Paclitaxel	................................................................................................	14	
1.3.3.	 Tacrolimus	..............................................................................................	15	
1.3.4.	 Dexamethasone	......................................................................................	16	
1.3.5.	 Antibodies	..............................................................................................	17	
1.4.	 Biopolymers	used	as	a	drug	carriers	in	the	prevention	of	restenosis	............	18	
1.5.	 Limitations	of	currently	available	stents	........................................................	20	
1.5.1.	 In-stent	restenosis	..................................................................................	21	
1.5.2.	 Late	stent	thrombosis	.............................................................................	24	
1.6.	 Ideal	stent	requirements	................................................................................	26	
1.7.	 Biomaterials	used	for	coronary	stent	application	..........................................	27	
1.8.	 Polyhydroxyalkanoates	..................................................................................	28	
1.8.1.	 Types	of	PHAs	and	their	properties	........................................................	29	
1.8.2.	 Biocompatibility	of	PHAs	........................................................................	32	
1.8.3.	 Blood-biomaterial	interactions	...............................................................	33	
1.8.4.	 Biodegradability	of	PHAs	........................................................................	35	
1.8.5.	 Biosynthesis	of	Poly(3-hydroxyalkanoates)	............................................	36	
1.8.5.1.		Synthesis	of	short	chain	length	polyhydroxyalkanoates	......................	38	
1.8.5.2.	Synthesis	of	medium	chain	length	polyhydroxyalkanoates	..................	40	
1.8.6.								Microbial	production	of	PHAs	................................................................	41	
1.8.6.1.	Gram-positive	bacteria	..........................................................................	41	
1.8.6.2.	Gram-negative	bacteria	.........................................................................	42	
1.8.6.3.	Archea	...................................................................................................	43	
1.8.6.4.	Mixed	microbial	cultures	(MMC)	...........................................................	44	
1.8.7.	 Polyhydroxyalkanoate	recovery	.............................................................	45	
1.8.8.	 Economical	production	of	Poly(3-hydroxyalkanoates)	...........................	47	
1.8.8.1.	Cheap	carbon	sources	suitable	for	PHA	production	..............................	48	
1.8.8.2.	Genetically	engineered	strains	..............................................................	49	
1.8.8.3.	Optimisation	of	polymer	recovery	–	downstream	processes	................	51	
1.8.8.4.	Efficient	fermentation	strategies	...........................................................	52	
1.8.9.	 Synthesis	of	PHA	blends	and	composites	...............................................	52	
1.8.10.	Applications	of	PHAs	..................................................................................	55	
1.8.10.1.	Biomedical	applications	.......................................................................	55	
TABLE	OF	CONTENTS	
	
	 v	
Aims	and	objectives	................................................................................................	62	
Chapter	2	Materials	and	Methods	...........................................................................	65	
2.1.	Materials	.............................................................................................................	66	
2.1.1.	Bacterial	strains	............................................................................................	66	
2.1.2.	Cell	line	and	cell	culture	materials	...............................................................	66	
2.1.3.	Chemicals	and	kits	........................................................................................	66	
2.2.		Media	composition	.............................................................................................	67	
2.3.		Bioreactors	.........................................................................................................	69	
2.4.	Experimental	methods	........................................................................................	72	
2.4.1.	P(3HB)	production	by	Bacillus	subtilis	OK2	and	Bacillus	cereus	SPV	using	a	
range	of	carbon	sources	at	shaken	flask	level.	.......................................................	72	
2.4.2.	P(3HB)	production	by	Cupriavidus	necator	using	a	range	of	carbon	sources	at	
shaken	flask	level	...................................................................................................	72	
2.4.3.	Production	of	P(3HB)	by	Bacillus	subtilis	OK2	in	bioreactor	.........................	73	
2.4.4.	Production	of	mcl-PHAs	by	Pseudomonas	mendocina	CH50	using	a	range	of	
carbon	sources	at	shaken	flask	level	......................................................................	74	
2.4.5.	Production	of	mcl-PHAs	in	bioreactors	........................................................	74	
2.5.	Extraction	of	Poly(3-hydroxyalkanoates)	from	biomass	......................................	75	
2.5.1.	Solvent	dispersion	method	...........................................................................	75	
2.5.2.	Soxhlet	extraction	........................................................................................	75	
2.6.	Structural	characterization	of	scl-PHA	.................................................................	76	
2.6.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	....	76	
2.6.2.	Gas	Chromatography-Mass	Spectrometry	(GC-MS)	.....................................	76	
2.6.3.	Nuclear	magnetic	resonance	(NMR)	............................................................	77	
2.6.4.	Thermal	analysis	-	Differential	Scanning	Calorimetry	(DSC)	.........................	77	
2.6.5.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	...................	78	
2.7.	Temporal	profiling	of	the	PHA	production	during	fermentation	........................	78	
2.7.2.	pH	measurements	........................................................................................	79	
									2.7.3.		Analytical	methods	......................................................................................	79	
2.8.	Production	of	oligo-PHA	and	material	characterisation	......................................	80	
2.8.1.	Acidic	hydrolysis	of	P(3HHx-3HO-3HD-3HDD)	..............................................	80	
2.8.2.	P(3HHx-3HO-3HD-3HDD)	hydrolysis	kinetics	...............................................	81	
2.9.	Blend	film	fabrication	..........................................................................................	81	
2.10.	P(3HB)/oligo-PHA	composite	film	fabrication	with	barium	sulphate	................	81	
2.11.	Tubes	manufacturing	by	using	dip	moulding	technique	...................................	82	
2.11.1.	Preparation	of	the	tubes	with	incorporated	drug	......................................	83	
2.11.2.	Preparation	of	composite	tubes	with	barium	sulphate	.............................	83	
2.11.3.	Characterization	of	PHA	blends,	composites	and	tubes	.............................	84	
2.11.3.1.	Ageing	experiments	.............................................................................	84	
2.11.3.2.	Tensile	test	..........................................................................................	84	
2.11.3.3.	Differential	scanning	calorimetry	(DSC)	..............................................	84	
TABLE	OF	CONTENTS	
	
	 vi	
2.11.3.4.	Static	contact	angle	analysis	................................................................	84	
2.11.3.5.	Scanning	electron	microscopy	(SEM)	..................................................	85	
2.11.3.6.	X-ray	microtomography	(MicroCT)	......................................................	85	
2.11.3.7.	Surface	roughness	analysis	..................................................................	85	
2.11.3.8.	X-ray	diffraction	(XRD)	.........................................................................	85	
2.11.3.9.	Protein	adsorption	study	.....................................................................	86	
2.12.	In	vitro	release	studies	of	rapamycin	using	UV-Vis	spectrometry	.....................	86	
2.13.	 In	 vitro	 release	 studies	 of	 tacrolimus	 using	 High	 Performance	 Liquid	
Chromatography	(HPLC)	.............................................................................................	86	
2.14.	In	vitro	cell	culture	studies	................................................................................	87	
2.14.1.	Cell	growth	and	maintenance	....................................................................	87	
2.14.2.	Sample	preparation	and	cell	seeding	.........................................................	87	
2.14.3.	MTT	assay	...................................................................................................	88	
2.14.4.	SEM	imaging	of	HMEC-1	cells	.....................................................................	88	
2.14.5.	Live/	dead	measurements	..........................................................................	88	
2.14.6.	Indirect	cytotoxicity	studies	.......................................................................	89	
2.15.	Haemocompatibility	studies	..............................................................................	89	
2.15.1.	Haemolysis	studies	.....................................................................................	89	
2.15.2.	Whole	blood	clotting	..................................................................................	90	
2.15.3.	Monocyte	and	neutrophil	activation	studies	.............................................	91	
2.15.3.1.	Sample	preparation	.............................................................................	91	
2.15.3.2.	Whole	blood	staining	with	activation	antibodies	................................	91	
2.15.3.3.	Flow	cytometry	analysis	......................................................................	92	
2.16.	In	vitro	degradation	studies	of	the	tubes	..........................................................	92	
2.16.1.	Thermal	and	mechanical	properties	...........................................................	92	
2.16.2.	Surface	morphology	...................................................................................	93	
2.16.3.	Water	uptake,	weight	loss	and	pH	measurements	....................................	93	
2.17	Statistical	analysis	...............................................................................................	93	
Chapter	3	Production	and	characterisation	of	scl-PHAs	............................................	94	
3.	Introduction	............................................................................................................	95	
3.1.	Screening	experiments	........................................................................................	96	
3.2.	Production	of	P(3HB)	using	Bacillus	subtilis	OK2	and	glucose	as	the	sole	carbon	
source	.........................................................................................................................	97	
3.3.	P(3HB)	characterization	.......................................................................................	99	
3.3.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	....	99	
3.3.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	...................................	100	
3.3.3.	Nuclear	Magnetic	Resonance	(NMR)	.........................................................	102	
3.3.4.	Molecular	weight	analysis	of	P(3HB)	produced	by	Bacillus	subtilis	OK2	....	103	
3.3.5.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	......................	104	
3.3.6.	Mechanical	characterisation	of	the	P(3HB)	solvent	cast	films	...................	105	
TABLE	OF	CONTENTS	
	
	 vii	
3.3.7.	Thermal	analysis	of	the	neat	P(3HB)	neat	films	after	7	weeks	of	storage	at	
room	temperature	...............................................................................................	106	
3.3.8.	Mechanical	characterisation	of	the	neat	P(3HB)	films	after	7	weeks	of	storage	
at	room	temperature	...........................................................................................	107	
3.4.	Discussion	..........................................................................................................	109	
Chapter	4	Production	and	characterisation	of	mcl-PHAs		.......................................	113	
4.	Introduction	..........................................................................................................	114	
4.1.	Screening	experiments	......................................................................................	115	
4.2.	Characterisation	of	the	waste	frying	oil	used	to	produce	mcl-PHAs	.................	117	
4.2.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	117	
4.2.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	...................................	118	
4.2.3.	Nuclear	Magnetic	Resonance	(NMR)	.........................................................	120	
4.3.	Production	of	P(3HHx-3HO-3HD-3HDD)	using	Pseudomonas	mendocina	CH50	and	
waste	frying	oil	as	a	sole	carbon	source	...................................................................	123	
4.4.	Mcl-PHA	characterisation	..................................................................................	124	
4.4.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	124	
4.4.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	...................................	125	
4.4.3.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	......................	128	
4.4.4.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	(GPC)	.......	129	
4.5.	Discussion	..........................................................................................................	130	
Chapter	5	Development	of	Poly(3-hydroxybutyrate)/oligo	-PHA	blends	................	136	
5.	Introduction	.............................................................................................................	137	
5.1.	Development	of	oligo-P(3HHx-3HO-3HD-3HDD)	...............................................	140	
5.1.1.		Oligo-PHA	characterisation	.......................................................................	140	
5.1.1.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	
(ATR/FT-IR)	.......................................................................................................	141	
5.1.1.2.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	...............	141	
5.1.1.3.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	(GPC)	142	
5.2.	Development	of	P(3HB)/oligo-PHA	blends	........................................................	143	
5.2.1.	Blend	characterisation	................................................................................	144	
5.2.1.1.	 Thermal	 analysis	of	 the	blend	 films	after	7	weeks	of	 storage	at	 room	
temperature	-	ageing	experiments	..................................................................	144	
5.2.1.2.	Mechanical	characterisation	of	the	blend	films	after	7	weeks	of	storage	
at	room	temperature	-	ageing	experiments	.....................................................	146	
5.3.	Surface	topography	studies	...............................................................................	149	
5.3.1.	Scanning	Electron	Microscopy	of	the	P(3HB)/oligo-PHA	blends	................	149	
5.3.3.	Water	contact	angle	measurements	..........................................................	151	
5.3.4.	Protein	adsorption	analysis	........................................................................	152	
5.4.	In	vitro	biocompatibility	studies	........................................................................	153	
5.4.1	Cell	viability	studies	.....................................................................................	154	
TABLE	OF	CONTENTS	
	
	 viii	
5.4.2.	Scanning	Electron	Microscopy	...................................................................	155	
5.4.3	Confocal	microscopy	of	HMEC-1	cells	on	the	P(3HB)	and	its		blends	..........	156	
5.5.	Haemocompatibility	studies	..............................................................................	158	
5.5.1.	Haemolysis	study	........................................................................................	158	
5.5.2.	Whole	blood	clotting	..................................................................................	159	
5.5.3.	White	cell	activation	...................................................................................	160	
5.5.3.1.	Whole	blood	staining	..........................................................................	161	
5.5.3.2.	Blood	activation	with	LPS	....................................................................	162	
5.5.3.3.	Monocyte	and	neutrophil	activity	after	incubation	with	neat	P(3HB)	and	
P(3HB)/oligo-PHA	blends	..................................................................................	164	
5.6.	 Discussion	.....................................................................................................	165	
Chapter	6	Development	of	Poly(3-hydroxybutyrate)/oligo-PHAs	composites	........	172	
6.	 Introduction	.....................................................................................................	173	
6.1.	Development	of	Poly(3-hydroxybutyrate)/oligo-PHAs	composites	..................	175	
6.2.	P(3HB)/oligo-PHA	composite	characterisation	.................................................	175	
6.2.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	175	
6.2.2.	 Thermal	 properties	 of	 the	 composites	 of	 P(3HB)/oligo-PHA	 blends	 with	
barium	sulphate	after	7	weeks	of	storage	at	room	temperature	........................	177	
6.2.3.	Mechanical	properties	of	the	composites	of	P(3HB)/oligo-PHA	blend	in	ratio	
90/10	with	barium	sulphate	after	7	weeks	of	storage	at	room	temperature	......	179	
6.3.	Surface	analysis	.................................................................................................	181	
6.3.1.	Scanning	Electron	Microscopy	(SEM)	.........................................................	181	
6.3.2.	Surface	roughness	analysis	.........................................................................	182	
6.3.3.	Contact	angle	measurement	......................................................................	183	
6.3.4.	Protein	adsorption	on	the	surface	of	the	composites	containing	BaSO4	...	185	
6.3.5.	XRD	analysis	................................................................................................	186	
6.4.	In	vitro	biocompatibility	studies	........................................................................	187	
6.4.1.	MTT	assay	...................................................................................................	187	
6.4.2.	SEM	.............................................................................................................	188	
6.4.3.	Indirect	cytotoxicity	....................................................................................	189	
6.4.4.	MicroCT	scan	of	the	composite	samples	....................................................	191	
6.5.	In	vitro	haemocompatibility	studies	..................................................................	192	
6.5.1.	Haemolysis	study	........................................................................................	192	
6.5.2.	Whole	blood	clotting	..................................................................................	193	
6.5.3.	Monocytes	and	neutrophils	activity	after	incubation	with	P(3HB)/oligo-PHAs	
composites	...........................................................................................................	194	
6.6.	Discussion	..........................................................................................................	195	
Chapter	7	Poly(3-hydroxybutyrate)/oligo-PHAs	tubes	manufacturing	....................	199	
7.	Introduction	.............................................................................................................	200	
7.1.	P(3HB)/oligo-PHA	tube	manufacturing	by	dip	moulding	technique	.................	201	
TABLE	OF	CONTENTS	
	
	 ix	
7.2.	Tube	characterization	........................................................................................	202	
7.2.1.	Tube	dimensions	........................................................................................	202	
7.2.2.	Tubes	characterisation	after	7	weeks	of	storage	at	room	temperature	and	
incubation	in	DMEM	media	at	37°	C	....................................................................	202	
7.2.2.1.	 Thermal	 properties	 of	 P(3HB)/oligo-PHA	 tubes	 stored	 for	 7	 weeks	 at	
room	temperature	...........................................................................................	203	
7.2.2.2.	Mechanical	properties	of	P(3HB)/oligo-PHA	tubes	stored	for	7	weeks	at	
room	temperature	...........................................................................................	204	
7.2.2.3.	Mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	after	incubation	in	
DMEM	media	at	37°	C	for	7	weeks	...................................................................	205	
7.2.3.	Scanning	Electron	Microscopy	of	the	P(3HB)/oligo-PHA	tubes	..................	208	
7.3.	In	vitro	degradation	studies	..............................................................................	209	
7.3.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	209	
7.3.2.	Thermal	properties	–	Differential	Scanning	Calorimetry	............................	210	
7.3.3.	pH	measurements	during	degradation	studies	of	neat	PHA	tubes	............	211	
7.3.4.	Weight	loss	(%)	of	the	neat	tubes	during	degradation	studies	..................	212	
7.3.5.	Water	uptake	(%)	of	the	neat	tubes	during	degradation	studies	...............	213	
7.3.6.	Surface	studies	of	the	degraded	tubes	.......................................................	214	
7.4.	Manufacturing	of	the	P(3HB)/oligo-PHA	90/10	tubes	coated	with	monolayer	of	
PCL-PEG550	..............................................................................................................	216	
7.4.1.		Thermal	analysis	of	PCL-PEG550	...............................................................	216	
7.4.2.		P(3HB)/oligo-PHA	90/10	tubes	coated	with	PCL-PEG550	manufacturing	.	217	
7.4.3.	Characterisation	of	P(3HB)/oligo-PHA	tubes	coated	with	monolayer	of	PCL-
PEG550…….	...........................................................................................................	217	
7.4.3.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	
(ATR/FT-IR)	.......................................................................................................	217	
7.4.3.2.	Thermal	properties	of	the	PCL-PEG550	coated	PHA	tube	...................	218	
7.4.3.3.	Mechanical	properties	of	the	PCL-PEG550	coated	PHA	tube	..............	220	
7.4.3.4.	SEM	......................................................................................................	222	
7.5.	 Manufacturing	 of	 P(3HB)/oligo-PHA	 composite	 tubes	 with	 addition	 of	 5	 wt%	
barium	sulphate	and	their	characterization	.............................................................	223	
7.5.1.	Thermal	properties	.....................................................................................	224	
7.5.2.	Mechanical	properties	................................................................................	225	
7.5.3.	SEM	.............................................................................................................	226	
7.5.4.	MiroCT	........................................................................................................	227	
7.6.	In	vitro	biocompatibility	studies	of	the	range	of	manufactured	PHA	tubes	......	228	
        7.6.1.	Protein	adsorption…………………………………………………………………………....……228	
7.6.2.	MTT	assay	...................................................................................................	229	
7.6.3.	Indirect	cytotoxicity	study	..........................................................................	231	
7.6.4.	SEM	.............................................................................................................	232	
7.7.	In	vitro	haemocompatibility	studies	..................................................................	234	
TABLE	OF	CONTENTS	
	
	 x	
7.7.1.	Haemolysis	study	........................................................................................	234	
7.7.2.	Whole	blood	clotting	..................................................................................	235	
7.7.3.	Monocytes	and	neutrophils	activation	.......................................................	236	
7.8.	Discussion	..........................................................................................................	238	
Chapter	8	Development	of	P(3HB)/oligo-PHA	tubes	with	incorporated	drug	.........	245	
8.	Introduction	.............................................................................................................	246	
8.1.	Drugs	characterisation	......................................................................................	247	
	8.1.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy).….251	
8.1.2.	Differential	Scanning	Calorimetry	..................................................................	249	
8.2.	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 and	 incorporated	 drug	
manufacturing	..........................................................................................................	251	
8.3.	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550	and	incorporated	drug		
characterisation	.......................................................................................................	252	
8.3.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	252	
8.3.2.	Scanning	Electron	Microscopy	...................................................................	254	
8.3.3.	Drug	release	studies	...................................................................................	255	
8.4.	In	vitro	biocompatibility	studies	........................................................................	257	
       	8.4.1.	Protein	adsorption…………………………………….……………………………………….……257	
8.4.2.	Cell	viability	study	.......................................................................................	259	
8.4.3.	Scanning	Electron	Microscopy	...................................................................	260	
        8.4.4.	Indirect	cytotoxicity	study………………………………………………..……………………..261	
8.5.		Haemocompatibility	studies	.............................................................................	262	
8.5.1.	Haemolysis	study	........................................................................................	262	
8.5.2.	Whole	blood	clotting	study	........................................................................	263	
8.5.3.	Monocytes	and	neutrophil	activation	........................................................	265	
8.6.	In	vitro	degradation	study	.................................................................................	266	
8.6.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	..	266	
								8.6.2.	Thermal	properties	–	Differential	Scanning	Calorimetry	............................	268	
8.6.3.	 Mechanical	 properties	 of	 the	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-
PEG550	with	incorporated	drugs	.........................................................................	270	
8.6.4.	pH	measurements	during	degradation	studies	of	neat	PHA	tubes	............	271	
									8.6.5.	Weight	loss	(%)	of	the	neat	tubes	during	degradation	studies	..................	272	
8.6.6.	Water	uptake	(%)	of	the	neat	tubes	during	degradation	studies	...............	273	
8.6.7.	Surface	studies	of	the	degraded	tubes	.......................................................	274	
8.7.	Discussion	..........................................................................................................	276	
Chapter	9	Conclusions	and	future	work	.................................................................	282	
9.1.	Conclusions	........................................................................................................	283	
9.2.	Future	work	.......................................................................................................	290	
References	............................................................................................................	293	
LIST	OF	FIGURES	
	
	 xi	
Figure	1:	Stent	implantation	in	the	narrowed	artery………………………….…………………………5	
Figure	2:	Chemical	structure	of	rapamycin	....................................................................	12	
Figure	3:	Chemical	structure	of	paclitaxel	......................................................................	14	
Figure	4:	Chemical	structure	of	tacrolimus	....................................................................	15	
Figure	5:	Chemical	structure	of	dexamethasone	...........................................................	17	
Figure	6:	Schematic	of	the	arterial	wall.	........................................................................	22	
Figure	7:	Schematic	of	the	restenosis	cascade	lesion	development.	.............................	24	
Figure	8:	Mechanism	of	 the	development	of	 the	 late	 in-stent	 thrombosis	 in	 the	drug	
eluting	stents	in	correlation	to	time	after	stent	deployment	........................................	25	
Figure	9:	Polyhydroxyalkanoates	granules	inside	bacterial	cells.	..................................	28	
Figure	10:	The	general	structure	of	Polyhydroxyalkanoates.	.........................................	29	
Figure	 11:	Biosynthesis	 pathways	 of	 short	 chain	 length	 (scl-PHA)	 and	medium	 chain	
length	(mcl-PHA)	polyhydroxyalkanoates	......................................................................	39	
Figure	12:	The	5	L	stirred	tank	bioreactor	used	in	this	study	.........................................	70	
Figure	13:	15L	stirred	tank	bioreactor	used	in	this	study	...............................................	71	
Figure	14:	20	L	stirred	stainless	steel	tank	bioreactor	used	in	this	study.	.....................	71	
Figure	15:	Schematic	representation	for	the	steps	involved	in	the	scl-PHAs	production	in	
using	Bacillus	subtilis	OK2	and	or	Bacillus	cereus	SPV.	...................................................	72	
Figure	16:	Schematic	representation	for	of	the	steps	involved	in	the	PHAs	production	
using	Cupriavidus	necator	or	Pseudomonas	mendocina	CH50.	.....................................	73	
Figure	17:	Soxhlet	apparatus	set	up	for	polymer	extraction.	........................................	76	
Figure	 18:	 PTL-MMB02	 Millimeter	 Grade	 Desktop	 Programmable	 Dip	 Coater	 and	
internal	chamber	with	prepared	tubes	on	the	mandrels.	..............................................	82	
Figure	19:	Temporal	profile	of	PHA	production	by	Bacillus	subtilis	OK2	using	Kannan	and	
Rehacek	media	with	35g/L	of	glucose	as	the	sole	carbon	source.	.................................	98	
Figure	20:	 ATR-FTIR	 spectrum	of	 the	polymer	produced	by	Bacillus	 subtilis	OK2	with	
35g/L	glucose	as	a	carbon	source.	..................................................................................	99	
Figure	21:	 (A)	Gas	chromatogram	of	the	polymer	extracted	from	Bacillus	subtilis	OK2	
biomass	and	(B)	mass	spectrum	of	a	peak	with	Rt=4.1	min	identified	using	NIST	library	
as	methyl	ester	of	3-hydroxybutyric	acid.	....................................................................	100	
Figure	 22:	 Gas	 chromatogram	 of	 reference	 standards	 of	 methyl	 esters	 of	 3-
hydroxyalkanaotes.	......................................................................................................	101	
Figure	23:	(A)	1H	NMR	and	(B)	13C	NMR	spectra	of	P(3HB)	confirming	the	polymer	to	be	
P(3HB)	homopolymer..	.................................................................................................	102	
Figure	 24:	 Molecular	 weight	 distribution	 and	 cumulative	 molecular	 weight	 of	 neat	
P(3HB)	polymer	produced	using	Bacillus	subtilis	OK2.	.................................................	103	
Figure	 25:	 DSC	 thermograms:	 first	 heating	 cycle	 and	 second	 heating	 cycle	 of	 P(3HB)	
obtained	from	Bacillus	subtilis	OK2	using	35g/L	glucose	as	the	sole	carbon	source.	..	104	
Figure	26:	 Summary	of	 the	DSC	 thermograms	of	 P(3HB)	neat	 films	during	1	week,	 3	
weeks,	5	weeks	and	7	weeks	of	storage	(first	heating	cycle).	......................................	107	
LIST	OF	FIGURES	
	
	 xii	
Figure	27:	The	evolution	of	(A)	an	ultimate	tensile	strength,	(B)	elongation	at	break	and	
(C)	Young’s	modulus	during	7	weeks	of	storage	of	neat	P(3HB).	.................................	109	
Figure	28:	ATR-FTIR	spectrum	of	the	waste	frying	oil	used	as	a	carbon	source	for	mcl-
PHAs	production	indicating	the	important	peaks	of	the	spectrum.	.............................	117	
Figure	29:	Gas	chromatogram	of	the	composition	of	the	waste	frying	oil	used	for	mcl-
PHA	production	as	a	carbon	source.	............................................................................	118	
Figure	30:	Mass	spectra	of	peaks	obtained	by	gas	chromatography	of	waste	frying	oil	
sample.	.........................................................................................................................	119	
Figure	31:	 (A)	 1H	NMR	and	 (B)	 13C	NMR	spectra	of	waste	 frying	oil	used	 for	mcl-PHA	
production	as	the	carbon	source.	................................................................................	121	
Figure	32:	Temporal	profile	of	PHA	production	by	Pseudomonas	mendocina	CH50	using	
MSM	medium	with	20g/L	of	waste	frying	oil	as	a	sole	carbon	source.	........................	123	
Figure	33:	ATR-FTIR	spectrum	of	the	polymer	produced	from	Pseudomonas	mendocina	
CH50	with	20g/L	waste	frying	oil	as	a	carbon	source		..................................................	124	
Figure	34:	Gas	chromatogram	of	the	polymer	extracted	from	biomass	of	P.	mendocina	
CH50.	Methyl	benzoate	was	used	as	an	internal	standard.	.........................................	125	
Figure	35:	Mass	spectra	of	peaks	obtained	 from	GC-MS	of	polymer	obtained	 from	P.	
mendocina	and	waste	frying	oil.	..................................................................................	126	
Figure	36:	The	thermal	properties	of	the	P(3HHx-3HO-3HD-3HDD)	copolymer	obtained	
from	P.	mendocina	using	waste	frying	oil	as	the	carbon	source.	.................................	128	
Figure	 37:	 Molecular	 weight	 distribution	 and	 cumulative	 molecular	 weight	 of	 neat	
P(3HHx-3HO-3HD-3HDD)	 obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	 waste	
frying	oil	as	the	carbon	source.	....................................................................................	129	
Figure	38:	ATR-FTIR	spectrum	of	the	oligo-PHA	after	20	hours	of	hydrolysis.	.............	141	
Figure	39:	Summary	of	thermal	properties	of	the	oligo-PHA	after	of	hydrolysis.	.......	142	
Figure	40:	Solvent	cast	films	of:	(A)	P(3HB)	neat	film,	(B)	P(3HB)/oligo-PHA	blend	film	in	
ratio	95/5,	(C)	P(3HB)/oligo-PHA	blend	film	in	ratio	90/10,	(D)	P(3HB)/oligo-PHA	blend	
film	in	ratio	80/20	........................................................................................................	144	
Figure	41:	DSC	thermograms	of	first	cycle	of	P(3HB),	oligo-PHA	and	P(3HB)/oligo-PHA	
blends	(ratios:	95/5,	90/10,	80/20)	aged	for	7	weeks	at	room	temperature.	..............	146	
Figure	 42:	 The	 evolution	 of	 ultimate	 tensile	 strength	 (A),	 Young’s	 modulus	 (B)	 and	
elongation	at	break	(C),	during	aging	of	neat	P(3HB)	and	its	blends	with	oligo-PHA.	..	148	
Figure	43:	SEM	images	of	the	neat	P(3HB)	film	and	P(3HB)/oligo-PHA	blend	films.	...	150	
Figure	44:	Surface	roughness	of	neat	P(3HB)	and	its	blends	with	oligo-PHA	..............	151	
Figure	45:	 Static	water	 contact	angle	measurements	 for	 the	neat	P(3HB)	 film	and	 its	
blends	with	oligo-PHA	(n=3;	error	bars=±SD).	.............................................................	152	
Figure	46:	Protein	adsorption	on	the	films	of	neat	P(3HB)	and	its	blends	with	oligo-PHA	
(n=3;	error	bars=±SD).	..................................................................................................	153	
Figure	 47:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)	 film	 and	
P(3HB)/oligo-PHA	blend	film	samples	at	day	1,	3	and	7	(n=3;	error	bars=±SD).	..........	154	
LIST	OF	FIGURES	
	
	 xiii	
Figure	48:	SEM	images	of	the	surfaces	of	(A)	neat	P(3HB)	and	(B-D)	P(3HB)/oligo-PHA	
blends	in	ratios:	95/5	(B),	90/10	(C),	80/20	(D)	respectively)	after	culturing	HMEC-1	cells	
for	7	days.	.....................................................................................................................	156	
Figure	49:	Representative	confocal	micrographs	of	live	HMEC-1	cells	(green)	and	dead	
HMEC-1	cells	(red)	on	different	PHA	materials	at	day	7.	.............................................	157	
Figure	50:	Haemolysis	rates	of	the	P(3HB)	and	P(3HB)/oligo-PHA	blends	in	percent	after	
1h	of	incubation	at	37°C	(n=3).	....................................................................................	158	
Figure	51:	Whole	blood	clotting	after	30	minutes	and	90	minutes	of	incubation	on	the	
neat	P(3HB),	P(3HB)/oligo-PHA	blends	and	PL38	medical	grade.	................................	159	
Figure	52:	Flow	cytometry	histograms	of	stained	fresh	whole	blood	without	any	material	
with	addition	of	markers	(B,	C)	and	without	markers	(A).	...........................................	162	
Figure	53:	Flow	cytometry	histograms	of	stained	fresh	whole	blood	activated	with	LPS	
with	two	different	sets	of	markers	(A,	B).	....................................................................	163	
Figure	54:	Composites	of	P(3HB)/oligo-PHA	in	ratio	90/10	with	(A)	1	wt%,	(B)	3	wt%,	(C)	
5	wt%	of	barium	sulphate.	...........................................................................................	175	
Figure	55:	ATR-FTIR	spectrum	of	the	P(3HB)/oligo-PHA	composites	with	BaSO4.	.......	176	
Figure	 56:	 DSC	 thermograms	 of	 P(3HB)/oligo-PHA	 blend	 in	 the	 ratio	 90/10	 and	
composite	films	with	a	BaSO4	aged	for	7	weeks	at	room	temperature.	......................	178	
Figure	 57:	 Changes	 in	 the	 ultimate	 tensile	 strength	 (A),	 Young’s	 modulus	 (B)	 and	
elongation	at	break	(C),	during	aging	of	neat	P(3HB)/oligo-PHA	blend	and	its	composites	
with	BaSO4.	...................................................................................................................	180	
Figure	58:	SEM	micrographs	of	surface	of	(A)	P(3HB)/oligo-PHA	blend	without	addition	
of	barium	sulphate,	P(3HB)/oligo-PHA	composite	with	addition	of	(B)	1wt%,	(C)	3wt%	
and	(D)	5wt%	of	barium	sulphate.	...............................................................................	182	
Figure	59:	Surface	roughness	of	P(3HB)/oligo-PHA	blend	(90/10)	and	composites	with	
BaSO4	(n=3;	error	bars=±SD).	.......................................................................................	183	
Figure	60:	Static	water	contact	angle	measurements	of	 the	P(3HB)/oligo-PHA	 in	ratio	
90/10	films	(n=3)	with	different	concentrations	of	barium	sulphate	..........................	184	
Figure	61:	Protein	adsorption	to	the	composites	measured	by	BCA	assay	..................	185	
Figure	62:	XRD	patterns	of	P(3HB)/oligo-PHA	90/10	blend	and	composites	with	1%,	3%	
and	5	wt%	BaSO4.	.........................................................................................................	186	
Figure	 63:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composite	film	samples	on	day	1,	day	3	and	day	7	(n=3;	error	bars=±SD).	.................	187	
Figure	 64:	 SEM	 images	 of	 the	 surfaces	 of	 P(3HB)/oligo-PHA	 blend	 90/10	 (A)	 and	
P(3HB)/oligo-PHA	90/10	composites	with	1	wt%	BaSO4	(B),	3	wt%	BaSO4	(C)	and	5	wt%	
BaSO4	(D)	after	culturing	HMEC-1	cells	for	7	days.	......................................................	189	
Figure	 65:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composites	film	samples	at	day	1	and	day	3	(n=3;	error	bars=±SD).	...........................	190	
Figure	 66:	MicroCT	micrographs	 demonstrated	 x-ray	 absorption	 by	 barium	 sulphate,	
presented	 in	the	concentrations:	0	wt%,	1	wt%,	3	wt%	and	5	wt%	in	the	PHAs	based	
composites	in	comparison	with	a	neat	P(3HB)/oligo-PHA	blend	in	ratio	90/10.	.........	191	
LIST	OF	FIGURES	
	
	 xiv	
Figure	67:	Haemolysis	rates	of	the	P(3HB)/oligo-PHA	blend	and	composites	with	barium	
sulphate	after	1h	of	incubation	at	37°C	(n=3).	.............................................................	192	
Figure	68:	Whole	blood	clotting	after	30	minutes	and	90	minutes	of	incubation	on	the	
neat	P(3HB)/oligo-PHA	blend	90/10,	composites	with	1	wt%,	3	wt%	and	5	wt%	barium	
sulphate	and	PL38	(n=3;	error	bars=±SD).	...................................................................	193	
Figure	 69:	 Production	 of	 PHA	 tubes	 (needle	 2.54mm	 diameter,	 78mm	 length)	 A-B	
prepared	by	using	dip	coating	technique.	....................................................................	201	
Figure	70:	Tubes	stored	for	7	weeks	at	room	temperature,	dry	(Figure	A)	and	in	DMEM	
media	incubated	at	37°C	(Figure	B).	.............................................................................	202	
Figure	 71:	 DSC	 thermograms	 of	 P(3HB)/oligo-PHA	 tubes	 aged	 for	 7	 weeks	 at	 room	
temperature.	................................................................................................................	204	
Figure	 72:	 The	 changes	 of	 ultimate	 tensile	 strength	 (a),	 Young’s	 modulus	 (b)	 and	
elongation	at	break	 (c),	during	aging	of	neat	P(3HB)/oligo-PHA	 tubes	 stored	at	 room	
temperature	and	incubated	in	DMEM	media	at	37°C	for	7	weeks.	.............................	207	
Figure	73:	SEM	images	of	the	P(3HB)/oligo-PHA	tubes.	..............................................	208	
Figure	 74:	 ATR-FTIR	 spectrum	 of	 the	 P(3HB)/oligo-PHA	 tubes	 during	 6	 months	 of	
degradation	study..	......................................................................................................	209	
Figure	75:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	during	6	months	of	degradation	
study	(first	heating	cycle)..	...........................................................................................	211	
Figure	76:	pH	changes	of	PBS	after	incubation	with	P(3HB)/oligo-PHA	tubes	for	6	months	
(n=3).	............................................................................................................................	212	
Figure	77:	Weight	loss	(%WL)	by	the	P(3HB)/oligo-PHA	tubes	for	a	period	of	6	months	
(n=3).	............................................................................................................................	213	
Figure	78:	Water	absorption	 (%WU)	by	 the	P(3HB)/oligo-PHA	tubes	 for	a	period	of	6	
months	(n=3)..	..............................................................................................................	214	
Figure	 79:	 SEM	 micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	 after	 6	 months	 of	
degradation	study.	.......................................................................................................	215	
Figure	80:	DSC	thermogram	of	PCL-PEG550	neat	polymer.	.........................................	216	
Figure	81:	ATR/FTIR	spectra	of	neat	P(3HB)/oligo-PHA	90/10	tube	and	P(3HB)/oligo-PHA	
90/10	tube	coated	with	monolayer	of	PCL-PEG550	.....................................................	218	
Figure	82:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550	after	
1	and	7	weeks	of	storage	(first	heating	cycle).	.............................................................	219	
Figure	83:	The	comparison	of	(A)	the	ultimate	tensile	strength,	(B)	Young’s	modulus	and	
(C)	elongation	at	break	(C)	during	aging	of	neat	P(3HB)/oligo-PHA	tubes	and	tubes	with	
monolayer	of	PCL-PEG550	stored	at	different	conditions	for	7	weeks.	.......................	223	
Figure	84:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	a	monolayer	of	PCL-
PEG550…………………………………………………………………………………………………………………….228	
	Figure	 85:	 DSC	 thermograms	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	 with	 5	 wt%	
barium	sulphate	after	1	week	and	7	weeks	of	storage.	...............................................	225	
Figure	 86:	 SEM	 micrographs	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	 with	 5	 wt%	
barium	sulphate.	..........................................................................................................	227	
LIST	OF	FIGURES	
	
	 xv	
Figure	 87:	MicroCT	micrographs	 demonstrated	 x-ray	 absorption	 by	 barium	 sulphate,	
presented	in	the	P(3HB)/oligo-PHA	composite	tubes,	containing	5	wt%	BaSO4.	.........	228	
Figure	88:	Protein	adsorption	to	the	neat	P(3HB)/oligo-PHA,	coated	with	PCL-PEG550	
and	composite	tubes	measured	by	BCA	assay	(n=3;	error	bars=±SD).	........................	229	
Figure	89:	Cell	proliferation	study	of	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	neat	tubes,	
coated	with	monolayer	of	PCL-PEG550	and	composite	tubes	with	5	wt%	barium	sulphate	
tube	samples	on	day	1,	day	3	and	7	(n=3;	error	bars=±SD)..	.......................................	230	
Figure	90:	Indirect	cytotoxicity	study	of	the	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	neat	
tubes,	coated	with	monolayer	of	PCL-PEG550	and	composite	tubes	with	5	wt%	barium	
sulphate	tube	samples	on	day	1	and	day	3	(n=3;	error	bars=±SD).	..............................	231	
Figure	91:	M	images	of	the	surfaces	of	P(3HB)/oligo-PHA	neat	tubes	(A),	PCL-PEG550	
coated	tubes	(B)	and	composite	tubes	(C)	after	culturing	HMEC-1	cells	for	7	days.	....	233	
Figure	92:	Haemolysis	rates	of	the	P(3HB)/oligo-PHA	neat	tubes,	tubes	coated	with	PCL-
PEG550	and	composite	tube	with	barium	sulphate..	...................................................	234	
Figure	93:	Whole	blood	clotting	after	30	minutes	and	90	minutes	of	incubation	on	the	
neat	P(3HB)/oligo-PHA	tubes,	coated	with	PCL-PEG550	and	composite	tubes	with	5	wt%	
barium	sulphate.	sulphate	and	PL38	(n=3;	error	bars=±SD).	.......................................	235	
Figure	 94:	 ATR/FTIR	 spectrum	 of	 rapamycin	 powder	 indicating	 characteristic	 peaks	
typical	to	chemical	bonds	observed	in	rapamycin.	......................................................	248	
Figure	95:	ATR/FTIR	 spectrum	of	Tacrolimus	 indicating	characteristic	peaks	 typical	 to	
chemical	bonds	observed	in	tacrolimus.	......................................................................	249	
Figure	96:	DSC	thermograms	of	rapamycin	registered	during	first	heating	cycle.	.......	250	
Figure	97:	DSC	thermograms	of	tacrolimus	registered	during	first	heating	cycle.	......	250	
Figure	 98:	 ATR/FTIR	 spectra	 of	 neat	 P(3HB)/oligo-PHA	 tube	 with	monolayer	 of	 PCL-
PEG550	 in	comparison	to	P(3HB)/oligo-PHA	tube	with	 incorporated	rapamycin	within	
PCL-PEG550	 coating	 indicating	 major	 peaks	 characteristic	 for	 PHA,	 PCL-PEG550	 and	
rapamycin	and	tacrolimus………………………………………………………………………………………..256	
Figure	99:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	monolayer	of	PCL-
PEG550	with	incorporated	rapamycin.	........................................................................	254	
Figure	100:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	monolayer	of	PCL-
PEG550	with	incorporated	tacrolimus……………………………………………………………………..258	
Figure	101:	 In	 vitro	 release	profile	of	 rapamycin	 from	P(3HB)/oligo-PHA	90/10	blend	
tube	coated	with	a	monolayer	of	PCL-PEG550,	for	a	period	of	90	days.	.....................	256	
Figure	102:	Cumulative	release	of	tacrolimus	within	90	days	of	study	(n=3).	.............	257	
Figure	 103:	 Protein	 adsorption	 to	 the	 P(3HB)/oligo-PHA	 90/10	 blend	 tubes	 with	
incorporated	 drugs:	 rapamycin	 or	 tacrolimus	 in	 PCL-PEG550	 polymeric	 matrix	 (n=3;	
error	bars=±SD).	...........................................................................................................	258	
Figure	104:	Cell	proliferation	study	of	the	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	tubes	
coated	 with	 monolayer	 of	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	 tacrolimus	
samples	on	day	1,	3	and	7	(n=3;	error	bars=±SD).	.......................................................	259	
LIST	OF	FIGURES	
	
	 xvi	
Figure	 105:	 SEM	 micrographs	 of	 the	 HMEC-1	 cells	 attached	 to	 the	 surfaces	 of	
P(3HB)/oligo-PHA	 tubes	 containing	 rapamycin	 (A),	 and	 tacrolimus	 (B)	 after	 7	 days	of	
culturing.	......................................................................................................................	260	
Figure	 106:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
tubes	coated	with	monolayer	of	PCL-PEG550	with	incorporated	rapamycin	or	tacrolimus	
samples	on	day	1,	3	(n=3;	error	bars=±SD).	.................................................................	261	
Figure	107:	Haemolysis	 rates	of	 the	P(3HB)/oligo-PHA	 tubes	 coated	with	PCl-PEG550	
with	incorporated	rapamycin	or	tacrolimus	after	1h	of	incubation	at	37°C	(n=3).	......	263	
Figure	108:	Summary	of	whole	blood	clotting	results	after	30	minute	and	90	minutes	of	
incubation	on	the	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550	with	rapamycin	or	
tacrolimus.	Tissue	culture	plastic	was	used	as	the	control	(n=3;	error	bars=±SD).	......	264	
Figure	109:	ATR-FTIR	spectrum	of	the	P(3HB)/oligo-PHA	tubes	with	rapamycin	(A)	and	
tacrolimus	(B)	after	3	months	incubation	in	PBS.	........................................................	267	
Figure	110:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	with	incorporated	rapamycin	
(A)	and	tacrolimus	(B)	during	3	months	of	degradation	study.	....................................	269	
Figure	 111:	 pH	 changes	 of	 PBS	 after	 incubation	 of	 P(3HB)/oligo-PHA	 tubes	 with	
incorporated	rapamycin	or	tacrolimus	for	3	months	(n=3).	........................................	271	
Figure	 112:	 Weight	 loss	 (%WL)	 of	 the	 P(3HB)/oligo-PHA	 tubes	 with	 incorporated	
rapamycin	or	tacrolimus	for	a	period	of	3	months	(n=3)..	...........................................	272	
Figure	113:	Water	absorption	(%WU)	by	the	P(3HB)/oligo-PHA	tubes	with	incorporated	
rapamycin	or	tacrolimus	for	a	period	of	3	months	(n=3)..	...........................................	273	
Figure	 114:	 SEM	micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	with	 rapamycin	 after	 3	
months	of	degradation	study.	......................................................................................	274	
Figure	 115:	SEM	micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	with	 tacrolimus	 after	 3	
months	of	degradation	study.	......................................................................................	275	
LIST	OF	TABLES	
	
	 xvii	
Table	1:	Summary	of	material	properties	typical	for	mcl-PHA	and	scl-PHA.	.................	31	
Table	2:	Experimental	set-up	for	staining	with	different	types	of	antibodies.	..............	91	
Table	3:	Summary	of	the	results	obtained	during	screening	experiments	performed	for	
the	production	of	novel	scl-PHA	production.	.................................................................	96	
Table	4:	 Summary	of	molecular	weight	analysis	of	 the	P(3HB)	obtained	 from	Bacillus	
subtilis	OK2	and	glucose	as	the	carbon	source	............................................................	104	
Table	5:	Summary	of	the	thermal	properties	of	the	fresh	P(3HB)	polymer	obtained	using	
B.	subtilis	OK2..	.............................................................................................................	105	
Table	6:	Summary	of	the	mechanical	properties	of	neat	P(3HB)	solvent	cast	films	without	
storage	(n=3).	...............................................................................................................	106	
Table	 7:	 Summary	 of	 the	 thermal	 properties	 of	 the	 P(3HB)	 films	 during	 7	 weeks	 of	
storage	at	room	temperature.	.....................................................................................	106	
Table	8:	Summary	of	the	mechanical	properties	of	the	P(3HB)	solvent	cast	films	during	
7	weeks	of	storage	at	room	temperature	(n=3).	..........................................................	108	
Table	9:	Summary	of	the	screening	experiments	used	for	the	production	of	mcl-PHAs	by	
Pseudomonas	mendocina	CH50	using	various	carbon	sources.	...................................	116	
Table	 10:	 Fatty	 acids	 composition	 (mol	 %)	 of	 waste	 frying	 oil	 used	 for	 mcl-PHA	
production.	...................................................................................................................	120	
Table	11:	The	summary	of	 the	chemical	 shifts	observed	 in	 1H	NMR	of	 the	 fatty	acids	
presented	in	the	waste	frying	oil.	.................................................................................	122	
Table	12:	The	summary	of	the	chemical	shifts	observed	in	13C	NMR	spectrum	of	the	fatty	
acids	presented	in	the	waste	frying	oil.	........................................................................	122	
Table	 13:	 Monomer	 composition	 mcl-PHA	 synthesised	 by	 P.	 mendocina	 with	 waste	
frying	oil	as	a	carbon	source.	........................................................................................	127	
Table	14:	Summary	of	the	thermal	properties	of	the	P(3HHx-3HO-3HD-3HDD)	copolymer	
obtained	from	P.	mendocina	using	waste	frying	oil	as	the	carbon	source	...................	128	
Table	 15:	 Summary	 of	 molecular	 weight	 analysis	 of	 the	 P(3HHx-3HO-3HD-3HDD)	
obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	 waste	 frying	 oil	 as	 the	 carbon	
source.	..........................................................................................................................	129	
Table	16:	Summary	of	hydrolysis	kinetics	of	P(3HHx-3HO-3HD-3HDD)	copolymer.	....	140	
Table	17:		Thermal	properties	of	the	oligo-PHA	after	20	hours	of	hydrolysis	..............	142	
Table	 18:	 Summary	 of	 molecular	 weight	 analysis	 of	 the	 P(3HHx-3HO-3HD-3HDD)	
obtained	from	Pseudomonas	mendocina	CH50	and	waste	frying	oil	as	the	carbon	source	
after	2	hours	of	hydrolysis..	..........................................................................................	143	
Table	 19:	 Summary	 of	 the	 thermal	 analysis	 of	 P(3HB)/hydrolysed	 P(3HHx-3HO-3HD-
3HDD)	blends	during	7	weeks	of	storage.	....................................................................	145	
Table	20:	Summary	of	the	mechanical	properties	of	P(3HB)/oligo-PHA	blends	during	7	
weeks	of	storage	(n=3).	................................................................................................	147	
Table	21:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	whole	blood	incubated	with	neat	P(3HB),	P(3HB)/oligo-PHA	blends	in	ratios:	95/5,	
LIST	OF	TABLES	
	
	 xviii	
90/10,	 80/20	 PHAs	 and	 PL38	 and	 stained	with	 specific	markers	 in	 order	 to	 evaluate	
monocyte	and	neutrophil	activity.	...............................................................................	161	
Table	22:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 activated	 with	 LPS	 and	 stained	 with	 specific	markers	 in	 order	 to	
evaluate	monocyte	and	neutrophil	activity.	................................................................	163	
Table	23:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	whole	blood	incubated	with	neat	P(3HB),	P(3HB)/oligo-PHA	blends	in	ratios:	95/5,	
90/10,	80/20	PHAs	and	PL38;	 and	 stained	with	 specific	markers	 in	order	 to	evaluate	
monocyte	and	neutrophil	activity.	...............................................................................	164	
Table	24:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	composites	with	
1,3	and	5	wt%	barium	sulphate	during	7	weeks	of	storage.	........................................	177	
Table	25:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	composites	
with	1,3	and	5	wt%	barium	sulphate	during	7	weeks	of	storage	at	room	temperature	
(n=3).	............................................................................................................................	179	
Table	26:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 incubated	 with	 P(3HB)/oligo-PHA	 blend	 90/10,	 P(3HB)/oligo-PHA	
composites	 with	 1%	wt,	 3%	wt	 and	 5%	wt	 barium	 sulphate	 and	 PL38;	 stained	 with	
specific	markers	in	order	to	evaluate	monocyte	and	neutrophil	activity.	...................	194	
Table	27:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	during	7	
weeks	of	storage..	........................................................................................................	203	
Table	28:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	during	
7	weeks	of	storage	at	room	temperature.	...................................................................	205	
Table	29:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	during	
7	weeks	of	storage	in	DMEM	media	at	37°	C	for	7	weeks.	...........................................	206	
Table	30:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	during	6	
months	of	degradation	study..	.....................................................................................	210	
Table	31:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	with	
PCL-PEG550	after	1	and	7	weeks	of	storage.	...............................................................	219	
Table	32:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	
with	PCL-PEG550	after	1	and	7	weeks	of	storage	(n=3).	..............................................	220	
Table	33:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	composite	tubes	
with	5	wt%	barium	sulphate	after	1	and	7	weeks	of	storage..	.....................................	224	
Table	34:	 Summary	of	 the	mechanical	properties	of	 the	P(3HB)/oligo-PHA	composite	
tubes	with	5	wt%	barium	sulphate	after	1	and	7	weeks	of	storage	(n=3).	..................	225	
Table	35:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 with	 P(3HB)/oligo-PHA	 90/10	 neat	 tube,	 P(3HB)/oligo-PHA	 90/10	
tube	 coated	with	PCL-PEG550,	P(3HB)/oligo-PHA	composite	 tube	with	5%	wt	barium	
sulphate	and	PL38;	and	stained	with	specific	markers	in	order	to	evaluate	monocyte	and	
neutrophil	activity.	.......................................................................................................	237	
Table	36:	Dimensions	of	tubes	produced	using	P(3HB)/oligo-PHA	blend	coated	with	PCL-
PEG550	with	incorporated	drug.	..................................................................................	251	
LIST	OF	TABLES	
	
	 xix	
Table	37:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 with	 P(3HB)/oligo-PHA	 90/10	 tube	 coated	 with	 PCL-PEG550,	
P(3HB)/oligo-PHA	 tube	 coated	 with	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	
tacrolimus	and	PL38	stained	with	specific	markers	in	order	to	evaluate	monocyte	and	
neutrophil	activity.	.......................................................................................................	265	
Table	38:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	containing	
rapamycin	or	tacrolimus	after	3	months	of	degradation	study.	..................................	268	
Table	39:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	with	
rapamycin	or	tacrolimus	during	month	1,	2	and	3	of	the	degradation	study.	.............	270	
LIST	OF	ABBREVIATIONS	
	
	 xx	
PCI:	Percutaneous	Coronary	Intervention	
CABG:	Coronary	Artery	Bypass	Grafting	
BMS:	Bare	metallic	stent	
DES:			Drug	eluting	stent	
FBR:	Foreign	body	reaction	
TE:	Tissue	Engineering	
FDA:	United	States	Food	and	Drug	Administration	
SMC:	Smooth	Muscle	Cells	
NPs:	Nanoparticles	
PHA:	Polyhydroxyalkanoates	
PDLLA:	Poly(-D,L-lactic	acid)	
L-PLCL:	Poly(L-lactide-co-caprolactone)	
PGA:		Poly(glycolic	acid)	
PLA:	Poly(lactic	acid)	
PLLA:	Poly(L-lactic)	acid	
TCP:	Tissue	Culture	Plastic	
PCL:	Poly(ε-caprolactone)	
Scl-PHA:	Short	chain	length	polyhydroxyalkanoate	
Mcl-PHA:	Medium	chain	length	polyhydroxyalkanoate	
P(3HB):	Poly(3-hydroxybutyrate)	
P(3HB-co-3HV):	Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)	
P(4HB):	Poly(4-hydroxybutyrate)	
P(3HB-co-4HB):	Poly(3-hydroxybutyrate-co-4-hydroxybutyrate)	
P(3HB-co-3HHx):	Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)	
P(3HO-co-3HHx):	Poly(3-hydroxyoctanoate-co-3-hydroxyhexanoate)	
P(3HB-co-3HO):	Poly(3-hydroxybutyrate-co-3-hydroxyoctanoate)	
P(3HO-co-3HD):	Poly(3-hydroxyoctanoate-co-3-hydroxydecanoate)	
P(3HO-co-3HD-co-3HDD):	Poly(3-hydroxyoctanoate-co-3-hydroxydecanoate-co-3-
hydroxydodecanoate)	
P(3HV):	Poly(3-hydroxyvalerate)	
P(3HHx-co-3HO-co-3HD-co-3HDD):	Poly(3-hydroxyhexanoate-co-3-hydroxyoctanoate-co-3-
hydroxydecanoate-co-3-hydroxydodecanoate)	
Scl-mcl-PHA:	Short	chain	length-medium	chain	length	polyhydroxyalkanoate	
PEG:	Polyethylene	glycol	
PVA:	Poly(vinyl	alcohol)	
CoA:	Coenzyme	A		
MSM:	Mineral	Salt	Medium		
OD:	Optical	Density		
DOT:	Dissolved	Oxygen	Tension		
GC:	Gas	Chromatography		
GC-MS:	Gas	Chromatography-	Mass	Spectrometry	
SEM:	Scanning	electron	microscopy	
HPLC:	High	Performance	Liquid	Chromatography	
XRD:	X-ray	diffraction	
FTIR:	Fourier	Transform	Infrared	Spectroscopy	
LIST	OF	ABBREVIATIONS	
	
	 xxi	
NMR:	Nuclear	magnetic	resonance	
DSC:	Differential	scanning	calorimetry	
LPS:	Lipopolysaccharides	
PBS:	Phosphate	buffer	saline	
DMEM:	Dulbecco's	modified	Eagle's	medium	
FBS:	Foetal	Bovine	Serum	
MTT:	(3-(4,5-Dimethylthiazol-2-yl)-2,5	diphenyltetrazolium	bromide	
SD:	Standard	deviation	
wt%:	Weight	percent	
Mn:	Average	molecular	weight		
MW:	Weight	average	molecular	weight		
%WU:	Water	absorption		
%	WL:	Weight	loss		
C/N:	Carbon	to	nitrogen	ratio		
Rt:	Retention	time	
mL:	Millilitre	
ppm:	Parts	per	million	
rpm:	Revolutions	per	minute	
mM:	Milimolar	
Tg:	Glass	transition	temperature	
Tm:	Melting	temperature	
TC:	Crystallisation	temperature	
PDI:	Polydispersity	index	
TS:	Tensile	strength	
ΔHf:	Enthalpy	of	fusion	
XC:	Degree	of	crystallinity	
Dcw:	Dry	cell	weight	
Rq:	Root	mean	square	
PLGA:	Poly(lactic-co-glycolic	acid)	
BVS:	Bioresorbable	vascular	stent	
mTOR:	Mechanistic	target	of	rapamycin	
PCL-PEG550:	Poly(caprolactone-ethylene	glycol	)–	550	
PVP:	Poly(vinylpyrrolidone)	
MRI:	Magnetic	Resonance	Imaging	
PDS:	Polydioxanone	
SDS:	Sodium	dodecyl	sulphate	
HMEC-1:	Human	microvascular	endothelial	cells	
HaCaT:	Immortalized	human	keratinocytes	
MicroCT:	Micro	computed	tomography	
EGCG:	Epigallocatechin-3-O-gallate	
	
	
		
	
	
	
	
	
	
Chapter	1	
Introduction	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER	1	
	
	 2	
1.1.	Coronary	artery	disease	
Coronary	artery	disease	(CAD)	is	the	most	important	contributor	to	the	mortality	and	
economic	burden	associated	with	cardiovascular	disease	(CVD).	CVD	is	leading	cause	of	
death	worldwide.	In	United	Kingdom,	the	mortality	due	to	cardiovascular	disease	has	
been	 placed	 right	 after	 cancer.	 In	 2015	 in	 UK	 over	 158,000	 deaths	 were	 caused	 by	
cardiovascular	disease,	which	is	equivalent	to	27.4%	of	all	deaths	in	men	and	25.2%	in	
women	(BHF	statistics,	2017).	Only	in	European	Union,	cardiovascular	disease	costs	210	
billion	euros	per	year	(European	Cardiovascular	Disease	Statistics,	2017).	CAD	is	caused	
by	the	deposition	of	plaque	in	the	coronary	artery	which	results	in	reduced	blood	flow	
and	nutrient	supply	to	the	heart	(Hirase	and	Node,	2012).	This	might	lead	to	heart	attack,	
clot	formation	or	stroke.	The	main	risk	factors	include:	high	blood	pressure,	smoking,	
diabetes,	obesity,	hypercholesterolemia	and	sedentary	lifestyle	(Hamrefors,	2017;	Yusuf	
et	al.,	2004).	
The	first	successful	surgical	treatment	of	coronary	artery	disease	was	performed	using	
coronary	artery	bypass	grafting	(CABG)	in	1960s.	This	procedure	included	grafting	of	a	
small	 fragment	of	an	artery	taken,	usually	 from	another	part	of	the	body	around	the	
blocked	artery	to	restore	blood	supply	to	the	heart	(Choi	et	al.,	2009).	In	1977,	the	first	
balloon	angioplasty	was	performed	by	Grüntzig	(Grüntzig	et	al.,	1979).	The	technique	
involved	placement	of	a	deflated	balloon	in	the	narrowed	vessel	followed	by	inflation,	
which	 resulted	 in	 the	 compression	 of	 the	 plaque	 towards	 the	 vessel	 walls,	 hence	
opening	up	the	artery.	In	1987,	the	first	coronary	artery	stent	was	implanted	by	Sigwart	
and	co-workers	(Sigwart	et	al.,	1987).	The	coronary	artery	stent	was	designed	to	provide	
mechanical	support	to	the	vessel	wall,	which	facilitated	the	opening	of	the	artery	and	
prevented	any	further	narrowing	(Nazneen	et	al.,	2012).		
Currently	 CAD	 treatments	 require	 percutaneous	 coronary	 intervention	 (PCI),	 which	
involves	balloon	angioplasty	and	stent	implantation	(Iqbal	et	al.,	2013).	Only	in	United	
Kingdom,	97,376	PCIs	were	performed	in	2015,	which	is	60%	an	increase	in	comparison	
to	 2001.	 At	 present,	 over	 80%	 of	 cardiovascular	 interventions	 in	 UK	 involve	 stent	
deployment,	out	of	which	85.7%	use	drug	eluting	stents	 (DES)	 (Ludman	et	al.,	NAPCI	
report,	2015;	Sun	et	al.,	2014).	
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1.2.	Coronary	stents	
Coronary	stents	are	medical	devices,	which	are	delivered	to	the	artery	in	the	collapsed	
form	 and	 inflated	 inside	 narrowed	 blood	 vessel.	 This	 results	 in	 compressing	 plaque	
against	the	artery	wall	and	restore	the	normal	blood	flow	(Grabow	et	al.,	2010).	It	is	very	
important	 to	 understand	 that	 coronary	 stent	 does	 not	 act	 as	 a	 tissue	 engineering	
scaffold	(TES).	The	main	function	of	stent	is	to	widen	and	support	the	narrowed	artery,	
whereas,	the	main	role	of	tissue	engineering	scaffold	is	to	repair,	replace	or	regenerate	
damaged	or	 injured	 tissues	or	 organs.	 Tissue	 engineering	 scaffold	 approach	 requires	
combination	of	three	main	elements,	such	as	biomaterial	3D	scaffold,	seeded	with	cells	
with	or	without	addition	of	bioactive	agents,	such	as	growth	factors,	in	order	to	simulate	
body	environment,	allow	cell	attachment	and	new	tissue	development	(O’Brien,	2011;	
Chan	 and	 Leong,	 2008).	 Coronary	 stents	 require	 only	 suitable	 material,	 which	 will	
mechanically	support	blood	vessel	during	natural	healing	of	the	artery	 injured	during	
angioplasty	and	stent	deployment	 (Waksman,	2006).	However,	high	biocompatibility,	
non-toxicity,	 thromboresistance,	 suitable	 mechanical	 properties,	 are	 expected	 from	
materials	considered	for	stent	application	as	well	as	TE	scaffolds.	Additionally,	stents	can	
be	used	as	local	drug	delivery	vehicles	in	order	to	release	drugs	and	reduce	the	risk	of	
restenosis,	a	side	effect,	associated	with	stent	deployment	(Regar	et	al.,	2001),	which	
will	be	described	in	details	in	section	1.5.		
Stents	are	meshed	tubular	3D	structures,	made	from	metals	or	polymers.	Over	100	types	
of	stents	are	available	in	the	market,	mainly	for	vascular	lesions	(Stoeckel	et	al.,	2002).	
Coronary	stent	dimensions	are	designed	to	have	 length	between	8mm	to	38mm	and	
diameter	from	2mm	to	4mm	(Borovetz	et	al.,	2004).	Materials	for	stent	manufacturing	
can	be	formed	into	wires,	sheets	or	tubes.	The	techniques	used	for	stent	production	are:	
laser	cutting,	electrode	discharge	machining,	waterjet-cutting,	photochemical	etching	
from	tubing,	braiding	and	knitting	(Kathuria,	2006;	Stoeckel	et	al.,	2002).	Coronary	stents	
are	 known	 to	 reduce	 some	 major	 side	 effects	 of	 balloon	 angioplasty,	 such	 as	 re-
narrowing	 of	 the	 artery	 caused	 either	 by	 reforming	 of	 the	 blockage	 or	 new	 tissue	
formation	(Takayama	et	al.,	2011).	Currently	available	stents	can	be	divided	into	three	
main	 groups:	 bare	 metal	 stents	 (BMS),	 drug-eluting	 stents	 (DES)	 and	 bioresorbable	
vascular	stents	(BVS)	(Iqbal	et	al.,	2013).	
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1.2.1.	Bare	metallic	stents	
The	stents	that	were	initially	developed	had	very	high	metallic	density,	resulting	in	a	high	
incidence	of	stent	thrombosis;	accompanied	by	failure	in	deployment	and	embolization	
(Serruys	et	al.,	1991).	Although,	stents	reduced	the	risk	of	restenosis	compared	to	plain	
balloon	angioplasty,	there	was	still	a	significant	risk	of	in-stent	restenosis,	which	could	
be	associated	with	high	morbidity	and	mortality.	Application	of	bare	metallic	stents	after	
balloon	angioplasty	has	eliminated	vessel	elastic	recoil	and	negative	remodelling,	which	
resulted	in	a	significant	reduction	of	restenosis	from	30-50%	to	20%	(Lowe	et	al.,	2002).		
Stents	are	delivered	 to	 the	vessel	on	a	 catheter	 through	a	guide	wire	and	expanded	
restoring	normal	blood	flow	to	the	heart	(Figure	1).	Considering	the	type	of	deployment	
stents	can	be	divided	 into:	balloon-expandable	or	self-expandable.	Depending	on	the	
type	 of	 expansion,	 stents	 require	 different	 material	 properties.	 For	 example,	 self-
expanding	 stents	need	 to	have	 low	elastic	modulus	and	high	yield	 stress,	due	 to	 the	
specific	 manufacturing	 diameters,	 which	 should	 be	 larger	 than	 the	 diameter	 of	 the	
target	structure.	Balloon	expandable	stents	must	be	able	to	maintain	expanded	shape	
and	used	materials	require	low	yield	stress.	Therefore,	for	a	balloon	expandable	stent,	
316L	 stainless	 steel	 is	 the	 most	 common	 choice	 due	 to	 its	 excellent	 mechanical	
properties.	However,	due	to	its	limited	biocompatibility	and	ferromagnetic	properties,	
other	 non-corrosive	materials	 have	 been	 considered,	 such	 as	 platinum-iridium	 alloy,	
tantalum,	cobalt-chromium	alloy,	and	titanium	(Zahora	et	al.,	2007).	For	self-expanding	
stents	Nitinol,	a	nickel-titanium	alloy	has	been	widely	used	because	of	material	shape	
memory	 and	 high	 elasticity,	 which	 allows	 stent	 self-expansion	 during	 deployment	
(Barras	and	Myers,	2000).	The	drawback	of	this	material	is	the	high	risk	of	immunogenic	
response	due	to	Ni	ions	release	from	the	alloy	(Shabalovskaya,	1996).		
CHAPTER	1	
	
	 5	
	
Figure	1:	Stent	implantation	in	the	narrowed	artery.	(Source:	National	Heart,	Blood	and	
Lung	Institute	https://www.nhlbi.nih.gov/health/health-topics/topics/stents).	
The	 coronary	 artery	 stent	 is	 considered	 as	 a	 foreign	 body;	 hence	 there	 is	 an	
inflammatory	 response	 triggered	 by	 the	 immune	 system	 (Jamshidi	et	 al.,	 2008).	 The	
inflammatory	 response	 is	 a	 response	 of	 the	 body	 environment	 to	 the	 injury	 and	
implanted	material	or	prosthesis.	Usually	it	 involves	series	of	events,	 including	blood-
material	interaction,	acute	inflammation,	chronic	inflammation,	foreign	body	reaction	
and	fibrous	capsule	development	(Anderson	et	al.,	2001).	Immediately	after	contact	of	
biomaterial	with	tissues	and	blood,	proteins	adsorb	on	the	surface	of	the	material	and	
mediate	thrombus	and	provisional	matrix	formation.	This	matrix	consists	mainly	fibrin	
and	products	released	by	activated	platelets,	inflammatory	cells	and	endothelial	cells.	
Acute	inflammation	occurs	within	minutes	to	days	after	injury.	Usually	in	involves	blood	
proteins	infiltration	and	leukocytes	migration	from	the	blood	vessel	to	the	site	of	the	
injury,	 followed	 by	 neutrophils	 and	 monocytes	 activation.	 Acute	 inflammation	 is	
dominated	 by	 presence	 of	 neutrophils,	 which	 normally	 destroy	microorganisms	 and	
degrades	foreign	body.	However,	due	to	the	difference	in	size	between	an	implant	and	
neutrophils	 cell,	 “frustrated	 phagocytosis”	 event	 may	 occur.	 This	 process	 involves	
production	 of	 free	 oxygen	 radicals	 and	 lysozyme	 proteases	 by	 leukocytes	 with	 an	
intention	to	degrade	the	biomaterial.	Neutrophils	have	very	short	life	spun,	therefore	
they	 are	 replaced	 by	 monocytes,	 macrophages	 and	 lymphocytes,	 which	 are	
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determinants	 of	 chronic	 inflammation,	 followed	 by	 foreign	 body	 reaction	 (FBR)	
(Anderson	et	al.,	2008).	FBR	consists	an	accumulation	of	macrophages	and	foreign	body	
giant	cells,	which	may	remain	for	the	lifetime	of	the	implant.	The	last	phase	of	the	body	
response	 to	 biomaterials	 is	 fibrosis	 or	 fibrous	 encapsulation,	 which	 decreases	 the	
efficiency	of	an	implant	and	may	leads	to	its	failure	(Bryers	et	al.,	2012).	Therefore,	novel	
materials	are	being	explored	for	the	production	of	stents	with	improved	properties,	such	
as	higher	biocompatibility,	greater	mechanical	strength	and	tailorable	biodegradability	
(Williams	and	Martin,	2005).		
1.2.2.	Drug-eluting	stents	(DES)	
 
Drug-eluting	stents	(DES)	were	developed	to	reduce	or	totally	eliminate	the	side	effects	
associated	with	 the	application	of	metallic	 stents,	especially	 restenosis	 (Gogas	et	al.,	
2012).	Drug	eluting	stents	reduced	the	restenosis	rate	from	40%	to	5%.	DES	are	metallic	
stents	coated	with	a	polymer	layer	containing	drugs,	capable	of	releasing	one	or	more	
bioactive	substance	into	the	blood	stream	and	surrounding	tissue.	Development	of	the	
DES	 significantly	 diminished	 the	 use	 of	 bypass	 surgery	 as	 a	 treatment	 of	 restenosis,	
which	is	one	of	the	long-term	side	effects	after	stent	deployment	(Moses	et	al.,	2003).	
A	wide	range	of	different	materials	and	drugs	have	been	tested.		
The	drug	eluting	stents	have	several	advantages.	The	active	agents	may	be	delivered	
directly	to	a	target	site	in	a	suitable	therapeutic	dose,	preventing	the	risk	of	restenosis	
and	 reducing	 the	 toxic	 effects	 of	 the	 systemic	 delivery	 of	 the	 same	 drug	 at	 higher	
concentration	 (Acharya	 and	 Park,	 2006).	 The	 use	 of	 DES	 has	 been	 widened	 from	
coronary	 interventions	 to	 bifurcation	 lesions,	 complex	 lesions,	 inlet	 main	 trunk	 and	
multivessel	 disease.	However,	 late	 stent	 thrombosis	has	become	an	 issue	associated	
with	this	type	of	devices	(McFadden	et	al.,	2004).		
DES	 reduced	 the	 restenosis	 rate	 to	 up	 to	 10%	 by	 the	 inhibiting	 effect	 of	 drugs	 on	
proliferation	of	vascular	smooth	muscle	cells.	Although	the	restenosis	rate	was	reduced,	
presence	of	drugs	usually	impeded	the	normal	healing	process	by	inhibiting	proliferation	
of	endothelial	 cells.	 This	may	 lead	 to	a	high	 risk	of	 late	 thrombosis	and	 require	dual	
antiplatelet	therapy	(Morice	et	al.,	2002).	Moreover,	the	polymer	in	the	coating	layer	
can	 cause	 inflammatory	 response	 and	 hypersensitivity	 reactions	 (i.e.	 dyspnea,	 rash,	
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hives,	fever),	which	can	lead	to	myocardial	infarction	and	sudden	death	(Nebeker	et	al.,	
2006;	Iakovou	and	Colombo,	2005).		
Development	 of	 coronary	 artery	 stents	 was	 a	 huge	 achievement	 in	 the	 invasive	
cardiology.	However,	both,	bare	metallic	stents	as	well	as	drug	eluting	stents	still	have	
their	limitations.	Both	types	of	stents	provided	support	to	the	arterial	wall.	However,	in	
the	long-term	perspective,	presence	of	a	metallic	scaffold	in	the	artery	resulted	in	the	
development	of	side	effects,	such	as	in	stent	restenosis	and	late	thrombosis	(described	
in	the	section	1.5.).	Therefore,	there	was	need	for	a	novel	solution,	which	can	overcome	
the	 limitations	 of	 the	 previous	 generations	 of	 the	 coronary	 stents.	 This	 is	 how	 the	
concept	of	biodegradable	stents	appeared.		
1.2.3.	Biodegradable	stents	
The	main	role	of	the	stent	is	to	provide	a	mechanical	support	to	the	arterial	walls	until	
the	vessel	heals,	which	is	between	6	to	12	months.	After	this,	a	permanent	implant	is	
not	 needed.	 Therefore,	 the	 concept	 of	 biodegradable	 stents	 was	 introduced	 that	
perform	 their	 function	 and	 then	 slowly	 disappear	 within	 18	 months.	 The	 main	
advantages	 of	 biodegradable	 stents	 are:	 shorter	 dual-antiplatelet	 therapy,	 which	
reduces	the	risk	of	bleeding,	no	need	for	surgical	removal,	absence	of	a	foreign	body	in	
the	 long	run	reducing	the	potential	 inflammatory	response	and	enhances	the	natural	
healing	 process	 of	 the	 artery	 wall	 (Waksman,	 2006).	 Arterial	 wall	 is	 very	 sensitive	
towards	 mechanical	 injury.	 Only	 touching	 with	 catheter	 is	 sufficient	 to	 damage	 the	
endothelial	layer,	which	results	in	cell	detachment	and	death	of	endothelial	cells.	This	
causes	 immediate	healing	response	by	platelets	adhesion	and	thrombus	formation	 in	
order	 to	 cover	 and	 protect	 injured	 place.	 	 Healing	 process	 is	 supported	 by	 smooth	
muscle	cells	proliferation	leading	to	the	reconstruction	of	the	arterial	wall	(Van	Erven	et	
al.,	1991).	Although	biodegradable	stents	were	introduced	around	20	years	ago,	most	
of	 them	 have	 failed	 during	 preclinical	 evaluation	 (Sun	 et	 al.,	 2014).	 The	 polymeric	
biodegradable	stents,	which	disappear	slowly	after	implantation,	are	hence	promising	
novel	 stent	 technologies	 that	 can	 be	 loaded	with	 various	 types	 of	 drugs	 or	multiple	
agents	(Peng	et	al.,	1996;	Mani	et	al.,	2007).	A	fully	biodegradable	coronary	stent	should	
meet	certain	criteria.	The	stent	material	as	well	as	 its	degradation	products	must	be	
biocompatible.	The	structural	 integrity	of	the	stent	must	be	maintained	for	at	 least	6	
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months	and	 full	degradation	should	occur	within	18	months.	The	degradation	of	 the	
scaffold	must	 not	 result	 in	 the	 release	of	 large	pieces	of	 degraded	material	 into	 the	
lumen.	The	stent	must	be	introduced	into	the	vessel	by	balloon	or	self-expansion.	The	
stent	must	not	move	after	deployment	and	be	equipped	with	radiopaque	markers	for	
safe	monitoring	(Venkatraman	et	al.,	2008).		Hence,	many	different	biomaterials	can	act	
as	potential	platforms	 for	biodegradable	coronary	artery	stents.	To	date	polymers	as	
well	as	biodegradable	metals	have	been	considered.	Many	different	polymers	have	been	
investigated,	 such	 as	 poly(L-lactic	 acid)	 (PLLA),	 poly(D,L-lactic	 acid)	 (PDLLA)	 and	
poly(lactic-co-glycolic	acid)	(PLGA).	However,	there	have	been	some	concerns	related	to	
their	immunogenic	response	and	unsuitable	mechanical	properties	(Van	der	Giessen	et	
al.,	 1996).	 Polymers	 are	 pliable	 to	 deformation.	 They	 might	 require	 special	 storage	
conditions,	 like	 for	 example	 very	 low	 temperatures	 in	 order	 to	 avoid	 aging	 of	 the	
material	 (Waksman	and	Pakala,	2010).	Polymers	are	not	radiopaque	in	nature,	which	
requires	 an	 addition	 of	 contrast	 agents	 or	 radiopaque	markers.	 All	 these	 properties	
make	 the	 use	 of	 polymers	 as	 a	 base	material	 for	 coronary	 stent	 a	 very	 challenging	
application	 (Agrawal	 et	 al.,	 1992).	 Many	 studies	 have	 been	 performed	 towards	
overcoming	these	limitations.  
Apart	 from	 polymers,	 some	 metals,	 such	 as	 magnesium	 and	 iron	 are	 also	 being	
considered	for	biodegradable	coronary	stents.	Biodegradable	metals	have	exceeded	the	
mechanical	properties	of	the	polymers	and	can	be	more	comparable	to	stainless	steel	
(SS316L)	used	as	a	standard	material	for	coronary	stent	application	(Balcon	et	al.,	1997).	
The	good	biocompatibility	of	magnesium	makes	 it	a	potential	 target	material	 for	this	
application.	 However,	 it	 is	 very	 unstable	 in	 body	 fluids,	 which	 accelerates	 the	
degradation.	Moreover,	the	degradation	profile	of	neat	magnesium	is	not	suitable	for	
coronary	stents.	It	undergoes	rapid	degradation,	which	results	in	the	loss	of	mechanical	
stability	of	the	scaffold	before	the	end	of	the	arterial	remodelling	process.	Therefore,	
alloys	of	magnesium	with	other	metals,	such	as	aluminium	or	yttrium	with	rare	earth	
elements	have	been	developed	(Waksman	et	al.,	2009).	The	results	of	the	clinical	trials	
demonstrated	 clinical	 safety	 of	 magnesium	 stents.	 Struts	 were	 not	 present	 after	 4	
months.	However,	radial	strength	was	lost	much	earlier	and	was	insufficient	to	prevent	
the	 negative	 remodelling	 associated	 with	 Percutaneous	 Coronary	 Intervention	 (PCI)	
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(Erbel	et	al.,	2002).	High	level	of	restenosis	(around	50%)	was	observed	after	4	months	
due	to	the	lack	of	incorporation	of	any	antiproliferative	drug.	After	1	year,	the	targeted	
revascularisation	 level	was	only	at	45%.	This	 required	 further	 improvements,	 such	as	
increased	degradation	time	and	incorporation	of	drugs.	One	of	the	options	was	to	apply	
a	coating	with	biopolymeric	 layer,	which	would	decrease	the	degradation	rate	of	the	
magnesium	alloys	as	well	as	can	be	a	matrix	for	bioactive	agents,	which	can	prevent	the	
development	of	restenosis.	Such	a	stent,	AMS-3	Mg	alloy,	produced	by	Biotronik,	was	
coated	with	PLGA	containing	paclitaxel.	Animal	studies	demonstrated	presence	of	the	
stent	 after	 4	months.	 Further	 improvement	 was	 obtained	 by	 addition	 of	 rare	 earth	
elements	or	other	metals,	such	as	calcium,	zirconium	and	lithium.	Bioabsorbable	stents,	
containing	magnesium	 and	 zinc	 (Zn),	 calcium	 (Ca),	 yttrium	 (Y)	 and	manganese	 (Mn)	
demonstrated	 improved	 corrosion	 resistance	 in	 simulated	 body	 fluid,	 promising	
degradation	profile	and	high	biological	response			in	animal	models	(Hänzi	et	al.,	2010).		
Iron	 is	 another	 possible	 metal	 considered	 for	 stent	 application,	 due	 to	 its	 good	
mechanical	 properties	 and	 high	 biocompatibility.	 The	 first	 iron-based	 stent	
demonstrated	promising	results	(Peuster	et	al.,	2001).		The	stents	were	able	to	provide	
mechanical	support	during	the	remodelling	process	and	beyond.	High	biocompatibility	
was	maintained.	 The	 degradation	 or	 corrosion	 products	were	 non-toxic	 and	 did	 not	
trigger	any	 inflammatory	response.	However,	the	major	problem	were	ferromagnetic	
properties,	which	interfere	with	magnetic	resonance	imaging	during	stent	deployment	
(Ramadugu	et	al.,	2016)	and	very	slow	degradation	rate	in	the	body,	which	weakened	
the	potential	of	pure	iron	to	become	the	perfect	material	for	biodegradable	coronary	
stent	development	(Peuster	et	al.,	2006).	Therefore,	iron	alloys	have	been	developed	to	
speed	up	the	degradation	rate	and	improve	the	properties	of	the	material.	For	example,	
addition	of	20-35%	of	Mn	within	the	alloy	resulted	in	similar	mechanical	properties	to	
stainless	steel	(Hermawan	et	al.,	2008).	The	in	vitro	degradation	rate	was	2	times	higher,	
but	 still	 insufficient	 to	meet	 the	 requirement	 for	 an	 ideal	material,	 i.e.	 material	 for	
coronary	stent	should	be	stable	for	the	first	6	months	and	completely	degrade	within	
18-24	months.	There	 is	a	 lack	of	 results	 from	 in	vivo	 study	on	this	alloy,	which	could	
confirm	long-term	safety	and	performance	under	physiological	conditions	(Hermawan	
et	 al.,	 2010).	 Another	 approach	 to	 improve	 the	 degradation	 rate	 of	 the	 iron	 was	
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modification	of	the	iron	structure	using	an	electroforming	process.	Obtained	material	
demonstrated	more	minor	microstructure,	which	resulted	in	more	efficient	degradation	
of	 the	material	 (Moravej	et	 al.,	 2010a;	Moravej	et	 al.,	 2010b).	 Although,	 concept	 of	
biodegradable	stent	could	be	an	ideal	solution	for	treatment	of	coronary	artery	disease,	
the	ideal	biomaterial	has	not	been	found	yet.			
1.2.3.1.	Absorb	Bioresorbable	Vascular	Scaffold	(BVS)	
	
Absorb	is	the	first	commercially	available	fully	biodegradable	polymeric	coronary	artery	
stent,	which	has	been	approved	by	the	U.S.	Food	and	Drug	Administration	(FDA)	in	2016.	
It	is	made	from	poly-L-lactic	acid	(PLA)	coated	with	a	layer	of	poly-D,L-lactic	acid	(PDLLA).	
Complete	degradation	of	this	scaffold	occurs	within	three	years	(Okamura	et	al.,	2010).	
The	 clinical	 trial	 data	demonstrated	normal	 functionality	 of	 the	 treated	 vessels	 after	
compete	 stent	 disappearance.	 It	 contains	 100µg/cm2	 of	 everolimus	 to	 prevent	
restenosis.	 The	 coating	 properties	 allow	 80%	 drug	 release	 within	 30	 days	 after	
implantation.	The	strut	 thickness	 is	150µm	(Ormiston	et	al.,	2008).	Polymers	are	not	
radiopaque;	therefore,	platinum	markers	have	been	incorporated	within	the	scaffold	of	
the	Absorb	stent,	which	allows	imaging	and	monitoring	under	X-ray	(Gogas	et	al.,	2012).	
After	 preliminary	 data,	 the	 design	 of	 the	 stent	 was	 changed	 to	 zigzag	 segments	
connected	 with	 bridges,	 to	 achieve	 uniform	 strut	 distribution	 and	 enhanced	 radial	
strength	 and	 support	 to	 the	 vessel	 wall	 (Serruys	 et	 al.,	 2012).	 PLLA	 degrades	 by	
hydrolysis	to	the	corresponding	oligomers,	metabolised	by	the	Krebs	cycle.	Lactic	acid	is	
converted	to	pyruvate	and	transformed	by	decarboxylation	and	oxidation	to	acetyl-CoA,	
which	can	enter	Krebs	cycle	and	be	eliminated	from	the	body.	During	first	three	months	
of	drug	release	after	the	stent	implantation,	revascularisation	takes	place.	Within	this	
time	 frame,	 the	 antiproliferative	 drug	 is	 completely	 released	 and	 radial	 strength	 is	
maintained.	Revascularisation	is	followed	by	the	restoration	phase,	when	hydrolysis	of	
PLLA	occurs	 and	 entire	 stent	 structure	 becomes	unstable.	 Radial	 strength	decreased	
steadily	 and	within	 6	months	 neointima	 covered	 almost	 100%	 of	 the	 struts.	 After	 6	
months	 a	 resorption	 phase	 occurred,	 where	 the	 remaining	 part	 of	 the	 scaffold	 was	
absorbed	 slowly	 (Oberhauser	 et	 al.,	 2009).	 The	 most	 significant	 weight	 loss	 was	
observed	 between	 12	 and	 15	 months	 (Prabhu	 and	 Hossainy,	 2006).	 After	 stent	
degradation,	the	platinum	markers	remained	integrated	in	the	arterial	wall	and	marked	
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the	original	site	of	implantation.	Currently,	Abbott	biodegradable	stent,	known	under	
the	name	Absorb	GT1	BVS	 is	available	 in	100	countries.	 Initial	outcomes	from	clinical	
trials	are	similar	to	the	Abbott	Xience	metallic	drug	eluting	stent.	Possible	side	effects	
can	be	related	to	the	device,	such	as	an	allergic	reaction	to	the	stent	material,	the	drug	
everolimus,	platinum	marker	or	procedure	related	problems,	such	as	internal	bleeding,	
irritation	 or	 infection	 at	 the	 catheter	 site.	 Absorb	 cannot	 be	 used	 for	 patients	 with	
known	allergy	to	PLA	or	platinum	or	those	that	are	not	able	to	take	aspirin	with	other	
antiplatelet	agents	for	an	extended	period	of	time.	There	is	still	lack	of	information	about	
clinical	performance	of	the	device	and	its	long-term	outcomes.	This	along	with	device	
delivery	 issue	 and	high	 cost	 has	 confined	 the	 application	of	Absorb	 in	 the	 European	
market	(Lu	et	al.,	2016).	Absorb	BVS	revision	1.1	is	the	second	version	of	the	Absorb	GT1	
BVS,	FDA	approved.	The	major	improvements	in	this	device	were	related	to	the	scaffold	
design.	The	in-phase	zigzag	segments	linked	by	bridges	replaced	the	out-of-phase	zigzag	
segments	present	in	the	design	of	the	Absorb	GT1	BVS.	This	resulted	in	the	prolonged	
radial	 support	 to	 the	 vessel	walls.	 Although	 second	 generation	 of	 the	 bioresorbable	
stent	 demonstrated	 improvement	 in	 the	 functionality	 in	 the	 body,	 it	 has	 still	 some	
limitations.	The	most	important	drawback	is	related	to	the	rapid	ageing	of	the	material,	
which	requires	storage	at	-20°C	and	the	shelf	life	of	the	device	is	only	3	months.	Also,	
expansion	of	the	stent	beyond	0.5	mm	results	in	strut	fractures.	In	addition,	it	cannot	be	
implanted	to	treat	hard-calcified	lesions.	PLLA	degrades	to	highly	acidic	products,	which	
can	 trigger	 inflammatory	 response	 and	 has	 poor	 surface	 characteristics	 preventing	
complete	endothelialisation.	Surgeons	require	special	training	before	they	are	able	to	
carry	 out	 the	 stent	 deployment	 procedure.	 Additionally,	 Absorb	 stent	 is	much	more	
expensive	in	comparison	to	commonly	used	bare	metallic	stents	(Gogas	et	al.,	2014).	
1.3. Drugs	used	in	drug	eluting	stents	
Drug	 eluting	 stents	 were	 designed	 to	 prevent	 restenosis,	 the	 most	 common	
complication	after	balloon	angioplasty.	Considering	the	mechanism	of	the	development	
of	 restenosis,	 a	 few	 classes	 of	 drugs	 were	 proposed.	 Those	 included:	
immunosuppressive,	anti-inflammatory,	antithrombogenic	and	anti-proliferative	drugs.	
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Additionally,	some	research	groups	are	focused	on	the	addition	of	antibodies,	such	as	
anti-CD34	or	antiplatelet	GPIIb/IIIa	as	bioactive	compounds	(Deconinck	et	al.,	2008).	
1.3.1. Rapamycin	and	its	analogues	
	
Rapamycin,	also	known	as	sirolimus	belongs	to	the	group	of	natural	macrolides,	which	
demonstrates	 immunosuppressive	properties	 (Figure	2).	 It	was	 isolated	 in	1975	 from	
Streptomyces	hygroscopicus.	Rapamycin	obtained	FDA	approval	in	1999	for	application	
to	 prevent	 renal	 transplant	 rejection.	 Few	 other	 analogues	 of	 rapamycin	 have	 been	
developed,	 such	 as	 everolimus,	 biolimus-A9	 and	 temrapamycin	 (Costa	 and	 Simon,	
2005).		
	
Figure	2:	Chemical	structure	of	rapamycin	(Pan	et	al.,	2009).	
Rapamycin	has	a	form	of	pro-drug,	which	can	bind	to	specific	proteins,	such	as	12kDa	
FK506	binding	protein	(known	as	FKBP-12),	present	in	the	cytoplasmic	matrix	(Li	et	al.,	
2014).	Rapamycin	is	a	hydrophobic	drug	with	low	solubility	in	aqueous	solutions.	It	has	
lipophilic	properties	and	hence	can	pass	through	cell	membranes.		
Rapamycin	inhibits	DNA	synthesis,	by	binding	to	the	receptor	cytosolic	FK-506	binding	
protein-12	 (FKBP12).	 This	 is	 12kDa	 in	 size,	 which	 catalyses	 peptidyl-prolyl	 cis-trans	
isomerization.	 FKBP12	 protein	 is	 upregulated	 in	 neointimal	 smooth	 muscle	 cells	
(Sabatini	et	al.,	1994).	A	complex	of	FKBP12	and	rapamycin	attaches	to	the	mechanistic	
target	 of	 rapamycin	 (mTOR)	 and	 inhibits	 its	 activation.	 mTOR	 is	 a	 serine-threonine	
kinase,	 a	 protein	 that	 regulates	 cell	 growth	 and	 proliferation,	 protein	 synthesis	 and	
transcription	in	the	cell	cycle.	Binding	of	rapamycin	to	mTOR	is	controlled	by	a	raptor,	
which	is	a	regulatory	protein	associated	with	TOR	(Schmelzle	and	Hall,	2000).	The	actual	
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mechanism	of	the	inhibiting	effect	of	rapamycin	on	mTOR	at	the	molecular	level	is	not	
yet	fully	understood.	The	mTOR	participates	in	the	transition	between,	G1	and	S	phase,	
connected	with	DNA	replication.	It	has	been	observed	that	rapamycin	arrests	the	cell	
cycle	towards	the	G1	phase	(Braun-Dullaeus	et	al.,	1999).		
During	in	vitro	study,	it	was	found	that	rapamycin	at	a	concentration	1	ng/mL,	inhibited	
DNA	synthesis	and	cell	growth	(Marx	et	al.,	1995).	In	porcine	animal	model	rapamycin	
stopped	 restenosis	 in	 coronary	 arteries	 after	 angioplasty.	 Hence,	 application	 of	
Rapamycin	resulted	in	a	meaningful	reduction	in	coronary	stenosis	(Gallo	et	al.,	1999).	
Metallic	 stents	 coated	 with	 the	 nonerodable	 polymeric	 matrix	 with	 incorporated	
rapamycin	were	investigated	in	vivo.	It	was	found	that	a	high	dose	of	rapamycin	reduced	
neointimal	formation	by	45%	in	comparison	to	the	control	after	28	days	(Klugherz	et	al.,	
2000).	Another	study	was	performed	on	the	porcine	model	with	stainless	steel	stents	
coated	with	a	polymeric	layer	containing	rapamycin.	The	results	obtained	demonstrated	
30%	reduction	of	late	in-stent	restenosis	in	comparison	to	the	uncoated	stent	(Carter	et	
al.,	 2006).	 	 It	was	 reported	 that	 long-term	 systemic	 treatment	with	 rapamycin	 after	
kidney	transplantation	may	give	serious	adverse	effects,	such	as	hypercholesterolemia	
and	 hypertriglyceridemia	 (Morrisett	 et	 al.,	 2002;	 Brattstrom	 et	 al.,	 1998).	 Different	
animals	react	differently	after	systemic	treatment	with	rapamycin	(Collier	et	al.,	1990).	
However,	none	of	the	side	effects	listed	above	were	observed	after	stent	implantation	
(Oberhoff	et	al.,	2002).		
Zotarolimus	 and	 everolimus	 are	 analogues	 of	 rapamycin.	 They	 demonstrated	 similar	
therapeutic	activity	 like	rapamycin.	Rapamycin	analogues	were	developed	in	order	to	
improve	the	hydrophilic	properties	of	the	drug,	which	allows	oral	and	intravenous	drug	
administration.	 They	 bind	 to	 cytosolic	 FK-506	 binding	 protein-12	 and	 inhibit	 the	
proliferation	 of	 smooth	 muscle	 cells	 and	 T-cells	 (Kar	 et	 al.,	 2003).	 Three	 different	
zotarolimus	eluting	 stents	were	 studied	during	clinical	 trials:	Prefer	 stent,	Endeavour	
stent	 and	 zotarolimus-eluting	 stent,	 named	 ZoMaxxTM.	 They	 were	 compared	 with	
CypherTM	stent	 loaded	with	 rapamycin.	The	 results	were	satisfactory	 (Serruys	et	al.,	
2006).	No	significant	differences	were	observed	in	comparison	to	the	CypherTM	stent	
(Kandzari	and	Leon,	2006).	Also,	several	everolimus	stents	were	studied.	The	bioactive	
agent	was	incorporated	within	Polylactic	acid,	PLA	and	added	as	an	outside	monolayer	
on	the	metallic	stent.	The	results	suggested	that	the	stents	containing	everolimus	were	
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more	efficient	 in	the	prevention	of	restenosis	than	bare	metallic	stents	(Grube	et	al.,	
2004).	 Overall,	 rapamycin	 as	 well	 as	 its	 analogues	 efficiently	 reduced	 the	 risk	 of	
development	of	in-stent	restenosis	(Silber,	2005).		
1.3.2. Paclitaxel	
	
Paclitaxel,	also	known	as	Taxol	was	isolated	in	1971	from	the	yew	tree,	Taxus	brivifola	
(Wani	et	al.,	1971).	It	belongs	to	the	group	of	diterpenoids,	containing	a	complex	taxane	
ring	in	the	centre.	The	side	chain	bonded	to	the	taxane	ring	at	carbon	number	13	and	is	
essential	for	its	antitumor	activity	(Figure	3).	Modification	of	the	side	chain	(Figure	3)	
has	 resulted	 in	 the	 development	 of	 the	 paclitaxel	 analogue,	 named	 docetaxel.	 The	
modifications	include	presence	of	the	hydroxyl	group	on	carbon	number	10	and	tert-
butyl	 carbamate	 ester	 on	 the	 side	 chain	 in	 comparison	 to	 the	 acetate	 group	 and	
benzamide	present	in	the	paclitaxel	(Żwawiak	and	Zaprutko,	2014).	
	
Figure	3:	Chemical	structure	of	paclitaxel	(Ringel	and	Horwitz,	1991).	
Currently,	 paclitaxel	 can	 be	 obtained	 by	 a	 semi	 synthetic	 process	 using		
10-desacetylbaccatin,	which	is	a	precursor	found	in	yew	leaves	(Nicolaou	et	al.,	1994).	
One	of	the	drawbacks	of	this	drug	is	its	limited	solubility.	Therefore,	it	has	to	be	delivered	
using	a	mixture	of	ethanol	and	polyethoxylated	castor,	 in	ratio	1:1,	which	may	cause	
reactions	of	hypersensitivity.	Paclitaxel	as	well	as	its	analogues	act	as	mitotic	inhibitors.	
These	drugs	are	mainly	used	in	the	treatment	of	ovarian,	breast,	 lung,	head,	bladder,	
neck	 and	 eosophageal	 cancer	 (Seidman,	 1998).	 Paclitaxel	 is	 one	 of	 the	 cytoskeletal	
drugs,	which	specifically	binds	to	the	β-tubulin	subunit	in	the	microtubules.	This	results	
in	accelerated	accumulation	of	the	microtubules	and	its	derivatives	in	the	mitotic	phase	
CHAPTER	1	
	
	 15	
of	the	cell	cycle.	This	can	either	trigger	cell	apoptosis	or	a	return	to	the	G	phase	without	
cell	division	(Rowinsky	and	Donehower,	1995).	Paclitaxel	is	thus	able	to	disrupt	cellular	
proliferation	and	migration.	Additionally,	it	has	immunomodulatory	properties,	due	to	
its	capacity	to	induce	IL-12	production,	which	supports	immune	dysfunctions	caused	by	
the	 tumour	 (Farb,	 2001).	 Animal	 models	 have	 demonstrated	 that	 paclitaxel	 at	 a	
concentration	200µg	per	stent	reduced	neointimal	and	endothelial	cell	proliferation	up	
to	180	days.	However,	the	arteries	showed	incomplete	healing	(Drachman	et	al.,	2000).	
Another	 clinical	 trial,	 investigated	 polymer-free	 stainless	 steel	 stents,	 containing	 2-3	
µg/mm2	 of	 paclitaxel,	 adhered	 to	 the	 stent	 surface	 and	 demonstrated	 ordinary	
antirestenosis	effect	(Gershlick	et	al.,	2004).		
1.3.3. Tacrolimus	
	
Tacrolimus	 (FK506)	 (Figure	4)	belongs	to	 the	group	of	macrolide	 lactones,	which	was	
isolated	 from	 the	 bacterial	 strain	 Streptomyces	 tsukubaesis	 (Tanaka	 and	Marusawa,	
1987).	It	was	applied	as	an	immunosuppressive	agent	after	solid	organ	transplantation,	
for	example	heart,	pancreas,	lung,	liver,	kidney	(Plosker	and	Foster,	2000).	Tacrolimus	
belongs	 to	 the	 group	 of	 calcineurin	 inhibitors	 and	 can	 be	 used	 in	 the	 treatment	 of	
autoimmune	 diseases,	 such	 as	 autoimmune	 chronic	 active	 hepatitis,	 inflammatory	
bowel	 disease,	 nephrotic	 syndrome,	 Crohn’s	 disease,	 autoimmune	 inner	 ear	 disease	
(Sadaba	et	al.,	2004;	Shapiro	et	al.,	1999;	Singer,	1998;	Van	Thiel	et	al.,	1995).		
1 	
Figure	4:	Chemical	structure	of	tacrolimus	(Tanaka	et	al.,	1987).	
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The	 half-life	 of	 tacrolimus	 inside	 the	 human	 body	 is	 from	 8.7	 to	 11.3	 hours	
(Venkataramanan	et	al.,	1995).	Tacrolimus	can	cause	several	adverse	effects,	including:	
neurotoxicity,	 nephrotoxicity,	 gastrointestinal	 toxicity,	 hyperkalaemia,	 hypertension,	
and	myocardial	hypertrophy	(Morales	et	al.,	2001;	Nakata	et	al.,	2000).	The	mechanism	
of	action	of	tacrolimus	is	similar	to	zotarolimus	and	everolimus,	which	include	inhibition	
of	 calcineurin,	 calcium	and	calmodulin-dependent	phosphatase	activity	by	binding	 to	
calcium,	 calmodulin,	 and	 calcineurin	 through	 the	 immunophilin	 FK506	 protein	 12.	
Immunophilins	 are	 involved	 in	 the	 protein	 folding	 process.	 Formation	 of	 drug-
immunophilin	complex	results	in	arrested	transfer	of	activated											T-cells	transcription	
factor.	This	encourages	 the	proliferation	of	helper	T-cells,	mediated	by	 interleukin-2,	
which	is	connected	to	the	immune	response	associated	with	allograft	rejection	(Spencer	
et	al.,	1997).	Tacrolimus	can	be	metabolised	either	by	the	liver	or	intestinal	microsomes	
(Lampen	 et	 al.,	 1995).	 The	 solubility	 of	 tacrolimus	 is	 within	 the	 range	 4-12	 μg/mL.	
However,	 it	 is	 highly	 soluble	 in	 organic	 solvents,	 such	 as	 ethanol,	 methanol	 and	
chloroform	(Tamura	et	al.,	2003).	Bioavailability	of	tacrolimus	may	vary	from	5%	to	93%	
(Wallemacq	et	al.,	1998).	Around	95%	of	tacrolimus	is	eliminated	from	the	body	by	the	
biliary	route	(Moller	et	al.,	1999).	Tacrolimus	has	also	been	used	in	drug	eluting	stents.	
Recently,	a	stent	named	Janus,	which	has	tacrolimus	within	the	carbofilm,	a	polymer-
free	monolayer,	was	demonstrated	to	be	safe	for	use	by	patients	(Garcia-Tejada	et	al.,	
2007).		
	
1.3.4. Dexamethasone	
	
Dexamethasone	(Figure	5)	belongs	to	the	group	of	corticosteroid	medication,	used	in	
the	treatment	of	various	inflammatory	diseases.		It	is	a	very	strong	anti-inflammatory	
and	immunosuppressive	drug,	able	to	inhibit	proliferation	of	fibroblasts,	smooth	muscle	
cells	and	macrophages	(Zhou	et	al.,	2005).	Therefore,	it	was	considered	as	a	bioactive	
agent	for	application	in	drug-eluting	stents.		
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Figure	5:	Chemical	structure	of	dexamethasone	(Elks	and	Ganellin,	2014).	
Several	 studies	have	been	performed	to	 investigate	possible	application	of	 this	drug.	
Han	and	 co-workers	 studied	BiodivYsio	Matrix	 LO	 stent	with	a	high	 concentration	of	
dexamethasone.	The	results	were	very	encouraging.	These	stents	reduced	the	amount	
of	major	 cardiac	events	and	 in-stent	 restenosis	 after	6	months	 in	 comparison	 to	 the	
control	 stents	 (Han	et	 al.,	 2006).	 Another	 research	 group	 investigated	 stents	 named	
Dexamet	during	clinical	trials.	It	was	observed	that	stents	coated	with	dexamethasone	
resulted	in	substantially	less	lumen	loss	compared	to	BMS	(Konig	et	al.,	2007).	Although,	
the	initial	results	obtained	in	animal	models	were	very	promising,	the	data	from	clinical	
trials	 have	 been	 contentious	 (Hämäläinen	 et	 al.,	 2013).	 Therefore,	 an	 idea	 of	
incorporating	both	drugs,	such	as	rapamycin	and	dexamethasone	has	appeared	(van	der	
Hoeven	et	al.,	2008).	However,	further	studies	are	required	to	achieve	a	final	conclusion.	
1.3.5. Antibodies	
	
Antibodies	have	been	considered	as	bioactive	agents	for	coronary	stents.	The	main	role	
of	 antibodies	 is	 this	 device	 was	 to	 stimulate	 cell	 growth	 in	 the	 vessel	 wall.	 Faster	
endothelialisation	will	result	in	the	faster	integration	of	stents	in	the	arterial	wall,	which	
will	 reduce	 the	 risk	 of	 thrombosis.	 Application	 of	 stents	with	 antibodies	 should	 also	
reduce	the	time	required	for	 the	antithrombogenic	drug	therapy.	Guowei	Fu	and	co-
workers	developed	an	efficient	method	for	direct	attachment	of	anti-CD34	antibodies	
into	a	nanoporous	stainless	steel	stent.	The	developed	device	demonstrated	enhanced	
endothelialisation	in	both:	in	vitro	as	well	as	in	vivo	studies	(Guowei	Fu	et	al.,	2016).	In	
another	study,	Aggarwal	and	co-workers	studied	antiplatelet	GPIIb/IIIa	antibody	eluting	
cellulose	coated	stainless	steel	stent	in	an	animal	model.	This	study	demonstrated,	that	
incorporation	 of	 antibodies	 significantly	 reduced	 platelet	 accumulation	 in	 the	 stent	
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neighbourhood.	 However,	 the	 effects	 were	 temporary	 and	were	 determined	 by	 the	
presence	 of	 antibodies.	 After	 complete	 release	 of	 all	 antibodies,	 the	 stent	 lost	 its	
antithrombogenic	 effect.	 Therefore,	 other	 solutions	 need	 to	 be	 considered,	 such	 as	
incorporation	of	 antithrombogenic	 agents,	 such	as	heparin,	 hirudin	 and	glycoprotein	
IIb/IIIB	(Aggarwal	et	al.,	1996).		
1.4. Biopolymers	used	as	a	drug	carriers	in	the	prevention	of	restenosis	
Polymers	 are	 used	 as	 drug	 carriers	 for	 drug	 delivery	 applications.	 Homopolymers,	
copolymers,	blends	of	polymers	and	composites	have	been	 investigated.	Most	of	the	
work	has	been	carried	out	using	biodegradable	materials	(Ranade	and	Hollinger,	1996).	
The	main	goal	for	any	drug	eluting	device	id	to	deliver	bioactive	agent	at	the	right	time,	
to	 the	 appropriate	 location	 in	 sufficient	 concentration	 over	 designed	 period	 of	 time	
(Raval	et	al.,	2010).		Controlled	drug	release	is	expected	from	drug	eluting	stents	in	order	
to	prevent	restenosis	without	any	toxic	effect	(Wise,	2000).	Controlled	drug	release	can	
be	 achieved	 by	 few	mechanisms,	 such	 as:	 diffusion,	 degradation	 by	 surface	 or	 bulk-
erosion	 or	 an	 active	 efflux.	 The	 main	 drug	 release	 mechanism	 in	 DES	 is	 based	 on	
diffusion,	either	directly	from	polymeric	matrix	or	from	reservoir	systems,	where	drug	is	
encapsulated	 inside	 polymeric	 structure	 and	 release	 by	 diffusion	 through	 polymeric	
membrane	(Kamath	et	al.,	2006).		Polylactic	acid,	polyglycolic	acid	and	their	copolymers	
have	been	used	in	different	drug	delivery	devices	due	to	their	high	biocompatibility	and	
appropriate	degradation	profiles	for	this	application.	Drug	release	depends	on	several	
factors,	such	as	nature	of	the	drug,	polymer	degradation	rate,	water	permeability	and	
interactions	between	drug	and	polymer	surface	(Lao	et	al.,	2008).	Several	biomaterials	
and	 different	 drugs	 were	 studied	 in	 order	 to	 reduce	 or	 inhibit	 the	 development	 of	
restenosis.	PLGA	was	the	most	commonly	used	material.	Release	of	the	drugs	occurred	
by	controlled	biological	degradation	or	diffusion	(Schliecke	and	Schmidt,	2003).	Wang	
and	co-workers	studied	multilayer	stents	where	each	 layer	was	made	using	different	
materials,	 in	 order	 to	 allow	 controlled	 release	 of	 rapamycin.	 PLLA	 was	 used	 as	 the	
platform	material,	 as	 the	 core	 of	 the	 stent.	Whereas	 PLGA	was	 the	matrix	 for	 drug	
incorporation.	 Cho	 and	 co-workers	 studied	 poly(lactide-co-caprolactone)	 films	 with	
incorporated	epigallocatechin-3-O-gallate	(EGCG),	which	was	discovered	in	green	tea.	
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This	substance	has	antithrombotic,	anti-inflammatory	and	antiproliferative	properties.	
It	was	found,	that	EGCG	release	took	place	via	diffusion.	This	resulted	in	the	inhibition	
of	smooth	muscle	cells	(SMC)	migration,	suppression	of	platelet	activation	and	adhesion	
(Cho	et	al.,	2008).	In	another	study,	rapamycin-eluting	stainless	steel	stent	was	coated	
with	 two	 layers	 containing	 three	 polymeric	 biomaterials,	 such	 as:	 PLLA,	 PLGA	 and	
poly(vinylpyrrolidone)	 (PVP)	 with	 incorporated	 drug.	 Half	 amount	 of	 the	 drug	 was	
released	by	day	7,	and	complete	 release	occurred	within	48	days	 (Dani	et	al.,	2008).	
Sousa	and	co-workers	(2003)	reported	significant	reduction	in-stent	restenosis	in	DES	in	
comparison	to	bare	metallic	stents	by	introduction	of	rapamycin	or	paclitaxcel	within	
polymeric	coating	(Sousa	et	al.,	2003).	
The	fabrication	of	drug	eluting	stents	can	be	a	challenge.	The	currently	used	methods,	
such	 as	dip	 coating	 and	 spray	 coating	 are	more	 suitable	 for	 hydrophobic	drugs	 than	
water-soluble	 drugs	 or	 deoxyribonucleic	 acid.	 It	 was	 found,	 that	 stents	 coated	 with	
oligonucleotides	 in	 water	 soluble	 polymer	 demonstrated	 limited	 delivery	 efficiency,	
which	 had	 negative	 impact	 on	 the	 therapeutic	 effect	 of	 the	 device.	 Therefore,	
nanoparticle-eluting	 stents	 were	 produced	 by	 cationic	 electrodeposition	 coating	
technology	to	overcome	this	limitation	(Nakano	et	al.,	2009).		PLGA	in	general	has	been	
a	 preferred	 material	 used	 in	 drug	 delivery	 related	 to	 prevention	 of	 restenosis.	
Additionally,	targeting	molecules	can	be	attached	to	the	surface	of	the	polymer,	which	
can	be	recognised	by	vectors	allowing	travel	to	the	target	tissue.	Chorny	and	co-workers	
developed	magnetic	 nanoparticles	made	 from	 PLA	with	 incorporated	 paclitaxel.	 The	
results	were	up	to	10	times	more	successful	than	the	non-magnetic	system	in	smooth	
muscle	cells	 (Chorny	et	al.,	2010).	Another	researcher,	Luderer	and	co-workers,	2011	
synthesised	 PLA	 nanoparticles	 loaded	 with	 rapamycin	 for	 controlled	 drug	 delivery.	
However,	produced	nanoparticles	inhibited	viability	and	proliferation	of	endothelial	as	
well	as	smooth	muscle	cells	(Luderer	et	al.,	2011).		
	
	
	
	
	
CHAPTER	1	
	
	 20	
1.5. Limitations	of	currently	available	stents		
Currently,	 three	types	of	stents,	such	as	bare	metallic	stents,	drug	eluting	stents	and	
biodegradable	stents	have	been	used	to	treat	coronary	artery	disease.	However,	each	
type	of	 these	devices	has	some	 limitations.	For	example,	application	of	bare	metallic	
stents	 results	 still	 with	 high	 rate	 of	 restenosis.	 Moreover,	 BMS	 remain	 in	 the	 body	
permanently	 and	 can	 lead	 to	 complications,	 mainly,	 inflammation	 and	 in-stent	
restenosis	(Serruys	et	al.,	199).	Hypersensitivity	reaction	to	nickel	and	molybdenum	was	
reported	in	10%	of	patients	after	BMS	implantation	(Koster	et	al.,	2000).	Drug	eluting	
stents	 were	 developed	 to	 resolve	 some	 issues	 related	 to	 BMS,	 like	 for	 example	
restenosis.	However,	deployment	of	DES	resulted	in	appearance	of	another	side	effect,	
named	 as	 late	 thrombosis,	 which	 will	 be	 described	 in	 section	 1.5.2.	 Moreover,	
deployment	 of	 DES	 lead	 to	 delayed	 endothelialisation,	 caused	 by	 release	 of	 anti-
proliferative	agents.	Endothelial	cells	are	able	to	covered	bare	metallic	stents	within	6-
7	months,	whereas	DES	achieve	50%	endothelialisation	after	3	years	(Joner	et	al.,	2006).	
Drug	 eluting	 stents	 are	 usually	 made	 from	 metals,	 hence	 remain	 in	 the	 body	
permanently	 and	 can	 lead	 to	 similar	 side	 effects	 as	 BMS	 (Sun	 et	 al.,	 2013).	 Also	
hypersensitivity	 reaction	 towards	 polymeric	 coatings	 have	 been	 reported	 in	 patients	
after	DES	deployment	(Jeewandara	et	al.,	2014).	Biodegradable	stents	were	developed	
in	order	to	overcome	the	limitations	of	previously	described	stents.	However,	the	results	
are	 still	 not	 satisfactory.	 Although,	 magnesium	 and	 iron	 have	 been	 considered	 as	
biodegradable	 metals	 for	 stents,	 due	 to	 their	 high	 biocompatibility,	 they	 represent	
degradation	profile,	unsuitable	for	this	application.	Magnesium	degrades	too	fast,	hence	
cannot	 support	 the	 vessel	 wall	 for	 required	 period	 of	 time	 (Erbel	 et	 al.,	 2007).	
Degradation	rate	of	an	iron	stent	is	very	slow;	hence	it	acts	similarly	to	the	commonly	
use	bare	metallic	 stents	 (Peuster	et	al.,	 2006).	Biodegradable	polymers	on	 the	other	
hand,	 have	weaker	mechanical	 properties	 in	 comparison	 to	metals.	 Therefore,	 stent	
thickness	has	to	be	much	greater	than	metallic	stents	and	cannot	be	used	in	small	blood	
vessels.	 Moreover,	 recoil	 after	 expansion	 have	 been	 observed.	 Polymers	 cannot	 be	
visible	under	X-Ray,	which	 is	additional	 limitation	of	 this	materials	 (Ramadugu	et	al.,	
2016).	 Limitations	 associated	 with	 biodegradable	 PLLA	 polymeric	 stent	 have	 been	
described	previously	in	section	1.2.3.1.	
CHAPTER	1	
	
	 21	
The	major	function	of	stent	 is	to	support	vessel	wall	and	prevent	elastic	recoil	of	the	
coronary	 artery.	 The	 reaction	 between	 the	 stent	 and	 the	 vessel	 wall	 has	 been	
extensively	 studied	 in	 animal	models	 (Ashby	et	 al.,	 2002).	 It	was	 found	 that	 porcine	
coronary	arteries	reacted	similarly	to	injury	as	the	human	vessels.	Balloon	angioplasty	
alone	as	well	as	the	stent	deployment	causes	serious	mechanical	 injury	to	the	vessel	
wall.	This	leads	to	thick	neointima	formation	within	20-24	days.	The	thickness	is	related	
to	the	deepness	of	the	injury	(Schwartz,	1992).		
Stent	 implantation	 is	usually	accompanied	by	side	effects	such	as	thrombosis	and	 in-
stent	restenosis.	The	risk	of	stent	thrombosis	is	the	highest	in	the	first	month	after	stent	
implantation	and	in	70%	cases	leads	to	myocardial	infarction	or	sudden	death.	Unlike	
thrombosis,	 in-stent	 restenosis	 usually	 occurs	 between	 6-12	 months	 of	 stent	
implantation	(Wilson	and	Cruden,	2013).	In-stent	restenosis	is	defined	as	the	narrowing	
or	lumen	loss	of	over	50%	following	stent	deployment.	In-stent	restenosis	is	primarily	
induced	by	neointimal	proliferation;	however,	 there	are	a	number	of	 known	 factors,	
which	may	affect	the	appearance	of	in-stent	restenosis,	such	as	diabetes	mellitus,	lesion	
length,	number	of	stents,	 stent	design	and	the	 lumen	diameter	 (Hoffman	and	Mintz,	
2000).	Around	20%	of	patients	with	BMS	require	a	second	intervention	within	the	first	
12	months	after	stent	deployment	because	of	the	reduction	of	the	lumen	size	caused	by	
the	development	of	in	stent-restenosis	(Fischman	et	al.,	1994). 
1.5.1. In-stent	restenosis	
	
As	mentioned	above,	balloon	angioplasty,	followed	by	stent	implantation	causes	injury	
to	the	vessel	wall.	An	artery	is	a	multilayer	structure,	which	contains	three	major	layers	
(Figure	6).	Tunica	externa,	named	also	adventitia	is	the	most	external	layer	of	the	artery	
wall,	which	connects	 the	vessel	 to	 the	surrounding	 tissues.	This	 layer	contains	highly	
dense	 connective	 tissue	 with	 elastin	 and	 collagenous	 fibres.	 Tunica	media	 is	 placed	
under	the	adventitia;	it	is	the	thickest	layer,	built	mainly	from	smooth	muscle	cells.	This	
layer	plays	a	very	important	role,	which	is	to	support	the	vessel	wall	and	regulation	of	
blood	flow	and	pressure.	Tunica	intima,	called	interna	is	the	inner	most	layer,	containing	
simple	 squamous	 epithelium	 surrounded	 by	 connective	 tissue	 with	 elastic	 fibres	
(Birkenhauer	et	al.,	2004).		
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Figure	6:	Schematic	of	the	arterial	wall.	(Source:	SEER	Training	Modules,	Module	Name.	
U.	S.	National	Institutes	of	Health,	National	Cancer	Institute.	Day	of	access:	02/02/2017;	
https://training.seer.cancer.gov/).	
The	changes	within	the	arterial	environment	that	occur	right	after	stent	deployment,	
might	 lead	 to	 in-stent	 restenosis.	 Restenosis	 is	 developed	 as	 an	 effect	 of	 a	 healing	
process	of	the	arterial	wall	caused	by	mechanical	injury	during	balloon	angioplasty	and	
stent	 implantation.	 It	 involves	two	main	processes,	neointimal	hyperplasia	and	vessel	
remodelling	 (Forrester	 et	 al.,	 1991).	 	 The	 mechanism	 of	 in-stent	 restenosis	 at	 the	
molecular	 level,	occurring	after	stent	deployment,	was	proposed	by	Welt	and	Rogers	
(2005).	Figure	7	demonstrates	various	phases,	which	happens	after	stent	implantation	
until	the	formation	of	a	restenosis	lesion.	At	the	beginning,	stent	deployment	results	in	
the	 denudation	 of	 the	 most	 internal	 layer,	 named	 endothelium.	 In	 addition,	 the	
compression	of	 the	plaque	can	cause	delamination	within	 inner	 layers	of	 the	arterial	
wall,	such	as	tunica	media	or	even	externa.	The	whole	artery	is	stretched.	Fibrins	along	
with	platelets	are	embedded	directly	at	the	wounded	site.		The	platelets	get	activated	
and	 express	 P-selectin,	 an	 adhesive	 molecule,	 which	 recruits	 the	 leucocytes.	 The	
leukocytes	 bind	 closely	 across	 adhesive	 molecules	 by	 direct	 attachment	 to	 platelet	
receptors	 or	 through	 cross-linking	with	 fibrinogen.	 In	 the	 next	 stage,	 the	 leucocytes	
migrate	through	the	layer	of	platelets	and	fibrin	as	well	as	tissues.	This	is	mediated	by	
chemokines,	 such	 as	 interleukin	 6	 (IL-6),	 interleukin	 8	 (IL-8)	 or	 monocyte	
chemoattractant	protein	(MCP)-1,	released	by	smooth	muscle	cells	(SMCs),	present	in	
the	arterial	wall	and	resident	macrophages.	The	next	step	is	referred	to	as	the	“cellular	
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proliferation	phase”.	Prolonged	release	of	growth	factors	by	platelets;	leukocytes	and	
SMCs	stimulate	migration	of	smooth	muscle	cells	into	the	neointima.	The	newly-created	
neointima	contains	SMC,	extracellular	matrix	and	macrophages	enrolled	within	a	few	
weeks.	Cell	proliferation,	observed	in	this	phase,	plays	a	crucial	role	in	further	restenosis	
development.	 After	 several	 weeks,	 the	 last	 phase	 of	 remodelling	 occurs.	 The	 main	
change	 observed	 during	 this	 period	 is	 a	 higher	 production	 of	 extracellular	 matrix,	
composed	of	various	types	of	collagens	and	proteoglycans,	which	are	the	key	elements	
of	the	fully	formed	restenosis	plaque	(Welt	and	Rogers,	2002).		
Rapamycin,	an	 immunosuppressive	drug	has	been	proven	to	 inhibit	all	phases	of	 the	
restenosis	cascade.	 It	has	been	reported	to	 inhibit	synthesis	of	collagen	and	proteins	
participating	in	an	extracellular	matrix	formation.	Moreover,	it	inhibits	smooth	muscle	
cells	migration.	Rapamycin	is	effective	within	the	wide	range	of	18-1200	µg	per	18mm	
stent	 length	 in	 animal	models.	 The	 current	 dose	 applied	on	 the	 stent	 is	 140	µg/cm2	
(Costa	and	Simon,	2005).		
However,	to	date	there	is	only	one	successful	method	of	treatment	for	restenosis,	called	
vascular	brachytherapy.	This	method	is	based	on	local	delivery	of	either	beta	or	gamma	
radiation,	delivered	by	specially	designed	catheter	to	prevent	neointima	tissue	growth.	
Brachytherapy	 has	 been	 approved	 by	US	 FDA	 as	 a	 technique	 safe	 to	 be	 use	 for	 the	
treatment	of	 the	 in-stent	 restenosis.	 The	drawback	of	 this	method	 is	 that	 the	 target	
vessel	revascularization	rate	is	only	20%	(Waksman,	2000).	There	is	therefore	a	real	need	
for	an	efficient	therapy	for	the	prevention	of	in-stent	restenosis.		
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Figure	7:	Schematic	of	the	restenosis	cascade	lesion	development.	A-	vessel	structure	
before	 intervention,	 B	 –	 changes	 in	 the	 artery	 environment	 immediately	 after	 stent	
implantation,	 C,	 D-	 leukocyte	 recruitment	 and	 infiltration	 associated	 with	 constant	
release	of	cytokines,	E	–	neointimal	thickening	and	smooth	muscle	cells	proliferation,	F	
–	restenosis	lesion	formed	(Taken	from:	Welt	and	Rogers,	2002).	
1.5.2. Late	stent	thrombosis	
	
Depending	on	the	time	after	the	stenting	procedure	thrombosis	can	be	divided	in	to	two	
types:	early	thrombosis,	which	occurs	within	the	first	30	days	after	the	procedure,	which	
usually	is	related	to	the	procedural	factors,	such	as	incomplete	stent	expansion,	plaque	
detachment	 from	 residual	 lesion,	 internal	 fractures.	 The	 second	 type,	 called	 late	
thrombosis	appears	between	1	to	12	months	after	stent	deployment.	This	type	is	related	
to	 the	delayed	healing	process	of	 the	arterial	wall	 (Figure	8)	 (Joner	et	al.,	 2006)	and	
usually	results	in	myocardial	infarction	or	death	(Camenzind	et	al.,	2007).	Sometimes,	
thrombosis	in	drug	eluting	stents	occurs	after	a	year.	This	is	very	late	thrombosis,	which	
is	related	to	abnormal	response	of	the	vessel	wall	to	the	implant,	which	can	be	caused	
by	 a	 hypersensitive	 reaction.	 	 The	 new	 phenomenon,	 called	 “neoartheriosclerosis”,	
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which	is	neointima	with	atherosclerotic	occurrence,	seems	to	have	a	crucial	role	in	the	
development	of	very	late	thrombosis	(Komiyama	et	al.,	2015).	
	
Figure	 8:	Mechanism	of	 the	development	 of	 the	 late	 thrombosis	 in	 the	drug	 eluting	
stents	in	correlation	to	time	after	stent	deployment	(Nakazawa,	2011).	
The	 molecular	 basis	 of	 the	 mechanism	 of	 late	 in-stent	 thrombosis	 is	 still	 unknown	
(Fischman	et	al.,	1994;	Serruys	et	al.,	1994).	There	is	a	hypothesis,	that	several	factors,	
such	an	insufficient	expansion	of	the	stent,	fracture	of	the	polymer	stent,	inflammation	
triggered	by	metal	or	polymer	and	delayed	healing	might	 induce	platelet	aggregation	
and	 fibrin	 deposition	 in	 the	 drug	 eluting	 stent,	 delayed	 arterial	 healing	 caused	 by	
incomplete	reendothelialization	and	persistence	of	fibrin	was	observed	in	the	patients	
who	died	due	to	late	thrombosis,	(Morice	et	al.,	2002).		Some	procedure	related	factors,	
such	 as:	 smaller	 final	 lumen	 dimensions,	 caused	 by	 stent	 underexpansion	 or	
malapposition,	stent	length,	persistent	slow	coronary	blood	flow,	placement	of	multiple	
stents,	 positive	 remodelling	 play	 a	 significant	 role	 in	 late-thrombosis	 development	
(Kereiakes	 et	 al.,	 2000).	 There	 are	 also	 patient-related	 factors,	 like	 advanced	 age,	
diabetes,	renal	failure	and	stenting	 in	acute	myocardial	 infarction,	correlated	with	an	
increased	risk	of	stent	thrombosis	(Park	et	al.,	2006;	Ong	et	al.,	2005).		The	thickness	of	
polymer	struts	as	well	as	the	type	of	the	polymeric	material	also	play	an	important	role	
(Nakazawa	 et	 al.,	 2011).	 Moreover,	 drugs	 used	 in	 DES,	 which	 slow	 down	
endothelialisation	may	 have	 a	 contribution	 in	 the	 development	 of	 prothrombogenic	
conditions	 (Stähli	et	al.,	2006).	Currently,	FDA	recommends	dual	antiplatelet	 therapy	
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with	aspirin	and	clopidogrel	for	more	than	12	months	to	prevent	DES	related	thrombosis	
(Takayama	et	al.,	2011).	
1.6. 	Ideal	stent	requirements	
Requirements	for	the	ideal	stent	have	been	clearly	formulated	(Regar	et	al.,	2001;	
Sangiorgi	et	al.,	2007;	Mani	et	al.,	2007).	The	perfect	stent	should	be:	
a) biodegradable	 in	 nature,	 to	 provide	 scaffolding	 and	 allow	proper	 healing;	
after	that	to	slowly	degrade	to	non-toxic	products	
b) flexible,	trackable	to	be	able	to	pass	through	winding	vessels	
c) radio-opaque	with	good	MRI	compatibility,	to	allow	monitoring	in	assessing	
the	in	vivo	location	of	the	stent	during	deployment	and	follow-up	period	
d) thromboresistant,	 the	material	 should	 be	 compatible	 with	 blood	 and	 not	
attract	platelets	to	adhere	and	accumulate	
e) able	to	release	drugs,	stents	should	act	as	drug	carrier	vehicle	and	provide	
local	drug	delivery	in	a	controlled	manner	
f) have	proper	mechanical	properties,	such	as	high	tensile	strength	to	provide	
strong	mechanical	support	to	the	vessel	wall;	sufficient	flexibility	in	order	to	
be	 crimped	on	 the	balloon	 catheter	 supported	by	 a	 guide	wire;	 the	 stent	
should	undergo	sufficient	expansion	and	conform	to	the	vessel	wall	
g) suitable	surface	characteristics,	such	as	surface	chemistry	and	topography	to	
allow	endothelialisation	and	in	case	of	metallic	stents	additionally	an	ability	
to	prevent	corrosion	induced	by	formation	of	oxide	films	
h) excellent	 haemo-	 and	 biocompatibility,	 the	 material	 must	 not	 cause	 side	
effects	in	the	body	
i) relatively	 inexpensive	 to	 manufacture—the	 stent	 material	 should	 be	
available	to	purchase	by	general	patients	
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1.7. Biomaterials	used	for	coronary	stent	application	
Biomaterials	are	of	great	interest	for	coronary	stents	due	to	their	high	biocompatibility	
and	 biodegradability.	 Poly(L-lactic)	 acid,	 poly(D-lactic)	 acid,	 polycaprolactone	 and	
poly(glycolic)	 acid	 have	 been	 commonly	 used	 for	 the	 fabrication	 of	 bioresorbable	
coronary	stents	(Eberhart	et	al.,	2003).	PLLA	and	PGA	have	high	tensile	strength	values;	
therefore,	can	be	used	for	different	types	of	designs.	The	complete	degradation	of	PLLA	
requires	24	months,	whereas	for	PGA	it	requires	from	6	to	12	months.	PLLA	has	been	
used	 for	 several	 medical	 applications,	 especially	 for	 devices,	 which	 require	 great	
strength	 and	 toughness	 from	 the	 material,	 such	 as	 orthopaedic	 and	 cardiovascular	
devices	or	 sutures.	Moreover,	PLLA	can	be	processed	by	various	 techniques,	 such	as	
electrospinning,	moulding,	extrusion	as	well	as	solvent	casting	(Zilberman	and	Eberhart,	
2006).	PCL	is	a	semicrystalline	polymer	with	lower	tensile	strength	and	Young’s	modulus	
values	 in	 comparison	 to	 PLLA	 and	 PGA.	 PCL,	 exhibits	 much	 higher	 flexibility	 in	
comparison	to	PLLA.	It	has	much	lower	glass	transition	temperature	(-60°C)	and	melting	
temperature	around	60°C.	Polydioxanone	(PDS)	has	also	been	investigated	for	coronary	
stent	development,	due	to	its	excellent	biocompatibility.	It	has	lower	strength	and	glass	
transition	 temperature	 similar	 to	 PCL	 (Pachence	 and	 Kohn,	 2000).	 The	 first	
bioresorbable	stent	was	developed	by	Tamai	and	co-workers.	It	was	called	Igaki/Tamai	
and	was	made	using	PLLA,	was	balloon	expandable	with	a	zigzag	coil	design.	The	strut	
thickness	was	0.17mm	and	had	self-expanding	capacity.	However,	the	initial	expansion	
required	 high	 temperature	 (70°C).	 Further	 expansion	 required	 the	 application	 of	 a	
pressure	gradient.	The	most	important	innovation	proposed	by	Tamai	was	the	unique	
“zigzag”	 stent	 design	 (Tamai	 et	 al.,	 1999;	 2000).	 Initial	 results	 on	 Igaki/Tamai	 stents	
demonstrated	 reduction	 of	 stenosis	 in	 a	 porcine	 model.	 Stents	 showed	 long-term	
biocompatibility	with	minimal	 immunogenic	response	after	16	weeks.	There	were	no	
stent	thrombosis	events.	The	restenosis	rate	after	6	months	of	clinical	trials	was	10.5%	
(Tsuji	et	al.,	2001).		The	success	of	a	bioresorbable	stent	is	dependent	on	a	combination	
of	 several	 factors,	 such	 as	 excellent	 biocompatibility,	 controlled	 degradation	 rate,	
mechanical	properties,	the	manufacturing	ability	and	also	a	proper	design	(Zilberman	
and	Eberhart,	2006).		
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Within	the	group	of	biomaterials	with	great	potential	in	coronary	stent	development	are	
polyhydroxyalkanoates	 (PHAs)	 which	 are	 biopolyesters	 produced	 by	 bacteria	 under	
nutrient	limiting	conditions,	which	will	be	described	in	details	in	the	following	section.	
1.8. Polyhydroxyalkanoates	
Polyhydroxyalkanoates	(PHAs)	are	a	group	of	biodegradable	biopolymers	produced	by	
various	microorganisms	as	an	intracellular	reserve	of	carbon	and	energy	(Lu	et	al.,	2009;	
Kumbhakar	et	al.,	2012;	Matias	and	Rodrigues,	2011).	Due	to	their	specific	physical	and	
chemical	properties,	they	can	be	used	as	a	substitute	of	traditional	plastics.		PHAs	are	
biodegradable	 and	 biocompatible;	 hence	 they	 can	 be	 used	 for	 a	 range	 of	 medical	
applications	including	the	production	of	biodegradable	coronary	artery	stents	such	as	
those	described	in	the	section	1.3.	(Basnett	and	Roy,	2010;	Chen,	2009).			
Polyhydroxyalkanoates	accumulate	in	the	form	of	inclusion	bodies,	0.2-0.5	microns	in	
diameter,	 within	 the	 cytoplasm	 (Figure	 9).	 They	 are	 produced	 under	 conditions	 of	
nutrient	 limitation	 with	 one	 of	 the	 growth	 components,	 such	 as	 nitrogen,	 sulphur,	
oxygen,	 magnesium	 or	 phosphorus	 in	 limiting	 concentration,	 with	 excess	 of	 carbon	
(Anderson	and	Dawes,	1990;	Khanna	and	Srivastava,	2005;	Chen	et	al.,	2001;	Thakor	et	
al.,	 2006).	 Various	 organic	 compounds	 such	 as:	 carbohydrates,	 lipids,	 fatty	 acids,	
alkanes,	alkenes,	organic	acids,	aromatic	compounds,	and	many	others	can	be	used	as	a	
carbon	source	for	PHA	production	(Sudesh	et	al.,	2000).	
	
Figure	 9:	 Polyhydroxyalkanoates	 granules	 inside	 bacterial	 cells.	 (Source:	 Chen	 et	 al.,	
2001).	
Polyhydroxyalkanoates	 are	 esters	 of	 3,-4,-5,-6-hydroxyalkanoic	 acid.	 The	 chemical	
structure	of	PHAs	is	presented	in	Figure	10.	Each	monomer	unit	includes	a	side	chain	
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group	(R),	which	is	usually	a	saturated	alkyl	group.	Rarely,	unsaturated	or	branched	alkyl	
groups	can	also	be	found	(Lu	et	al.,	2009).	
	
Figure	10:	The	general	structure	of	Polyhydroxyalkanoates.	(x	=	number	of	methylene	
groups	in	the	backbone;	n	=	1000–10	000;	R	=	alkyl	groups,	C1-C13)	(Nigmatullin	et	al.,	
2015).	
Each	PHA	molecule	contains	from	600	to	35,000	(R)-hydroxy	fatty	acid	monomer	units	
(Khanna	and	Srivastava,	2005).		
1.8.1. Types	of	PHAs	and	their	properties	
	
Polyhydroxyalkanoates	have	some	properties	similar	to	traditional	plastics,	for	example:	
thermoplasticity,	hydrophobicity,	high	molecular	weight	(Thakor	et	al.,	2006).	Physical	
properties	 of	 PHAs	 are	 dependent	 primarily	 on	 the	 number	 of	 carbon	 atoms	 in	 the	
monomer	unit.	Homopolymers,	random	copolymers	and	block	copolymers	of	PHAs	can	
be	 produced	 depending	 on	 the	 bacterial	 species	 and	 growth	 conditions.	 Over	 150	
different	PHA	monomers	have	been	reported	so	far	(Loo	and	Sudesh,	2007;	Gao	et	al.,	
2011).	Monomers	 can	 include	aromatic	 or	 aliphatic	 side	 chains	or	 can	be	 chemically	
modified	in	order	to	improve	the	functionality	and	applicability	of	the	polymer	(Lu	et	al.,	
2009).	 PHAs	 are	 divided	 into	 two	 main	 groups:	 short-chain	 length	 (scl),	 where	 the	
monomer	contains	3	 to	5	carbon	atoms,	and	medium-	chain	 length	 (mcl),	where	 the	
number	of	carbon	atoms	in	the	monomer	is	between	6	and	14	(Madison	and	Huisman,	
1999).	Scl-PHAs	are	normally	brittle,	crystalline,	stiff	and	have	high	melting	temperature.	
Scl-PHAs	can	demonstrate	different	thermal	behaviour,	due	to	the	various	states	of	the	
polymer	including	amorphous,	semi-crystalline	and	crystalline	states.	Scl-PHAs	exhibit	
double	or	multiple	melting	peaks	depending	on	the	structure	and	morphology	of	the	
crystals	(Ding	et	al.,	2011).	However,	P(4HB),	a	scl-PHA	is	highly	elastomeric	with	high	
tensile	strength,	which	makes	this	material	very	attractive	for	biomedical	applications,	
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such	as	sutures.	Very	often	P(4HB)	is	produced	as	a	copolymer	along	with	P(3HB)	after	
addition	 of	 specific	 precursors,	 such	 as	 1,4-butanediol	 or	 γ-butyrolactone	 into	 the	
feedstock.	Mcl-PHAs	are	biopolymers,	which	are	elastomeric	in	nature	with	low	melting	
point,	low	glass	transition	temperature.	Usually	they	do	not	undergo	cold-crystallisation.	
Mcl-PHAs	 represent	a	group	of	 soft	materials	with	 low	tensile	 strength	and	very	 low	
values	 of	 Young’s	 Modulus	 in	 comparison	 to	 scl-PHAs.	 Their	 elastomeric	 nature	
increases	with	the	length	of	the	side	chain	(Khanna	and	Srivastava,	2005;	Williams	et	al.,	
1999;	 Loo	 and	 Sudesh,	 2007).	 Their	 properties	 make	 them	 an	 attractive	 group	 of	
biomaterials	for	example	for	soft	tissue	engineering	(Abe	et	al.,	2012).	
Scl-mcl-PHAs	are	copolymers	of	short	chain	length	PHAs	and	medium	chain	length	PHAs	
and	exhibit	intermediate	properties	in	comparison	to	scl	or	mcl	polymers	on	their	own	
(Matsusaki	et	 al.	 2000).	 For	 example,	 they	 exhibit	 high	 tensile	 strength	 but	 are	 also	
flexible	at	the	same	time.	Both	the	thermal	and	mechanical	properties	are	dominated	
by	the	type	of	monomer	present	as	the	major	component.	For	example,	P(3HB-co-3HHx)	
copolymer	containing	17mol	%	3HHx	unit	had	twice	the	value	of	elongation	at	break	as	
compared	to	the	copolymer	with	only	10	mol	%	3HHx.	Melting	temperature	for	these	
copolymers	was	in	the	range	120-127°C.	Presence	of	3HHx	unit	did	not	affect	the	tensile	
strength	of	the	material	as	well	as	its	glass	transition	temperature	(Sudesh	et	al.,	2000;	
Lauzier	et	al.,	1992).		
Blending	 of	 scl	 and	 mcl-PHAs	 also	 allows	 the	 production	 of	 novel	 material	 with	
intermediate	properties,	suitable	for	various	applications	(Doi	et	al.,	1995).	PHA	based	
blends	will	be	described	in	the	section	1.8.9.		
Polyhydroxyalkanoates	represent	group	of	biopolymers	with	broad	range	of	properties.	
PHAs	represent	several	advantages,	such	as	natural	origin	material,	production	by	using	
renewable	materials,	 high	 biocompatibility	 and	 non-toxicity.	 The	 summary	 of	 typical	
material	properties	of	scl-PHA	and	mcl-PHA	is	presented	in	Table	1.		
P(3HB),	which	belongs	to	scl-PHA	group	represents	completely	different	properties	than	
mcl-PHA.	 Hence,	 the	 material	 selection	 needs	 to	 be	 based	 on	 the	 final	 material	
properties	required	for	chosen	application.		
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Table	1.	 Summary	of	material	 properties	 typical	 for	mcl-PHA	and	 scl-PHA	 (Rai	et	al.,	
2011;	Ojumu	et	al.,	2004;	Sudesh	et	al.,	2000).	
Material	property	 Mcl-PHA	 Scl-PHA	(P3HB)	
Thermal	properties:	
• Glass	transition	
temperature	(Tg)	
(°C)	
• Melting	
temperature	
(Tm)	(°C)	
	
-36	to	-48	
	
	
39-55	
	
0-15	
	
	
140-175	
Mechanical	properties	
• Tensile	strength	
(MPa)	
• Young’s	Modulus	
(MPa)	
• Elongation	at	
break	(%)	
	
1-9	
	
10-15	
	
280-1000	
	
20-40	
	
1000-3500	
	
4-10	
Crystallinity	degree	(%)	 30-38	 60-80	
Biocompatibility	
Highly	biocompatible	with	
several	cell	lines	
Highly	biocompatible	with	
several	cell	lines	
Biodegradability	 Biodegradable	 Biodegradable	
Toxicity	of	polymer	and	
degradation	products	
Non-toxic	 Non-toxic	
Processability	
Suitable	for	several	
techniques	without	using	
elevated	temperatures,	
such	as	solvent	casting,	dip	
moulding,	freeze-drying,	3D	
printing,	electrospinning	
Suitable	for	several	
techniques,	such	as	
solvent	casting,	dip	
moulding,	extrusion,	
electrospinning,	freeze-
drying,	electrospinning,	
injection	moulding	
	
Although,	PHAs	demonstrate	superior	properties	in	comparison	to	other	polymers,	PHAs	
have	also	few	limitations.	One	of	the	biggest	concerns	is	related	to	high	production	cost	
and	limited	availability.	Therefore,	PHAs	cannot	compete	with	cheap	synthetic	polymers	
available	 in	 large	 amounts.	 Another	 drawback	 is	 related	 to	 processability.	Mcl-PHAs	
have	low	temperature	of	melting,	therefore	cannot	be	used	for	techniques	required	high	
temperatures.	 P(3HB)	 has	much	 higher	 Tm	 value	 than	mcl-PHA,	 but	 it	 demonstrated	
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susceptibility	to	thermal	degradation	in	temperature	above	melting	point.	Additionally,	
PHAs	are	considered	as	materials	exhibiting	insufficient	mechanical	properties:	scl-PHA	
are	stronger	but	brittle,	whereas	mcl-PHA	are	very	elastomeric	but	weak	(Li	et	al.,	2016).		
This	 project	 will	 try	 to	 address	 some	 of	 the	 limitations	 mentioned	 above,	 such	 as	
economical	 production	 of	 mcl-PHAs,	 material	 processability	 and	 enhancement	 of	
material	properties.		
1.8.2. Biocompatibility	of	PHAs	
	
High	biocompatibility	is	required	for	any	material,	which	meant	to	be	used	for	medical	
applications.	This	would	apply	to	biomaterials,	implants,	medical	devices	and	prosthesis.	
The	levels	of	biocompatibility	differ	between	different	materials	and	depend	on	several	
factors,	such	as	shape,	porosity,	functional	groups,	mechanical	properties	and	surface	
charge.	Human	blood	contains	between	3	to	10mg	per	100mL	of	3-hydroxybutyric	acid	
(3HB),	 as	 a	 compound	 associated	 with	 ketone	 body	 formation	 (Pawan	 and	 Semple,	
1983).		P(3HB)	is	found	in	transmembrane	channels	in	eukaryotic	and	prokaryotic	cell	
membranes	 (Reusch,	 2000).	 Therefore,	 it	 is	 expected	 that	 implants	 or	 sutures	made	
from	 PHAs	 containing	 P(3HB)	 should	 not	 trigger	 an	 immune	 response	 in	 the	 body	
(Brigham	 and	 Sinskey,	 2012).	 Moreover,	 in	 vitro	 cell	 study	 has	 confirmed	 high	
biocompatibility	of	P(3HB)	 towards	a	 range	of	different	 cell	 lines	 (Misra	et	al.,	 2006;	
Shishatskaya	 et	 al.,	 2004).	 Sevastianov	 and	 co-workers	 measured	 the	
haemocompatibility	of	PHAs	and	demonstrated	 that	both	P(3HB)	and	P(3HB-co-3HV)	
were	compatible	with	blood	and	do	not	trigger	any	immune	response	(Sevastianov	et	
al.,	 2003).	 P(3HB)	 have	been	 studied	 intensively	 for	 hard	 tissue	 engineering	 and	has	
demonstrated	 good	 biocompatibility	 with	 several	 cell	 lines,	 such	 as	 fibroblasts,	
chondroblasts	or	osteoblasts	(Köse	et	al.,	2003).	Biocompatibility	of	P(3HB)	films	has	also	
been	confirmed	in	vivo.	The	tissue	reaction	to	the	implanted	material	did	not	differ	from	
an	 inert	 glass	 plate	 (Muhammadi	 et	 al.,	 2015).	 The	 high	 biocompatibility	 can	 be	
explained	by	the	presence	of	P(3HB)	oligomers	and	HB	in	animal	tissues	under	normal	
conditions	in	comparison	to	the	chemically	synthesised	polymers,	such	as	polylactides	
or	polyglycolides	(Jirage	et	al.,	2013).		
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Mcl-PHA	 is	 another	 very	 interesting	 group	of	biopolymers.	 They	are	usually	 soft	 and	
highly	elastomeric.	Therefore,	they	have	gained	interest	as	a	potential	candidate	for	soft	
tissue	engineering.	Bagdadi	et	al.,	observed	high	compatibility	of	neat	P(3HO)	cardiac	
patches	with	neonatal	ventricular	rat	myocytes	(Bagdadi	et	al.,	2017).	Blending	of	scl	
and	mcl-PHA	was	carried	out	to	obtained	materials	with	intermediate	properties.	For	
example,	 mcl/scl-PHA	 blends,	 P(3HO)/P(3HB),	 have	 demonstrated	 good	 support	 of	
growth	and	proliferation	of	human	microvascular	endothelial	cells	(HMEC-1)	(Basnett	et	
al.,	2013)	as	well	as	NG108-15	neuronal	cells	(Lizarraga	et	al.,	2015).	In	another	study,	
Qu	and	co-workers	have	reported	the	development	of	P(3HB-co-3HHx)	scaffold	coated	
with	 fibronectin	and	additional	 surface	 functionalization	by	plasma	 treatment.	These	
modifications	 led	 to	 increased	attachment	and	proliferation	of	human	umbilical	 vein	
endothelial	cells	(HUVECs)	as	well	as	smooth	muscle	cells	isolated	from	the	rabbit	aorta	
(RaSMCs)	(Qu	et	al.,	2005).	The	P(3HB-co-3HHx)	copolymer	promoted	differentiation	of	
mesenchymal	 stem	 cells	 into	 chondroblasts,	 which	 can	 be	 applied	 for	 cartilage	
regeneration	(Yan	et	al.,	2011).	Naveen	et	al.,	2015	have	observed	good	biocompatibility	
of	mcl-PHAs	with	mesenchymal	stromal	cells	(Naveen	et	al.,	2015).	
Due	to	their	high	biocompatibility,	PHAs	have	become	significant	candidates	as	a	group	
of	biomaterials	for	various	biomedical	applications	 including	their	usage	for	 implants,	
prosthesis,	scaffolds	and	other	medical	devices	in	tissue	engineering.		
1.8.3. Blood-biomaterial	interactions	
	
High	compatibility	of	the	implant	with	blood	is	required	especially	for	the	scaffolds	or	
devices	 used	 for	 vascular	 repair,	 grafts,	 stents	 and	 heart	 valves,	where	 contact	with	
blood	 is	constant.	 Interactions	between	blood	and	the	material	are	very	complicated	
and	 contain	 many	 stages	 connected	 with	 each	 other	 (Tsai	 et	 al.,	 1999).	 Healthy	
endothelium	 has	 anticoagulant	 properties.	 However,	most	 of	 the	materials,	 such	 as	
polymers	or	metals,	their	oxides	and	alloys,	used	for	medical	devices,	can	activate	the	
body	 inflammatory	 response	 (Ratner,	 2007).	 Immediately	 after	 implantation,	 protein	
adsorption	 occurs	 on	 the	 surface,	 followed	 by	 platelet	 adhesion.	 If	 proteins	 are	
denatured,	coagulation	factors	are	activated,	which	switches	the	coagulation	cascade	
and	causes	an	inflammatory	response.	Appearance	of	these	three	elements	within	a	few	
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minutes	 after	 contact	 with	 a	 foreign	 material	 lead	 to	 thrombus	 formation	 and	
fibrinolysis.	Longer	contact	may	result	in	complete	closure	of	the	vessel,	or	calcification	
as	 well	 as	 changes	 in	 the	 mechanical	 properties	 of	 the	 material.	 Fibrinogen,	 blood	
clotting	enzymes	and	blood	proteins	are	crucial	for	the	development	of	material	related	
to	clotting	(Forbes	and	Courtney,	1994).	Several	studies	have	been	performed	towards	
better	recognition	of	the	blood-material	interaction	mechanisms	at	a	molecular	level.	
Many	different	types	of	polymers	and	other	materials	have	been	investigated.	Special	
attention	was	paid	to	the	materials,	which	demonstrated	low	protein	adsorption.	It	was	
found,	that	PEG,	zwitterionic	groups	and	polycarboxybetaine	methacrylate	were	able	to	
prevent	 fibrinogen	 adsorption	 (Zhang	 et	 al.,	 2006).	 Blood-material	 interaction	 can	
trigger	inflammatory	response,	which	may	lead	to	the	implant	rejection.	Initial	contact	
between	 the	 biomaterial	 and	 blood	 results	 in	 plasma	 protein	 adsorption	 as	 well	 as	
activation	of	the	plasma	cascade	systems.	The	amount	of	protein	attached	to	the	surface	
differs	between	the	materials	(Courtney	et	al.,	1994).		
Surface	characteristics,	 such	as	chemical	composition,	presence	of	 functional	groups,	
incorporation	of	particles,	crystallinity,	roughness,	porosity,	released	products	as	well	as	
degradation	products	can	affect	the	interactions	between	the	material	and	the	blood	
cells	(Bacakova	et	al.,	2011).	Surface	roughness	significantly	affects	platelets	adhesion.	
Higher	roughness	attracts	platelets	more	than	smooth	surfaces	 (Braune	et	al.,	2010).	
The	wettability	of	the	material	is	also	very	important.	However,	the	optimum	value	of	
the	 contact	 angle,	 required	 for	 cell	 attachment	 is	 still	 controversial.	 It	 is	 commonly	
known	 that	 cells	 prefer	 to	 attach	 to	 the	 weakly	 hydrophilic	 surfaces	 (contact	 angle	
around	 60o),	whereas	 highly	 hydrophilic	 or	 hydrophobic	 surfaces	 have	 been	 used	 to	
inhibit	cell	adhesion.	Highly	hydrophilic	surfaces	prevent	adsorption	of	proteins.	On	the	
other	 hand,	 proteins	 adsorbed	 to	 the	 strongly	 hydrophobic	materials	 are	 in	 inactive	
form,	which	inhibit	cell	adhesion	(Bacakova	et	al.,	2011).	it	is	also	well	known	fact,	that	
several	 cell	 lines	 attach	 and	 proliferate	 on	 the	 surfaces	 of	 PHAs,	 which	 are	 mainly	
hydrophobic	in	nature	(Chen,	2009).	These	observations	bring	to	the	general	conclusion	
that	material-cells	interaction	is	a	very	complex	phenomenon,	which	depends	on	several	
factors	and	some	mechanisms	have	not	yet	been	discovered.		
Restrained	hydrophilic	and	positively	charged	materials	encourage	cell	attachment	due	
to	the	adhesion	of	specific	molecules,	such	as	vitronectin	and	fibronectin,	which	make	
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specific	sites	accessible	for	the	cell	adhesion	receptors.	Surface	charge	also	plays	a	very	
important	 role.	 The	 internal	 wall	 of	 the	 artery	 is	 negatively	 charged,	 as	 well	 as	 the	
platelets,	hence	they	repel	from	the	wall.	Cells	tend	to	attach	to	the	positively	charged	
surfaces	 better	 than	 to	 negatively	 charged	 surfaces.	 This	 can	 additionally	 lead	 to	 an	
activation	of	the	complement	system	and	increase	the	inflammatory	response	(Franke	
and	Jung,	2012).	Therefore,	many	research	groups	have	focused	on	the	modifications	of	
the	 surfaces	 of	 the	materials.	 There	 are	 three	 different	 approaches,	 such	 as	 surface	
passivation,	which	is	a	coating	with	a	thin	layer	of	protective	material,	incorporation	of	
biomolecules,	 such	 as	 mimicking	 the	 environment	 of	 the	 vascular	 wall.	 Surface	
passivation	requires	surface	modifications	in	order	to	lower	or	completely	eliminate	the	
interactions	between	the	material	and	proteins.	This	can	be	obtained	for	example	by	
modifications	with	zwitterionic	polymers	(Yang	et	al.,	2009).		Those	are	also	known	as	
polybetaines,	which	contain	the	same	number	of	cationic	and	anionic	groups	within	the	
repeating	unit	and	have	the	overall	zero	charge	(Laschewsky,	2014).	The	ideal	protein	
resistant	material	should	be	hydrophilic,	electrically	neutral,	incorporate	hydrogen	bond	
acceptors	but	be	deprived	of	hydrogen	bonds	donors	(Ostuni	et	al.,	2001).			
1.8.4. Biodegradability	of	PHAs	
	
PHA	degradation	is	defined	by	a	number	of	factors	including	weight	loss,	reduction	of	
molecular	weight,	degree	of	crystallinity	and	change	of	mechanical	properties	(Mergaert	
et	al.,	1993).	PHA	degradation	are	influenced	by	the	properties	of	the	polymer,	surface	
area,	type	and	activity	of	enzymes,	pH,	temperature,	moisture,	salinity,	oxygen	levels,	
shape	and	size	of	the	sample	(Boyandin	et	al.,	2013;	Hiraishi	and	Khan,	2003).	It	has	been	
demonstrated	 that	 the	 copolymer	 P(3HB-co-4HB)	 can	 degrade	 quicker	 than	 the	
homopolymer	P(3HB)	(Doi	et	al.,	1990).	On	the	other	hand,	Boyandin	and	co-workers	
demonstrated	faster	P(3HB)	degradation	than	P(3HB-co-3HV)	copolymer.	It	was	found	
that	degradation	rate	of	films	was	almost	two	times	faster	than	pellets	(Boyandin	et	al.,	
2013).	P(3HB-co-3HV)	is	not	affected	by	moisture	and	does	not	degrade	under	normal	
conditions	of	storage	(Mergaert	et	al.,	1993).	The	P(3HB)	homopolymer	was	found	to	
degrade	within	6	months	in	the	animal	models	(Kostopoulos	and	Karring	1994;	Luklinska	
and	Bonfield,	1997).	Whereas	in	another	experiment,	copolymers	of	P(3HB-co-3HV)	and	
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P(3HB-co-3HHx)	 degraded	 completely	 within	 3	 months,	 when	 implanted	
subcutaneously	(Philip	et	al.,	2007).	Degradation	rate	of	PHAs	can	be	accelerated	by	an	
addition	of	other	materials,	which	degrades	faster,	like	for	example	PLA	or	gelatine.	Li	
et	 al.,	 investigated	 the	 influence	 of	 the	 addition	 of	maleic	 anhydrate	 into	 P(3HB-co-
3HHx)	copolymer	grafts.	After	21	weeks,	the	graft	material	underwent	over	21%	weight	
loss	 in	 comparison	 to	 the	 neat	 copolymer	 (7.3%)	 (Li	et	 al.,	 2008).	UV	 treatment	 has	
beneficial	impact	on	the	degradation	of	PHAs.	For	example,	P(3HB-co-3HHx)	films	made	
from	 UV	 treated	 polymer	 powders	 demonstrated	 accelerated	 degradation	 after	 15	
weeks.	Moreover,	UV	radiated	material	enhanced	the	cell	attachment	and	proliferation	
of	L929	fibroblast	cell	 line	 (Shangguan	et	al.,	2006).	Miller	and	Williams,	 investigated	
gastrointestinal	 patches,	 based	 on	 P(3HB).	 After	 1	 year	 in	 the	 buffer	 solution,	 the	
molecular	weight	of	P(3HB)	have	decreased	by	half.	Incubation	of	P(3HB)	with	enzyme,	
such	as	pancreatin	resulted	in	three	times	accelerated	degradation	rate	in	comparison	
to	hydrolytic	degradation	(Miller	and	Williams,	1987).	In	another	study,	P(3HB)	blended	
with	atactic	PHB	was	studied	for	bowel	defect	in	the	rat	model.	After	twenty-six	weeks	
only	 small	 residues	of	patch	were	present	 in	one	animal.	The	defect	was	completely	
healed.	The	results	demonstrated	complete	degradability	of	the	PHA	biomaterial	in	the	
time	 sufficient	 for	 such	 application	 (Freier	et	 al.,	 2002).	 P(3HO)	 scaffolds,	 implanted	
subcutaneously,	was	relatively	slow.	After	40	weeks,	the	molecular	weight	of	implanted	
P(3HO)	was	two	time	lower	than	the	not	implanted	control	(Williams	et	al.,	1999).	
	
1.8.5. Biosynthesis	of	Poly(3-hydroxyalkanoates)	
	
Polyhydroxyalkanoates	play	a	very	important	role	in	bacterial	metabolism.	PHA	granules	
usually	play	the	role	of	energy	storage	during	unfavourable	conditions,	such	as	nutrient	
limitation.	When	the	ambient	environmental	conditions	return	to	those	preferred	for	
bacterial	culture	development,	PHA	 inclusions	can	be	used	to	support	growth.	 It	was	
discovered,	that	bacteria,	which	harbour	PHAs	have	increased	tolerance	against	some	
agents,	such	as	heat	tolerance,	osmotic	shock	or	UV	irradiation	(Kadouri	et	al.,	2005).		
PHAs	can	be	produced	according	 to	various	metabolic	pathways.	The	summary	of	all	
discovered	 metabolic	 pathways	 up	 to	 date	 is	 presented	 in	 Figure	 11.	 From	 a	 total	
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number	of	13	pathways,	scl-PHA	can	be	produced	by	10	different	metabolic	pathways	
(A-J	on	the	figure)	and	mcl-PHA	by	4	(Chen	2010;	Lu	et	al.,	2009,	Madison	and	Huisman	
1999).	
PHA	biosynthesis	can	be	carried	out	by	different	metabolic	pathways	in	the	wild-type	as	
well	 as	 genetically	 modified	 strains	 (Figure	 11).	 They	 are	 synthesised	 by	 several	
enzymatic	 reactions	 from	 acetyl-CoA,	 in	 the	 presence	 of	 substrate	 specific	 PHA	
synthases	located	in	the	cytosol	of	PHA	accumulating	bacteria	(Du	and	Yu,	2002).	Most	
of	the	bacteria	are	able	to	synthesize	scl-PHAs,	such	as	P(3HB)	or	mcl-PHAs,	containing	
medium	 chain	 length	 3-hydroxy	 fatty	 acids	 (Koller	 et	 al.,	 2010).	 The	 PHA	metabolic	
pathways	 include	 several	 biochemical	 reactions,	 such	 as	 the	 Krebs	 cycle,	 glycolysis,	
Calvin	Cycle,	serine	pathway,	β-oxidation,	de	novo	fatty	acid	synthesis	and	amino	acid	
catabolism	(Shilalipi	and	Nirupama,	2012;	Steinbüchel	et	al.,	1992).	The	type	of	reaction	
selected	 for	 the	biosynthesis	of	PHAs	depends	mainly	on	 the	 type	of	 carbon	 source,	
availability	 of	 nutrients	 and	 the	 bacterial	 strain	 used.	Metabolism	 of	 some	 bacterial	
strains,	 such	 as	 Cupriavidus	 necator	 or	 Pseudomonas	 sp.	 is	 very	 sensitive	 towards	
nutrient	balance	in	the	surrounding	environment.	For	example,	nutrient-rich	conditions	
inhibit	PHA	synthesis,	due	 to	 the	production	of	excess	 coenzyme	A	during	 the	Krebs	
cycle.	This	results	in	the	blockage	of	3-ketothiolase	PhaA	and	the	utilization	of	all	acetyl-
coA	for	cell	growth	(Ratledge	and	Kristiansen,	2001).	Whereas	under	nutrient	limiting	
conditions	in	the	presence	of	excess	carbon,	the	concentration	of	coenzyme	A	allows	
acetyl-CoA	to	be	directed	to	PHA	biosynthesis	pathways	for	PHA	accumulation	(Jung	and	
Lee,	2000).	Figure	11	demonstrates	various	routes	of	scl-PHA	production	(labelled	from	
A	to	J)	and	mcl-PHA	production	(routes	J-M).	It	is	well	known	that	(R)-hydroxyacyl-CoA	
([R]-3-HA-CoA)	 is	 the	 most	 common	 precursor	 for	 PHA	 production.	 However,	 the	
metabolism	of	 cyclohexanol	 to	6-hydroxyhexanoyl-CoA	and	4,5-alkanolactone	 to	4,5-
hydroxyacyl-CoA	(4,5-HA-CoA)	shown	in	metabolic	routes	L	and	M,	have	been	recently	
proposed	as	the	alternative	precursors,	which	can	lead	to	PHA	biosynthesis	(Chen,	2010;	
Lu	 et	 al.,	 2009).	 Nevertheless,	 the	 possible	 pathways,	 L	 and	 M	 require	 further	
investigation.	Discovery	of	larger	number	of	metabolic	pathways	will	help	bioprocessing	
engineers	 to	 achieve	 optimal	 utilisation	 of	 the	 carbon	 source	 and	 enhance	 polymer	
production.	
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1.8.5.1.		Synthesis	of	short	chain	length	polyhydroxyalkanoates	
 
P(3HB)	 is	 the	most	 studied	polymer	 from	 the	PHA	 family.	 Production	of	 P(3HB)	 involves	
three	enzymatic	reactions	involving	the	enzymes:	thiolase,	reductase	and	polymerase.	The	
first	reaction	involves	the	condensation	of	two	acetyl	coenzyme	A	(acetyl-CoA)	molecules	
into	acetoacetyl-CoA	by	b-ketoacyl-CoA	thiolase	(encoded	by	phbA).	This	is	followed	by	the	
reduction	 of	 acetoacetyl-CoA	 to	 (R)-3-hydroxybutyryl-CoA	 by	 an	 NADPH-dependent	
acetoacetyl-CoA	dehydrogenase	(encoded	by	phbB)	occurs.	Finally,	P(3HB)	precursors,	(R)-
3-hydroxybutyryl-CoA	 monomers	 are	 polymerised	 to	 poly(3-hydroxybutyrate)	 by	 P(3HB)	
polymerase	 (encoded	 by	 phbC).	 This	 metabolic	 pathway	 is	 typically	 found	 in	 Ralstonia	
eutropha	 and	 Zooglea	 raminera	 (Rehm,	 2006).	 Other	 microorganisms	 are	 also	 able	 to	
produce	P(3HB)	by	using	completely	different	metabolic	pathways.	For	example,	Aeromonas	
caviae	uses	an	enoyl-CoA	hydratase	for	the	formation	of	the	(R)-3-hydroxy	monomer	from	
crotonyl-CoA	or	hexenoyl-CoA.	It	can	synthesise	copolymer,	which	contains	3HB	and	3HHx	
units,	when	olive	oil	or	fatty	acids	with	even	number	of	carbon	atoms	were	used	as	the	sole	
carbon	source.	Interestingly,	growth	on	fatty	acids	mainly	resulted	in	the	production	of	the	
3HV	unit	with	slight	amount	of	3HB	(Doi	et	al.,	1995).	The	metabolic	pathway	for	P(3HB-co-
3HHx)	copolymer	production	in	Aeromonas	caviae	 is	similar	to	the	pathway	proposed	for	
P(3HB)	production	from	Rhodospirillum	rubrum	by	of	Moskowitz	and	Merrick.	The	proposed	
pathway	included	two	hydratases,	each	specific	to	the	R	and	S	enantiomer.	R.	rubrum	is	able	
to	produce	P(3HB-co-3HV)	 from	short	and	medium	chain	acids,	 (Moskowitz	and	Merrick,	
1969).	 This	 pathway	was	described	30	 years	 ago.	However,	Madison	 and	Huisman	drew	
attention	 to	 this	 pathway	 as	 a	 way	 to	 obtain	 scl-mcl-PHA	 copolymers	 (Madison	 and	
Huisman,	1999).	Methylobacterium	rhodesenium	is	another	example	of	bacteria,	which	uses	
two	hydratases	for	P(3HB)	synthesis.	In	addition,	NADH	dependent	and	NADH-independent	
acetoacetyl-CoA	reductases	have	been	characterised.	For	this	strain,	the	carbon	source	is	
crucial	for	the	timing	of	P(3HB)	production.	For	example,	growth	on	methanol,	resulted	in	
the	shift	of	P(3HB)	formation	until	stationary	phase,	whereas	presence	of	fructose	triggered	
P(3HB)	formation	during	exponential	phase	(Mothes	et	al.,	2007).	Some	bacteria,	such	as	
Rhodococcus	ruber	and	Nocardia	corallina	were	able	to	accumulate	PHAs,	including	3HV	unit	
when	grown	on	the	feed,	containing	sugars,	without	addition	of	typical	HV	precursors,	like	
valerate	or	propionate	(Valentin	and	Dennis.	1996).	They	usually	used	the	methylmalonyl-
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CoA	pathway,	from	which	3HV	unit	originates.	Succinyl-CoA	is	converted	to	methylmalonyl-
CoA,	which	is	decarboxylated	to	propionyl-CoA	(Williams	et	al.,	1994).	
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1.8.5.2.	Synthesis	of	medium	chain	length	polyhydroxyalkanoates	
	
Mcl-PHAs	were	discovered	by	de	Smet	and	co-workers	in	1983	(de	Smet,	et	al.,	1983).	
Intense	studies	discovered	that	Pseudomonas	 from	the	rRNA	homology	group	 I	were	
able	to	produce	PHAs	with	the	chemical	structure	directly	related	to	the	length	of	the	
fatty	acid	or	alkane	used	as	the	carbon	source	(Lageveen	et	al.,	1988).	When	the	carbon	
source	contained	between	6	to	12	carbon	atoms,	PHAs	produced	had	the	same	main	
chain	 length	 as	 the	 carbon	 source,	 or	 were	 shorter	 by	 2,	 4	 or	 6	 carbon	 atoms	 in	
comparison	 to	 original	 compounds	 (Huisman	et	 al.,	 1989).	Mixtures	 of	 two	 or	more	
different	carbon	sources	reflected	on	the	composition	of	the	copolymers.	For	example,	
P.	oleovorans,	when	grown	on	a	mixture	of	octane	and	1-octene	was	able	to	produce	
copolymer	with	the	ratio	between	monomer	with	double	bonds	(poly(3-hydroxyoctene)	
and	 monomer	 containing	 only	 saturated	 carbon	 chains	 (poly(3-hydroxyoctanoate)	
varied	from	0%	up	to	50%	according	to	the	amount	of	1-octene	in	the	feed	mixture.	Mcl-
PHA	biosynthesis	pathway	follows	the	fatty	acid	oxidation	(Figure	11).	Fatty	acids	are	
shortened	by	two	atoms	of	carbon,	which	are	released	in	the	form	of	acetyl-CoA.	The	
product	of	the	reaction	is	oxidised	from	acyl-CoA	to	3-ketoacyl-CoA.	The	precursor	of	
mcl-PHAs,	named	(R)-3-hydroxyacyl-CoA	have	to	be	synthesised.	Finally,	the	polymerase	
synthetises	mcl-PHAs.	The	PHA	synthase	enzymes	have	specificity	from	C6	to	C14	with	
preference	for	C8,	C9	and	C10	monomers	(Lageveen	et	al.,	1988).	Subsequent	research	
suggested	that	the	activity	of	PHA	synthases	may	affect	the	molecular	weight	of	the	final	
polymer.	In	addition,	further	in	vitro	and	in	vivo	analysis	implied	that	the	ratio	between	
substrate	and	enzyme	was	a	major	factor,	which	affected	the	molecular	weight	of	the	
final	polymer	(Kraak	et	al.,	1997).		
Pseudomonas	 species	 are	 able	 to	 produce	 mcl-PHAs	 from	 carbohydrates.	 When	
Pseudomonas	 fluorescens	 was	 grown	 on	 sugars,	 the	 mcl-PHA	 obtained,	 contained	
mainly	C8	and	C10	long	chains	(Huijberts	et	al.,	1992).	PHA	production	from	glucose	is	
connected	with	the	fatty	acid	biosynthesis	pathway	and	utilises	(R)-3-hydroxyacyl-ACP.	
When	 using	 sugars,	 additionally	 this	 internal	 product	 has	 to	 be	 converted	 to	 (R)-3-
hydroxyacyl-CoA.	It	was	found,	that	phaG	was	responsible	for	this	transformation	(Rehm	
et	 al.,	 1998).	 	 Few	 Pseudomonas	 sp.	 are	 able	 to	 produce	 scl-mcl	 copolymers	 from	
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unrelated	 carbon	 sources,	 such	 as	 carbohydrates	 or	 1,3-butanediol	 (Steinbüchel	 and	
Wiese,	 1992).	 This	 type	 of	 scl-mcl-PHA	 production	 is	 an	 exception.	 Usually	 physical	
restrictions	can	limit	formation	of	blended	granules,	containing	both	types	of	PHAs.	Even	
recombinant	Pseudomonas	putida,	which	contains	in	addition	to	phaC,	a	copy	of	the	R.	
eutropha	phaC	were	shown	to	accumulate	separate	granules	of	P(3HB)	and	mcl-PHA	
(Preusting	et	al.,	1993).		
1.8.6.	Microbial	production	of	PHAs	
 
Polyhydroxyalkanoates	are	produced	by	over	70	genera	of	bacteria	and	Archea	(Poli	et	
al.,	2011;	Lu	et	al.,	2009).	The	specific	microbial	groups	are	described	 in	the	sections	
below.		
1.8.6.1.	Gram-positive	bacteria	
	
Gram-positive	 bacteria	 have	 been	 found	 to	 be	 able	 to	 produce	 PHAs.	 P(3HB)	 was	
discovered	 for	 the	 first	 time	 in	Bacillus	megaterium	by	 Lemoigne	 (Lemoigne,	 1926).	
Within	 this	 group	 of	 bacteria,	 several	 genera,	 such	 as:	 Bacillus,	 Caryophanon,	
Clostridium,	 Corynebacterium,	 Micrococcus,	 Microlunatus,	 Microcystis,	 Nocardia,	
Rhodococcus,	Staphylococcus,	Streptomyces	have	been	known	to	be	PHAs	producers	(Lu	
et	al.,	2009).	Gram-positive	bacteria	produce	mainly	scl-PHAs.	The	polymer	yield	can	be	
up	to	50%	dry	cell	weight	(Valappil	et	al.,	2007).	Some	of	the	strains	are	able	to	produce	
mcl	 and	 scl-mcl-PHA	 copolymers	 under	 specific	 conditions.	 For	 example,	 Bacillus	
megaterium	was	 found	 to	produce	P(3HB)	 from	glycerol	and	succinic	acid	 in	mineral	
medium	with	addition	of	nitrogen.	The	same	strain	produced	scl-mcl-PHAs	in	the	same	
media	without	nitrogen.	In	addition,	the	same	strain	was	able	to	accumulate	mcl-PHAs,	
when	grown	on	octanoic	acid	 in	the	absence	of	nitrogen	(Shahid	et	al.,	2013).	Gram-
positive	 bacteria	 have	 lower	 polymer	 accumulation	 in	 comparison	 to	 Gram-negative	
bacteria.	Nevertheless,	the	main	advantage	of	using	Gram-positive	bacteria	is	the	lack	
of	 lipopolysaccharides	 (LPS)	within	 the	 cell	wall,	which	 can	 trigger	 an	 immunological	
response	 (Ray	 et	 al.,	 2013).	 It	 is	 worth	mentioning,	 that	 some	 of	 the	 Gram-positive	
species,	 mainly	 Corynebacterium,	 Nocardia,	 Rhodococcus,	 were	 found	 to	 produce	
lipoglycans,	whereas	others,	such	as:	Bacillus,	Clostridium,	and	Staphylococcus	produce	
lipoteichoic	acids,	which	have	immunogenic	properties	similar	to	LPS	(Sutcliffe,	1995).	
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Since	 then	many	 research	groups	 investigated	biocompatibility	of	PHAs	produced	by	
gram	 positive	 bacteria.	 Obtained	 results	 confirmed	 high	 biocompatibility	 of	 these	
polymers	to	various	cell	lines	in	vitro	as	well	as	in	vivo	(Francis	et	al.,	2016;	Bian	et	al.,	
2012;	Misra	et	al.,	2010;	Valappil	et	al.,	2007).		
1.8.6.2.	Gram-negative	bacteria	
	
A	lot	of	different	Gram-negative	bacteria	are	capable	of	production	PHA.	For	efficient	
production	 of	 scl-PHAs,	mainly	 Cupriavidus,	Azohydromonas	 (previously	 classified	 as	
Alcaligenes)	 and	Burkholderia	 species	have	been	used.	 For	example,	Azohydromonas	
lata	produced	up	to	88%	dry	cell	weight	of	P(3HB)	from	various	carbohydrates,	such	as:	
glucose,	fructose	and	sucrose	(Wang	and	Lee,	1997).	On	the	other	hand,	Burkholderia	
sp.	USM	could	synthesize	up	to	69	%	of	dry	biomass	of	P(3HB)	from	fatty	acids	(Chee	et	
al.,	2010).	Cupriavidus	necator	seems	to	be	the	most	universal	strain,	which	can	produce	
P(3HB)	with	high	yield	of	up	to	88.9%	dry	cell	weight	(dcw)	from	various	types	of	carbon	
sources,	 such	 as	CO2,	 sugars,	n-alkanoic	 acids	 and	 vegetable	oils	 (Chakraborty	et	 al.,	
2009;	 Gomez	 et	 al.,	 1996).	 Methylotrophs,	 are	 another	 group	 of	 bacteria,	 able	 to	
produce	 scl-PHAs	 from	 alcohols.	 For	 example,	Methylobacterium	 extorquens	 utilises	
methanol	to	produce	P(3HB)	(46%	dcw),	whereas	Paracoccus	denitrificans	produced	up	
to	24%	dcw	of	P(3HV)	from	n-pentanol	(Mokhtari-Hosseini	et	al.,	2009;	Yamane	et	al.,	
1996).	 Methanol	 is	 a	 cheaper	 carbon	 source	 than	 sugar,	 therefore	 selection	 of	
methylotrophs	 can	 be	 an	 option	 towards	 reduction	 of	 the	 PHA	 production	 cost.	
However,	 optimisation	 studies	 are	 required	 to	 improve	 productivity	 and	 PHA	
accumulation	rate	within	the	biomass	(Khanna	and	Srivastava,	2005).		
Gram-negative	 bacteria	 are	 among	 the	 main	 producers	 of	 mcl-PHAs.	 Various	
Pseudomonas	 sp.	 are	 able	 to	 produce	 a	 range	of	mcl-PHA	homopolymers	 as	well	 as	
copolymers.	The	average	level	of	polymer	yield	is	around	30%	dcw.	However,	some	of	
the	strains,	such	as	P.	putida	mt-2,	could	produce	up	to	77	%	dcw	mcl-PHA	from	octanoic	
acid	 (Shahid	 et	 al.,	 2013).	 Some	 Pseudomonas	 species,	 such	 as	 P.	 marginalis,	 P.	
mendocina,	P.	putida	GPo1and	P.	oleovorans	synthesized	scl-mcl-PHA	copolymers,	using	
a	 range	of	n-alkanoates	and	1,3-butanediol	as	 carbon	sources	 (Lee	et	al.,	 1995).	The	
number	 of	 strains	 of	 Pseudomonas	 putida	 are	 able	 to	 convert	 very	 toxic	 pollutants	
containing	aromatic	compounds	to	mcl-PHAs	(Nikodinovic	et	al.,	2008).	Interestingly,	P.	
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putida	CA-3,	P.	aeruginosa	PAO1,	P.	frederiksbergensis	GO23,	P.	putida	GO16	and							P.	
putida	GO19	could	utilize	crude	pyrolysis	products	from	a	range	of	plastics	for	mcl-PHA	
production	(Guzik	et	al.,	2014).	PHA	accumulation	has	been	observed	in	Gram-negative	
bacteria	 from	extreme	environments,	 such	as	high	salinity	or	high	 temperatures.	For	
example,	the	thermophilic	Thermus	thermophilus	HB8	utilised	whey	and	produced	35%	
dcw	scl-mcl-PHA	copolymer	at	70°C	(Pantazaki	et	al.,	2009).	The	halophilic	Halomonas	
boliviensis	LC1	accumulated	56%	dcw	of	P(3HB)	 from	starch	hydrolysate	using	0.77M	
NaCl	(Quillaguamán	et	al.,	2004).	Application	of	extremophiles	has	several	advantages	
such	as	lower	sterility	demand	and	there	is	no	need	for	pre-treatment	of	waste	effluents.		
Although,	the	Gram-negative	bacteria	represent	a	wide	range	of	possibilities,	the	main	
concern	 is	due	to	presence	of	LPS	 in	 the	outer	cell	membrane,	which	may	trigger	an	
immunological	 response	 and	 exclude	 them	 from	 biomedical	 applications	 (Ray	 et	 al.,	
2013).	 Endotoxins	 can	 be	 eliminated	 by	 repeated	 solvent	 extractions	 with	 oxidizing	
agents,	 like	 sodium	hypochlorite.	However,	 this	will	 further	 increase	 the	cost	of	PHA	
production	(Wampfler	et	al.,	2010).		
1.8.6.3.	Archea	
 
Archea	are	considered	as	extremophiles,	which	can	survive	in	hot	springs,	salt	lakes	and	
oceans	(Oren	et	al.,	2008).	In	Archea,	only	one	group	of	species	was	found	to	be	able	to	
accumulate	 PHAs.	 Those	 are	 halophilic	 species,	 which	 require	 extremely	 high	
concentrations	of	sodium	chloride,	optimally	5%	to	grow	(Danson	and	Hough,	1997).	
The	main	 PHA	 producers	 from	 the	Archeabacteria	 belong	 to	 the	 genera:	Haloferax,	
Halalkalicoccus,	 Haloarcula,	 Halobacterium,	 Halobiforma,	 Halococcus,	 Halopiger,	
Haloquadratum,	Halorhabdus,	Halorubrum,	Halostagnicola,	Haloterrigena,	Natrialba,	
Natrinema,	 Natronobacterium,	 Natronococcus,	 Natronomonas,	 and	 Natronorubrum	
(Han	et	al.,	2010).	They	can	convert	many	carbon	sources,	such	as:	glucose,	fatty	acids	
and	 complex	 sources,	 like	 starch,	 biodiesel	waste	 or	 vinasse	 (Hermann-Krauss	et	 al.,	
2013).	The	main	polymers	obtained	belong	to	the	scl-PHA	family.	Haloarcheal	strains	are	
able	to	produce	homopolymers:	P(3HB)	and	P(3HV)	or	copolymers	containing	3HV	and	
3HB	monomer	units.	Most	of	the	strains	accumulate	PHA	at	a	low	content,	up	to	22%	
dcw.	However,	Haloferax	mediterranei	was	reported	as	the	best	PHA	producer,	which	is	
able	 to	 accumulate	 between	 50	 to	 70%	 dcw	 (Bhattacharyya	 et	 al.,	 2012).	 P(3HB)	
CHAPTER	1	
	
	 44	
production	required	phosphorus	limiting	conditions	(Lillo	and	Rodriguez-Valera,	1990).	
Application	of	extremely	halophilic	strains	is	associated	with	several	challenges	including	
the	fact	that	high	salt	concentration	results	in	increased	cost	of	the	chemicals	for	media	
preparation	as	well	results	in	the	corrosion	of	stainless	steel	fermenters	(Quillaguamán	
et	al.,	2010).	On	the	one	hand,	the	risk	of	contamination	is	very	low,	therefore,	the	costs	
related	 to	 sterilisation	can	be	excluded.	Another	very	 interesting	aspect	 is	 related	 to	
polymer	recovery.	The	huge	advantage	of	usage	of	haloarcheal	strain	is	the	ability	of	the	
cells	 to	 lyse	 in	 distilled	water	 and	 release	 PHA	 granules,	which	 can	 be	 separated	 by	
centrifugation	(Chen	et	al.,	2010).	This	will	have	a	meaningful	impact	on	the	reduction	
of	extraction	costs	as	well	as	make	the	recovery	process	simple,	solvent	free	and	more	
ecologically	friendly	(Poli	et	al.,	2011).		
1.8.6.4.	Mixed	microbial	cultures	(MMC)	
 
One	of	the	approaches	to	lower	the	production	cost	of	PHAs	is	an	application	of	defined	
or	 undefined	 co-cultures,	 which	 contains	 two	 or	 more	 microorganisms.	 “Defined”	
means	 selected	 deliberately,	 according	 to	 the	 targeted	 outcomes.	 Presence	 of	 an	
additional	 strain	 may	 lead	 to	 the	 utilisation	 of	 more	 complicated	 carbon	 sources,	
including	 a	mixture	 of	 different	 chemical	 compounds,	 which	 can	 be	 toxic	 or	 has	 an	
inhibiting	 effect	 on	 a	 single	 microbial	 culture.	 	 Co-cultures	 have	 been	 successfully	
applied	 for	 PHA	 production.	 For	 example,	 Nikodinovic	 and	 co-workers	 reported	
bioconversion	 of	 pyrolysis	 oil	 into	 PHAs	 by	 three	 different	 strains	 of	 Pseudomonas	
putida.	This	carbon	source	contained	mainly	a	mixture	of	aromatic	compounds,	such	as:	
ethylbenzene,	toluene,	xylene	and	styrene.	Each	of	the	strains	was	able	to	utilise	only	
one	of	the	chemical	compounds	listed	above.	Overall,	higher	biomass	was	obtained	and	
polymer	yield	was	similar	to	one	obtained	from	the	best	monoculture.	A	single	bacterial	
strain	used	with	such	complex	carbon	sources	may	lead	to	inhibition	of	growth	of	the	
strain	which	is	not	able	to	utilise	a	particular	carbon	source	(Nikodinovic	et	al.,	2008).	
Another	 approach	 was	 used	 by	 Ganduri	 and	 co-workers,	 who	 used	 co-cultures	 for	
P(3HB)	production.	In	this	system,	one	organism	was	used	to	convert	the	carbon	source	
to	a	product,	which	was	then	used	by	the	second	strain	to	produce	PHAs.	For	example,	
Lactobacillus	delbrueckii	and	Lactobacillus	lactis	were	used	to	convert	sugars	to	lactate,	
which	was	 easily	 used	by	Cupriavidus	 necator	 for	 P(3HB)	 production	 (Ganduri	et	 al.,	
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2005).	There	was	also	a	trial	to	moderate	biogas,	obtained	from	anaerobic	digesters	to	
aerobic	PHA	production.	Preliminary	 results	 looked	promising,	however,	 this	concept	
still	needs	further	validation	(Ha	et	al.,	2012).	There	are	a	lot	of	challenges	associated	
with	mixed	cultures.	One	of	the	challenges	is	connected	to	ensure	right	fermentation	
parameters,	which	will	 result	 in	efficient	 conversion	of	 the	carbon	source	 into	PHAs.	
Sometimes	two	different	types	of	bacteria	require	opposite	conditions	of	oxygen	supply.	
Therefore,	selection	of	the	right	bioreactor	design	is	crucial.	Another	challenge	applies	
to	 harvesting	 and	 separation	 of	 PHA-producers	 from	 non-PHA-containing	 biomass.	
Extraction	 of	 the	 polymer	 from	 both	 fractions	 would	 increase	 the	 cost	 of	 polymer	
recovery.	Two-stage	 fermentation	 systems	would	be	 ideal;	however,	 this	will	 further	
increase	production	costs	(Tan	et	al.,	2014).		
Several	wild-type	bacteria	have	been	previously	investigated	for	the	biosynthesis	of	scl-
mcl-PHAs	including	Rhodospirillum	rubrum,	Rhodocyclus	gelatinosus	and	Rhodococcus	
sp.	 Due	 to	 the	 poor	 yield	 of	 polymers	 using	 wild	 type	 bacteria,	 some	 recombinant	
strains,	 such	 as	Cupriavidus	 necator,	Aeromonas	 hydrophila,	 Pseudomonas	 putida	 or	
Escherichia	coli	have	been	used	for	PHA	production	(Bhubalan	et	al.,	2010).		
1.8.7. 	Polyhydroxyalkanoate	recovery	
	
PHAs	accumulate	as	insoluble	granules	inside	bacterial	cells.	Polymer	can	be	recovered	
from	the	biomass	by	a	process	called	extraction.	The	polymer	recovery	process	contains	
a	 few	 steps,	 which	 are:	 polymer	 extraction,	 purification,	 concentration	 and	
precipitation.	Depending	on	the	method	used,	the	order	might	change.		
The	extraction	methods,	commonly	used	can	be	divided	into	four	main	groups,	such	as:	
solvent	 extraction,	 chemical	 digestion,	 enzymatic-based	 digestion	 or	 combination	
methods.	Among	all	of	them,	solvent	extraction	is	the	most	commonly	used	to	obtain	
polymer	 with	 high	 purity.	 Few	 solvents,	 such	 as:	 chloroform,	 1,2-dichloroethane,	
propylene	carbonate	and	methylene	chloride	were	studied	(Muhammadi	et	al.,	2015).	
It	is	worth	to	mention,	that	in	contrast	to	mcl-PHAs,	scl-PHAs	are	not	soluble	in	acetone.	
This	 solvent	 can	 be	 used	 to	 separate	 the	 two	 types	 of	 polymers	 (Yao	 et	 al.,	 1999).		
Usually,	 solvent	 extraction	 of	 PHAs	 occurs	 due	 to	 increased	 permeability	 of	 the	
membrane	by	the	solvent	along	with	simultaneous	dissolution	of	the	polymeric	granules	
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(Kunasundari	and	Sudesh,	2011).	During	the	extraction	step	the	biomass	is	treated	with	
solvents	for	a	specified	period	of	time.	Cell	walls	become	disrupted,	which	allows	the	
solvent	to	penetrate	inside	the	bacterial	cells	and	dissolve	polymer	granules.	During	the	
purification	 step,	 debris	 are	 separated	 from	 the	 polymer	 solution	 either	 by	
centrifugation	or	filtration.	The	polymer	solution	is	then	concentrated	by	evaporation	
and	precipitated	in	the	ice-cold	ethanol,	methanol	or	a	mixture	of	both	to	obtain	the	
pure	polymer.		
However,	it	was	observed	that	solvent	extraction	in	mcl-PHAs	resulted	in	a	significant	
reduction	 of	 molecular	 weight	 (Ramsay	 et	 al.,	 1994).	 	 A	 novel	 method	 for	 scl-PHA	
extraction	 was	 established	 by	 Koller	 and	 co-workers,	 who	 used	 the	 “anti-solvent”	
acetone	under	increased	temperature	and	pressure	in	a	closed	system,	resulting	in	the	
recovery	of	scl-PHAs	with	similar	purity	to	other	established	methods.	Volatile	liquids,	
such	as	an	acetone	along	with	alcohols	and	other	low	molecular	ketones	were	found	to	
be	 called	 “scl-PHA	 anti-solvents”	 and	 used	 at	 temperature	 above	 boiling	 point	 and	
pressure	of	7bar.	Acetone	as	a	solvent,	presented	many	advantages	such	as	recyclability,	
affordable	 price,	 low	 impact	 on	 molecular	 weight,	 suitability	 for	 extraction.	 Special	
equipment,	containing	two	closed	vessels	with	filtration	unit	was	designed.	The	main	
advantage	of	this	method	is	short	time	(20	minutes),	possibility	of	solvent	recycling	and	
high	purity	of	the	product	(Koller	et	al.,	2013).	In	the	chemical	digestion	method	sodium	
hypochlorite	was	used	to	dissolve	biomass.	PHA	granules	are	separated	from	debris	by	
centrifugation.	This	method	is	simple;	however,	it	is	well	known	that	polymers	recovered	
by	chemical	digestion	have	lower	molecular	weight	in	comparison	to	other	extraction	
methods	due	to	polymer	degradation	(Berger	et	al.,	1989).	To	overcome	this	limitation,	
sodium	hypochlorite	can	be	mixed	with	chloroform,	which	can	protect	the	polymer	from	
degradation	by	sodium	hypochlorite	(Hahn	et	al.,	1994).	Enzymatic	digestion	requires	
more	gentle	conditions	than	the	other	two	methods.	A	cocktail	of	enzymes,	containing	
proteases,	nucleases	and	lysozymes	along	with	detergents,	like	for	example	SDS,	have	
been	used	to	eliminate	all	non-PHA	parts	of	the	biomass.	PHAs	are	concentrated	through	
crossflow	filtration	(Koning	et	al.,	1996).	Yang	and	co-workers	reported	application	of	
another	type	of	detergent,	called	linear	alkylbenzene	sulfonic	acid	as	an	alternative	to	
SDS.	This	resulted	in	significant	reduction	(80%)	of	the	amount	of	required	detergent	in	
comparison	to	SDS.	However,	the	drawback	of	this	method	was	the	amount	of	polymer	
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accumulated	inside	the	cells.	This	method	was	efficient	in	the	biomass	containing	larger	
amounts	of	PHAs	(Yang	et	al.,	2011).	The	main	disadvantage	of	the	chemical	methods	is	
a	large	amount	of	surfactant-containing	wastewater.		Moreover,	the	molecular	weight	
loss	 in	enzymatic	digestion	 is	negligible.	This	method	offers	a	number	of	advantages,	
such	as	lower	health	risk,	easy	and	more	environmentally	friendly.	However,	high	price	
of	enzymes,	make	this	process	less	attractive	(Kapritchkoff	et	al.,	2006).		
Supercritical	CO2	mixture	with	other	solvents	can	be	applied	to	recover	highly	pure	PHAs	
from	biomass.	This	method	has	been	used	in	industry	for	extraction	of	fragrances	and	
caffeine	or	removal	of	residual	solvents	from	pharmaceutical	products.	In	combination	
with	other	solvents,	 like	for	example:	ethyl	acetate,	hexane,	THF,	methylene	chloride	
and	acetylene	dichloride,	supercritical	CO2	can	be	used	to	extract	PHAs	with	a	high	yield	
and	purity,	which	might	be	useful	in	the	reduction	of	impurities	caused	by	the	endotoxin	
from	genetically	modified	E.	coli	(Williams	et	al.,	1999).		
Recently,	novel	biological	methods	for	P(3HB)	recovery	have	been	developed.	Biological	
methods	are	based	on	the	consumption	of	dried	bacterial	biomass	by	insects	or	animals.	
PHA	granules	were	excreted	by	animals	and	purified.	These	methods	eliminate	usage	of	
hazardous	solvents.	However,	this	type	of	polymer	recovery	at	the	industrial	scale	still	
has	to	be	confirmed	(Kunasundari	et	al.,	2017;	Murugan	et	al.,	2016).	
1.8.8. 	Economical	production	of	Poly(3-hydroxyalkanoates)	
	
The	main	 problem	 associated	with	 large	 scale	 production	 of	 PHAs	 is	 their	 high	 cost	
(Castilho	et	al.,	2009).	The	carbon	source	is	known	as	the	main	contributor	in	the	high	
price	of	polyhydroxyalknanoates.	The	cost	of	PHA	production	has	been	estimated	by	Lee	
(1996)	as	3–4	US$/kg,	which	is	5-10	times	more	expensive	than	traditional	plastics	(Lee,	
1996).	Production	cost	of	1kg	of	polypropylene	costs	less	than	a	dollar	(Suriyamongkol	
et	al.,	2007).	Over	50%	of	the	total	cost	of	PHA	production	is	the	carbon	source,	used	in	
large	quantities	during	the	fermentation	process.	Various	strategies	have	been	explored	
in	order	to	lower	the	price	and	make	the	whole	process	more	efficient.	This	includes:	
using	cheap	carbon	sources,	design	of	genetically	engineered	strains,	enhancement	of	
downstream	and	upstream	processes	(Kosseva	and	Rusbandi,	2018;	Singh	et	al.,	2015;	
Luckachan	and	Pillai,	2012;	Chen,	2009).		
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1.8.8.1.	Cheap	carbon	sources	suitable	for	PHA	production	
	
Cheap	carbon	sources	can	be	divided	into	few	groups.	One	of	them	are	molasses,	such	
as	sugarcane,	sugarbeet	and	soy	molasses.	Sugarcane	molasses	have	been	used	for	PHA	
production.	For	example,	Akaraonye	et	al.,	reported	successful	production	of	P(3HB)	by	
Bacillus	cereus	SPV	and	sugarcane	molasses.	The	obtained	polymer	yield	was	over	61%	
dcw	in	the	shaken	flasks	(Akaraonye	et	al.,	2012).	In	another	report,	Bacillus	megaterium	
was	able	to	produce	P(3HB)	from	molasses	in	shaken	flasks	with	a	polymer	yield	of	46.2%	
dcw	(Gouda	et	al.,	2001).	Additionally,	some	recombinant	strains,	 like	for	example	A.	
vinelandii	UWD	mutant	and	E.	coli	were	able	to	accumulate	PHAs	when	sugar	molasses	
were	 used	 as	 the	 carbon	 source	 (Liu	 et	 al.,	 1998;	 Chen	 et	 al.,	 1997).	 However,	 the	
problem	associated	with	general	applicability	of	molasses	is	related	to	the	downstream	
decolourisation	process.	This	creates	extra	cost	which	diminishes	the	positive	impact	on	
the	PHA	cost	 reduction	 (Chanprateep,	2010).	The	second	group	 include	whey	and	 its	
hydrolysates,	 like	 for	 example:	 hydrolysed	 soy	 and	malt,	 hydrolysed	whey	and	whey	
(Koller	et	al.,	2005).	 	Starches	are	commonly	available	and	are	cheap	carbon	sources.	
However,	most	of	the	bacterial	strains	were	not	able	to	grow	on	raw	starch.	It	requires	
further	processing,	which	increases	the	price	of	the	carbon	source.	Haas	et	al.,	reported	
high	productivity	of	P(3HB)	 from	saccharified	potato	 starch	using	Ralstonia	eutropha	
(Haas	 et	 al.,	 2008).	 In	 another	 study,	 Kim	 and	 Chang	 studied	 various	 modes	 of	
fermentation	 using	Azotobacter	 chroococcum	 and	 starch.	 They	 obtained	 the	 highest	
yield	 74%	 dcw	 P(3HB)	 yield	 from	 the	 shaken	 flask	 culture.	 Oxygen	 limitation	 was	
required	to	obtain	high	polymer	accumulation	(Kim	and	Chang,	1998).	Another	group	of	
raw	materials	 to	 be	 considered	 are	 lignocellulosic	 raw	materials,	 like:	wood,	 xylose,	
hemicellulosic	hydrolysates,	wheat	bran	(Tamer	et	al.,	1997).	Another	group	of	sources	
of	 carbon	 include	 fats,	waste	 cooking	oils	 and	 vegetable	oils	 (Solaiman	et	al.,	 2006).	
Several	research	groups	have	focused	their	work	on	the	PHA	production	from	vegetable	
oils.	Especially,	Pseudomonas	species	are	able	to	utilise	oils	and	fatty	acids	for	mcl-PHA	
production.	In	another	study,	wild	and	recombinant	C.	necator	were	successfully	used	
for	efficient	PHA	production	from	soybean	oil	with	the	final	polymer	yield	above	70%	
dcw	(Kahar	et	al.,	2004).	Hassan	et	al.,	reported	production	of	PHAs	from	palm	oil	by	
Rhodobacter	sphaeroides	with	67%	dcw	polymer	content	(Hassan	et	al.,	1996).	Glycerol	
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from	 the	 production	 of	 biodiesel	 is	 another	 potential	 cheap	 carbon	 source	 for	 PHA	
production	(Baei	et	al.,	2009).	Cavalheiro	and	co-workers	reported	P(3HB)	production	
from	waste	glycerol	using	C.	necator.	The	polymer	productivity	achieved	was	1.1g/L	and	
the	 final	 yield	 obtained	 was	 50%	 dcw	 (Cavalheiro	 et	 al.,	 2009).	 In	 another	 study,	
Mozumder	et	al.,	reported	efficient	PHA	production	and	obtained	63%	dcw	PHA	yield	by	
using	a	three-stage	fermentation	(Mozumber	et	al.,	2014).	An	industrial	and	domestic	
wastewater	were	used	for	economical	production	of	PHAs	(Shamala	et	al.,	2012).	Few	
reports	 demonstrated	 successful	 utilisation	 of	 wastewater	 for	 PHA	 production.	 For	
example,	Martinez	et	al.,	worked	on	the	production	of	PHAs	from	C.	necator	and	treated	
olive	 mill	 wastewater	 and	 obtained	 a	 yield	 of	 55%	 dcw	 with	 11%	 of	 HV	 monomer	
(Martinez	et	al.,	2015).	Khardenavis	et	al.,	obtained	67%	dcw	PHA	accumulation	from	a	
mixed	culture	fed	with	wastewater	derived	from	rice	grain	distillery	(Khardenavis	et	al.,	
2007).	 Another	 group	 of	 potential	 carbon	 sources	 are	 agricultural	 waste,	 such	 as:	
harvestable	parts	of	plants,	plant	extracts,	flower	and	fruit	extracts	(Aditi	et	al.,	2015).	
Koller	and	co-workers	included	vinegar	waste,	food	waste,	plastic	waste	and	landfill	gas	
as	 a	 potential	 carbon	 source	 for	 PHA	 production	 (Koller	 et	 al.,	 2010).	 However,	 the	
lignocellulosic	materials	require	additional	treatment,	which	result	in	the	hydrolysis	and	
sugar	monomer	formation.	Cesario	et	al.,	reported	72%	dcw	PHA	accumulation	by	using	
Burkholderia	sacchari	DSM17165	from	wheat	straw	hydrolysate	(Cesario	et	al.,	2014).	
Although	various	carbon	sources	have	been	investigated	in	order	to	reduce	the	cost	of	
PHA	production,	the	golden	standard	for	an	ideal	cheap	carbon	source	has	not	yet	been	
discovered.	 Most	 of	 the	 cheap	 carbon	 sources	 require	 additional	 processing,	 which	
involves	expensive	enzymes	and	raises	 the	price	of	 the	substrate.	 In	addition	to	 this,	
further	purification	of	the	polymer	might	be	required	to	avoid	presence	of	any	potential	
contaminants	 originating	 from	 the	 carbon	 source,	 which	 further	 increases	 the	
production	cost	(Nor	Aslan,	et	al.,	2016).	
1.8.8.2.	Genetically	engineered	strains	
	
The	cost	of	PHA	using	the	natural	producer,	wild	type	strain	A.	eutrophus	was	calculated	
to	 be	within	 the	 range	 15–30.00$	 per	 kg	 (Zinn	et	 al.,	 2001)	which	 is	 18	 times	more	
expensive	than	polypropylene.	However,	the	use	of	recombinant	E.	coli	as	a	producer	of	
PHA,	can	lower	price	to	4.00$	per	kg,	which	is	similar	to	PLA	or	other	polyesters.	The	
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price	of	PHAs	should	not	exceed	5.00$	per	kg	in	order	to	be	economically	viable	(Lee,	
1996).		
Development	of	novel	genetically	engineered	strains	is	one	of	the	strategies	to	increase	
polymer	accumulation	within	the	biomass	and	reduction	of	total	PHA	production	costs.	
Engineered	Halomonas,	which	overexpress	a	cell	division	inhibitor	protein	MinCD,	are	
able	to	obtain	higher	P(3HB)	yield	and	facilitate	downstream	processing,	which	reduces	
the	production	cost	(Tan	et	al.,	2014).	Liu	and	co-workers	suggested	engineering	strains	
towards	higher	tolerance	of	wider	range	of	carbon	sources	(Liu	et	al.	2014).	Using	of	
recombinant	E.	coli	gives	higher	 level	productivity	and	high	cell	density	 fermentation	
(Bhatia	et	al.,	2015).	Deletion	of	genes	of	E.	coli,	 such	as	deletion	of	mtgA	and	mreB	
improve	 the	 production	 of	 PHAs	 thanks	 to	 increasing	 the	 volumetric	 capacity	 of	 the	
bacterial	cell	(Kadoya	et	al.,	2015).	Zhang	et	al.,	reported	construction	of	an	E.	coli	strain,	
able	 to	 produce	 PHA	 and	 succinate	 by	 overexpressing	 the	 phaC1	 gene	 from	 P.	
aeruginosa.	This	resulted	in	the	production	of	an	mcl-PHA	copolymer,	containing	3HO	
and	3HD	units,	when	glycerol,	glucose	and	fatty	acids	were	used	as	a	feedstock	(Zhang	
et	al.,	2010).	Povolo	et	al.,	cloned	the	E.	coli	lac	genes	along	with	the	PHA	depolymerase	
gene	and	introduced	it	into	C.	necator.	This	resulted	in	a	recombinant	strain	which	was	
able	to	grow	on	waste	material	with	lactose	and	produced	PHAs	in	higher	yield	than	wild	
type	C.	necator	(Povolo	et	al.,	2010).			
PHA	synthase,	PhaC,	is	the	key	enzyme	used	for	the	polymerisation	of	PHAs.	Many	phaC	
genes	have	been	cloned	and	resulted	in	an	enhancement	of	PHA	production	(Lane	and	
Benton	2015).	The	modified	strain	Rhodosprillum	rubrum,	which	overexpressed	phaC	
genes	achieved	higher	productivity	in	comparison	to	the	control	wild	type	strain	(Jin	and	
Nikolau	2014).	Moreover,	the	phaC1	gene	can	be	engineered	into	yeasts,	like	Yarrowia	
lipolytica,	which	can	result	in	obtaining	precursors	for	PHAs	production.	Yeasts	are	not	
able	to	produce	PHAs	naturally	due	to	the	lack	of	expression	of	internal	PHA	synthase.	
However,	 they	 can	 produce	 PHA	 precursors	 (3-hydroxy-acyl-CoA)	 as	 a	 result	 of	 β-
oxidation	of	fatty	acids,	which	can	be	used	as	substrates	for	mcl-PHAs	production	(Gao	
et	al.	2015).	Application	of	highly	active	synthases	can	increase	polymerisation	activity	
and	hence	the	amount	of	polymer	accumulated	inside	the	bacterial	cell	within	the	same	
period	of	time.		For	example,	highly	active	PhaC	from	Chromobacterium	sp.	USM2	has	8	
times	more	polymerisation	activity	than	the	synthase	from	C.	necator	(Bhubalan	et	al.,	
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2010).	Engineering	by	changing	metabolic	pathways	is	an	efficient	way	to	improve	PHA	
productivity.	Several	metabolic	pathways	for	PHA	production	have	been	discovered	and	
described	 previously	 in	 the	 section	 1.9.5.	 Zhang	 and	 co-workers	 reported	 combined	
engineering	 of	 serine-deamination	 pathway	 and	 the	 Entner-Doudoroff	 (ED)	 pathway	
and	 expressed	 these	 in	 E.	 coli.	 However,	 this	 resulted	 in	 excessive	 accumulation	 of	
pyruvate.	Therefore,	further	improvement	was	made	by	overexpressing	the	pyruvate-
dehydrogenase	complex	in	order	to	overcome	this	limitation.	As	a	result,	they	obtained	
enhanced	P(3HB)	production	in	E.	coli	from	different	carbon	sources,	such	as	glucose,	
xylose	 and	 glycerol.	 A	 large	 number	 of	 research	 groups	 have	 dedicated	 attention	 to	
design	bacteria	that	are	able	to	produce	PHAs	by	both	the	pathways	mentioned	above	
(Zhang	et	al.,	2013).		Apart	from	enhancement	of	polymer	production,	manipulation	in	
metabolic	pathways	can	result	in	obtaining	novel	types	of	PHAs	with	additional	desirable	
properties	(Escapa	et	al.,	2011).	
1.8.8.3.	Optimisation	of	polymer	recovery	–	downstream	processes	
	
PHA	granules	are	hydrophobic,	soluble	in	a	range	of	organic	solvents.		The	traditional	
approach	 towards	 polymer	 recovery	 from	 biomass	 requires	 large	 amounts	 of	 toxic	
solvents,	such	as	chloroform,	methylene	chloride	or	acetone,	which	raise	the	total	cost	
of	the	final	product	(Naranjo	et	al.,	2013).	Dimethyl	carbonate,	named	“green	solvent”,	
can	be	used	as	a	substitute	to	traditional	solvents	and	effective	for	the	PHA	extraction	
from	mixed	culture	(Samori	et	al.,	2015).	Ideally,	extracellular	secretion	of	PHAs,	which	
will	eliminate	the	need	for	separation	and	purification,	can	reduce	costs	significantly.	
Rahman	and	co-workers	used	recombinant	E.	coli	to	exhibit	favourable	P(3HB)	secretion,	
hence	contribute	to	the	reduction	of	downstream	costs.	They	developed	a	system	to	
secrete	P(3HB)	by	using	phasins,	low	molecular	weight	structural	proteins,	which	bind	
to	the	surface	of	P(3HB)	granules.	In	general,	Gram-negative	bacteria	are	able	to	export	
compounds	by	 six	 secretory	pathways	 (Desvaux,	et	al.,	 2009).	However	 recombinant	
proteins	can	be	targeted	to	type	I	or	II	secretory	pathways.	Type	I	secretory	pathway	can	
translocate	proteins	up	 to	900kDa	 from	cytoplasm	 to	extracellular	medium	 in	Gram-
negative	 bacteria	 without	 protein-periplasm	 interplay	 (Mergulhão	 et	 al.,	 2005).	
Translocation	 of	 PHB	 granules	 is	 possible	 after	 reduction	 of	 the	 granule	 size.	
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Overexpression	of	phasins,	which	bind	into	PHB	result	in	efficient	decrease	in	the	size	of	
the	PHB	granules.	Rahman	and	co-workers	demonstrated	successful	indirect	secretion	
of	PHB	and	phasin	PhaP1	from	E.	coli	by	using	signal	peptide	HlyA	via	type	I	secretory	
pathway.	Development	 of	 a	 secretion	mechanism	will	 simplify	 the	 polymer	 recovery	
system	 by	 elimination	 of	 cell	 disruption	 steps	 involved	 in	 the	 extraction	 process	
(Rahman	et	al.,	2013).		
1.8.8.4.	Efficient	fermentation	strategies	–	improvement	in	upstream	
processes	
	
Production	 of	 PHAs	 can	 be	 improved	 by	 improving	 the	 fermentation	 process.	 PHA	
biosynthesis	involves	several	variables,	such	as	type	of	carbon	source,	temperature,	pH,	
precursor	supply,	air	supply,	harvesting	time	and	stirrer	speed.	Therefore,	optimisation	
of	fermentation	kinetics	has	an	impact	on	PHA	production.	For	example,	Chen	and	co-
workers,	 optimised	 fermentation	 by	 mixing	 cultures,	 feeding	 strategies	 and	 applied	
constant	pH	control	over	the	time	of	fermentation	(Chen	et	al.,	2015).	Lack	of	oxygen	in	
the	environment	resulted	in	improved	PHA	production	(Davis	et	al.,	2015).	Fermentation	
strategy	plays	a	very	 important	 role	 in	 the	PHA	production.	For	example,	continuous	
fermentation	 offers	 better	 results	 in	 terms	 of	 the	 obtained	 biomass	 and	 polymer	
productivity	as	compared	to	batch	cultivation	(Amulya	et	al.,	2015;	Marang	et	al.,	2014).	
Koller	and	Braunegg,	2015	studied	a	multistage	system,	containing	series	of	connected	
continuous	 bioreactors	 in	 order	 to	 obtain	 novel	 materials	 with	 higher	 polymer	
productivity.	This	system	will	allow	production	of	novel	copolymers,	containing	blocks	
or	 larger	 number	 of	 different	monomer	 units	 to	meet	 the	market	 demands	 for	 the	
material	with	specific	properties	(Koller	and	Braunegg,	2015).		
1.8.9. 	Synthesis	of	PHA	blends	and	composites	
 
Physical	 blending	with	particles	or	other	polymers	 in	 the	most	 common	approach	 in	
order	 to	 overcome	 or	 improve	 some	 of	 the	 properties	 of	 the	 materials,	 such	 as	
brittleness	in	case	of	scl-PHAs.	For	example,	inorganic	particles	have	a	positive	impact	
on	 toughness	 and	 processability	 of	 scl-PHAs	 by	 decrease	 in	 spherulite	 size	 and	
enhancement	 in	nucleation	density	 (Ding	et	al.,	2011).	Many	different	particles	were	
introduced	to	PHAs,	such	as	of	tungsten	disulphide	inorganic	nanotubes,	boron	nitride,	
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talc,	 hydroxyapatite,	 bioglasses,	 carbon	 nanotubes	 and	 zinc	 stearate	 (Naffakh	 et	 al.,	
2014;	Wang	et	al.,	2010;	Shan	et	al.,	2011).	Organic	particles	might	be	 introduced	to	
PHAs,	such	as	nano-cellulose,	chitosan	and	bacterial	cellulose	nanocrystals	(Martinez-
Sanz	et	al.,	2014).	Moreover,	addition	of	nanoparticles,	like	for	example	titanium	dioxide	
(TiO2)	or	clay,	can	improve	thermal	stability	of	scl-PHAs	(Wu	et	al.,	2008;	Mook	Choi	et	
al.,	 2003).	 Addition	 of	 reinforcing	 agents	 have	 a	 positive	 impact	 on	 mechanical	
properties.	 For	 example,	 P(3HB-co-3HV)	 and	 graphene	 nanocomposites	 presented	
significantly	higher	storage	modulus	as	compared	to	neat	P(3HB-co-3HV)	(Sridhar	et	al.,	
2013).	 Another	 example	 described	 addition	 of	 hydroxyapatite	 and	 silane-modified	
hydroxyapatite	 to	 PHBV	 and	 sample	 preparation	 by	melt	 extrusion.	 As	 a	 result,	 the	
toughness	 as	well	 as	 strength	 and	 stiffness	of	 the	material	was	 improved	 (Oner	 and	
Idotlhan,	 2016).	 Cellulose	 nanowhiskers	 were	 found	 to	 be	 very	 efficient	 reinforcing	
agents	 for	PHBV.	They	promoted	chain	orientation	and	significantly	 improved	tensile	
strength,	Young’s	modulus	value	and	storage	modulus	(Patricio	et	al.,	2013).		
Blending	 scl-PHAs	 with	 other	 polymers	 has	 a	 practical	 and	 economic	 impact.	 This	
method	is	simple,	quick	and	cost	efficient.	Interactions	between	component	polymers	
within	the	blends	create	its	miscibility.	Usually	blends	of	the	polymers	can	have	three	
different	states	of	miscibility,	which	are	either	miscible,	immiscible	or	partially	miscible	
(Yu	 et	 al.,	 2006).	 Good	miscibility	may	 result	 in	 uniform	 polymer	 blends	 with	 novel	
material	 properties	 (Tanadchangsaeng	 and	 Yu,	 2013).	 Added	polymers	 can	be	 either	
biodegradable	(e.g.	PHAs,	polycaprolactone	(PCL),	poly(lactic	acid)	(PLA),	poly(butylene	
succinate)	(PBS),	poly(propylene	glycol),	lignin	and	plant	fibers)	or	non-degradable	(e.g.	
polystyrene,	polymethyl	methacrylate,	polyurethanes)	(Jian	et	al.,	2010;	Ma	et	al.,	2014;	
Nagarajan	et	al.,	2013).	Many	research	groups	have	focused	their	study	on	P(3HB)/PLLA	
blends.	 For	 example,	 Furukawa	 and	 co-workers	 studied	 P(3HB)/PLLA	 and	 P(3HB-co-
3HHx)/PLLA	 blends.	 They	 found	 that	 both	 blends	were	 immiscible.	 However,	 blends	
containing	P(3HB-co-3HHx)	copolymer	with	PLLA	were	more	compatible.	Analysis	of	the	
cold	 crystallisation	 temperature	 proposed	 mixed	 semicrystalline	 structure	 of	 both	
developed	PHAs/PLLA	blend	materials	described	above.	PHA	copolymers	when	present	
within	the	PLLA	matrix	in	low	concentration	did	not	crystallise	(Furukawa	et	al.,	2007).	
Interestingly,	 blends	 of	 P(3HB)	 with	 PDLLA	 prepared	 at	 room	 temperature	 were	
immiscible.	 But	 the	 same	blends	 produced	 at	 high	 temperature	demonstrated	 some	
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level	of	miscibility.	Addition	of	PDLLA	significantly	affected	the	behaviour	of	P(3HB).	A	
significant	decrease	of	melting	temperature	and	crystallinity	of	P(3HB)	were	observed.	
A	slight	improvement	in	the	mechanical	properties	in	elongation	at	break	was	achieved	
in	 comparison	 to	 neat	 P(3HB)	 (Zhang	et	 al.,	 1996).	 Park	 and	 co-workers	 studied	 the	
influence	of	the	molecular	weight	of	P(3HB)	and	monoaxial	drawing	at	glass	transition	
temperatures	of	the	dominant	compound	in	the	blend	with	PLLA	on	the	properties	of	
the	 materials.	 Commercially	 available	 bacterial	 origin	 P(3HB)	 as	 well	 as	 ultra-high	
molecular	weight	P(3HB)	obtained	from	recombinant	E.	coli	were	used	with	PLLA.	Both	
systems	 were	 immiscible.	 In	 the	 system	 with	 commercial	 P(3HB)	 dominated	 blends	
improvement	in	the	mechanical	properties	was	observed.	PLLA	played	a	reinforcing	role	
in	this	blend,	which	allowed	good	interaction	between	both	polymers,	which	resulted	in	
an	increase	in	the	mechanical	properties,	such	as	tensile	strength	and	Young’s	Modulus.	
Blends	based	on	ultra-high	molecular	weight	P(3HB),	the	mechanical	properties	were	
significantly	 improved	due	to	the	orientation	of	PLLA	chains	achieved	during	the	cold	
drawing	 as	 a	 result	 of	 interphase	 tangling	of	 very	 long	polymeric	 chains	 (Park	et	 al.,	
2004).	P(3HB)	was	also	mixed	with	other	PHAs	to	enhance	the	properties.	Addition	of	
P(3HO)	resulted	in	obtaining	an	immiscible	system	and	phase	separation,	which	has	a	
negative	impact	on	the	mechanical	properties	of	the	blend	(Dufresne	and	Vincendon,	
2000).	 In	 another	 example,	 P(3HB)	 was	 mixed	 with	 P(3HB-co-3HV)	 copolymer,	
containing	various	amounts	of	the	3HV	unit.	It	was	found	that	increased	amount	of	the	
3HV	unit	resulted	in	a	higher	degree	of	phase	separation	and	weaker	miscibility	between	
both	 components.	 To	 obtain	 co-crystallisation	 between	 two	 or	 more	 compounds,	
certain	criteria	need	to	be	met	including,	miscibility	at	the	melt	stage,	similar	crystalline	
structure	and	crystallisation	rates.	In	all	blends,	there	is	a	competition	between	phase	
separation	 and	 cocrystallisation.	 Good	 miscibility	 prevents	 phase	 separation,	 which	
allows	to	meet	requirements	for	cocrystallisation	(Saito	et	al.,	2001).	
There	was	also	work	on	the	blending	of	starch	and	P(3HB)	in	order	to	fabricate	miscible	
blends.	The	blend	was	compatible,	which	was	confirmed	by	DSC	analysis,	i.e.	only	one	
glass	transition	temperature	was	detected.	The	optimal	amount	of	starch	required	to	
maintain	 the	 mechanical	 property	 was	 found	 to	 be	 30	 wt%.	 Results	 demonstrated	
enhanced	 properties	 of	 the	 blend	 in	 comparison	 to	 neat	 P(3HB)	 as	 well	 as	 a	 cost	
reduction,	since	starch	is	one	of	the	cheapest	biopolymers	(Godbole	et	al.,	2003).			
CHAPTER	1	
	
	 55	
The	main	 problem	 associated	with	 blending	 is	miscibility	 between	 the	 components.	
Therefore,	 a	 lot	 of	 different	 types	 of	 compatibilizers,	 like	 oxidized	 polyethylene	wax	
(OPW)	have	been	used	to	overcome	this	limitation	(Rosa	et	al.,	2007).	Another	type	of	
material,	such	as	wood	flour,	tannic	acids	and	plant	polyphenols	were	used	to	improve	
mechanical	 properties	 of	 scl-PHAs	 (Jandas	 et	 al.,	 2013;	 Gregorova	 et	 al.,	 2009).	 For	
example,	lignin	powder	was	added	to	P(3HB)	as	a	nucleating	agent.	Addition	of	lignin	
resulted	in	reduction	of	the	half-time	for	crystallisation,	but	did	not	change	structure	of	
crystals	and	crystallinity	degree.	The	results	obtained	confirmed	the	application	of	lignin	
as	a	proper	nucleating	agent	for	the	crystallisation	of	P(3HB)	(Weihua	et	al.,	2004).		
	
1.8.10.	Applications	of	PHAs	
	
Due	to	its	characteristics,	biodegradable	PHAs	can	be	used	in	a	variety	of	applications	
including	medicine,	pharmacy,	 implants,	packaging,	 chemical	 industry,	 food	 industry,	
industrial	microbiology,	cosmetology,	agriculture	and	photography	(Ray	and	Kalia,	2017;	
Chen,	2010;	Ojumu	and	Solomon,	2004;	Thakor	et	al.,	2006).	In	this	thesis,	we	will	focus	
on	the	biomedical	applications	of	PHA.	
	
1.8.10.1.	Biomedical	applications	
	
One	of	the	greatest	potential	of	PHAs	is	related	to	the	area	of	medicine,	which	includes	
wound	management,	nerve	 regeneration,	drug	delivery	 system,	 stents,	 repair	of	 soft	
tissue	and	hard	tissue	and	heart	tissue	engineering	(Misra	et	al.,	2010).	
	
Tissue	engineering	
	
The	main	aim	of	tissue	engineering	is	to	provide	products,	which	can	restore,	maintain	
and	 improve	function	of	 injured,	diseased	or	replaced	organs,	tissues	or	cells	 (Langer	
and	Vacanti,	1993).	The	main	approach	is	to	use	either	biomaterial	scaffolds,	promoting	
cell	attachment	and	proliferation;	infusion	of	isolated	cells	or	the	combination	of	both,	
which	is	implantation	of	polymeric	scaffolds	seeded	with	special	type	of	cells,	depending	
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on	 the	 application	 (Bettinger,	 2009).	 Tissue	 engineering	 scaffolds	 are	 designed	 to	
provide	a	support	structure	for	the	engineered	tissue.	Rejection	of	the	implant	can	be	
minimized	by	using	autologous	cells,	and	or	by	administering	immunosuppressive	drugs	
(Bell	et	al.,	1981).	The	properties	of	the	materials	for	scaffolds	in	tissue	engineering	have	
been	 already	 specified	 by	 Knight	 and	 Evans,	 2004.	 They	 have	 to	 meet	 certain	
requirements,	 such	 as	 non-toxicity	 and	 high	 biocompatibility	 and	 should	 be	 non-
carcinogenic.	 Apart	 from	 this	 they	 have	 to	 be	 able	 to	 be	 sterilised,	 deployed	 by	 the	
surgeon,	have	appropriate	mechanical	properties	and	topography	which	will	allow	cell	
attachment	and	proliferation	as	well	as	be	able	to	incorporate	drugs	and	other	bioactive	
molecules,	such	as	growth	factors,	peptides	and	antibodies	(Ravichandran	et	al.,	2012;	
Knight	et	al.,	2004).		
PHAs	have	been	intensively	investigated	for	biomedical	applications.	The	properties	of	
PHAs	 can	be	 tailored	by	 adding	different	 types	 of	 blocks,	 various	 treatments	 can	be	
performed	on	the	surface	to	allow	the	attachment	of	bioactive	agents.	Apart	from	that,	
scaffolds	can	be	fabricated	by	a	broad	range	of	techniques,	which	allows	the	production	
of	 the	appropriate	design	 suitable	 for	 the	 specific	application	 (Williams	et	al.,	 1999).	
PHAs,	its	blends	and	composites	have	been	used	for	the	production	of	sutures,	tacks,	
staples,	screws,	bone	plates,	surgical	meshes,	repair	patches	and	orthopaedic	pins	(Dai	
et	 al.,	 2009).	 Also,	 several	medical	 devices,	 such	 as:	 stents,	 nerve	 conduits,	 artificial	
cartilage,	wound	dressing,	artificial	skin	and	drug	delivery	carriers	have	been	developed	
using	PHAs	(Bian	et	al.,	2009;	Wang	et	al.,	2008).	Rai	et	al.,	2011,	reported	development	
of	 scaffolds	 based	 on	 P(3HO)	 homopolymer	 for	 soft	 tissue	 engineering.	 Material	
supported	 attachment	 and	 proliferation	 of	 human	 adult	 low	 calcium	 temperature	
keratinocytes	 (HaCaT).	 This	 study	 demonstrated	 suitability	 of	 mcl-PHA	 scaffolds	 for	
wound	healing	applications	(Rai	et	al.,	2011).	PHA	based	blends	were	also	considered	
for	 various	 biomedical	 applications.	 For	 example,	 Basnett	 et	 al.,	 2013	 reported	
development	of	P(3HO)/P(3HB)	blends	for	biomedical	applications.	Addition	of	P(3HB)	
resulted	 in	 the	 significant	 improvement	 of	 mechanical	 properties,	 such	 as	 tensile	
strength	and	Young’s	Modulus	and	the	protein	adsorption	to	the	surface	in	comparison	
to	 neat	 P(3HO).	 Material	 was	 considered	 as	 highly	 biocompatible	 and	 suitable	 for	
various	types	of	medical	applications	(Basnett	et	al.,	2013).	In	another	study,	Lizarraga-
Valderrama	 et	 al.,	 2015,	 demonstrated	 development	 of	 P(3HB)/P(3HO)	 blends	 for	
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peripheral	nerve	regeneration.	Blends	with	75	wt%	of	P(3HB)	resulted	 in	significantly	
higher	 compatibility	 to	NG108-15	neuronal	 cells,	 especially	 in	 the	 context	 of	 neurite	
extension.	 	Therefore,	this	composition	was	recommended	as	potential	candidate	for	
nerve	 conduit	 in	 peripheral	 nerve	 repair	 (Lizarraga-Valderrama	 et	 al.,	 2015).	 Many	
different	 types	 of	 PHA	 based	 composites	 have	 been	 developed	 for	 bone	 tissue	
engineering.	 Changing	mechanical	 and	 topographical	 properties	 by	 addition	of	 other	
materials	have	allowed	them	to	be	used	in	a	variety	of	applications.	Misra	et	al.,	2010,	
demonstrated	suitability	of	P(3HB)/BioglassTM	composites	containing	carbon	nanotubes	
as	a	 functional	 scaffold	material	 for	bone	 tissue	engineering	 (Misra	et	al.,	 2010a).	 In	
another	 study	 Misra	 et	 al.,	 reported	 the	 development	 of	 3D	 highly	 porous	
P(3HB)/bioglass	 composite	 foams	 for	 bone	 tissue	 engineering.	 This	 novel	 material	
demonstrated	 antimicrobial	 properties	 against	 Staphylococcus	 aureus	 due	 to	 the	
presence	 of	 bioglass.	 Addition	 of	 carbon	 nanotubes	 induced	 electrical	 conductivity.	
Obtained	3D	scaffold	allowed	vascularisation	in	the	animal	model	(Misra	et	al.,	2010b).	
Recently,	 Akaraonye	 et	 al.,	 2016	 reported	 results	 on	 two	 types	 of	 P(3HB)	magnetic	
nanocomposites,	 containing	 either	 magnetic	 nanoparticles	 or	 ferrofluid	 as	 smart	
materials	for	bone	regeneration.	Presence	of	magnetic	particles	or	ferrofluid	resulted	in	
enhanced	Young’s	Modulus	values	and	crystallinity.	Moreover,	scaffolds	demonstrated	
higher	biocompatibility	to	MG-63	cells	in	comparison	to	neat	P(3HB)	and	tissue	culture	
plastic.	Hence	 confirm	 suitability	 for	 bone	 tissue	 repair	 (Akaraonye	et	 al.,	 2016a).	 In	
another	study,	Akaraonye	et	al.,	used	P(3HB)	with	microfibrillated	bacterial	cellulose	for	
articular	 cartilage	 regeneration,	 especially	 in	 load	 bearing	 joints.	 The	 developed	 3D	
scaffolds	 had	 high	 porosity	 and	 surface	 area.	 The	 scaffolds	 demonstrated	 similar	
topography	 to	 the	 extracellular	 matrix	 and	 exhibited	 high	 biocompatibility	 towards	
chondrogenic	ATDC5	cells	 (Akaraonye	et	al.,	2016b).	Cheng	et	al.,	demonstrated	that	
P(3HB)	promoted	proliferation	of	L929	cells	by	preventing	apoptotic	and	necrotic	cell	
death.	 This	 can	 be	 useful	 in	 the	 applications,	 that	 require	 regeneration	 of	 the	 large	
amounts	 of	 cells.	 In	 another	 study,	 they	 confirmed	 that	 P(3HB-co-3HHx)	 copolymer	
microparticles	also	promoted	L929	cell	proliferation	(Cheng	et	al.,	2006).		
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Cardiovascular	tissue	engineering	
	
Cardiovascular	 tissue	 engineering	 includes	 blood	 vessels	 regeneration,	 valves	
development,	heart	patch	development	and	coronary	stent	development.	Biomaterials	
used	routinely	in	cardiovascular	tissue	engineering	include:	polymers,	such	as	polylactic	
acid,	polyglycolic	acid	and	hydrogels,	like	collagen,	fibrin	and	hyaluronic	acid	(Truskey,	
2016).	 PHAs	 have	 also	 been	 considered	 for	 these	 applications.	 For	 example,	 Poly(3-
hydroxybutyrate)	has	been	studied	for	cardiovascular	applications.	Although	it	belongs	
to	scl-PHA,	containing	strong	and	stiff	materials,	it	demonstrated	promising	results	for	
application	 in	 cardiac	 regeneration	or	 vascular	 repair.	One	of	 the	 first	 reports	 about	
potential	application	of	P(3HB)	as	a	patch	for	pericardium	regeneration	was	published	
in	1992	by	Malm	and	co-workers.	After	24	months,	the	polymer	was	still	present	in	the	
sheep	model	P(3HB)	was	not	found	to	enhance	platelet	aggregation	(Malm	et	al.,	1992).	
Two	years	later	the	same	group	studied	P(3HB)	transannular	patches	in	animal	models.	
Although	 many	 macrophages	 were	 present,	 P(3HB)	 did	 not	 accelerate	 platelet	
aggregation.	Moreover,	 the	 regenerated	vessel	demonstrated	 similar	 functionality	 to	
the	native	pulmonary	 artery	 (Malm	et	 al.,	 1994).	 The	P(3HB-co-3HV)	 copolymer	was	
used	 along	 with	 polylactic	 acid	 and	 polyglycerol	 sebacate	 to	 form	 fibre	 sheets	 as	 a	
pericardial	patch	for	myocardium	repair.	These	electrospun	fibres	were	also	successfully	
used	to	fabricate	porous	tubing	for	pericardium	repair	(Kenar	et	al.,	2010).	Badgadi	et	
al.,	reported	various	types	of	cardiac	patches	based	on	the	neat	P(3HO).	It	was	observed,	
that	 incorporation	 of	 fibres	 or	 porosity	 enhanced	 cell	 attachment	 and	 proliferation.	
Therefore,	P(3HO)	based	constructs	can	be	considered	as	a	strong	candidate	for	cardiac	
tissue	regeneration	(Bagdadi	et	al.,	2017).	In	another	experiment,	P(3HO)	was	made	in	
to	3D	porous	scaffolds	and	seeded	with	endothelial	cells	for	replacement	of	the	tricuspid	
heart	valve.	The	seeded	cells	formed	a	confluent	 layer	on	the	scaffold.	(Sodian	et	al.,	
2000a).	 Another	 polymer,	 Poly(4-hydroxybutyrate),	 which	 exhibits	 exceptional	
elastomeric	properties	in	comparison	to	other	members	of	the	scl-PHA	group	was	also	
used	 in	 cardiovascular	 tissue	 engineering.	 However,	 it	 has	 demonstrated	 rapid	
degradation	 in	 vivo,	which	 limited	 its	 applicability	 in	 this	 area	 (Chen	and	Wu,	 2005).	
However,	P(4HB)	was	also	used	as	a	replacement	of	the	pulmonary	valve	in	an	animal	
model.	 After	 24	 weeks,	 there	 was	 no	 stenosis	 or	 thrombosis	 observed.	 The	 results	
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obtained	confirmed	the	suitability	of	this	material	for	pulmonary	valve	repair	(Stock	et	
al.,	2000).	 In	another	study	Sodian	et	al.,	 studied	P(4HB)	as	a	bulk	material	 for	heart	
valve	fabrication.	However,	P(4HB)	did	not	meet	the	requirements	during	in	vivo	study.	
The	material	had	prolonged	degradation	rate,	and	was	stable	in	the	body	environment,	
which	led	to	incomplete	replacement	and	could	potentially	cause	side	effects	(Sodian	et	
al.,	2000b).	P(3HB-co-4HB)	copolymer	was	used	for	the	development	of	artificial	blood	
vessels.	The	amount	of	elastin	 found	 in	 the	animal	model	was	160%	higher	 than	 the	
P(3HB-co-3HHx)	studied	previously	 for	 this	application	 (Cheng	et	al.,	2008).	Coronary	
stents	are	demanding	medical	devices,	which	require	specific	material	properties.	One	
of	the	very	important	factors	to	consider	is	the	excessive	vascular	smooth	muscle	cell	
proliferation,	which	might	 be	 induced	 by	 injury	 to	 the	 vessel	wall	 or	 insufficient	 re-
endothelialisation.	Application	of	suitable	biopolymers	can	solve	these	problems.	Ideal	
stent	requirements	were	listed	in	the	section	1.7.	The	stent	should	be	stable	inside	the	
body,	made	from	the	non-immunogenic	and	non-toxic	materials.	The	material	should	
demonstrate	 high	 biocompatibility	 towards	 endothelial	 cells	 to	 reduce	 immunogenic	
response	and	the	development	of	restenosis.	Most	of	the	tested	biomaterials	tested	for	
coronary	stent	development	demonstrated	tissue	incompatibility	(Regar	et	al.,	2001).	
PHAs	 can	 be	 considered	 for	 this	 application.	 Various	 types	 of	 PHAs	 have	 been	
investigated	 for	 this	 application.	 For	 example,	 Basnett	 et	 al.,	 2013	 reported	
P(3HO)/P(3HB)	 blends	 for	 biomedical	 application,	 especially	 coronary	 artery	 stents.	
Blends	demonstrated	improved	mechanical	properties	and	enhanced	biocompatibility	
in	comparison	to	neat	P(3HO)	(Basnett	et	al.,	2013).	Another	example	is	the	ReBioStent	
(2013-2016)	Project,	an	European	Union’s	Seventh	Framework	Programme	(FP7).	One	
of	 the	 main	 approaches	 of	 this	 project	 was	 to	 investigate	 the	 use	 of	 PHAs	 for	 the	
development	of	Reinforced	Bioresorbable	Therapeutic	Drug	Eluting	Stents.	
	
Drug	delivery	
	
Polyhydroxyalkanoates	 are	 considered	 as	 very	 attractive	 group	 of	materials	 for	 drug	
delivery.	This	 is	due	to	their	proven	biocompatibility	and	material	properties,	such	as	
degradation	 kinetics	 and	 non-toxicity.	 Moreover,	 PHAs	 as	 natural	 biopolymers	 are	
produced	 according	 to	 natural	 metabolic	 pathways	 without	 any	 additional	 chemical	
CHAPTER	1	
	
	 60	
catalysts,	which	usually	are	toxic	and	can	contaminate	the	final	polymer	after	chemical	
synthesis.	 Apart	 from	 that,	 PHAs	 demonstrate	 higher	 stereochemical	 purity	 as	
compared	 to	 synthetic	 materials,	 which	 can	 be	 produced	 as	 a	 mixture	 of	 both	
configurations	 and	 require	 additional	 separation	 after	 synthesis	 (Pouton	 and	Akhtar,	
1996).	PHAs	were	considered	as	drug	delivery	vehicles	for	the	first	time	in	1980s,	when	
neat	P(3HB)	and	P(3HB-co-3HV)	copolymer	were	investigated	as	a	vehicle	for	oral	drug	
administration	(Korsatko	et	al.,	1983;	Gould	et	al.,	1987).	Since	then	research	in	this	area	
has	 progressed	 substantially.	 P(3HB)	 and	 PLA	microspheres	 have	 been	 compared	 in	
order	to	release	the	anticancer	agent,	lomustine	by	Bissery	et	al.,	1985.	It	was	found,	
that	 the	 amount	 of	 drug	 released	 from	 P(3HB)	 was	 higher,	 possibly	 due	 to	 greater	
porosity	(Bissery	et	al.,	1985).	Various	polymers	from	the	PHA	family	have	been	studied	
for	controlled	drug	delivery,	due	to	their	diverse	properties.	PHAs	degrade	much	slower	
than	polylactides,	therefore	they	can	be	successfully	used	for	prolonged	drug	delivery	
(Gogolewski	et	al.,	1993).	Also,	material	properties	of	the	scl-PHAs	allow	formulation	of	
microspheres	and	nanoparticles	with	encapsulated	drugs.	Various	types	of	PHAs	have	
been	explored	as	a	polymer	matrix	for	different	drug	delivery	devices.	For	example:	In	
vitro	release	study	of	P(3HB-co-3HV)	rods	containing	antibiotics,	such	as	gentamycin	or	
sulperazone	demonstrated	presence	of	drugs	 in	 the	body	within	2	weeks.	 P(3HB-co-
3HV)	 copolymer,	 containing	 20%	 3HV	 within	 the	 monomer	 unit	 demonstrated	
controlled	release	of	antibiotics	for	up	to	60	days	(Gurselt	et	al.,	2002).	In	another	similar	
study,	Rossi	and	co-workers	obtained	similar	results.	Higher	amount	of	3HV	within	the	
scl-PHA	copolymer	resulted	in	sustainable	drug	release	for	a	longer	period	of	time	and	
the	 amount	 of	 released	drugs	were	higher	 than	 in	 neat	 P(3HB).	Moreover,	 the	 drug	
delivery	systems	were	haemocompatible	and	did	not	induce	any	negative	effect	on	the	
blood	 cells	 (Rossi	 et	 al.,	 2004).	 Francis	 et	 al.,	 reported	 production	 of	 P(3HB)	 based	
microspheres	 and	 multifunctional	 scaffolds,	 microsphere/composite	 scaffolds	 with	
encapsulated	gentamycin	for	bone	tissue	regeneration.	Controlled	slow	release	of	the	
drug	was	achieved	in	the	composite	scaffold,	whereas	burst	release	of	the	same	drug	
was	observed	from	neat	P(3HB)	microspheres	(Francis	et	al.,	2011;	Francis	et	al.,	2010).	
Zinn	 et	 al.,	 2001,	 demonstrated	 a	 rapid	 release	 of	 rifampicin	 and	 tetracycline	
encapsulated	in	neat	P(3HB)	microspheres.	These	results	indicated	the	influence	of	the	
degree	of	crystallinity	on	the	release	kinetics.	 	The	PHAs	with	lower	crystallinity	were	
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more	suitable	for	cumulative	release	profiles	(Zinn	et	al.,	2001).	P(3HHx-co-3HO),	mcl-
PHAs	copolymer,	was	mixed	with	a	polyamidoamine	dendrimer	to	create	drug	delivery	
system	for	tamulosin,	a	drug	used	for	treatment	of	benign	prostate	hyperplasmia.	This	
construct	was	found	to	enhance	the	release	of	the	drug	in	vivo	(Wang	et	al.,	2003).	Also,	
P(3HB)	 microspheres,	 containing	 the	 anti-cancer	 drug,	 rubomycin,	 inhibited	 the	
proliferation	 of	 carcinoma	 cells	 in	 the	 mice	 model	 (Shishatskaya	 et	 al.,	 2008).	 PHA	
granule	binding	proteins,	called	PhaP	were	used	in	the	receptor-mediated	targeted	drug	
delivery	system,	containing	PHA	nanoparticles	with	hydrophobic	drugs,	PhaP	and	ligands	
linked	to	it.	PhaP-PHA	nanoparticles	complex	were	transported	to	targeted	cells,	which	
were	 hepatocellular	 carcinoma	 cells.	 The	 ligand-PhaP-PHA	 drug	 delivery	 system	
demonstrated	effectiveness	in	vitro	as	well	as	in	vivo	in	the	animal	models	(Yao	et	al.,	
2008).		
Hence,	 Polyhydroxyalkanoates	 are	 a	 group	 of	 biomaterials	 with	 very	 high	 potential	
towards	biomedical	applications.	Their	unique	properties,	such	as	high	biocompatibility,	
biodegradability,	 non-toxicity	 and	 tuneable	mechanical	 and	 thermal	properties	make	
them	especially	attractive	for	medical	devices,	such	as	coronary	stents.	Moreover,	some	
PHA-based	 products	 have	 received	 the	 FDA	 clearance.	 For	 example,	 TephaFLEX	
absorbable	sutures,	which	is	first	PHAs-based	medical	device,	made	from	P(4HB)	gained	
FDA	clearance	in	2007.	That	was	a	mile	stone	in	the	use	of	PHAs	in	biomedical	areas.	In	
2009	Aesculap	AG	received	CE	Mark	for	MonoMax	monofilament	absorbable	sutures	in	
Europe,	made	from	TephaFlex	fibers	(Chen,	2009).	 
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Aims	and	objectives		
	
The	main	aim	of	 this	project	was	 to	obtain	novel	biomaterials,	based	on	PHAs,	using	
Pseudomonas	mendocina	CH50	 and	Bacillus	 subtilis	OK2,	 suitable	 for	medical	 device	
development	with	focus	on	coronary	artery	stents.		
	
Specific	objectives	of	this	project	were:		
	
1. Production	of	the	novel	PHAs	by	using	different	bacterial	strains	and	a	range	of	
various	carbon	sources	and	their	characterisation.		
	Screening	experiments	were	performed	in	order	to	obtain	novel	PHAs.	The	polymers	
produced	were	chemically	characterised	using	Fourier	Transform	Infrared	Spectroscopy	
(FTIR)	and	chemically	identified	using	Gas	Chromatography	Mass	Spectrometry	(GC-MS).	
Selected	materials	were	characterised	further	by	Nuclear	Magnetic	Resonance	(NMR)	
analysis.	Thermal	properties	of	 the	selected	materials	were	studied	using	Differential	
Scanning	Calorimetry	(DSC)	and	mechanical	properties	were	tested	using	tensile	testing.		
2. Development	 of	 novel,	 biocompatible	 and	 biodegradable	 P(3HB)/oligo-PHA	
blends.		
Three	 different	 compositions	 of	 the	 blends	 of	 P(3HB)/oligo-PHA	 were	 studied	 with	
respect	to	their	mechanical	properties	using	tensile	testing	and	thermal	properties	using	
DSC.	 In	 addition,	 the	 microstructural	 properties	 were	 investigated	 using	 Scanning	
Electron	Microscopy	(SEM),	surface	roughness	analysis,	protein	adsorption	and	contact	
angle	measurement.	 Thermal	 and	mechanical	 properties	were	 also	 studied	 during	 7	
weeks	of	storage	at	the	room	temperature	in	order	to	investigate	the	effect	of	ageing	
on	the	properties	if	the	blends.		Biocompatibility	of	these	P(3HB/oligo-PHA)	blends	were	
tested	 using	 human	 dermal	 microvascular	 endothelial	 cells	 (HMEC-1).	
Haemocompatibility	 studies	were	 also	 carried	 out	 to	 investigate	 the	 reaction	 of	 the	
blood	cells	after	direct	contact	with	the	material.	
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3. Development	of	novel,	biocompatible	and	biodegradable	multifunctional	2D	
biodegradable	 P(3HB)/oligo-PHA	 composites	 with	 barium	 sulphate	 as	 a	
radiopaque	agent.		
A	 selected	blend	 film	 composition	P(3HB/oligo-PHA)	90/10	was	mixed	with	different	
amounts	of	barium	sulphate	in	order	to	obtain	radiopaque	composites.	Materials	were	
characterised	with	 respect	 to	 their	mechanical	 properties	 using	 tensile	 test,	 thermal	
properties	 using	 DSC	 and	 microstructural	 properties	 using	 SEM,	 MicroCT,	 protein	
adsorption	 and	 contact	 angle	measurements.	 They	were	 also	 characterised	 for	 their	
bioactivity	 using	 HMEC-1	 cells	 to	 assess	 their	 suitability	 in	 the	 development	 of	
biodegradable	 stents.	 Direct	 and	 indirect	 cytotoxicity	 studies	 were	 performed.	
Haemocompatibility	studies	were	carried	out	to	 investigate	the	reaction	of	the	blood	
cells	after	direct	contact	with	the	material.	
4. Manufacturing	of	the	P(3HB)/oligo-PHA	tubes	by	dip	moulding	technique.	
P(3HB)/oligo-PHA	 90/10	 blend	 were	 selected	 for	 tube	 manufacturing	 by	 the	 dip	
moulding	technique	as	a	potential	candidate	for	coronary	stent	application.	Tubes	were	
characterised	with	respect	to	the	mechanical	and	thermal	properties	within	7	weeks	of	
storage	 at	 room	 temperature	 in	 order	 to	 investigate	 the	 effect	 of	 ageing	 on	 the	
properties	of	the	material.	Tubes	were	also	incubated	in	DMEM	media	at	37°C	in	order	
to	mimic	 in	 vivo	 conditions	 and	 observe	 influence	 of	 the	 body	 environment	 on	 the	
material	 properties.	 In	 addition,	microstructural	 studies	were	 performed	 using	 SEM,	
microCT	and	protein	adsorption	studies.	HMEC-1	were	grown	on	the	 tubes	 to	assess	
their	 biocompatibility	 to	 the	 developed	 biomaterial.	 Direct	 and	 indirect	 cytotoxicity	
studies	were	performed.	Haemocompatibility	studies	were	carried	out	to	investigate	the	
reaction	of	the	blood	cells	after	direct	contact	with	the	material.	Degradation	studies	
were	also	carried	out	to	confirm	suitability	of	the	selected	materials	for	coronary	stent	
application.	
5. Incorporation	 of	 the	 drugs,	 such	 as	 rapamycin	 or	 tacrolimus	 in	 the	
P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 as	 a	 platform	material	 for	
development	of	drug	eluting	biodegradable	stent.	
P(3HB)/oligo-PHA	90/10	blend	tubes	were	coated	with	PCL-PEG550	with	incorporated	
rapamycin	or	 tacrolimus	 (1-1.5µg/mm2)	 and	were	 characterised	 for	 their	mechanical	
properties	using	 tensile	 testing,	 thermal	properties	using	DSC	and	 surface	properties	
CHAPTER	1	
	
	 64	
using	SEM	and	microCT.	Biocompatibility	of	these	blend	tubes	containing	drugs	were	
investigated	using	HMEC-1	to	investigate	the	effect	of	drug	loading.	Direct	and	indirect	
cytotoxicity	studies	were	performed.	Haemocompatibility	studies	were	carried	out	to	
investigate	 the	 reaction	 of	 the	 blood	 cells	 after	 direct	 contact	 with	 the	 material.	
Degradation	studies	were	also	carried	out	to	confirm	suitability	of	the	selected	materials	
for	 coronary	 stent	 application.	 Drug	 release	 studies	 were	 carried	 out	 using	 High	
Performance	 Liquid	 Chromatography	 (HPLC)	 or	UV-VIS	 for	 tacrolimus	 and	 rapamycin	
respectively.	
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2.1.	Materials	
2.1.1.	Bacterial	strains	
	
Various	 types	 of	 PHAs	 were	 produced	 by	 Cupriavidus	 necator	 (NCIMB	 10442),	
Pseudomonas	mendocina	CH50	(NCIMB	10541),	obtained	from	the	National	Collection	
of	the	Industrial	and	Marine	Bacteria	(NCIMB),	Bacillus	cereus	SPV,	obtained	from	the	
University	of	Westminster	 culture	 collection	and	Bacillus	 subtilis	OK2,	obtained	 from	
Prof.	Fujio	Kawamura,	Department	of	Life	Sciences,	Rikkyo	University.	Strains	cultures	
were	stored	on	agar	plates	in	the	fridge	at	+4°C	or	as	glycerol	stock	in	the	freezer	at	-
80°C.	
2.1.2.	Cell	line	and	cell	culture	materials	
 
Human	 dermal	 microvascular	 endothelial	 cells	 (HMEC-1)	 were	 obtained	 from	 the	
University	of	Westminster’s	cell	line	collection.		
2.1.3.	Chemicals	and	kits	
 
All	 the	 chemicals	 were	 purchased	 from	 Sigma-Aldrich	 (Dorset,	 UK)	 and	 VWR	
(Leicestershire,	UK).	Distilled	water	was	used	for	all	experiments.	Cell	culture	media	and	
other	reagents	were	purchased	from	Sigma-Aldrich,	Thermo	Fisher	Scientific	(Dartford,	
UK)	and	Lonza	(Basel,	Switzerland).	Live/Dead	viability/Cytotoxicity	Kit	was	purchased	
from	 Thermo	 Fisher	 Scientific	 (Dartford,	 UK)	 and	 PromoCell	 (Heidelberg,	 Germany).	
Protein	 estimation	 was	 done	 using	 the	 BCA	 estimation	 kit	 purchased	 from	 Sigma-
Aldrich.	Biodiesel	waste	was	obtained	from	Dr.	Godfrey	Kyazze’s	lab	at	the	University	of	
Westminster	(London,	UK).	Waste	frying	oil	was	obtained	from	Lion	King	Café	(London,	
UK).	 FITC	Mouse	Anti-Human	CD66b,	 PE	Mouse	Anti-Human	CD11b,	 PE	Mouse	Anti-
Human	CD86,	PerCP	Anti-Human	CD45	antibodies	were	purchased	from	BD	Biosciences	
(San	 Jose,	 US).	 Haemocompatibility	 study	 was	 carried	 out	 by	 Dr.	 Jurcevic’s	 lab	 at	
University	of	Westminster.	Rapamycin	was	purchased	from	LC	Laboratories	(Woburn,	
USA).	Tacrolimus	was	purchased	from	VWR	(Leicestershire,	UK).	Suspension	of	BaSO4	
nanoparticles	and	 isopropyl	alcohol	was	provided	by	Lucideon	Limited	 (Staffordshire,	
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UK).	PCL-PEG550	block	copolymer	was	synthetised	by	Vornia	Biomaterials	Ltd.	(Dublin,	
Ireland).		
2.2.		Media	composition		
Various	types	of	media	compositions	were	used	during	this	study	as	listed	in	the	section	
below.		
Nutrient	Broth	No	2	composition	(Sigma	Aldrich,	UK)	
	
Chemical	compound	 Amount	(g/L)	
Meat	peptone	 4.3	
Casein	peptone	 4.3	
Sodium	chloride	 6.4	
	
Mineral	Salt	Medium	(MSM)	composition	–	second	stage	(Rai	et	al.,	2011):	
	
Medium	constituent	 Concentration	(g/L)	
Ammonium	sulphate	 0.45	
Sodium	hydrogen	phosphate	 3.42	
Potassium	dihydrogen	phosphate	 2.38	
Magnesium	sulphate	 0.40	
Trace	elements	solution	 1.0	mL	
	
	MSM	media	composition	–	production	media	(Tian	et	al.,	2000):	
	
Medium	constituent	 Concentration	(g/L)	
Ammonium	sulphate	 0.50	
Sodium	hydrogen	phosphate	 3.80	
Potassium	dihydrogen	phosphate	 2.65	
Magnesium	sulphate	 0.40	
Trace	elements	solution	 1.0	mL	
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Composition	of	Trace	elements	solution	(TES)	(Rai	et	al.,	2011):	
	
Constituent	 Concentration	(g/L)	
CoCl2	 0.22	
CaCl2	 7.80	
FeCl3	 9.70	
NiCl3	 0.12	
CrCl3	·6H2O	 0.11	
CuSO4·5H2O	 0.16	
	
List	of	carbon	sources	used	for	PHAs	production	with	MSM	media:	
	
Carbon	source	 Concentration	(g/L)	 Bacterial	strain	
Glycerol	 20	 Pseudomonas		mendocina	CH50	
Waste	frying	oil	 20	 Pseudomonas		mendocina	CH50	
Sugarcane	molasses	 20	 Pseudomonas		mendocina	CH50	
Rapeseed	oil	 20	 Pseudomonas		mendocina	CH50	
Grapeseed	oil	 20	 Pseudomonas		mendocina	CH50	
Sunolive	oil	 20	 Pseudomonas		mendocina	CH50	
Sucrose,	biodiesel	waste	 10;	20	 Pseudomonas		mendocina	CH50	
Lauric	acid,	1,4-butanediol	 10;	10	 Pseudomonas		mendocina	CH50	
Sucrose,	Υ-butyrolactone	 20;	10	 Pseudomonas		mendocina	CH50	
Biodiesel	waste	 50	 Pseudomonas		mendocina	CH50	
Rapeseed	oil,	sucrose	 10;	10	 Pseudomonas		mendocina	CH50	
Glucose,	heptanoic	acid	 5;	0.3	 Pseudomonas		mendocina	CH50	
Sucrose,	valeric	acid	 20;	1.0	 Pseudomonas		mendocina	CH50	
Sodium	octanoate,	
hexanoic	acid	
2.5;	2.3	 Cupriavidus	necator	
Rapeseed	oil,	fructose	 10;	10	 Cupriavidus	necator	
γ-butyrolactone	 10	 Cupriavidus	necator	
Sodium	octanoate,		
γ-butyrolactone	
3.34;	10	 Cupriavidus	necator	
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	Modified	Kannan	and	Rehacek	(K-R)	medium	composition	–	production	media	
(Kannan	and	Rehacek,	1970):	
	
Medium	constituent	 Concentration	(g/L)	
Ammonium	sulphate	 5.0	
Potassium	chloride	 3.0	
Yeast	extract	 2.5	
Glucose	 35.0	
	
List	of	carbon	sources	used	for	PHA	production	with	K-R	media:	
	
Carbon	source	 Concentration	(g/L)	 Bacterial	strain	
Fructose	 20	 Bacillus	cereus	SPV	
Glucose	 35	 Bacillus	subtilis	OK2	
	
2.3.		Bioreactors	
	5	L	Bioreactor	
	
The	5	L	bioreactor	used	in	this	study	was	a	stirred	tank	with	2	Rushton	turbine	impellers	
and	buffers.	The	vessel	was	a	320	series	Fermac	(Electrolab	Biotech	Ltd,	Tewkesbury,	
UK)	and	total	volume	was	5	L	(Figure	12).	The	working	volume	used	in	this	study	was	
3.5L.	The	vessel	temperature	was	controlled	with	a	wrap-around	heating	belt.		pH	was	
controlled	by	Hamilton,	EasyFerm	Plus	K8	120mm	pH	sensor.	Dissolved	oxygen	tension	
(DOT)	was	controlled	by	Hamilton,	OxyFerm	K8	FDA	120mm	dO	sensor.	The	bioreactor	
sterilization	was	carried	out	in	an	autoclave	at	121°C	for	30	minutes.		
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Figure	12:	The	5	L	stirred	tank	bioreactor	used	in	this	study	(Fermac	320,	Electrolab	
Biotech	Ltd).		
15	L	Bioreactor	
	
15L	bioreactor	(Aplikon	Biotechnology)	was	a	stirred	tank	with	2	Rushton	turbine	and	
marine	impellers	with	an	outside	diameter	of	45mm,	60	mm	75	mm	or	85	mm	(Figure	
13).	The	vessel	was	a	single	wall	glass	autoclavable	bioreactor	and	total	volume	was	15	
L.	The	working	volume	used	in	this	study	was	10L	and	the	aspect	ratio	working	volume	
was	1.5.	The	vessel	temperature	was	controlled	by	Pt-100	sensor	in	thermo	well	in	top	
plate	and	with	a	wrap-around	heating	jacket	via	bioreactor	wall.	The	pH	was	controlled	
by	12	mm	classic	pH	sensor	AppliSens	 (Sensor	 Innovation).	Dissolved	oxygen	 tension	
(DOT)	was	controlled	with	12	mm	classic	polarographic	DO2	sensor	(AppliSens	425mm)	
(Sensor	 Innovation)	 electrodes.	 The	 optical	 density	 was	 measured	 online	 by	 non-
invasive	biomass	monitor	Bug	Lab	BE	2100.	The	process	was	monitored	online	using	
BioXpert	software.	The	bioreactor	sterilization	was	carried	out	in	an	autoclave	at	121°C	
for	30	minutes.		
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Figure	13:	15L	stirred	tank	bioreactor	used	in	this	study	(Applikon	Biotechnology).	
 
20	L	Stainless	Steel	Bioreactor	
	
The	20	L	bioreactor	was	a	stirred	tank	with	2	Rushton	turbine	impellers	and	buffers.	The	
vessel	 was	 a	 420	 FerMac	 series	 and	 total	 volume	 was	 20	 L	 (Figure	 14).	 The	 vessel	
temperature	 was	 controlled	 with	 a	 standard	 Pt	 100	 temperature	 sensor.	 pH	 was	
controlled	by	Hamilton,	EasyFerm	Plus	K8	325mm	pH	sensor.	Dissolved	oxygen	tension	
(DOT)	was	controlled	by	stainless	steel	polarographic	dO	sensor,	Hamilton,	OxyFerm	K8	
FDA	325mm.		
	
Figure	 14:	 20	 L	 stirred	 stainless	 steel	 tank	 bioreactor	 used	 in	 this	 study	 (Electrolab	
Biotech	Ltd).	
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2.4.	Experimental	methods	
2.4.1.	P(3HB)	production	by	Bacillus	subtilis	OK2	and	Bacillus	cereus	SPV	using	
a	range	of	carbon	sources	at	shaken	flask	level.	
The	PHAs	production	using	B.	subtilis	OK2	and	B.	cereus	SPV	strains	was	carried	out	using	
one-stage	seed	culture	preparation	(Valappil	et	al.,	2007).	Sterile	nutrient	broth	(10%	of	
the	final	volume)	was	inoculated	with	a	single	colony	of	the	bacterial	strain	taken	from	
the	agar	plate	and	cultured	for	16	hrs	at	30°C	at	150rpm	in	shaking	incubator.	The	grown	
culture	was	then	used	for	inoculating	the	PHA	production	media	and	incubated	for	48hrs	
at	30°C	at	150rpm	(modified	Kannan	and	Rehacek	medium,	(section	2.2.)	After	48hrs,	
cells	were	harvested,	centrifuged,	washed	with	distilled	water	and	homogenised	for	10	
minutes	using	 T25	basic	 homogeniser	 (IKA	 Labortechnik).	 The	obtained	biomass	was	
lyophilised.	PHAs	were	extracted	 from	 lyophilised	cells.	 Figure	15	 shows	a	 schematic	
representation	of	the	steps	involved	in	the	production	of	PHAs	from	Bacillus	sp.		
	
	
	
Figure	15:	Schematic	representation	for	the	steps	involved	in	the	scl-PHAs	production	in	
using	Bacillus	subtilis	OK2	and	or	Bacillus	cereus	SPV.		
2.4.2.	P(3HB)	production	by	Cupriavidus	necator	using	a	range	of	carbon	sources	
at	shaken	flask	level	
The	PHA	production	using	C.	necator	was	carried	out	using	a	 two-stage	 seed	culture	
preparation	used	previously	when	culturing	Pseudomonas	mendocina	CH50	(Rai	et	al.,	
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2011;	Basnett	et	al.,	2013).	Sterile	nutrient	broth	(1%	of	the	final	volume	of	production	
media)	was	inoculated	with	a	single	colony	of	the	bacterial	strain	taken	from	the	agar	
plate.	The	culture	in	mid-log	phase	was	then	used	for	inoculating	the	PHA	MSM	second	
stage	media	(composition	in	section	2.2.).	After	24	hours,	second	stage	culture	was	used	
to	inoculate	production	media	(MSM,	section	2.2.)	and	incubated	for	48hrs	at	30°C	at	
150rpm.	After	48hr	cells	were	harvested.	The	downstream	process	remained	the	same	
as	described	 in	 the	section	2.4.1.	Figure	16	shows	a	 schematic	 representation	of	 the	
steps	followed	for	PHA	production	using	a	two-stage	culture	and	MSM	media.		
	
	
	
Figure	16:	Schematic	representation	for	of	the	steps	involved	in	the	PHAs	production	
using	Cupriavidus	necator	or	Pseudomonas	mendocina	CH50.		
2.4.3.	Production	of	P(3HB)	by	Bacillus	subtilis	OK2	in	bioreactor	
 
The	P(3HB)	production	was	 carried	out	 in	 5L	 and	20	 L	 bioreactors.	 Bioreactors	were	
sterilized	with	distilled	water.	K-R	media	salts	and	glucose	were	sterilised	separately	and	
added	to	the	bioreactor	aseptically.	Sterile	nutrient	broth	(10%	of	the	final	volume	of	
production	media)	was	inoculated	with	a	single	colony	of	Bacillus	subtilis	OK2	taken	from	
the	agar	plate.	The	culture	in	mid-log	phase	was	then	used	for	inoculating	the	bioreactor.	
The	air	flow	rate	was	set	at	1vvm.	The	stirrer	speed	was	set	to	200rpm.	pH	was	adjusted	
to	6.8	at	the	beginning	of	the	fermentation.	Bacteria	were	grown	for	48	hours,	at	30°C,	
200rpm	(Akaraonye	et	al.,	2010).	The	culture	was	harvested,	centrifuged,	washed	twice	
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with	water,	homogenised	and	freeze-dried.	Polymer	was	extracted	by	Soxhlet	extraction	
(described	in	section	2.5.2.).		
2.4.4.	Production	of	mcl-PHAs	by	Pseudomonas	mendocina	CH50	using	a	range	
of	carbon	sources	at	shaken	flask	level	
 
The	mcl-PHA	production	using	P.	mendocina	was	 carried	out	using	a	 two-stage	 seed	
culture	preparation	as	described	in	the	section	2.4.2.	Sterile	nutrient	broth	(1%	of	the	
final	volume	of	production	media)	was	inoculated	with	a	single	colony	of	P.	mendocina	
taken	from	the	agar	plate.	The	culture	in	mid-log	phase	was	then	used	for	inoculating	
the	PHA	MSM	second	stage	media	(composition	shown	in	section	2.2.)	and	grown	at	
30°C,	200	rpm	for	24	hr.	Obtained	second	stage	culture	was	used	to	inoculate	production	
media	(MSM,	table	in	section	2.2.)	and	grown	at	30°C,	140rpm	for	48	hours	(Rai	et	al.,	
2011;	Bagdadi	et	al.,	2017).	The	volume	of	the	seed	culture	used	was	10	%	of	the	final	
working	 volume	 of	 the	 production	media.	 After	 48hrs	 cells	 were	 harvested	 and	 the	
downstream	process	remained	the	same	as	described	in	the	section	2.4.2.		
2.4.5.	Production	of	mcl-PHAs	in	bioreactors	
 
The	mcl-PHA	production	was	carried	out	in	5L	and	20	L	bioreactors.	Bioreactors	were	
sterilized	with	distilled	water	and	waste	frying	oil.	MSM	salts,	magnesium	sulphate	were	
sterilised	separately	and	added	to	the	bioreactor	aseptically.	Trace	elements	solution	
was	filtered	through	0.22µm	filters	and	added	to	the	bioreactor	before	the	inoculation.	
The	 bioreactor	 was	 inoculated	 with	 second	 stage	 seed	 inoculum	 (10%	 of	 the	 final	
working	volume	of	the	bioreactor).	The	air	flow	rate	was	set	at	1vvm.	The	stirrer	speed	
was	set	to	200rpm.	pH	was	adjusted	to	7.0	at	the	beginning	of	the	fermentation.	Bacteria	
were	grown	for	48	hours,	at	30°C,	200rpm	(Rai	et	al.,	2011c;	Basnett	et	al.,	2017).	The	
obtained	 culture	 was	 harvested,	 centrifuged,	 washed	 twice	 with	 10%	 ethanol,	
homogenised	 and	 freeze-dried.	 Polymer	 was	 extracted	 by	 Soxhlet	 extraction	 as	
described	in	the	section	2.5.2.	
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2.5.	Extraction	of	Poly(3-hydroxyalkanoates)	from	biomass	
2.5.1.	Solvent	dispersion	method	
 
Polymer	 yield	 was	 estimated	 by	 extraction	 of	 the	 dried	 biomass	 by	 using	
chloroform/sodium	 hypochlorite	 dispersion	 method	 (Hahn	 et	 al.,	 1993).	 Lyophilised	
biomass	was	milled	in	to	the	fine	powder	and	placed	in	the	conical	flasks.	Per	every	0.3g	
of	biomass	5mL	of	80%	sodium	hypochlorite	solution	in	distilled	water	and	22.5mL	of	
chloroform	were	added	into	biomass	and	mixed	well.	The	biomass	was	incubated	for	2	
hours	at	30°C	in	the	orbital	shaker	(140rpm).	After	incubation,	the	slurry	was	centrifuged	
for	20	minutes	at	3900rpm.	This	resulted	in	phase	separation.	Three	layers	were	formed.	
The	top	two	layers,	containing	sodium	hypochlorite	and	cell	debris	were	discarded.	The	
bottom	layer,	containing	chloroform	and	dissolved	polymer	was	collected,	filtered	and	
concentrated.	Polymer	was	precipitated	using	ice-cold	methanol	in	the	ratio	1:10	under	
continuous	stirring	(Rai	et	al.,	2011).	Polymer	yield	was	calculated	as	a	percentage	of	dry	
cell	weight,	using	the	formula:		
Polymer	yield	(%	dcw)	=	(polymer	weight/biomass)*100	
2.5.2.	Soxhlet	extraction		
 
The	PHA	extraction	was	carried	out	using	 the	two-stage	Soxhlet	extraction	 (modified	
from	Soxhlet,	1879).	For	this,	dried	biomass	was	weighed,	crushed	into	the	fine	powder,	
placed	 in	 the	 extraction	 thimble	 (Whatman	 28mmx100mm)	 obtained	 from	 GE	
Healthcare	 Life	 Sciences.	 The	 thimble	 with	 biomass	 was	 placed	 inside	 the	 Soxhlet	
extractor	attached	to	round	bottom	flask,	which	contained	methanol	and	boiling	stones	
(Figure	17).	The	system	was	attached	to	the	condenser	and	refluxing	was	carried	out	at	
90°C	 for	 16	hours.	 In	 the	 first	 stage,	 biomass	was	depleted	 from	organic	 substances	
soluble	in	methanol.	After	this	the	solvent	was	discarded	and	replaced	with	chloroform	
and	refluxing	at	80°C	for	24	hours	in	order	to	isolate	PHAs	from	the	biomass.	Obtained	
chloroform	solution	with	dissolved	polymer	was	concentrated	in	a	Bűchi	Rotavapor	(R-
215)	 and	 polymer	 was	 precipitated	 out	 in	 ice-cold	 methanol	 and	 dried	 at	 room	
temperature.	 The	 polymer	 yield	 was	 calculated	 using	 the	 formula	 described	 in	 the	
section	2.5.1.	
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Figure	17:	Soxhlet	apparatus	set	up	for	polymer	extraction.		
	
2.6.	Structural	characterization	of	scl-PHA		
The	structural	characterization	of	the	polymer	obtained	from	B.	subtilis	OK2,	B.	cereus	
SPV	and	C.	necator	was	carried	out	using	FTIR,	GC-MS	and	NMR.	
2.6.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
 
The	ATR-FTIR	spectra	of	the	polymers	were	recorded	using	the	Perkin-Elmer	Spectrum	
Two	Spectrometer	in	the	range	between	4000	to	450	cm−1.	The	spectral	resolution	was	
4	cm−1	and	spectra	were	generated	as	an	average	of	4	scans	(Shah,	2014).		
2.6.2.	Gas	Chromatography-Mass	Spectrometry	(GC-MS)	
 
Chemical	characterisation	of	the	obtained	polymer	was	carried	out	by	GC-MS	analysis	
conducted	 on	 samples	 of	 polymers	 subjected	 to	 methanolysis,	 which	 results	 in	 the	
formation	 of	 volatile	 esters	 detectable	 by	 GC.	 20mg	 of	 the	 polymer	 sample	 were	
dissolved	in	2mL	of	chloroform.	2mL	of	the	15%	of	sulphuric	acid	solution	in	methanol	
was	added	and	mixed	well.	20μL	of	methyl	benzoate	was	used	as	an	internal	standard.	
Methanolysis	 was	 carried	 out	 for	 4	 hours.	 For	 mcl-PHAs	 and	 waste	 frying	 oil	 the	
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methanolysis	was	carried	out	for	16	hours.	Next,	the	incubation	tubes	with	the	reaction	
mixture	were	cooled	down	on	ice	for	2	minutes.	2mL	of	water	was	added	to	the	mixture	
and	 vigorously	mixed.	 Tubes	were	 left	 on	 the	 stand	 until	 two	 layers	 separated.	 The	
organic	 layer	 was	 collected	 and	 dried	 over	 10mg	 of	 sodium	 sulphate	 and	 sodium	
bicarbonate,	 filtered	using	Whatman	No	1	 filter	paper	and	transferred	to	the	vial	 for	
further	analysis	(modified	from	Lageveen	et	al.,	1988).	
GC-MS	analysis	was	carried	out	using	a	Varian	GS/MS	system	consisting	Chrompack	CP-
3800	 gas	 chromatograph	 and	 Saturn	 200	 MS/MS	 block.	 The	 chromatograph	 was	
equipped	with	a	capillary	column	(Elite-5MS,	Perkin	Elmer,	UK)	30	m	in	length	0.25mm	
internal	 diameter	 and	 0.25	 m	 film	 thickness.	 The	 sample	 (1µL)	 in	 chloroform	 was	
injected	with	helium	(1mL/min)	as	the	carrier	gas.	The	injector	temperature	was	225◦C	
and	the	column	temperature	was	increased	from	40	to	240◦C	at	18◦C/min	and	held	at	
the	final	temperature	for	10	min	for	polymer	samples	and	prolonged	up	to	25	minutes	
for	waste	frying	oil.	
2.6.3.	Nuclear	magnetic	resonance	(NMR)	
 
The	 chemical	 structure	 of	 obtained	 polymers	 was	 determined	 by	 13C	 and	 1H	 NMR	
spectroscopy.	20mg	of	polymer	were	dissolved	in	1	mL	of	the	deuterated	chloroform	
(CDCl3)	and	transferred	into	an	NMR	tube.	The	chemical	shifts	were	referenced	against	
the	 residual	 solvent	 signals	 7.26ppm	and	 77.0ppm	 for	 1H	 and	 13C	 respectively.	NMR	
spectra	 were	 analysed	 using	 the	MestRec	 software	 package.	 The	 NMR	 analysis	 was	
carried	out	at	the	Department	of	Chemistry,	University	College	London,	UK.	
2.6.4.	Thermal	analysis	-	Differential	Scanning	Calorimetry	(DSC)	
 
Thermal	 analysis	 of	 polymers	 was	 conducted	 using	 a	 DSC	 214	 Polyma	 (Netzsch,	
Germany)	 equipped	 with	 Intracooler	 IC70	 cooling	 system,	 which	 provides	
measurements	from	-70oC.	Temperature	ramps	were	performed	under	nitrogen	flow	of	
60	mL	per	min.	The	initial	temperature	was	-70°C.	The	sample	was	heated	from	-70	to	
170°C	(mcl-PHAs)	or	200°C	(scl-PHAs)	at	heating	rate	of	10°C	per	min,	kept	 in	molten	
state	at	200°C	for	2	min	to	eradicate	sample	thermal	history	and	cooled	down	to	-70°C	
at	a	cooling	rate	of	20°C.min-1.	The	second	heating	cycle	from	-70	to	170°C	(mcl-PHAs)	
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or	200°C	(scl-PHAs)	was	conducted	at	scanning	speed	of	10°C.min-1.	For	mcl-PHAs	DSC	
thermograms	were	analysed	using	Proteus	7.0	software.	
2.6.5.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	
 
The	 molecular	 weight	 of	 the	 polymer	 described	 by	 the	 number	 average	 molecular	
weight,	(Mn)	and	weight	average	molecular	weight,	(Mw)	was	determined	by	carrying	
out	Gel	Permeation	Chromatography	analysis	(GPC).	PLgel	5µm	MIXED-C	(300x7.5	mm)	
column	were	calibrated	using	the	narrow	molecular	weight	polystyrene	standards	from	
162	 Da	 to	 15.000	 kDa.	 The	 eluent	 used	 was	 chloroform.	 2	 mg/mL	 of	 polymer	 was	
introduced	 into	the	GPC	system	at	a	 flow	rate	of	1	mL/min.	The	eluted	polymer	was	
detected	with	a	refractive	index	detector.	The	data	were	collected	and	analysed	using	
“Agilent	GPC/SEC”	software.		
2.7.	Temporal	profiling	of	the	PHA	production	during	fermentation	
The	progress	of	the	fermentation	was	monitored	by	taking	samples	in	3	hour	intervals	
and	analysed	them	in	order	to	estimate	glucose	and	nitrogen	concentration,	biomass	
content,	pH,	dissolved	oxygen	tension,	optical	density	and	polymer	accumulation.	
	
2.7.1	Optical	density	measurements	and	biomass	estimation	
	
Bacterial	 growth	 was	monitored	 by	measuring	 the	 optical	 density	 (OD).	 The	 optical	
density	 of	 the	 bacterial	 culture	 was	 measured	 at	 450nm	 (Pseudomonas	 mendocina	
CH50)	or	600nm	(Bacillus	subtilis	OK2)	in	the	spectrophotometer	using	media	as	a	blank	
(Single	 Beam	 Spectrophotometer,	 SB038,	 Cadex	 Inc.).	 Biomass	 (dry	 cell	 weight)	 was	
obtained	by	weighing	the	dried	pellet	of	the	cells	obtained	after	centrifugation	of	the	
grown	culture	at	13,200rpm	for	10	minutes	(Heraeus	Pico	17	Centrifuge,	Thermofisher	
Scientific,	MA,	US).	
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2.7.2.	pH	measurements	
 
Collected	samples	were	centrifuged	at	13,200	rpm	for	10	minutes.	pH	of	the	supernatant	
was	measured	using	Seven	Compact	pH	meter	(Mettler	Toledo	Ltd.,	Leicester).		
2.7.3.	Analytical	methods	
Reagents		
	
Dinitrosalicylic	acid	(DNS)	reagent	(Miller,	1959):		
Chemical	compound	 Amount	(g/L)	
NaOH	 10.0	
Sodium	sulphite	 0.5	
Dinitrosalicylic	acid	 10.0	
Phenol	 2.0	
	
Phenol-nitroprusside	buffer	(Rai	et	al.,	2011c):	
Chemical	compound	 Amount	(g/L)	
Na3PO4.12H2O	 3.0	
C6H7NaO7	 3.0	
C10H16N2O8	 0.3	
EDTA	 6.0	
Na2	[Fe(CN)5NO].2H2O	 0.02	
	
Alkaline	hypochlorite	reagent	(Rai	et	al.,	2011c):	
Chemical	compound	 Amount	(mL/100mL)	
NaOCl	 2.5	
1M	NaOH	 40.0	
	
Glucose	estimation	
	
Glucose	concentration	was	performed	using	Dinitrosalicylic	acid	(DNS)	assay	(modified	
from	 Miller,	 1959).	 2-hydroxy-3,5-dinitrobenzoic	 acid	 (3,5-dinitrosalicylic	 acid)	 is	
reacting	with	reducing	sugars	to	3-amino-5-nitrosalicylic	acid,	which	gives	brown	colour	
product	in	the	presence	of	reducing	sugar.	1mL	of	diluted	supernatant	was	incubated	
with	1mL	of	the	DNS	reagent	(section	2.7.3.)	in	the	water	bath	at	90°C	for	10	minutes.	
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330μL	of	40%	sodium	potassium	tartrate	solution	was	added	to	the	reaction	test	tubes	
to	prevent	colour	disappearance.	The	absorbance	was	read	at	575nm.	Distilled	water	
was	 used	 as	 a	 negative	 control.	 Glucose	 concentration	 was	 calculated	 from	 the	
calibration	curve.	
	
Nitrogen	estimation	
	
Nitrogen	in	the	ammonia	form	was	estimated	by	using	phenol-hypochlorite	method	(Rai	
et	al.,	2011c).	250μL	of	diluted	sample	was	mixed	with	100μL	of	nitroprusside	reagent	
(Section	2.7.3.),	150μL	of	alkaline	reagent	(section	2.7.3.)	and	incubated	in	the	absence	
of	light	for	45	minutes.	The	absorbance	was	read	at	635nm.	Ammonium	sulphate	was	
used	 as	 a	 positive	 control.	 Distilled	 water	 was	 used	 as	 a	 negative	 control.	 Nitrogen	
concentration	 was	 calculated	 from	 the	 calibration	 curve	 prepared	 for	 ammonium	
sulphate.		
	
Polymer	content	estimation	
	
Polymer	 yield	 was	 estimated	 by	 extraction	 of	 the	 dried	 biomass	 by	 using	
chloroform/sodium	hypochlorite	dispersion	method	as	described	in	the	section	2.5.1.	
2.8.	Production	of	oligo-PHA	and	material	characterisation	
2.8.1.	Acidic	hydrolysis	of	P(3HHx-3HO-3HD-3HDD)	
 
The	mcl-PHA	produced	by	P.	mendocina	using	waste	frying	oil	as	the	sole	carbon	source	
was	 subjected	 to	 partial	 depolymerisation	 by	 acidic	 hydrolysis	 (Tepha	 patent,	 2001,	
patent).	Hydrolysis	of	PHAs	in	acetic	acid	solution	provides	mild	conditions	leading	to	a	
slow	well-controlled	depolymerisation	of	aliphatic	polyester	chains.	For	this,	2g	of	the	
dry	mcl-PHA	copolymer	was	suspended	in	200mL	of	83%	solution	of	glacial	acetic	acid	
in	 distilled	 water	 and	 boiled	 at	 100-105°C	 for	 20	 hours.	 After	 the	 reaction	 was	
completed,	50mL	of	distilled	water	was	added	to	the	solution	and	the	flask	was	washed	
twice	with	50mL	of	chloroform.	The	mixture	was	transferred	into	the	separating	funnel.	
The	 organic	 layer	 was	 collected,	 dried	 over	 sodium	 sulphate,	 filtered	 and	 partially	
concentrated	 using	 the	 rotary	 evaporator.	 To	 complete	 evaporation	 of	 the	 volatile	
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solvent,	 the	 product	 was	 kept	 in	 the	 oven	 at	 40°C	 until	 the	 constant	 weight	 was	
achieved.	The	material	obtained	was	characterised	by	using	FTIR,	GC-MS,	NMR,	DSC	and	
GPC.	
2.8.2.	P(3HHx-3HO-3HD-3HDD)	hydrolysis	kinetics	
 
P(3HHx-3HO-3HD-3HDD)	copolymer	was	hydrolysed	as	described	in	the	section	2.8.1.	
7mL	samples	were	collected	in	3	hour	intervals	and	processed	to	obtain	polymer.	The	
amount	of	polymer	recovery	was	calculated	by	using	formula:	
%	polymer	recovery	=	(weight	of	dry	oligo-PHA	(g)/0.077g)	*100,	
where	0.077g	was	the	total	weight	of	polymer	expected	in	7mL	of	the	sample	
2.9.	Blend	film	fabrication		
The	neat	and	blend	films	fabrication	was	carried	out	by	dissolving	0.5	g	of	polymers:	
P(3HB)	and	hydrolysed	P(3HHx-3HO-3HD-3HDD)	in	ratios:	95/5;	90/10	and	80/20	in	10	
ml	of	chloroform	and	pouring	the	polymer	solution	in	60	mm	diameter	glass	petri	dishes	
(Lizarraga-Valderrama	et	al.,	2015).	The	polymer	was	dried	at	room	temperature	in	the	
incubator	Stuart	S160	(Bibby	Scientific	Limited,	Staffordshire,	UK)	until	complete	solvent	
evaporation.		
2.10.	P(3HB)/oligo-PHA	composite	film	fabrication	with	barium	sulphate	
The	composite	film	fabrication	was	carried	out	in	two	steps:	firstly	0.5	g	of	polymers:	
P(3HB)	 and	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 in	 ratio	 90/10	 was	 mixed	 barium	
sulphate	(BaSO4),	density	4.49g/cm3	was	milled	using	ZrO2	milling	media	and	dispersed	
in	 isopropanol	 (9	 wt%),	 particle	 size:	 0.3-3.0µm	 (Lucideon,	 UK)	 to	 obtain	 final	
concentrations	of	1,	 3	 and	5	wt%	BaSO4,	 in	 chloroform.	The	 composite	 solution	was	
poured	 into	 glass	 petri	 dishes	 and	 dried	 at	 the	 room	 temperature	 in	 order	 to	 allow	
complete	evaporation	of	isopropyl	alcohol.	0.5g	of	dried	composite	material	was	further	
dissolved	in	10mL	of	chloroform	and	cast	in	the	60	mm	diameter	glass	petri	dishes.	The	
polymer	was	dried	at	room	temperature	in	the	incubator	Stuart	S160	(Bibby	Scientific	
Limited,	 Staffordshire,	UK)	 until	 complete	 solvent	 evaporation.	 Isopropyl	 alcohol	 has	
higher	boiling	temperature	(82.6°C)	than	chloroform	(61.2°C),	which	results	in	different	
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evaporation	 rates	 of	 both	 solvents	 at	 room	 temperature.	 Hence	 presence	 of	 both	
solvents	 may	 affect	 uniform	 composite	 formation	 and	 has	 negative	 effect	 on	 the	
material	 morphology	 (e.g.	 increased	 porosity).	 Therefore,	 two-step	 composite	 films	
fabrication	was	performed	in	order	to	avoid	this	detrimental	effect.		
2.11.	Tubes	manufacturing	by	using	dip	moulding	technique	
The	 blend	 of	 P(3HB)/P(3HHx-3HO-3HD-3HDD)	 in	 ratio	 90/10	 was	 selected	 for	 tube	
manufacturing.	 Polymer	 concentration	 of	 4	 wt%	 in	 chloroform	 was	 used	 for	 the	
formation	 of	 tubes.	 Chloroform/1,1,2,2-tetrachloroethane	 solvent	 system	 with	
composition	70:30	wt/wt%	was	prepared	 (method	optimised	 in	 the	 lab).	Addition	of	
1,1,2,2-tetrachloroethane	 enabled	 to	 obtain	 stable	 solution	 of	 P(3HB),	 oligo-PHA	 in	
chloroform	 at	 room	 temperature.	 Higher	 boiling	 point	 of	 1,1,2,2-tetrachloroethane	
(146.7°C)	in	comparison	to	chloroform	(61.2°C)	allows	obtaining	an	optimal	evaporation	
rate	during	tube	formation	and	drying.		
Tubes	 were	 prepared	 by	 the	 dip	 moulding	 technique	 using	 PTL-MMB02	 Millimeter	
Grade	Desktop	Programmable	Dip	Coater	(1-200	mm/min)	(Figure	18).	
	
Figure	18:	PTL-MMB02	Millimeter	Grade	Desktop	Programmable	Dip	Coater	(right)	and	
furnace	with	prepared	tubes	on	the	mandrels	(left).	
The	 tubes	 were	 produced	 using	 mandrels	 of	 2.3-mm	 diameter	 using	 a	 homemade	
tooling	which	held	6	mandrels.	The	settings	for	mandrel	movement	were	150	and	200	
for	up	and	down	movement	correspondingly.	Dwell	time	of	1	sec	was	used	to	keep	the	
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mandrel	in	the	solution	while	drying	time	of	30	secs	was	set	to	allow	partial	drying	of	
the	 coating	 between	 the	 coating	 cycles.	 The	 total	 number	 of	 cycles	was	 20.	 Every	 5	
cycles,	the	drying	time	was	extended	until	3	minutes.	Coated	mandrels	were	dried	in	the	
furnace	at	50oC	overnight,	removed	from	the	mandrels	and	stored	at	room	temperature	
for	further	testing.	Dip	moulding	conditions	were	optimised	in	order	to	produce	tubes	
with	wall	 thickness	around	150	µm	 in	order	 to	compare	PHAs	with	currently	existing	
polymeric	stents.	Strut	thickness	of	currently	available	biodegradable	polymeric	stent	
“Absorb”	 is	 150	 µm.	 Uniformity	 of	 manufactured	 tubes	 were	 confirmed	 by	 SEM.	
Preliminary	mechanical	tests	were	conducted	to	characterise	tensile	properties	of	the	
tubes.		
2.11.1.	Preparation	of	the	tubes	with	incorporated	drug	
 
The	 neat	 tubes	 prepared	 were	 coated	 with	 an	 additional	 layer	 of	 polymer	 with	
incorporated	drug.	 For	 the	 polymeric	 coating	 12	wt/wt%	 solution	of	 PCL-PEG	550	 in	
tetrahydrofuran	(THF)	was	prepared.	The	amount	of	drug	required	for	coronary	stent	
application	is	1-1.5	ug/mm2	(Van	der	Hoeven	et	al.,	2005;	Serruys	et	al.,	2002).	Hence,	
the	concentration	of	drug	(tacrolimus	or	rapamycin)	in	the	polymer	solution	was	1.44	
wt	%,	based	on	polymer	deposition	per	mm2.	Dried	PHA	tubes	were	coated	in	the	PCL-
PEG	550	solution	at	room	temperature	using	dip	coating	technique.	The	dwell	time	was	
1s,	drying	time	30s	for	1	cycle.	The	coated	tube	was	left	for	24	hours	to	dry.	Tubes	were	
measured,	removed	from	the	mandrels	and	characterised.	
2.11.2.	Preparation	of	composite	tubes	with	barium	sulphate	
 
Composite	material	was	prepared	 in	two	stages	as	described	 in	the	section	2.10.	For	
this,	4g	of	the	blend	of	P(3HB)/oligo	–PHA	in	the	ratio	90/10	was	dissolved	in	chloroform	
with	5	wt%	barium	sulphate	solution	in	isopropanol	(9	wt%).	The	solution	obtained	was	
casted	into	the	glass	petri	dish	and	dried	completely.	For	tube	manufacturing,	4	wt/wt%	
solution	 of	 the	 composite	 material	 in	 chloroform	 and	 of	 1,1,2,2-tetrachloroethane	
(70:30)	was	prepared	at	room	temperature	and	used	for	tube	fabrication	as	described	
in	the	section	2.11.		
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2.11.3.	Characterization	of	PHA	blends,	composites	and	tubes	
2.11.3.1.	Ageing	experiments	
 
Obtained	PHA	based	blends,	composites	and	tubes	were	stored	at	ambient	temperature	
for	 a	 period	 of	 1,	 3,	 5	 and	 7	weeks	 and	 analysed	with	 respect	 to	 their	 thermal	 and	
mechanical	properties.			
2.11.3.2.	Tensile	test	
 
Tensile	 testing	was	carried	out	using	a	5942	Testing	Systems	(Instron)	equipped	with	
500N	load	cell	at	room	temperature.	The	test	was	conducted	using	films	of	5	mm	width	
and	length	of	3.5-5.0	cm.	Before	the	measurement,	thickness	and	width	of	the	specimen	
was	measured	in	several	places	and	an	average	value	was	used	for	the	calculation	of	the	
cross-sectional	 area.	 The	 gauge	 length	 of	 the	 sample	 holder	 was	 23	 mm.	 The	
deformation	rate	was	5	mm	per	minute.	Young's	modulus,	ultimate	tensile	strength	and	
elongation	at	break	were	calculated	from	the	stress-strain	curve.	The	average	values	for	
3	 specimens	were	 calculated.	 The	 data	 analysis	was	 carried	 out	 using	 the	 BlueHill	 3	
software.		
2.11.3.3.	Differential	scanning	calorimetry	(DSC)	
 
The	focus	of	the	DSC	analysis	was	on	characterisation	of	aged	samples	of	known	history.	
Therefore,	 the	 data	 presented	were	 obtained	 from	 a	 single	 heating	 run	 from	 -70	 to	
200°C	using	the	method	described	in	the	section	2.6.4.	
2.11.3.4.	Static	contact	angle	analysis	
 
Static	contact	angle	study	was	performed	to	measure	the	hydrophobicity/hydrophilicity	
of	 the	 PHA	 films.	 This	 was	 carried	 out	 using	 the	 KSV	 Cam	 200	 optical	 goniometer	
(Helsinki,	Finland).	About	200μL	of	deionized	water	was	dropped	onto	the	surface	of	the	
films	using	a	gas	tight	micro-syringe.	Soon	after	the	water	droplet	made	contact	with	
the	sample,	a	total	of	10	images	were	captured	with	a	frame	interval	of	one	second.	The	
analysis	of	the	images	was	performed	using	the	KSV	Cam	software.	Analysis	was	carried	
out	at	Eastman	Dental	Institute,	University	College	London,	UK.	
CHAPTER	2	
	
	 85	
2.11.3.5.	Scanning	electron	microscopy	(SEM)	
 
Surface	 topography	 of	 the	 PHA	 film	was	 studied	 using	 SEM.	 The	 film	 samples	were	
mounted	on	aluminium	stubs	(8mm	in	diameter)	and	these	were	gold	coated	using	a	
EMITECH-K550	gold	spluttering	device	for	2mins.	A	JOEL	5610LV-SEM	was	used	to	record	
images	of	the	surface	topography	of	both	film	types.	The	SEM	images	were	taken	with	
an	acceleration	voltage	of	10	kV	at	10	cm	working	distance.	This	study	was	carried	out	
at	the	Eastman	Dental	Hospital,	University	College	London.	
2.11.3.6.	X-ray	microtomography	(MicroCT)	
	
Tubes	and	composite	films	were	cut	in	to	pieces	between	2-4mm	long	and	about	1mm	
wide	and	mounted	upright	 into	the	MicroCT	holder	and	placed	on	the	MicroCT	stage	
within	the	SEM.	Bruker	SEM	software	was	used	to	operate	the	stage	to	obtain	the	X-Ray	
images	of	the	sample.	Series	of	X-Ray	images	was	collected	as	the	sample	was	turned	
through	180˚	at	1˚	intervals.	The	images	were	then	reconstructed	using	Bruker	software	
CTan,	CTVox	and	analysed	at	the	Eastman	Dental	Institute,	UCL,	UK.		
2.11.3.7.	Surface	roughness	analysis	
 
The	 surface	 roughness	 of	 the	 films	was	measured	 using	 a	 Sony	 Proscan	 1000	 Laser	
Profilometer	(Tokyo,	Japan).	The	 laser	used	was	model	131A,	which	had	a	measuring	
range	of	400-600μm,	a	resolution	of	0.02μm	and	a	maximum	output	of	10mW.	Scans	of	
0.5	mm2	were	obtained	from	each	sample.	Nine	random	coordinates	were	selected	from	
each	specimen	in	order	to	measure	the	root	mean	square	roughness	(Rq).	
2.11.3.8.	X-ray	diffraction	(XRD)	
 
X-ray	diffraction	(XRD)	analysis	was	performed	on	neat	P(3HB)	films,	blends	with	oligo-
PHA	 and	 composites	 with	 BaSO4.	 Samples	 were	 analysed	 on	 a	 Brüker	 D8	 Advance	
diffractometer	 in	 flat	 plate	 geometry,	 using	 Ni	 filtered	 Cu	 Ka,	 radiation.	 Data	 was	
collected	from	10	to	100°	with	a	primary	beam	slit	size	of	0.6	mm.	A	Brüker	Lynx	Eye	
silicon	strip	detector	was	used	and	a	step	size	of	0.02°	and	a	count	time	of	0.1	s	per	step.	
Samples	were	analysed	at	the	Eastman	Dental	Institute,	UCL,	UK.	
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2.11.3.9.	Protein	adsorption	study		
 
Protein	adsorption	assay	was	performed	using	foetal	bovine	serum,	(FBS).	1	cm2	polymer	
samples	were	incubated	in	400µl	of	FBS	at	37oC	for	24hrs.	After	incubation,	the	samples	
were	rinsed	3	 times	with	phosphate	buffer	saline,	 (PBS)	and	 incubated	 in	1mL	of	2%	
sodium	dodecyl	sulphate	(SDS)	in	PBS	for	24	hrs	at	room	temperature	under	vigorous	
shaking.	 The	 total	 amount	 of	 proteins	 adsorbed	 on	 the	 surface	 of	 the	 samples	 was	
quantified	using	the	Bicinchoninic	Acid	Protein	Assay	Kit	(The	Thermoscientific,	Pierce,	
Hemel	 Hempstead,	 UK).	 The	 absorbance	 of	 the	 samples	 was	 measured	
spectrophotometrically	 at	 562nm	 against	 a	 calibration	 curve,	 using	 bovine	 serum	
albumin.	The	samples	incubated	in	PBS	were	used	as	a	negative	control	(Misra	et	al.,	
2010).	The	assay	was	carried	out	in	triplicate.	
2.12.	In	vitro	release	studies	of	rapamycin	using	UV-Vis	spectrometry		
2cm	 long	 tubes	 coated	 with	 a	 polymer	 layer	 with	 incorporated	 rapamycin	 were	
immersed	in	2mL	of	PBS	release	medium	in	triplicate	and	incubated	at	37oC	for	90	days.	
A	sample	volume	of	1	ml	was	collected	at	predetermined	time	points	and	each	aliquot	
were	replaced	with	fresh	buffer	throughout	the	entire	release	study.	The	drug	content	
in	 the	 sample	 was	 analysed	 using	 Lambda	 35	 UV-Vis	 spectrometer	 (PerkinElmer,	
Waltham,	USA)	at	278nm	wavelength.	Rapamycin	standards	in	methanol	were	prepared	
by	 serial	 dilutions	 and	 analysed	 using	 a	 UV-Vis	 spectrometer.	 The	 concentration	 of	
released	drug	was	calculated	from	the	standard	curve	(Ma	et	al.,	2011).			
2.13.	 In	 vitro	 release	 studies	 of	 tacrolimus	 using	 High	 Performance	 Liquid	
Chromatography	(HPLC)	
The	release	studies	of	the	P(3HB)/oligo-PHA	tubes	with	incorporated	tacrolimus	were	
carried	out	as	described	 in	 the	section	2.12.	Tacrolimus	concentration	during	release	
study	was	measured	as	described	by	Patel	et	al.,	2013.	A	HPLC	system	containing	C18	
60RP	column	(dimensions	250nmx4.6mm,	5μm	in	particle	size)	was	used	to	measure	the	
amount	of	the	tacrolimus	released	to	PBS	from	the	incubated	tubes.	A	methanol	and	
water	solution	(80:20)	was	used	as	the	mobile	phase	(pH=6.0	adjusted	with	1N	HCl)	at	a	
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flow	rate	of	1	ml/min.	The	column	oven	temperature	was	set	to	50oC.	The	UV	detection	
wavelength	was	210	nm	and	20μl	sample	was	 injected	(Ultimate	3000	HPLC,	Dionex,	
Thermofisher).	Tacrolimus	standards	were	prepared	by	serial	dilutions	 in	acetonitrile.	
The	 released	 tacrolimus	 concentration	 was	 calculated	 from	 the	 standard	 curve.	
Obtained	 data	was	 analysed	 by	 using	 Chromeleon	 7.2	 chromatography	 data	 system	
software.	
2.14.	In	vitro	cell	culture	studies	
2.14.1.	Cell	growth	and	maintenance		
 
Human	microvascular	endothelial	cells	(HMEC-1)	were	grown	in	DMEM	supplemented	
with	10	%	heat	inactivated	foetal	bovine	serum,	1%	v/v	of	penicillin	and	streptomycin	
solution	(10,000	units	of	penicillin	and	10	mg	streptomycin	per	mL	in	0.9%	NaCl)	and	1%	
L-glutamine,	grown	at	37°C	with	95%	air	and	5	%	of	CO2	humidified	incubator.	Media	
was	pre-warmed	at	37°C.	Cell	 passages	were	 carried	out,	when	70%	confluence	was	
obtained.	For	cell	passage,	cells	were	rinsed	with	PBS	and	detached	from	the	flask	using	
a	2mL	of	10x	2.5%	trypsin	at	37°C	for	2	minutes.	The	reaction	was	stopped	by	addition	
of	8mL	of	supplemented	DMEM	media.	Cells	were	centrifuged	at	1000rpm	for	5	min	and	
the	resulting	pellet	was	resuspended	in	fresh	supplemented	DMEM.	Cells	were	seeded	
in	sterile	75	cm2	tissue	culture	flasks	and	cultured	at	37°C	with	95%	air	and	5	%	of	CO2	
humidified	incubator.	
2.14.2.	Sample	preparation	and	cell	seeding	
 
P(3HB)	 neat	 and	 blend	 film	 constructs	 were	 cut	 in	 to	 13mm	 diameter	 circles	 and	
sterilized	under	the	UV	light	for	30	minutes	each	side.	All	film	samples	were	soaked	in	
24well	plate	in	1mL	of	supplemented	DMEM	medium	for	16hrs	prior	to	cell	seeding.	Cell	
culture	 studies	were	performed	 in	 triplicates.	HMEC-1	cells	at	70	%	confluence	were	
used	 for	 the	 cell	 seeding.	 Cells	 were	 counted	 by	 using	 Trypan	 Blue	 (1:5)	 in	 the	
haemocytometer.	Around	20,000	cells	were	seeded	on	the	pre-wetted	constructs	in	a	
24	well	plate.	TCP	was	used	as	positive	control.	Wells	containing	media	without	cells	
were	used	as	negative	control.	Plates	were	incubated	at	37°C	with	5	%	of	CO2	and	media	
was	changed	every	2	days.	Cell	proliferation	was	assessed	at	day	1,	3	and	7	of	incubation.	
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2.14.3.	MTT	assay	
 
The	MTT	(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide)	colourimetric	
assay	(modified	from	Mosmann,	1983)	was	performed	on	the	constructs	containing	the	
cells	at	24,	48	and	72	hrs.	For	this,	500μl	of	a	12mM	MTT	solution	in	PBS	were	added	to	
each	well	at	day	1,	3	and	7	and	the	plates	were	incubated	for	four	hours	at	37°C	with	5%	
of	CO2.	After	incubation,	the	liquid	was	discarded	from	each	well	and	200μl	of	DMSO	
was	 added	 and	 kept	 for	 15	 minutes	 at	 37°C.	 200μl	 of	 the	 resulting	 solution	 were	
transferred	to	96	well	plates	and	the	absorbance	at	540	nm	was	measured	on	a	FluoStar	
Optima	plate	 reader	 (SMG	Labtech).	 The	absorbance	of	 the	 samples	was	normalised	
with	respect	to	the	positive	control	(standard	tissue	culture	plastic).	The	difference	in	
the	surface	areas	of	the	tissue	culture	plate	wells	and	the	films	were	considered	for	the	
calculation	of	the	%	cell	viability	on	the	films.	
2.14.4.	SEM	imaging	of	HMEC-1	cells		
 
For	 the	 SEM	 imaging,	 HMEC-1	 cells	 seeded	 on	 the	 PHA	 films	 were	 fixed	 using		
4%	 paraformaldehyde.	 These	 samples	 were	 dehydrated	 by	 several	 treatments	 with	
different	 solutions	 of	 ethanol	 (20%,	 50%,	 70%,	 90%,	 100%)	 for	 10	minutes,	 dried	by	
immersion	in	hexamethylsilizalane	for	2-5	minutes	and	left	in	a	fume	cupboard	for	at	
least	 an	 hour,	 gold	 coated	 and	 viewed	 under	 the	 SEM	 as	 described	 in	 the	 section	
2.12.3.5.	
2.14.5.	Live/	dead	measurements		
Live/dead	viability	assay	was	done	using	 fluorescence	dyes,	 such	as:	Calcein	AM	and	
Ethidium	homodimer-1.	Calcein-AM	is	used	to	determine	viable	cells,	by	conversion	of	
non-fluorescent	 form	 of	 Calcein,	 present	 in	 live	 cells	 to	 green	 fluorescent	 form	 by	
intracellular	 esterase.	 Ethidium	 homodimer-1	 emits	 red	 fluorescence	while	 bounded	
into	 DNA	 of	 dead	 cells.	 After	 growing	 the	 cells	 for	 1,	 3	 and	 7	 days	 on	 the	 polymer	
scaffolds,	the	culture	medium	was	removed	and	cells	rinsed	with	Dulbecco’s	Phosphate	
Buffered	Saline	(DPBS).	Then	300	µL	of	working	solution,	which	contains	2	µM	Calcein	
AM	and	4	µM	Ethidium	homodimer-1	in	DPBS	were	added	directly	to	cells	and	incubated	
for	30-45	minutes	in	the	absence	of	light	at	room	temperature	(ThermoFisher	Scientific	
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LIVE/DEAD™	Viability/Cytotoxicity	Kit	Protocol).	Following	incubation,	about	2mL	of	the	
DPBS	was	added	to	a	6	well	plate.	The	samples	were	imaged	using	40xW	objective	under	
the	confocal	microscope	(Leica	TCS	SP2).	
2.14.6.	Indirect	cytotoxicity	studies	
 
Indirect	 cytotoxicity	 study	was	 performed	 in	 order	 to	 confirm	 their	 biocompatibility.	
Cytotoxicity	of	different	extracts	obtained	after	incubation	of	PHAs	samples	with	DMEM	
media	for	24	hours	was	measured	by	the	MTT	assay.	10mm	discs	of	P(3HB)/oligo-PHA	
composites	or	10mm	tubes	were	prepared,	placed	in	the	polystyrene	24-well	plate	and	
sterilised	under	UV	lamps	for	30minutes	on	each	site.	500μl	of	DMEM	media	was	added	
into	 each	 well,	 containing	 scaffolds.	 All	 samples	 were	 prepared	 in	 triplicate.	
Simultaneously,	HMEC-1	cells	were	seeded	at	20,000	cells	per	well	in	24-well	plates	in	
500μl	of	 culture	medium	and	were	 incubated	at	37	 °C.	After	24	h	of	 incubation,	 the	
media	was	removed.	The	HMEC-1	cell	monolayer	was	washed	with	DPBS	and	exposed	
to	500μl	of	the	extract	obtained	after	incubation	with	PHA	based	scaffolds	and	incubated	
for	24	and	72	hours.	After	that	cells	were	washed	with	DPBS	and	quantified	by	MTT	assay	
as	described	in	section	2.14.3.		
2.15.	Haemocompatibility	studies	
Haemolysis,	whole	blood	clotting	assays	and	monocytes/neutrophils	activation	studies	
were	performed	to	investigate	haemocompatibility	of	the	PHAs	blends,	composites	and	
tubes	after	direct	contact	with	blood.		
2.15.1.	Haemolysis	studies	
Haemolysis	 study	was	performed	according	 to	 the	protocol	provided	by	Wang	et	al.,	
2013	with	some	modifications.	Lithium	heparin	whole	blood	was	diluted	4:5	in	sterile	
0.9%	 (v/v)	 sodium	 chloride	 solution.	 For	 the	 films,	 discs	 of	 10	 mm	 diameter	 were	
prepared,	washed	with	 sterile	 0.9%	NaCl	 and	 placed	 into	 the	wells	 of	 24	well	 plate	
(Sigma-Aldrich,	Dorset,	UK).	For	the	tubes,	the	0.0045g	of	polymer	tubes	(an	equivalent	
polymer	weight	 to	 the	10mm	discs)	were	washed	with	 sterile	 0.9%	NaCl	 and	placed	
inside	the	24	well	plate.	All	the	samples	were	prepared	in	triplicates	and	incubated	for	
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30	min	at	37°C	with	980µl	sodium	chloride	solution.	Standard	tissue	culture	plastic	with	
980µl	sodium	chloride	was	used	as	negative	control.	Wells	containing	980	µl	of	distilled	
water	 instead	of	NaCl	were	used	as	positive	control.	To	each	well	20µl	of	pre-diluted	
blood	was	added,	mixed	and	incubated	for	60	min	at	37°C	and	centrifuged	at	3000	rpm	
for	5	min.	200	µl	of	supernatant	were	transferred	to	a	96	well	plate	and	the	absorbance	
was	 measured	 at	 540	 nm.	 The	 haemolysis	 ratio	 (HR,	 in	 %)	 was	 calculated	 by	 using	
formula:	𝐻𝑎𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠	𝑟𝑎𝑡𝑖𝑜	(%) = 	 (𝐴	 − 	𝐴𝑛𝑒𝑔)	/	(𝐴𝑝𝑜𝑠	 − 	𝐴𝑛𝑒𝑔)	𝑥	100%,																												
where	A	is	the	absorbance	of	the	sample,	Aneg	is	the	absorbance	of	the	negative	control	
and	Apos	is	the	absorbance	of	the	positive	control.	
2.15.2.	Whole	blood	clotting	
The	whole	blood	clotting	assay	was	performed	as	previously	described	by	Motlagh	et	
al.,	2006	and	Huang	et	al.,	2005	with	some	modifications.	800µl	0.1M	calcium	chloride	
was	added	 to	4	ml	of	 tri-potassium	ethylenediaminetetraacetic	acid	 (K3-EDTA)	whole	
blood	in	order	to	activate	coagulation	cascade.	10	mm	diameter	film	samples	or	45mg	
tubes	were	prepared	and	placed	into	the	wells	of	a	polystyrene	24	well	plate	(Sigma-
Aldrich,	Dorset,	UK).	For	the	tubes,	the	45mm	of	polymeric	tubes	(an	equivalent	weight	
of	polymer	present	 in	 the	10mm	discs)	were	placed	 inside	 the	24	well	plate.	50µl	of	
activated	 blood	was	 applied	 directly	 on	 the	material,	 placed	 into	 each	well.	 For	 the	
negative	control	100	µl	of	0.9%	sodium	chloride	in	1	ml	of	blood	was	used	as	negative	
control.	 TCP	was	used	as	 the	 control.	After	 30	 and	90	min	of	 incubation	 at	 ambient	
temperature	the	coagulation	was	stopped	by	the	addition	of	1.5mL	distilled	water.	The	
erythrocytes	 not	 trapped	 in	 the	 thrombus	were	 lysed	 by	 addition	 of	 distilled	water,	
releasing	free	haemoglobin.	After	5	minutes,	200	µl	were	transferred	to	a	96	well	plate	
and	the	absorbance	was	measured	at	540	nm.	All	samples	were	prepared	in	triplicate.	
The	size	of	the	formed	blood	clot	was	calculated	as	the	percentage	of	blood	clotting:	𝐵𝑙𝑜𝑜𝑑	𝑐𝑙𝑜𝑡𝑡𝑖𝑛𝑔	(%) 	= 	 (𝐴𝑛𝑒𝑔	 − 	𝐴)	/	(𝐴𝑛𝑒𝑔	 − 	𝐴𝑝𝑜𝑠)	𝑥	100%																																									
where	Aneg	is	the	absorbance	of	the	negative	control,	A	is	the	absorbance	of	the	sample	
and	Apos	is	the	absorbance	of	the	positive	control.	
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2.15.3.	Monocyte	and	neutrophil	activation	studies		
 
Monocytes	and	neutrophils	are	two	types	of	white	blood	cells	taking	essential	part	of	
innate	 immune	system.	They	 take	part	 in	acute	 inflammatory	 response.	They	can	be	
activated	 for	 example	 by	 lipopolysaccharide,	 present	 in	 cell	 wall	 of	 Gram	 negative	
bacteria.	 In	 this	 study,	mcl-PHA	was	produced	by	Pseudomonas	mendocina,	which	 is	
Gram	negative	organism.	Therefore,	activation	study	on	both	types	of	white	blood	cells	
will	be	performed	in	order	to	 investigate	the	response	of	monocytes	and	neutrophils	
after	direct	contact	with	PHA	based	materials.		
2.15.3.1.	Sample	preparation	
 
For	 leukocyte	 activation	 analysis,	 samples	 which	 contained	 4.5mg	 of	 polymer	 were	
incubated	for	16	hours	with	1mL	of	blood	at	37°	C.	Whole	blood	and	blood	activated	
with	LPS	(100ng/mL)	were	used	as	negative	and	positive	control	respectively.	Two	types	
of	 antibodies	 were	 used:	 an	 activation	 antibody,	 which	 is	 CD11b-PE	 and	 selective	
antibodies,	 such	 as	 CD86-PE,	 CD45-PerCP	 and	 CD66b-FITC,	 which	 allow	 accurate	
location	of	neutrophils	and	monocytes	during	flow	cytometry	analysis.		
Table	2:	Experimental	set-up	for	staining	with	different	types	of	antibodies.	
No.	Experiment	 Blood	sample	 Antibodies	
1.	 Non-activated	whole	blood	 CD86-PE+CD45-PerCP	
2.	 Non-activated	whole	blood	 CD11b-PE+CD66b-FITC	
3.	 LPS	activated	whole	blood	 CD86-PE+CD45-PerCP	
4.	 LPS	activated	whole	blood	 CD11b-PE+CD66b-FITC	
5.	 Whole	blood	after	incubation	with	PHAs	 CD86-PE+CD45-PerCP	
6.	 Whole	blood	after	incubation	with	PHAs	 CD11b-PE+CD66b-FITC	
	
2.15.3.2.	Whole	blood	staining	with	activation	antibodies	
 
For	 leukocyte	 activation	 analysis,	 100μL	 of	whole	 blood,	 blood	 activated	 by	 LPS	 and	
blood	 after	 incubation	 with	 PHAs	 was	 added	 to	 flow	 cytometry	 and	 fluorescence-
activated	 cell	 sorting	 (FACS)	 tubes	 containing	 10μL	 of	 monoclonal	 anti-human	
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antibodies:	 CD66B	 conjugated	 with	 fluorescein	 isothiocynate	 (CD66b-FITC),	 CD86	
conjugated	 with	 phycoerythrin	 (CD86-PE),	 CD11b	 conjugated	 with	 phycoerythrin	
(CD11b-PE)	and	CD45	conjugated	with	peridinin	chlorophyll	protein	(CD45-PerCP).	The	
samples	were	gently	shaken	and	incubated	for	20	min	in	the	absence	of	light	at	room	
temperature.	Erythrocytes	were	then	lysed	with	2	ml	of	lysing	buffer	and	incubated	for	
10	 minutes	 at	 37°	 C.	 Samples	 were	 centrifuged	 at	 1500rpm	 for	 5	 minutes,	 the	
supernatant	was	discarded	and	replaced	with	2mL	of	PBS	and	centrifuged	again	at	the	
conditions	mentioned	above.	The	supernatant	was	discarded	and	replaced	by	200μL	of	
flow	cytometry	fixing	buffer	(containing	4%	formaldehyde)	and	were	analysed	by	using	
flow	cytometry.	Fresh	whole	blood	without	antibodies	was	used	as	negative	control.		
2.15.3.3.	Flow	cytometry	analysis	
Flow	cytometry	analyses	were	carried	out	in	a	centralized	laboratory	using	a	Cyan	ADP	
flow	 cytometer	 (Beckman	 Coulter,	 Inc.,	 Brea,	 USA),	 equipped	 with	 a	 488nm	 laser,	
530/40	and	575/25nm	band	pass	filters,	and	a	750-nm	long	pass	filter.	Determination	of	
CD11b	expression	on	neutrophils	 and	monocytes	was	performed	as	described	 in	 the	
section	2.16.3.2.	Cell-associated	fluorescence	was	measured	using	the	575/25-nm	filter.	
The	mean	of	the	relative	fluorescence	intensity	(MFI)	from	logarithmically	amplified	data	
expressed	as	linear	value	was	recorded	and	compared.	
2.16.	In	vitro	degradation	studies	of	the	tubes	
In	vitro	degradation	studies	of	the	fabricated	tubes	were	carried	out	according	to	the	
protocol	described	by	Misra	et	al.,	2008.	The	P(3HB)/oligo-PHA	tubes	were	studied	for	
a	period	of	6	months.	Tubes	were	weighed	and	incubated	in	5mL	of	phosphate	buffer	
saline	(PBS)	at	37°C.	All	the	degradation	related	studies	were	carried	out	in	triplicates.	
Samples	were	characterized	in	order	to	study	mechanical,	thermal,	molecular	weight,	
water	uptake	and	weight	loss,	pH	change,	and	surface	morphology.		
2.16.1.	Thermal	and	mechanical	properties		
Tubes	collected	from	PBS	solution	after	each	time	point	were	characterized	in	order	to	
study	changes	in	thermal	and	mechanical	properties	according	to	protocols	described	in	
the	section	2.6.4-2.6.5.	
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2.16.2.	Surface	morphology		
SEM	analyses	of	the	surface	of	the	degraded	tubes	were	carried	out	at	the	end	of	the	
1st,	2nd,	3rd,	4th,	5th	and	6th	month	study	to	see	changes	in	the	surface	morphology	of	the	
tubes	occurring	due	to	its	degradation.	The	sample	preparation	and	methodology	was	
the	same	as	described	in	section	2.11.3.5.	
2.16.3.	Water	uptake,	weight	loss	and	pH	measurements	
Degradation	kinetics	was	also	determined	by	measuring	the	%	water	uptake	(%WU)	and	
%	weight	loss	(%	WL).	For	these,	weight	of	the	dried	tubes	was	recorded.	Tubes	were	
immersed	in	PBS	and	kept	under	static	conditions	at	37oC	until	the	desired	time	point.	
At	the	end	of	each	time	point	the	tubes	were	collected	and	analysed	for	water	uptake	
and	 weight	 loss	 behaviour.	 For	 measuring	 the	 %	WU,	 the	 immersed	 samples	 were	
removed	at	given	time	points,	the	surface	was	gently	wiped	with	a	tissue	paper	and	the	
weight	 was	 recorded.	 Similarly,	 for	 measuring	 the	 weight	 loss,	 the	 samples	 were	
removed	 from	 the	PBS,	dried	at	37oC	overnight	and	weighed	dry.	Water	uptake	and	
weight	loss	were	calculated	using	the	following	equations:	
%WU=((M1-M2)/M2)*100	
%WL=((M0-M2)/M0)*100,	
where	M0	–	initial	weight	of	the	tube	before	incubation,	M1	–	weight	of	the	wet	tube	
after	incubation,	M2	–	weight	of	the	dry	tube	after	incubation.	
The	pH	changes	of	the	media	were	then	measured	at	the	end	of	each	incubation	time	
point.	
2.17	Statistical	analysis	
Obtained	results	were	presented	with	their	mean	standard	deviation	(mean	value	±	SD).	
Data	 were	 compared	 using	 Student’s	 t-test	 and	 ANOVA.	 The	 differences	 were	
considered	significant	when	p-value	was	below	0.05	(p<0.05).	p-value	greater	than	0.05	
(p>0.05)	was	interpreted	as	no	significant	difference.			
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3.	Introduction	
Polyhydroxyalkanoates	have	been	widely	explored	as	a	group	of	promising	biomaterials,	
for	biomedical	applications	(Rai	et	al.,	2011).	They	represent	a	broad	range	of	properties,	
which	depends	on	the	number	of	carbon	atoms	within	the	monomer	unit	(Laycock	et	
al.,	2013).	Short	chain	length	Poly(3-hydroxyalkanoates),	include	PHAs	with	monomer	
length	between	3	to	5	carbon	atoms	within	the	monomer	unit	(Verlinden	et	al.,	2007).	
Most	of	the	polymers	from	this	group	of	PHAs	have	the	material	properties,	such	as:	
high	crystallinity,	thermal	properties	similar	to	thermoplastics,	as	well	are	high	stiffness	
and	tensile	strength	(Pena	et	al.,	2014).	However	within	this	group	of	PHAs,	the	P(4HB)	
polymer	is	an	exception.	Unlike	other	scl-PHAs,		P(4HB)	has	low	melting	temperature,	
high	 tensile	 strength	 and	 is	 highly	 elastomeric.	 Scl-PHAs	 are	 represented	 by	 3-
hydroxypropionate	(3HP),	which	contain	3	carbon	atoms	within	the	monomer	unit,	3-
hydroxybutyrate	 (3HB)	 or	 4-hydroxybutyrate	 (4HB)	 with	 4	 carbon	 atoms	 and	 3-
hydroxyvalerate	(3HV)	with	5	carbon	atoms.	In	addition,	there	are	scl-PHA	copolymers	
which	 include	 Poly(3-hydroxybutyrate-co-3-hydroxyvalerate),	 P(3HB-co-3HV),	 poly(3-
hydroxybutyrate-co-4-hydroxybutyrate),	P(3HB-co-4HB),	which	represent	intermediate	
properties	 between	 both	monomers	which	 are	 dictated	 by	 the	main	monomer	 unit	
within	the	copolymer	(Akaraonye	et	al.,	2010).	Scl-PHAs	can	be	produced	by	different	
types	 of	 bacterial	 strains	 including	 Bacillus	 sp.,	 Cupriavidus	 necator,	 Cyanobacteria	
(Spirulina	platentis),	Burkholderia	sacchari	and	Methylobacterium	sp.	(Jau	et	al.,	2005;	
Mendonca	et	al.,	2013;	Yezza	et	al.,	2006).	Each	bacterial	strain	has	different	levels	of	
polymer	accumulation	within	the	cell	as	well	as	different	material	properties.	Scl-PHAs	
have	been	used	in	several	biomedical	applications,	such	as	drug	delivery,	bone	tissue	
engineering,	nerve	regeneration,	sutures	and	heart	valves	(Chen	and	Wang,	2013;	Grage	
et	al.,	2009;	Masaeli	et	al.,	2012).	The	main	application	 for	PHAs	 in	 this	work	was	to	
develop	biodegradable	coronary	artery	drug	eluting	stents.	Coronary	stents	are	known	
to	be	a	very	demanding	medical	device,	which	require	particular	material	properties,	
such	as	 strength	and	stiffness.	On	 the	other	hand,	 it	 also	needs	a	 certain	amount	of	
elastomeric	 property	 in	 order	 to	 be	 crimpable	 and	 deployable	 within	 the	 artery.	
Currently,	only	one	polymeric	stent	is	available	in	the	market,	made	using	poly(L-lactic	
acid)	PLLA,	a	stiff	polymer	(Abbott,	USA).	Although	this	product	is	currently	being	used	
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by	 clinicians,	 it	 presents	 several	 limitations	 as	 mentioned	 in	 the	 section	 1.4.1.	
Polyhydroxyalkanoates	can	be	an	alternative	solution	to	PLLA	as	a	platform	for	coronary	
artery	stents.	Hence,	the	main	objective	of	this	study	was	to	produce	scl-PHAs	using	a	
range	 of	 carbon	 sources	 and	 different	 bacterial	 strains.	 The	 selected	materials	were	
subjected	to	thorough	analysis	in	order	to	fully	characterise	the	properties	of	the	chosen	
material.	
	3.1.	Screening	experiments	
Screening	experiments	were	carried	out	in	order	to	obtain	scl-PHAs	using	four	different	
bacterial	strains,	such	as:	Pseudomonas	mendocina	CH50,	Cupriavidus	necator,	Bacillus	
cereus	SPV	and	Bacillus	subtilis	OK2.	A	range	of	different	carbon	sources	were	studied	
as	described	in	the	section	2.2.	A	summary	of	the	results	obtained	is	shown	in	the	Table	
3.		
Table	3:	Summary	of	the	results	obtained	during	screening	experiments	performed	for	
the	production	of	novel	scl-PHA	production.	
Bacterial	strain	 Carbon	source	
Polymer	yield	
(%	dcw)	
GC-MS	results	
Bacillus	cereus	SPV	 Fructose	 7.5	 3HB	
Bacillus	subtilis	OK2	 Glucose	 30.8	 3HB	
Cupriavidus	necator	
Sodium	octanoate,	
hexanoic	acid	
12.2	 3HB	
Rapeseed	oil,	
fructose	
9.0	 3HB	
Butyrolactone	 6.7	 3HB	
Sodium	octanoate,	
butyrolactone	
18.6	 3HB	
Pseudomonas	
mendocina	CH50	
Rapeseed	oil,	
sucrose	
22.5	 3HB	
Glucose,	heptanoic	
acid	
17.2	 3HB	
Sucrose,	valeric	acid	 7.0	 3HB,	3HV	
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Depending	 on	 the	 carbon	 source,	 mainly	 the	 P(3HB)	 homopolymer	 was	 obtained.	
Bacillus	 species	 were	 grown	 on	 carbohydrates	 as	 the	 sole	 carbon	 source.	 Both	
conditions	resulted	 in	P(3HB)	production.	The	polymer	yield	obtained	from	B.	subtilis	
OK2	was	much	higher	(30.8%	dcw)	than	B.	cereus	SPV	(7.5%	dcw)	when	grown	using	
fructose	as	 the	only	 carbon	source.	 It	 is	well	 known	 that	Bacillus	 species	are	able	 to	
metabolise	 sugars	 and	produce	 scl-PHAs,	mainly	 homopolymer	P(3HB)	 (Faccin	et	 al.,	
2013).		Cupriavidus	necator	produced	P(3HB),	when	grown	on	several	different	carbon	
sources.	 The	 obtained	 polymer	 yield	 was	 from	 6.7%	 dcw	 when	 grown	 using	 γ-
butyrolactone	 as	 the	 sole	 carbon	 source	 to	 18.6%	 dcw	 when	 γ-butyrolactone	 and	
sodium	octanoate	were	used	as	the	carbon	sources.	C.	necator	 is	a	well-known	strain	
used	for	PHA	production.	It	has	been	used	mainly	for	P(3HB)	production.	However,	it	is	
also	able	to	produce	P(3HB-co-4HB).	Engineered	strains	can	be	used	to	produce	scl-mcl-
PHA	copolymers,	such	as	P(3HB-3HHx).	P(3HB)	was	obtained	also	from	Pseudomonas	
mendocina	CH50	when	mixed	carbon	sources,	such	as	glucose	with	heptanoic	acid	or	
sucrose	with	rapeseed	oil,	were	used.	The	obtained	polymer	yield	was	17.2%	dcw	and	
22.5%	 dcw	 respectively.	 P(3HB-co-3HV),	 a	 scl-PHA	 copolymer	 was	 obtained	 by	
Pseudomonas	mendocina	CH50	when	valeric	acid	was	used	along	with	sucrose	as	the	
precursor	for	3HV	monomer	unit	within	the	copolymer.	Although,	Pseudomonas	species	
are	well	studied	as	the	main	sources	for	mcl-PHAs,	in	this	study,	P.	mendocina	was	able	
to	produce	also	short	chain	length	PHAs.		
The	P(3HB)	polymer	obtained	from	Bacillus	subtilis	OK2	was	selected	for	further	studies	
since	it	had	the	highest	polymer	yield.	This	was	characterised	with	respect	to	thermal	
properties,	mechanical	properties,	molecular	weight	and	chemical	identification.		
3.2.	 Production	of	 P(3HB)	using	Bacillus	 subtilis	OK2	and	 glucose	as	 the	 sole	
carbon	source	
P(3HB)	production	by	Bacillus	subtilis	OK2	using	glucose	was	carried	out	as	described	in	
the	section	2.4.3.	The	fermentation	was	carried	out	in	the	15L	bioreactor	for	48	hours.	
The	fermentation	profile	of	Bacillus	subtilis	OK2	grown	with	35g/L	of	glucose	was	studied	
for	 48	 hours	 (Figure	 19).	 Samples	 were	 taken	 at	 3	 hour	 intervals.	 Biomass,	 Optical	
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Density	 (OD600nm),	 pH,	 glucose	 consumption	 and	 polymer	 yield	 were	 monitored	 as	
described	in	the	section	2.7.		
 
Figure	19:	Temporal	profile	of	PHA	production	by	Bacillus	subtilis	OK2	using	Kannan	and	
Rehacek	media	with	35g/L	of	glucose	as	the	sole	carbon	source.			 	polymer	yield	(%	
dcw),	 	 optical	 density	 at	 600nm,	 pH,	 biomass	 (g/L),	 	 glucose	
concentration	(g/L).	
During	 fermentation,	 the	optical	density	 (OD)	 increased	gradually	until	 42	hours	and	
reached	a	maximum	value	of	7.9.	After	that	point,	the	OD	values	decreased.	Biomass	
concentration	increased	along	with	the	optical	density	of	the	bacterial	culture	up	to	27	
hours.	Maximum	biomass	concentration	of	4.7g/L	was	obtained	at	27	hours	and	then	
found	to	decrease.	The	pH	of	the	production	medium	was	set	to	6.8	at	the	beginning	of	
the	 process.	 During	 fermentation,	 the	 pH	 decreased	 from	 6.8	 until	 4.7	 at	 48	 hours.	
Utilisation	of	the	carbon	source	was	investigated	as	well.	The	results	showed	that	the	
glucose	concentration	decreased	from	its	initial	concentration	of	35	g/L	to	9.3	g/L	at	the	
end	of	the	fermentation.	Polymer	production	started	at	9	hrs	of	the	fermentation	and	
the	maximum	polymer	yield	(%	dcw)	was	obtained	at	48	hours	was	30.8%	dcw.		
In	this	study	production	of	PHA	was	carried	out	as	a	one-step	batch	cultivation	process	
in	 5L	 bioreactor	 using	 this	 relatively	 unexplored	 bacterial	 strain.	 The	 final	 biomass	
obtained	was	3.8	g/L,	and	polymer	yield	was	30.8	%	dcw	at	the	end	of	fermentation	at	
48	hours.		
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3.3.	P(3HB)	characterization		
Obtained	 polymer	 was	 chemically	 characterised	 using	 Attenuated	 Total	 Reflectance	
Fourier	 Transform	 Infrared	 Spectroscopy	 (ATR-FTIR),	 Gas	 Chromatography–Mass	
Spectrometry	 (GC-MS)	 and	 Nuclear	Magnetic	 Resonance	 (NMR)	 as	 described	 in	 the	
sections	2.6.1.-2.6.3.	Molecular	weight	analysis	was	performed	according	to	the	method	
described	in	the	section	2.6.5.	
3.3.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
The	 adsorption	 spectrum	 of	 the	 polymer	 produced	Bacillus	 subtilis	 OK2	 is	 shown	 in	
Figure	20.		
	
	
Figure	20:	 ATR-FTIR	 spectrum	of	 the	polymer	produced	by	Bacillus	 subtilis	OK2	with	
35g/L	 glucose	 as	 a	 carbon	 source	with	major	 characteristic	 peaks	 at	 1720.5	 cm-1	 for	
carbonyl	group	(C-O)	and	1276.5cm-1	for	–CH	group.		
	
FTIR-ATR	analysis	of	the	isolated	polymer	revealed	absorption	bonds	at	1720.5	cm-1	and	
1276.5	cm-1	(Figure	20)	corresponding	to	the	ester	carbonyl	group	and	the	-CH	group,	
respectively.	These	bands	are	characteristic	for	scl-PHAs	(Sun	et	al.,	2007)	and	hence	this	
result	confirmed	the	production	of	a	scl-PHA.	
CHAPTER	3	
	
	 100	
3.3.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	
	
The	 isolated	 polymer	 was	 subjected	 to	 methanolysis	 prior	 to	 GC-MS	 analysis,	 as	
described	in	the	chapter	2.6.2.	The	result	in	chromatograms	is	presented	in	the	Figure	
21A.		
	
	
Figure	21:	 (A)	Gas	chromatogram	of	the	polymer	extracted	from	Bacillus	subtilis	OK2	
biomass	and	(B)	mass	spectrum	of	a	peak	with	Rt=4.1	min	identified	using	NIST	library	
as	 methyl	 ester	 of	 3-hydroxybutyric	 acid.	Methyl	 benzoate	 was	 used	 as	 an	 internal	
standard	(Std).	
A) 
B) 
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The	GC	chromatogram	showed	one	peak	at	Rt=4.1min.	The	system	was	calibrated	using	
reference	standards	of	various	methyl	esters	of	3-hydroxyalkanotes	(Figure	22).		
	
Figure	 22:	 Gas	 chromatogram	 of	 reference	 standards	 of	 methyl	 esters	 of	 3-
hydroxyalkanaotes:	 3-hydroxybutyrate	 (3HB),	 3-hydroxyhexanoate	 (3HHx),	 3-
hydroxyoctanoate	 (3HO),	 3-hydroxydecanoate	 (3HD),	 3-hydroxydodecanoate	 (3HDD).	
Methyl	benzoate	(MB)	was	used	as	an	internal	standard.	
According	to	the	standard	chromatogram	(Figure	22),	the	peak	observed	at	4.1	minutes	
(Figure	21A)	corresponded	to	the	methyl	esters	of	3-hydroxybutyric	acid	(3HB).	Methyl	
benzoate	was	used	as	the	internal	standard	(Rt=6.4min.).	
Mass	 spectra	 analysis	 further	 demonstrated	 that	 the	 peak	 with	 Rt=4.1	minutes	 was	
comparable	with	the	MS	spectrum	of	the	methyl	ester	of	3-hydroxybutyric	acid	in	the	
MS	library	obtained	from	the	National	Institute	of	Science	and	Technology	(NIST)	(Figure	
21B).	The	m/z=103	peak	was	due	to	the	cleavage	between	carbon	atoms	number	3	and	
4.	The	peak	at	m/z=74	was	obtained	by	McLafferty	rearrangement	of	the	methyl	ester.	
The	ion	m/z=43	was	obtained	due	to	the	saturated	alkanoic	part	of	the	molecule	and	
from	the	methyl	ester	moiety	(Rijk	et	al.,	2005).	
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3.3.3.	Nuclear	Magnetic	Resonance	(NMR)	
	
1H	 and	 13C	 NMR	 confirmed	 the	 chemical	 structure	 of	 the	 obtained	 scl-PHA	 polymer	
produced	 by	 B.	 subtilis	 OK2	 using	 glucose	 as	 the	 sole	 carbon	 sources.	 The	 1H	 NMR	
spectrum	(Figure	23A)	of	the	scl-PHA	copolymer	obtained	from	B.	subtilis	OK2,	grown	
on	glucose	showed	3	peaks	corresponding	to	the	three	different	proton	environments	
from	P(3HB)	(Figure	23A).	Signals	of	the	methine	protons	(-CH)	at	5.3	ppm	corresponded	
to	the	protons	bonded	to	carbon	number	3	(-CH-	group).	The	peak	present	at	1.3	ppm	
corresponded	to	the	terminal	methyl	group	(-CH3).	The	signal	at	2.48	ppm	corresponded	
to	the	methylene	protons	(-CH2)	bonded	to	carbon	number	2.		
	
							 	
Figure	23:	(A)	1H	NMR	and	(B)	13C	NMR	spectra	of	P(3HB)	confirming	the	polymer	to	be	
homopolymer	P(3HB).	The	structure	of	P(3HB)	is	shown	as	an	insert	within	the	spectra.	
B) 
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The	13C	NMR	spectrum	showed	4	peaks	related	to	the	different	atoms	of	carbon	(Figure	
23B).	The	peak	at	 the	chemical	 shift	of	77.4	ppm	corresponded	to	 the	carbon	of	 the	
solvent	CDCl3.	The	peaks	present	at	169.4	ppm,	67.8	ppm,	40.7	and	19.9	corresponded	
to	C1	(C=O	group),	C3	(-CH-	group),	C2	(-CH2-	group)	and	the	terminal	carbon	atom	C4	(-
CH3	group)	in	the	3-hydroxybutyrate	monomer	unit.		
The	chemical	shifts	of	3HB	were	similar	to	those	obtained	from	previous	studies	(Doi	et	
al.,	1986).			
The	1H	NMR	and	13C	NMR	analysis	confirmed	the	structure	of	the	scl-PHA	as	the	P(3HB)	
homopolymer.		
	
3.3.4.	Molecular	weight	analysis	of	P(3HB)	produced	by	Bacillus	subtilis	OK2	
	
Gel	 Permeation	 Chromatography	 was	 used	 to	 characterize	 molecular	 weight	 of	 the	
P(3HB)	homopolymer.	The	results	obtained	are	shown	in	Table	4	and	Figure	24.	
 
Figure	24:	Molecular	weight	distribution	( )	and	cumulative	molecular	weight	( )	of	
neat	P(3HB)	polymer	produced	using	Bacillus	subtilis	OK2.	
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Table	4:	 Summary	of	molecular	weight	analysis	of	 the	P(3HB)	obtained	 from	Bacillus	
subtilis	OK2	and	glucose	as	the	carbon	source;	where	Mw=	weight	average	molecular	
weight,	Mn=	number	average	molecular	weight,	PDI=	polydispersity	index.	
Polymer	sample	 Mw	(kDa)	 Mn	(kDa)	 PDI	
P(3HB)	 582.4	 306.7	 1.9	
	
As	 shown	 in	 Table	 4,	GPC	 analysis	 demonstrated	 that	 the	weight	 average	molecular	
weight	(Mw)	of	the	P(3HB)	homopolymer	was	582.4	kDa	and	the	poly	dispersity	index	
was	1.9.	These	values	were	similar	to	those	obtained	by	Reddy	et	al.,	2009,	who	reported	
the	production	of	P(3HB)	from	Bacillus	sp.	88D	with	the	molecular	weight	range	from	
523-627kDa.	
	
3.3.5.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	
	
DSC	studies	were	carried	out	to	analyse	the	thermal	properties	of	the	freshly	produced	
P(3HB)	polymer.	Summary	of	the	thermal	properties	are	presented	in	the	Table	5	and	in	
the	 Figure	 25.	 The	 glass	 transition	 temperature	 (Tg)	 of	 the	 polymer	 was	 -10.7oC.	 A	
melting	event	was	observed	at	169.5oC.	
	
Figure	25:	DSC	thermograms:	first	heating	cycle	( )	and	second	heating	cycle	( )	of	
P(3HB)	obtained	from	Bacillus	subtilis	OK2	using	35g/L	glucose	as	the	sole	carbon	source.	
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The	 figure	 shows	 the	 normalised	 DSC	 heating	 curves	 with	 peak	 for	 glass	 transition	
temperature,	Tg	=	-10.7	oC	and	peak	for	melting	temperature,	Tm	=	169.5	oC.		
First	heating	cycle	is	used	in	general,	to	remove	the	thermal	history	of	the	material.	The	
actual	thermal	properties	of	the	material	appear	during	second	heating	cycle.	However	
ageing	 experiments	 are	 an	 exception.	 For	 those	 studies,	 the	 first	 heating	 cycle	 is	
considered.		
Table	5:	Summary	of	the	thermal	properties	of	the	fresh	P(3HB)	polymer	obtained	using	
B.	subtilis	OK2.	Where,	Tm	=	melting	temperature,	Tg	=	glass	transition	temperature,	Tc	=	
crystallisation	temperature,	DHf	=	enthalpy	of	fusion.	
Polymer	sample	 Tm	(°C)	 Tg	(°C)	 Tc	(°C)	 ΔHf	(J/G)	
P(3HB)	 169.5	 -10.7	 41.5	 82.5	
	
The	observed	Tg	and	Tm	values	were	similar	to	that	observed	for	the	short	chain	length	
PHAs	(Tm	above	60	oC	and	Tg	above	-25	oC)	(Zhang	et	al.,	2009).	Wellen	and	co-workers	
studied	the	melting	behaviour	of	P(3HB)	and	confirmed	the	presence	of	a	complex	peak,	
which	could	be	spread	into	three	separate	peaks	with	different	intensities	and	melting	
temperatures	(Wellen	et	al.,	2013).	The	glass	transition	temperature	highly	influences	
the	polymer	morphology	and	mechanical	properties.	Below	its	Tg,	the	polymer	is	 in	a	
glassy	state	and	is	in	a	hard	and	brittle	state;	while	above	Tg	the	polymer	is	in	a	rubbery	
state	and	is	relatively	soft	(Chanprateep	et	al.,	2010).		
	
3.3.6.	Mechanical	characterisation	of	the	P(3HB)	solvent	cast	films	
	
P(3HB)	neat	films	were	characterised	in	order	to	obtain	the	mechanical	properties	of	the	
polymer	 using	 tensile	 test	 as	 described	 in	 the	 section	 2.11.3.2.	 Three	 different	
parameters	have	been	measured,	such	as:	tensile	strength,	which	is	a	measure	of	the	
strength,	Young’s	Modulus,	which	is	a	measure	of	the	stiffness	and	elongation	at	break,	
which	 is	 a	 measure	 of	 ductility	 of	 the	 material.	 The	 summary	 of	 the	 mechanical	
properties	is	shown	in	Table	6.		
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Table	6:	Summary	of	the	mechanical	properties	of	neat	P(3HB)	solvent	cast	films	without	
storage;	including	tensile	strength,	elongation	at	break	and	Young’s	modulus	(n=3).	
Polymer	sample	
Tensile	strength	
(MPa)	
Young’s	Modulus	
(GPa)	
Elongation	at	
break	(%	strain)	
P(3HB)	film	 19.2±2.1	 0.8±0.01	 22.3±3.4	
	
Fresh	P(3HB)	films	have	tensile	strength	19.2±2.1MPa,	elongation	at	break	22.3±3.4%	
and	Young’s	Modulus	0.8±0.01GPa.	The	values	obtained	for	tensile	strength	as	well	as	
Young’s	 Modulus	 were	 lower	 than	 generally	 reported	 in	 literature.	 However,	 the	
elongation	at	break	is	much	higher	(Pachekoski	et	al.,	2009).	In	this	experiment,	material	
properties	 were	 obtained	 using	 fresh	 films	 within	 3	 days	 after	 complete	 solvent	
evaporation.	To	 investigate	 the	 influence	of	 the	 time	of	 storage,	 known	as	 “material	
ageing”,	on	the	thermal	and	mechanical	properties	of	the	P(3HB)	neat	films,	DSC	and	
tensile	 test	 analysis	 were	 performed	 after	 1,	 3,	 5	 and	 7	 weeks	 of	 storage	 at	 room	
temperature,	as	described	in	sections	2.11.3.1.-2.11.3.3.	
3.3.7.	Thermal	analysis	of	the	neat	P(3HB)	neat	films	after	7	weeks	of	storage	at	
room	temperature		
	
Thermal	 properties	 of	 the	 solvent	 cast	 films	 were	 studied	 for	 7	 weeks,	 in	 order	 to	
understand	the	impact	of	ageing	on	the	material.	The	results	obtained	are	summarised	
in	Table	7	and	Figure	26.	
Table	 7:	 Summary	 of	 the	 thermal	 properties	 of	 the	 P(3HB)	 films	 during	 7	 weeks	 of	
storage	at	room	temperature.	Where,	Tm	=	melting	temperature,	Tg	=	glass	transition	
temperature,	Tc	=	crystallisation	temperature,	DHf	=	enthalpy	of	fusion.	
Time	of	storage	
(weeks)	
Tg	(°C)	 Tc	(°C)	 Tm	(°C)	 ΔHf	(J/g)	
1	 -2.8	 35.9	 172.3	 83.22	
3	 -1.0	 40.1	 173.0	 82.16	
5	 -1.7	 41.6	 174.2	 84.35	
7	 0.2	 51.5	 172.5	 85.86	
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Figure	26:	DSC	thermograms	of	P(3HB)	neat	solvent	cast	films	during	1	week	( ),	3	weeks	
( ),	5	weeks	 ( )	and	7	weeks	 ( )	of	storage	at	 room	temperature	 indicating	melting	
peaks	(first	heating	cycle).	
The	time	of	storage	has	clearly	influenced	the	thermal	properties	of	the	material.	The	
glass	transition	temperature	 increased	from	-2.8°C	to	0.2°C	after	7	weeks	of	storage.	
Changes	were	also	observed	in	the	cold	crystallisation	temperature	as	in	the	enthalpy	
of	fusion.	Tc	values	increased	from	35.9°C	to	51.5°C,	ΔHf	values	followed	the	trend	of	Tc	
and	 increased	 from	 83.2	 to	 85.8	 J/g	 However,	 7	 weeks	 of	 storage	 did	 not	 result	 in	
changes	in	the	melting	temperature.		
3.3.8.	Mechanical	 characterisation	of	 the	neat	 P(3HB)	 films	 after	 7	weeks	of	
storage	at	room	temperature		
Mechanical	properties	of	 the	solvent	cast	 films	were	also	carried	out	 for	7	weeks,	 in	
order	to	check	the	effect	of	ageing	on	the	material.	The	results	obtained	are	summarised	
in	Table	8	and	Figure	27A-C.		
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Table	8:	Summary	of	the	mechanical	properties	of	the	P(3HB)	solvent	cast	films	during	
7	weeks	of	storage	at	room	temperature;	including	tensile	strength,	elongation	at	break	
and	Young’s	Modulus	(n=3).	
Time	of	storage	
(weeks)	
Tensile	strength	
(MPa)	
Young’s	Modulus	
(GPa)	
Elongation	at	
break	(%	strain)	
1	 19.2±2.1	 0.8±0.01	 12.8±1.5	
3	 19.1±0.2	 0.9±0.08	 9.3±0.5	
5	 20.5±0.5	 1.1±0.06	 7.4±1.2	
7	 21.5±2.7	 1.3±0.1	 5.9±0.2	
	
	
0
2
4
6
8
10
12
14
16
1 3 5 7
El
on
ga
tio
n	
at
	b
re
ak
	(%
	st
ra
in
)
Time	of	storage	(weeks)	
B)
CHAPTER	3	
	
	 109	
	
	
Figure	27:	The	evolution	of	(A)	an	ultimate	tensile	strength,	(B)	elongation	at	break	and	
(C)	Young’s	modulus	during	7	weeks	of	storage	at	room	temperature	of	neat	solvent	cast	
P(3HB)	films.	
Ageing	 has	 influenced	 the	 mechanical	 properties	 of	 the	 P(3HB)	 films.	 The	 tensile	
strength	has	 slightly	 increased	 from	19.2±2.1MPa	at	week	1	 to	 21.5±2.7MPa	after	 7	
weeks	of	storage.	The	Young’s	Modulus	values	significantly	increased	from	0.8±0.01	GPa	
after	week	1	to	1.3±0.1	GPa	after	week	7.	Elongation	at	break	decreased	from	12.8±1.5%	
after	week	1	 to	 5.9±0.2%	 strain	 after	week	7.	Hence,	 ageing	of	 P(3HB)	 enhanced	 its	
strength	and	stiffness	but	decreased	 its	elastomeric	properties.	The	material	became	
more	brittle	with	time.	
3.4.	Discussion	
Recent	studies	demonstrated	that	various	wild-type	as	well	as	genetically	engineered	
microorganisms	are	able	to	accumulate	scl-PHAs.	P(3HB)	 is	one	of	the	most	explored	
polyesters	 within	 the	 family	 of	 Polyhydroxyalkanoates	 (Karbasi	 et	 al.,	 2012).	 The	
polymer	yield,	varies	depending	on	the	bacterial	strain	used,	carbon	source,	conditions,	
fermentation	 mode	 and	 PHA	 production	 media	 (Shahid	 et	 al.,	 2013).	 For	 example:	
Alcaligenes	latus	was	able	to	accumulate	more	than	75%	dcw	of	P(3HB),	when	grown	on	
sucrose.	Bacillus	sp.,	cultured	on	sugarcane	produces	over	90%	dcw	of	P(3HB)	(Mozejko-
Ciesielska	 and	 Kiewisz,	 2016).	 P(3HB)	 have	 been	 produced	 commercially	 by	 several	
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1 3 5 7
Yo
un
g'
s	M
od
ul
us
	(G
Pa
)
Time	of	storage	(weeks)	
C)
CHAPTER	3	
	
	 110	
companies,	such	as:	Biomer	(Germany),	PHB	Industrial	S.A.	(Brazil)	and	Jiangsu	Nantian	
Group	(China)	(Chen,	2009;	Bugnicourt	et	al.,	2014).		
In	this	study	four	different	wild-type	strains:	Bacillus	cereus	SPV,	Bacillus	subtilis	OK2,	
Cupriavidus	necator	and	Pseudomonas	mendocina	CH50	were	studied	with	respect	to	
the	 production	 of	 scl-PHAs.	 All	microorganisms	 studied	were	 able	 to	 produce	 PHAs,	
mainly	P(3HB).	Bacillus	sp.	and	Cupriavidus	necator	are	well	known	P(3HB)	producers.	
Several	metabolic	pathways	are	involved	in	PHA	production	as	described	in	the	Chapter	
1.	The	main	enzyme	involved	in	the	biosynthesis	of	PHAs	is	the	PHA	synthase.	There	are	
four	classes	of	PHA	synthases,	class	I	PHAs	synthases,	found	in	Ralstonia	eutropha,	class	
II,	occurring	in	Pseudomonas	aeruginosa,	class	III,	present	in	Allochromatium	vinosum	
and	class	IV	in	Bacillus	megaterium	(Rehm,	2003).	Pseudomonas	sp.	are	mainly	mcl-PHA	
producers,	whereas	C.	necator	is	known	to	mainly	produce	P(3HB)	and	copolymers,	such	
as	P(3HB-co-3HV)	or	P(3HB-co-4HB)	(Wong	et	al.,	2012,	Bhubalan	et	al.,	2010;	Timm	and	
Steinbüchel,	1992).	
In	 this	 study	 a	 novel	 strain,	 Bacillus	 subtilis	 OK2	 was	 used	 for	 P(3HB)	 production.	
Production	of	P(3HB)	by	Bacillus	subtilis	OK2	has	only	been	reported	by	Sukan	et	al.,	
2015.	The	main	advantage	of	using	Bacillus	subtilis	over	Bacillus	cereus	is	that	B.	subtilis	
is	 classified	 as	 GRAS	 bacteria	 (“Generally	 Recognised	 as	 Safe”).		
Moreover,	 B.	 subtilis	 OK2	 in	 contrast	 to	 Gram-negative	 bacteria	 does	 not	 contain	
lipopolysaccharides,	 known	 endotoxins,	 as	 structural	 components	 of	 the	 cell	 wall.	
Therefore	P(3HB)	produced	by	B.	subtilis	OK2	minimizes	the	risk	of	material-mediated	
immunogenic	reactions	in	humans.	Out	of	all	the	bacterial	strains	tested	in	this	work,	
Bacillus	 subtilis	OK2	produced	 the	highest	amount	of	P(3HB)	polymer,	30.8%	dry	cell	
weight,	 when	 glucose	was	 used	 as	 the	 only	 carbon	 source.	 Sukan	 et	 al.,	 2015	 have	
reported	 production	 of	 P(3HB)	 from	 Bacillus	 subtilis	 OK2	 at	 the	 level	 of	 41%	 dcw.	
However,	in	his	study	orange	peel	was	used	as	the	carbon	source.	Akaraonye	et	al.,	2012	
observed	production	of	P(3HB)	by	B.	cereus	SPV	with	a	yield	of	up	to	61%	dcw,	when	
grown	on	sugarcane	molasses	as	the	carbon	source.		Pseudomonas	sp.	are	mainly	used	
for	mcl-PHA	production,	however,	in	this	study,	P(3HB)	as	well	as	P(3HB-co-3HV)	have	
been	produced	using	P.	mendocina,	albeit	at	a	relatively	low	yield.		
The	P(3HB)	homopolymer	produced	by	Bacillus	 subtilis	OK2	was	 selected	 for	 further	
analysis.	 FTIR,	 NMR	 and	 GC-MS	 analysis	 confirmed	 that	 the	 polymer	 obtained	 was	
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indeed	polyester	of	3-hydroxybutyric	acid.	Due	to	its	specific	material	properties,	P(3HB)	
has	been	extensively	studied	for	the	application	mainly	in	bone	tissue	regeneration	and	
drug	 delivery	 (Luef	 et	 al.,	 2015).	 For	 example,	 nanofibre	 mats	 of	 P(3HB)	 with	
incorporated	kanamycin	were	tested	against	S.	aureus	and	over	95%	of	the	drug	was	
successfully	 released	 within	 first	 8	 hours	 (Naveen	 et	 al.,	 2010).	 In	 another	 study	
Shishatskaya	 et	 al.,	 reported	 positive	 results,	 obtained	 after	 implantation	 of	 P(3HB)	
sutures	in	the	Wistar	rat	models	(breed	of	albino	rat;	first	rat	model	organism	developed	
for	medical	and	biological	research)	(Shishatskaya	et	al.,	2004).		
P(3HB)	was	characterised	with	respect	to	the	molecular	weight	of	the	material,	which	
was	detected	and	found	to	be	582.4	kDa.	The	molecular	weight	of	a	polymer	is	one	of	
the	most	significant	properties	affecting	the	processability	of	the	polymer.	 It	has	also	
been	shown,	that	different	bacterial	strains	are	able	to	produce	P(3HB)	with	different	
molecular	weight.	Taniguchi	et	al.,	2003,	observed	production	of	P(3HB)	from																			C.	
necator	with	a	molecular	weight	530	kDa,	when	grown	on	sesame	oil,	whereas	Kahar	et	
al.,	2004	reported	P(3HB)	production	from	C.	necator	with	molecular	weight	1.2	MDa,	
when	 grown	 on	 soybean	 oil.	 Kusaka	 et	 al.,	 1999,	 reported	 synthesis	 of	 P(3HB)	with	
ultrahigh	 molecular	 weight	 from	 5.0	 MDa	 to	 20.0	 MDa	 from	 recombinant	 E.	 coli,	
harbouring	 genes	 from	 Ralstonia	 eutropha	 H16.	 Rai	 et	 al.,	 2011	 compared	 various	
techniques	of	P(3HO)	extraction	using	different	solvents.	Soxhlet	extraction	resulted	in	
the	 low	 polymer	 yield	 but	 the	 highest	 purity	 product,	which	 is	 crucial	 in	 biomedical	
applications.	The	molecular	weight	of	the	polymer	obtained	from	Soxhlet	extraction	was	
comparable	with	the	molecular	weight	of	the	polymer	obtained	from	solvent	extraction	
using	 chloroform,	 but	 much	 larger	 than	 that	 obtained	 using	 the	 solvent	 dispersion	
method	(Rai	et	al.,	2011).	
In	order	to	fully	understand	the	mechanical	and	thermal	properties	 is	 it	necessary	to	
look	at	the	changes	 in	the	properties	of	P(3HB)	films	after	storage	time.	The	thermal	
properties	of	fresh	P(3HB)	films	and	after	7	weeks	of	ageing	were	found	to	be	different	
especially	for	glass	transition	temperature	and	cold-crystallisation	temperature.	The	two	
parameters,	 i.e.	 the	melting	event	as	well	 as	enthalpy	of	 fusion	 remain	 stable.	 From	
literature,	 the	 thermal	properties	of	P(3HB)	are:	Tg	value	 in	 the	 range	2-10°C	and	Tm	
between	174	to	178°C	(Reddy	et	al.,	2009;	Akaraonye	et	al.,	2012;	Ashby	et	al.,	2012;	
Zhang	et	al.,	1996).		However,	there	was	no	record	about	the	age	of	the	characterised	
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material.	Tg	and	Tm	values	obtained	in	this	study	were	lower	than	the	values	found	in	
the	 literature.	 The	 largest	 changes	 were	 observed	 in	 the	 cold-crystallisation	
temperature,	which	 increased	 from	36	 °C	 to	51.5	 °C.	 	 In	 this	 study,	melting	peak	 for	
P(3HB)	obtained	was	a	double	peak.	This	is	with	an	agreement	with	literature.	Multiple	
melting	 peaks	 of	 P(3HB)	 have	 been	 reported	 previously	 as	 a	 consequence	 either	 of	
conditions	 used	 during	 DSC	 analysis,	 polymorphism,	 different	 size,	 maturation	 and	
stability	of	crystals	or	physical	ageing	of	the	material	(Gunaratne	and	Shanks,	2005).		
It	is	well	known	that	the	P(3HB)	polymer	becomes	increasingly	brittle	with	the	time	of	
storage	 due	 to	 secondary	 crystallization,	 which	 occurred	 during	 ageing.	 This	 has	 an	
effect	on	 the	 tensile	 strength,	elongation	at	break	and	Young’s	Modulus	values.	This	
increased	brittleness	of	the	material	also	results	in	an	increase	of	stiffness	and	strength	
of	the	material.	The	usual	mechanical	properties	of	P(3HB)	reported	in	the	literature	are:	
Young’s	Modulus	round	1.1-3.5GPa,	tensile	strength	19-35MPa	and	elongation	at	break	
0.4-5.0%	(Chanprateep	et	al.,	2010;	Sigh	et	al.,	2015;	Sudesh	et	al.,	2000).	However,	the	
age	 of	 the	 studied	material	 was	 not	 mentioned.	 All	 three	mechanical	 properties	 of	
P(3HB)	produced	from	B.	subtilis	OK2	in	this	study	were	within	the	ranges	mentioned	in	
the	literature.		
The	 mechanical	 properties	 of	 the	 P(3HB)	 produced	 in	 this	 work	 were	 found	 to	 be	
unsuitable	 for	 use	 as	 a	 platform	 for	 coronary	 stent	 development.	 The	 elongation	 at	
break	 value	was	 found	 to	 be	 too	 low	 since	 the	 stent	 need	 to	 be	 crimped	 and	 then	
expanded	by	ballooning.	This	can	perhaps	be	achieved	by	creating	blends	of	P(3HB)	with	
more	elastomeric	mcl-PHAs.		The	final	material	should	have	a	high	tensile	strength	of	
30-50	MPa,	Young’s	modulus	above	1	GPa	and	an	elongation	at	break	around	10%.		
In	 conclusion,	 this	 study	 has	 demonstrated	 the	 ability	 of	 various	 bacterial	 strains	 to	
produce	 mainly	 P(3HB)	 using	 a	 range	 of	 the	 different	 carbon	 sources.	 This	 work	
confirmed	 the	 capability	 of	 a	 Gram-positive	 GRAS	 organism,	Bacillus	 subtilis	OK2	 to	
produce	P(3HB)	with	high	polymer	yield.	Characterisation	of	the	material	verified	the	
thermal	and	mechanical	properties	typical	to	P(3HB).	Due	to	its	high	brittleness,	P(3HB)	
has	 to	be	mixed	with	more	elastomeric	PHAs	 to	be	more	suitable	 for	coronary	stent	
application.
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4.	Introduction	
Polyhydroxyalkanoates	 are	 an	 emerging	 group	 of	 biomaterials,	 which	 can	 be	 an	
alternative	to	the	traditional,	petroleum	based	plastics.	PHAs	are	produced	by	a	wide	
variety	 of	 bacterial	 species	 usually	 under	 nutrient	 limiting	 conditions	with	 excess	 of	
carbon	source.	Scl-PHAs	have	been	produced	and	characterised	as	described	in	Chapter	
3.	The	second	type	of	PHAs	is	medium	chain	length	polyhydroxyalkanoates	(mcl-PHAs),	
which	contain	from	6	to	14	carbon	atoms	within	the	monomer	unit	(Oliveira	et	al.,	2007).	
This	group	of	PHAs	have	different	material	properties	in	comparison	to	scl-PHAs.	Mcl-
PHAs	are	very	elastomeric,	have	 low	crystallinity,	 low	melting	 temperature	and	glass	
transition	temperature	(Rai	et	al.,	2011).	The	drawback	of	mcl-PHAs	is	their	low	Young’s	
modulus	and	 tensile	 strength	values,	 therefore,	 they	 cannot	be	used	 in	 load	bearing	
applications.	Also,	their	low	Tg	and	Tm	values	make	them	suitable	only	for	very	specific	
applications,	due	to	restricted	methods	of	processing.	Among	mcl-PHAs	are	commonly	
represented	 by	 3-hydroxyhexanoate	 (3HHx),	 which	 has	 6	 carbon	 atoms	 within	 the	
monomer	unit,	3-hydroxyheptanoate	(3HHp)	with	7	carbon	atoms,	3-hydroxyoctanoate	
(3HO),	containing	8	atoms,	3-hydroxydecanoate	(3HD),	containing	10	carbon	atoms	and	
3-hydroxydodecanoate,	with	12	carbon	atoms	within	the	monomer	unit	(Basnett	et	al.,	
2017).	 Within	 mcl-PHA	 group,	 a	 lot	 of	 different	 types	 of	 copolymers	 have	 been	
produced,	 such	 as	 poly(3-hydroxyhexanoate-co-3-hydroxyoctanoate)	 P(3HHx-3HO),	
poly(3-hydroxyoctanoate-co-3-hydroxydecanoate)	 P(3HO-3HD)	 and	 poly(3-
hydroxyoctanoate-co-3-hydroxydecanoate-co-3	 hydroxydodecanoate)	 P(3HO-3HD-
3HDD)	(Anderson	and	Dawes,	1990).	Mcl-PHAs	can	be	produced	by	different	types	of	
Pseudomonas	 sp.,	 such	 as	 P.	 aeruginosa,	 P.	 putida,	 P.	 oleovorans,	 P.	mendocina,	 P.	
raguenesii,	P.	guezennei	and	P.	stutzeri	(Simon-Collin,	2009;	Simon-Collin,	2012).	Mcl-
PHA	production	was	also	achieved	by	using	Comamonas	testosteronii	or	recombinant	E.	
coli	 (Thakor	 et	 al.,	 2006;	 Wang	 et	 al.,	 2012).	 Mcl-PHAs	 have	 been	 used	 in	 several	
biomedical	applications,	such	as:	soft	tissue	engineering	or	biological	adhesives	(Chen	
and	Wu,	2005;	Williams	et	al.,	1999;	Pouton	and	Akhtar,	1996).	They	can	also	be	used	
as	an	additive	to	scl-PHAs	to	enhance	the	elastomeric	properties	of	the	scl-PHAs.			
High	production	cost	is	one	of	the	main	limiting	factors,	which	reduces	the	widespread	
application	of	mcl-PHAs	 (Singh	et	 al.,	 2009).	 Therefore,	 various	 strategies	have	been	
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introduced	to	make	the	PHA	production	more	economically	efficient.	These	will	include:	
PHA	 production	 from	 mixed	 cultures	 (Choi	 and	 Lee,	 1997),	 genetically	 engineered	
microorganisms,	cheap	carbon	sources	(Luckachan	and	Pillai,	2012)	as	well	as	changes	
in	fermentation	strategies	towards	continuous	fermentation	with	high	cultures	density	
(Chen,	 2009).	 	 Many	 different	 solutions	 have	 been	 tested	 to	 improve	 the	 yields,	
productivity	and	decrease	the	production	costs	of	PHAs,	 to	make	them	commercially	
available.	Over	50%	of	the	total	cost	is	due	to	the	price	of	carbon	source.	Various	types	
of	cheap	carbon	sources	and	waste	materials,	such	as	vegetable	oils,	waste	crops,	and	
side	products	from	fuel	industry	have	been	explored	in	order	to	significantly	reduce	the	
total	production	cost	(Anjum	et	al.,	2016;	Ciesielski	et	al.,	2015).		
The	 main	 objective	 of	 this	 study	 was	 to	 produce	 mcl-PHAs	 using	 Pseudomonas	
mendocina	CH50	using	a	range	of	cheap	carbon	sources	and	renewable	materials.	The	
selected	material	was	subjected	to	thorough	analysis	in	order	to	fully	characterise	the	
properties	of	the	chosen	material.	
	
4.1.	Screening	experiments	
	
Screening	experiments	were	carried	out	to	obtain	novel	mcl-PHAs	using	Pseudomonas	
mendocina	 CH50.	 The	 range	 of	 different	 carbon	 sources,	 including	 cheap	 carbon	
sources,	such	as	waste	frying	oil,	sugarcane	molasses,	vegetable	oils	and	biodiesel	waste	
have	been	investigated.	A	summary	of	the	results	is	shown	in	the	Table	9.	Depending	on	
the	type	of	carbon	source,	various	mcl-PHAs	copolymers	have	been	synthesised.	The	
monomer	units,	which	are	present	in	the	most	of	the	conditions	are	3-hydroxyocyanoate	
(3HO)	and	3-hydroxydecanoate	(3HD).	The	polymer	yield	(%	dcw)	is	also	shown	in	the	
Table	9.	
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Table	9:	Summary	of	the	screening	experiments	used	for	the	production	of	mcl-PHAs	by	
Pseudomonas	mendocina	CH50	using	various	carbon	sources.	
Bacterial	strain	 Carbon	source	
Polymer	yield	
(%	dcw)	
GC-MS	results	
Pseudomonas	
mendocina	CH50	
Glycerol	 4.2	 3HO,	3HD	
Waste	frying	oil	 38.0	
3HHx,	3HO,	3HD,	
3HDD	
Sugarcane	
molasses	
14.0	 3HO,	3HD	
Rapeseed	oil	 15.27	 3HO,	3HD	
Grapeseed	oil	 10.42	 3HO,	3HD,	3HDD	
Sunolive	oil	 8.8	 3HO,	3HD	
Biodiesel	waste	 38.9	
3HHx,	3HO,	3HD,	
3HDD	
Sucrose,	biodiesel	
waste	
16.8	 3HO,	3HD	
Lauric	acid,	
1,4-butanediol	
5.2	 3HO,	3HD,	3HDD	
Sucrose,	
butyrolactone	
4.33	
3HO,	3HD	
	
	
As	 seen	 in	 Table	 8,	 all	 studied	 carbon	 sources	 resulted	 in	 mcl-PHA	 accumulation.	
Pseudomonas	 sp.	 are	well-known	mcl-PHA	producers	 from	different	 types	 of	 carbon	
sources.	The	copolymer	P(3HO-3HD)	was	produced	using	glycerol,	sugarcane	molasses,	
rapeseed	oil,	sunolive	oil,	and	mixture	of	sucrose	with	biodiesel	waste	or																											γ-
butyrolactone.	The	terpolymer	P(3HO-3HD-3HDD)	was	obtained	from	grapeseed	oil	and	
lauric	 acid	 mixed	 with	 1,4-butanediol.	 A	 unique	 mcl-PHA	 copolymer,	 containing	 4	
monomer	units:	3HHx,	3HO,	3HD,	3HDD	was	obtained	when	P.	mendocina	was	grown	
using	waste	frying	oil	and	biodiesel	waste.	Obtained	polymer	yield	was	around	38-39.0%	
dcw.	
Due	to	its	high	yield	and	polymer	composition,	the	novel	mcl-PHA	copolymer	obtained	
from	Pseudomonas	mendocina	CH50	with	 20g/L	 of	waste	 frying	 oil	was	 selected	 for	
further	studies.		
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4.2.	Characterisation	of	the	waste	frying	oil	used	to	produce	mcl-PHAs	
Waste	 frying	 oil,	 used	 as	 the	 carbon	 source	 was	 chemically	 characterised	 using	
Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	(ATR-FTIR),	Gas	
Chromatography–Mass	Spectrometry	(GC-MS)	and	Nuclear	Magnetic	Resonance	(NMR)	
as	described	in	the	sections	2.6.1.-2.6.3.		
4.2.1.	Attenuated	Total	Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
 
Preliminary	characterisation	of	the	waste	frying	oil	was	carried	out	using	ATR/FTIR.	In	
the	ATR/FT-IR	spectrum	(Figure	28)	two	sharp	absorption	bands	at	2923.1	and	2853.6	
cm−1	were	observed	and	could	be	assigned	to	-CH2	asymmetric	vibrations	and	to	-CH3	
asymmetric	 vibrations	 respectively.	 In	 addition,	 a	 small	 peak	 at	 3009cm-1,	 which	
corresponds	to	=C-H	(configuration	cis)	stretching	was	also	observed.		The	spectra	also	
revealed	absorption	bands	at	1743.6	cm-1	corresponding	to	the	ester	carbonyl	group,	a	
short	peak	at	1655.0cm-1	corresponding	to	-C=C-	(cis	configuration)	stretching,	peaks	at	
1463.8cm-1	and	1377.5	cm-1,	corresponding	to	-C-H	bending	and	two	peaks	at	1236.2	
and	1161.1	cm-1	corresponding	to	the	-CO	stretching	group	and	-CH2	bending.	There	was	
also	observed	absorption	bands	at	722.2cm-1,	which	could	be	assigned	to	-(CH2)	bending.		
	
Figure	28:	ATR-FTIR	spectrum	of	the	waste	frying	oil	used	as	a	carbon	source	for	mcl-
PHAs	production	indicating	the	important	peaks	of	the	spectrum.	
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This	analysis	confirmed	the	presence	of	characteristic	bands	of	fatty	acids.	Sbihi	et	al.,	
2015	 have	 observed	 similar	 adsorption	 peaks,	 obtained	 from	 the	 analysis	 and	
characterisation	of	 fatty	acids	present	 in	 fat	 from	goat	milk	 (Sbihi	et	al.,	2015).	Also,	
Gomez	et	al.,	2011	have	observed	similar	FTIR	spectra	obtained	 from	the	analysis	of	
vegetable	oils	(Gomez	et	al.,	2011).		
4.2.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	
 
Chemical	 composition	 of	 obtained	 PHAs	 polymer	 was	 identified	 by	 Gas	
Chromatography-Mass	 Spectrometry	 analysis.	 The	 GC	 chromatogram	 showed	 three	
peaks	 at	 Rt=12.3minutes,	 Rt=13.4minutes	 and	 Rt=13.7minutes.	Methyl	 benzoate	was	
used	as	the	internal	standard	(Rt=6.5minutes.)	The	peaks	obtained	were	analysed	using	
the	NIST	library	(Figure	29).	
	
Figure	29:	Gas	chromatogram	of	the	composition	of	the	waste	frying	oil	used	for	mcl-
PHA	production	as	a	carbon	source.	Methyl	benzoate	was	used	as	an	internal	standard	
(Std).	
The	 mass	 spectra	 analysis	 demonstrated	 that	 the	 peak	 with	 Rt=12.3	 minutes	 was	
comparable	with	the	MS	spectrum	of	the	methyl	ester	of	9-octadecenoic	acid,	known	
also	as	oleic	acid	(Figure	30A).	Peak	with	Rt=13.4	minutes	was	comparable	with	the	MS	
spectrum	 of	 the	 methyl	 ester	 of	 9,12-octadecadienoic	 acid,	 known	 as	 linoleic	 acid	
(Figure	 30B).	 Peak	 with	 Rt=13.7	minutes	 was	 comparable	 with	 the	MS	 spectrum	 of	
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octadecanoic	acid	also	known	as	stearic	acid	(Figure	30C).	In	all	mass	spectra	m/z	ion	
peaks	characteristic	for	fatty	acids	have	been	observed.	Similar	MS	spectra	for	oleic	acid	
as	 well	 as	 linoleic	 acid	 are	 presented	 in	 the	 AOCS	 Lipids	 Library	 (source:	
http://lipidlibrary.aocs.org).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
\ 
Figure	30:	Mass	spectra	of	peaks	obtained	by	gas	chromatography	of	waste	frying	oil.	
Retention	 times	 (A)	12.3	min,	 (B)	13.4	min	and	 (C)	13.7min	 identified	using	 the	NIST	
A) 
B) 
C) 
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library	 as	 methyl	 esters	 of	 9-octadecenoic	 acid,	 9,12-octadecadienoic	 acid	 and	
octadecanoic	acid	respectively.			
Hence,	the	composition	of	waste	frying	oil	was	confirmed	as	9-octadecenoic	acid	(oleic	
acid),	9,12-octadecadienoic	acid	(linoleic	acid)	and	octadecanoic	acid	(stearic	acid).		The	
dominant	compound	in	waste	frying	oil	was	linoleic	acid	90.5mol%,	whereas	the	amount	
of	oleic	acid	was	only	8.6	mol	%	and	stearic	acid	0.9mol%	(Table	10).		
	
Table	 10:	 Fatty	 acids	 composition	 (mol	 %)	 of	 waste	 frying	 oil	 used	 for	 mcl-PHA	
production.		
Fatty	acid	 Molar	content	(mol	%)	
C18H34O2	 8.6	
C18H32O2	 90.5	
C18H36O2	 0.9	
	
4.2.3.	Nuclear	Magnetic	Resonance	(NMR)	
	
1H	and	 13C	NMR	 further	 confirmed	 the	 chemical	 structure	of	 the	 composition	of	 the	
waste	frying	oil.		The	1H	NMR	spectrum	(Figure	31A)	of	the	waste	frying	oil	showed	7	
peaks	corresponding	to	the	different	proton	environments	from	the	fatty	acids	(Figure	
31A).	 Individual	 signals	 derived	 from	 protons	 bonded	 to	 the	 carbon	 atoms	 for	
octadecanoic	acid,	9-octadecenoic	acid	and	9,12-octadecadienoic	acid	are	listed	in	Table	
11,	12.	
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Figure	31:	 (A)	 1H	NMR	and	 (B)	 13C	NMR	spectra	of	waste	 frying	oil	used	 for	mcl-PHA	
production	 as	 the	 carbon	 source.	 Chemical	 structures	 of	 stearic	 acid	 C18H36O2	 (red),	
linoleic	 acid	 C18H32O2	 (green)	 and	 oleic	 acid	 C18H34O2	 (black)	 are	 shown	 as	 an	 insert	
within	the	spectra.		
A) 
B) 
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Table	11:	The	summary	of	 the	chemical	 shifts	observed	 in	 1H	NMR	of	 the	 fatty	acids	
presented	in	the	waste	frying	oil.	
	 d,	ppm	
Proton	group	and	
bonded	carbon	
atoms	in	
Octadecanoic	acid	
(red	colour)	
Proton	group	and	
bonded	carbon	
atoms	in	
9-Octadecenoic	acid	
(black	colour)	
Proton	group	and	
bonded	carbon	atoms	in	
9,12-Octadecadienoic	
acid	
(green	colour)	
a.	 5.3	 -	 e-CH=CH-	 e1,	e2	-	CH=CH-	
b.	 2.7	 -	 -	 f-CH2-CH=	
c.	 2.3	 a-CH2-	 a-CH2-	 a-CH2-	
d.	 2.0	 -	 d1,	d2-CH2-CH=	 d1,	d2-CH2-CH=	
e.	 1.6	 b-CH2-	 b-CH2-	 b-CH2-	
f.	 1.3	 c-(CH2)n-	 c1,	c2-(CH2)	n-	 c1,	c2-(CH2)	n-	
g.	 0.9	 d-CH3	 f-CH3	 g-CH3	
The	 13C	 NMR	 spectrum	 showed	 11	 peaks	 related	 to	 signals	 from	 different	 atoms	 of	
carbon	(Figure	31B).	The	peak	at	the	chemical	shift	77.4	ppm	corresponds	to	the	carbon	
of	the	solvent	CDCl3.	The	summary	of	chemical	shifts	in	13C	NMR	of	octadecanoic	acid,	
9-octadecenoic	acid	and	9,12-octadecadienoic	acid	are	listed	in	Table	12.		
Table	12:	The	summary	of	the	chemical	shifts	observed	in	13C	NMR	spectrum	of	the	fatty	
acids	presented	in	the	waste	frying	oil.	
	
d,	ppm	
Octadecanoic	
acid	
9-0ctadecenoic	acid	
	
9,12-0ctadecadienoic	
acid	
1.	 180.2	 C1	 C1	 C1	
2.	 130.2	 -	 C2	 C2-C3	
3.	 128.1	 -	 C3	 C4-C5	
4.	 34.1	 C2	 C4	 C6	
5.	 31.5	 C3	 C5	 C7	
6.	 29.3	 C4-C8	 C6-C13	 C8-C12	
7.	 27.2	 -	 -	 C13	
8.	 25.7	 C9	 C14-C15	 C14	
9.	 24.7	 -	 C16	 C15	
10.	 22.6	 C10	 C17	 C16	
11.	 14.1	 C11	 C18	 C17	
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Both	 NMR	 spectra:	 1H	 and	 13C,	 confirmed	 the	 composition	 of	 the	 waste	 frying	 oil	
obtained	by	GC-MS	analysis.	The	waste	frying	oil	has	3	main	compounds	listed	below:	
9,12-octadecadienoic	acid,	9-octadecenoic	acid	and	octadecanoic	acid.	
4.3.	 Production	 of	 P(3HHx-3HO-3HD-3HDD)	 using	 Pseudomonas	 mendocina	
CH50	and	waste	frying	oil	as	a	sole	carbon	source	
The	growth	profile	of	Pseudomonas	mendocina	CH50	grown	with	20g/L	of	waste	frying	
oil	as	a	sole	carbon	source	was	studied	for	48	hours	(Figure	32).	Samples	were	taken	in	
3	hour	 intervals.	Biomass,	optical	density	(OD450nm)	and	pH	were	monitored.	Polymer	
yield	and	nitrogen	concentration	were	estimated.		
	
Figure	32:	Temporal	profile	of	PHA	production	by	Pseudomonas	mendocina	CH50	using	
MSM	medium	with	20g/L	of	waste	frying	oil	as	a	sole	carbon	source.		 	polymer	yield	
(%	dcw),	 Optical	Density	at	450nm,	 	pH,	 	biomass	 (g/L),	 	 	nitrogen	
concentration	(g/L).	
It	was	observed	that	the	Optical	Density	 (OD)	 increased	gradually	until	30	hours	 and	
reached	 a	maximum	 value	 8.5.	 After	 that	 the	OD	 decreased.	 Biomass	 concentration	
increased	 along	 with	 the	 optical	 density	 of	 the	 bacterial	 culture	 until	 30	 hours.	 A	
maximum	biomass	concentration	of	4.2g/L	was	obtained	at	30	hrs	and	then	the	values	
decreased.	pH	of	the	production	medium	was	set	to	7.0.	During	the	fermentation,	pH	
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decreased	from	7.0	until	6.67	at	48	hours.	Concentration	of	nitrogen	decreased	from	its	
initial	 value	 of	 0.5	 g/L	 to	 0.01	 g/L	 within	 27	 hours	 of	 fermentation	 indicating	 that	 a	
nitrogen-limiting	 environment	was	maintained	 during	 the	 fermentation.	 The	 polymer	
yield	increased	from	3.1%	dcw	at	9	hours	to	38.0%	dcw	after	48	hours.	
4.4.	Mcl-PHA	characterisation	
Obtained	 polymer	 was	 chemically	 characterised	 using	 Attenauted	 Total	 Reflectance	
Fourier	 Transform	 Infrared	 Spectroscopy	 (ATR-FTIR),	 Gas	 Chromatography–Mass	
Spectrometry	 (GC-MS)	 as	 described	 in	 the	 sections	 2.6.1.-2.6.2.	 Molecular	 weight	
analysis	was	performed	according	to	the	method	described	in	the	section	2.6.5.	
4.4.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
Preliminary	characterisation	of	the	polymer	was	carried	out	using	ATR/FTIR.	FTIR	spectra	
revealed	presence	of	an	absorption	bands	at	1736.9	cm-1	corresponding	 to	 the	ester	
carbonyl	 group	 and	 at	 1162.2	 cm-1	 corresponding	 to	 the	 -CO	 stretching	 group,	
characteristic	of	mcl-PHAs	(Randriamahefa	et	al.,	2003)	(Figure	33).	The	bands	at	2955.4	
cm-1,	2925.9	and	2856.8	cm-1	correspond	to	the	aliphatic	C-H	group	of	the	pendant	alkyl	
group	found	in	mcl-PHAs.	This	analysis	confirmed	the	presence	of	bands	characteristic	
for	mcl-PHAs	suggesting	the	production	of	mcl-PHA	by	P.	mendocina	using	waste	frying	
oil	as	a	carbon	source.	
	
Figure	33:	ATR-FTIR	spectrum	of	the	polymer	produced	from	Pseudomonas	mendocina	
CH50	with	20g/L	waste	frying	oil	as	a	carbon	source	indicating	the	important	peaks	of	
the	spectrum	characteristic	for	mcl-PHAs.	
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FTIR	analysis	confirmed	the	presence	of	the	peaks,	characteristic	of	medium	chain	length	
PHAs	(Simon-Colin	et	al.,	2008).		
	
4.4.2.	Gas	Chromatography	Mass	Spectrometry	(GC-MS)	
	
The	GC	chromatogram	showed	four	peaks	at	Rt=5.9	min,	Rt=7.7	min,	Rt=9.3	min,	Rt=10.7	
min	(Figure	34).	The	chromatographic	system	was	calibrated	using	reference	standards	
of	various	methyl	esters	of	3-hydroxyalkanotes	as	presented	in	Figure	22.	According	to	
the	 calibration,	 the	 peaks	 observed	 corresponded	 to	 the	 methyl	 esters	 of	 the	 3-
hydroxyhexanoic	 acid	 (3HHx),	 3-hydroxyoctanoic	 acid	 (3HO),	 3-hydroxydecanoic	 acid	
(3HD)	and	3-hydroxydodecanoic	acid	(3HDD),	respectively.	Methyl	benzoate	was	used	
as	the	internal	standard	(Rt=6.4min.)	(Figure	34).		
	
Figure	 34:	 Gas	 chromatogram	 of	 the	 mcl-PHA	 polymer	 produced	 by	 Pseudomonas	
mendocina	CH50	using	waste	frying	oil	as	the	carbon	source.	Methyl	benzoate	was	used	
as	an	internal	standard.	
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Figure	 35:	 Mass	 spectra	 of	 peaks	 obtained	 from	 GC	 of	 polymer	 produced	 by	 P.	
mendocina	and	waste	frying	oil.	Retention	times	(A)	6.0	min,	(B)	7.7	min,	(C)	9.3	min	and	
(D)	10.7	min	identified	using	the	NIST	library	as	methyl	esters	of	3-hydroxyhexanoic	acid,	
3-hydroxyoctanoic	 acid,	 3-hydroxydecanoic	 acid,	 and	 3-hydroxydodecanoic	 acid	
respectively.		
CHAPTER	4	
	
	
127	
The	 mass	 spectra	 obtained	 demonstrated	 that	 the	 peak	 with	 Rt=5.9minutes	 was	
comparable	with	the	MS	spectrum	of	the	methyl	ester	of	3-hydroxyhexanoic	acid	(Figure	
35A).	The	peak	with	Rt=7.7minutes	was	comparable	with	the	MS	spectrum	of	the	methyl	
ester	of	3-hydroxyoctanoic	acid	(Figure	35B).	Peaks	with	Rt=9.3	and	Rt=10.6	minutes	are	
similar	 with	 the	 MS	 spectra	 of	 the	 methyl	 ester	 of	 3-hydroxydecanoic	 acid	 and	 3-
hydroxydodecanoic	 acid	 respectively	 (Figure	35C	 and	D).	 In	 all	mass	 spectra	m/z	 ion	
peaks	characteristic	for	PHAs	have	been	observed,	such	as	peak	m/z=103	(α	cleavage	
between	carbon	atoms	number	3	and	4),	peak	at	m/z=74	(McLafferty	rearrangement	of	
the	methyl	ester).	The	ion	m/z=43	as	described	in	section	3.3.2.		
The	composition	of	the	obtained	polymer	was	confirmed	as	P(3HHx-3HO-3HD-3HDD).		
The	 dominant	 monomer	 units	 in	 these	 copolymers	 were	 3-hydroxyoctanoate	 and		
3-hydroxydecanoate.	 Table	 13	 presents	 the	 molecular	 composition	 of	 the	 mcl-PHA	
synthesised	by	P.	mendocina	using	waste	frying	oil.	The	monomer	content	was	derived	
from	 the	 GC-MS	 results	 using	 the	 calibration	 curve	 obtained	 using	methyl	 esters	 of															
3-hydroxyalkanoates	with	different	alkanoic	acids	described	in	the	Chapter	3.	As	can	be	
seen	from	the	Table	13,	the	shortest	(C6)	and	the	longest	(C12)	monomer	units	were	
only	slightly	more	than	10	mol%,	with	the	rest	of	the	polymer	consisting	of	almost	equal	
fractions	of	3-hydroxyoctanoate	and	3-hydroxydecanoate.	
Table	 13:	 Monomer	 composition	 mcl-PHA	 synthesised	 by	 P.	 mendocina	 with	 waste	
frying	oil	as	a	carbon	source.	
	 Molar	content,	mol%	
3HHx	 7.6	
3HO	 45.4	
3HD	 41.8	
3HDD	 5.2	
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4.4.3.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	
Thermal	analysis	of	the	P(3HHx-3HO-3HD-3HDD)	mcl-PHA	copolymer	were	performed	
by	DSC	as	described	in	section	2.6.2.	Summary	of	the	results	are	presented	in	Figure	36	
and	Table	14.	
	
Figure	36:	 The	DSC	 thermogram	of	 the	P(3HHx-3HO-3HD-3HDD)	copolymer	obtained	
from	P.	mendocina	using	waste	frying	oil	as	the	carbon	source.	( )	first	heating	cycle,	(
)	second	heating	cycle.		
Table	14:	Summary	of	the	thermal	properties	of	the	P(3HHx-3HO-3HD-3HDD)	copolymer	
obtained	from	P.	mendocina	using	waste	frying	oil	as	the	carbon	source;	Where,	Tm	=	
melting	temperature,	Tg	=	glass	transition	temperature,	Tc	=	crystallisation	temperature.	
Polymer	sample	 Tm	(°C)	 Tg	(°C)	 Tc	(°C)	
P(3HHx-3HO-3HD-3HDD)	 -	 -32.1	 -	
	
The	mcl-PHA	copolymer,	P(3HHx-3HO-3HD-3HDD,	obtained	from	vegetable	waste	frying	
oil	as	a	carbon	source	was	found	to	be	rubbery	amorphous	in	nature.	Neither	a	melting	
event	 nor	 a	 cold-crystallisation	 temperature	 were	 detected.	 Glass	 transition	
temperature	of	the	mcl-PHA	copolymer	was	-32.1°C	as	seen	in	Table	14.	The	polymer	
was	sticky	at	room	temperature.		
CHAPTER	4	
	
	
129	
	
4.4.4.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	(GPC)	
	
Molecular	weight	analysis	was	carried	out	according	to	the	procedure	described	in	the	
section	2.6.5.	The	results	of	the	molecular	weight	analysis	of	the	mcl-PHA	copolymer	
obtained	using	P.	mendocina	CH50	and	waste	frying	oil	are	shown	in	Figure	37	and	Table	
15.		
	
Figure	37:	Molecular	weight	distribution	( )	and	cumulative	molecular	weight	( )	of	
neat	 P(3HHx-3HO-3HD-3HDD)	 obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	
waste	frying	oil	as	the	carbon	source.	
Table	 15:	 Summary	 of	 molecular	 weight	 analysis	 of	 the	 P(3HHx-3HO-3HD-3HDD)	
obtained	 from	 Pseudomonas	 mendocina	 CH50	 using	 waste	 frying	 oil	 as	 the	 carbon	
source.	Mw=	weight	average	molecular	weight,	Mn=	number	average	molecular	weight,	
PDI=	polydispersity	index.		
Polymer	sample	 Mw	(kDa)	 Mn	(kDa)	 PDI	
P(3HHx-3HO-3HD-3HDD)	 210.7	 56.6	 3.7	
	
The	molecular	weight	(Mw)of	the	P(3HHx-3HO-3HD-3HDD)	obtained	in	this	study	was	
210.7	kDa,	which	is	higher	than	that	observed	in	the	literature	for	different	types	of	mcl-
PHAs.		
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4.5.	Discussion	
It	has	been	known	from	literature	that	various	types	of	Pseudomonas	sp.	are	able	to	
accumulate	mcl-PHAs,	mainly	copolymers.	In	this	study,	Pseudomonas	mendocina	CH50	
was	investigated	in	order	to	produce	mcl-PHAs	using	different	carbon	sources,	including	
cheap	 carbon	 sources	 and	 renewable	 materials.	 According	 to	 the	 literature	
Pseudomonas	 sp.	 readily	 use	 fatty	 acids	 for	 PHA	 production.	 Production	 of	mcl-PHA	
copolymers	 by	 Pseudomonas	 mendocina	 CH50	 using	 waste	 frying	 oil	 has	 not	 been	
reported	 so	 far.	 Waste	 frying	 oil	 was	 selected	 for	 the	 production	 of	 the	 mcl-PHA	
copolymer,	 identified	 as	 P(3HHx-3HO-3HD-3HDD).	 Prior	 to	 PHA	 production,	 the	
composition	of	the	carbon	source	was	investigated	and	confirmed	by	GC-MS	and	NMR	
analysis.	Analysis	of	waste	frying	oil	confirmed	the	composition	as:	 linoleic	acid,	oleic	
acid	and	stearic	acid.	Linoleic	acid	and	oleic	acid	are	unsaturated	fatty	acids.	Linoleic	acid	
contains	two	double	bonds,	including	the	9	and	12	carbon	atoms	within	the	fatty	acid	
chain.	Oleic	acid	has	only	one	double	bond	present	at	carbon	9.	Both	detected	fatty	acids	
have	18	carbon	atoms	within	 the	carbon	chain.	Each	vegetable	oil	 contains	a	unique	
composition	of	saturated	and	unsaturated	 fatty	acids.	All	 fatty	acids,	detected	 in	 the	
waste	 frying	 oil	 were	 mainly	 originated	 from	 vegetable	 oils,	 obtained	 from	 corn,	
cottonseed,	soybean,	peanuts	and	sunflower	(Demirbas,	2003).	However,	the	ratios	of	
specific	 components	 were	 different	 from	 that	 obtained	 in	 this	 project.	 This	 can	 be	
explained	by	the	fact	that	mixed	vegetable	oil,	rather	than	a	pure	source	of	oil	was	used	
for	frying.	
Vegetable	oils	are	most	widely	studied	as	a	potential	carbon	source	for	PHA	production	
with	 the	 various	 bacterial	 strains,	 like	 Cupriavidus	 necator	 and	 Pseudomonas	 sp.	
According	to	literature,	P(3HB)	concentration	of	up	to	90%	dry	cell	weight	was	obtained	
from	 C.	 necator	using	 canola	 oil	 and	 fructose	 in	 a	 three-stage	 fermentation	 (Lopez-
Cuellar	 et	 al.,	 2011).	 Cruz	 et	 al.,	 2015	 reported	 P(3HB)	 production	 from	Cupriavidus	
necator	DSM	428	using	cooking	oil	with	a	yield	of	63±10.7%	dcw.	Cupriavidus	necator	
was	also	used	for	PHA	production	using	emulsified	palm	oil	and	yields	obtained	varied	
from	37%	dcw	(Martino	et	al.,	2014)	in	a	batch	fermentation	up	to	79%	dcw	in	a	multiple	
batch	bioreactor	system	(Budde	et	al.,	2011).	Waste	frying	oil	has	also	been	investigated	
by	Verlinden	and	co-workers,	2011,	who	observed	an	enhanced	P(3HB)	production	using	
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waste	frying	oil	(polymer	yield	1.2g/L)	in	comparison	to	pure	vegetable	oils	(0.62g/L)	in	
shaken	flasks.	Follonier	et	al.,	2014	reported	mcl-PHA	production	yield	of	23.3%	dcw,	
when	 grape	 pomace	was	 used	 together	 with	waste	 frying	 oil	 as	 the	 carbon	 source.	
Similarly,	 Hwan	 et	 al.,	 2008	 observed	mcl-PHA	 copolymer	 production	 with	 yields	 of	
about	23.5%	dcw	from	waste	 frying	oil.	 	Hwan	et	al,	2008	observed	accumulation	of	
23.5%	dcw	of	mcl-PHAs	using	Pseudomonas	sp.	DR2	and	waste	frying	oil	as	the	carbon	
source.	 Gamal	 et	 al.,	 2013	 compared	 three	 different	 fermentation	 strategies	 using	
Pseudomonas	fluorescens	and	waste	frying	oil	as	the	carbon	source	for	PHA	production.	
One-stage	fermentation	resulted	with	33.7%	dcw	polymer	accumulation	after	60	hours.	
Two-stage	batch	fermentation	gave	50.1%	dcw	polymer	yields	after	54	hours.	High	cell	
density	 culture	 with	 continuous	 feeding	 resulted	 in	 the	 highest	 polymer	 content	 of	
55.3%	 of	 dry	 cell	 weight	 after	 54	 hours.	 Waste	 materials,	 usually	 comprise	 many	
different	compounds	in	their	composition.	According	to	results	obtained,	Pseudomonas	
mendocina	CH50	 seems	 to	 have	 preference	 for	 complex	 carbon	 sources	 rather	 than	
single	fatty	acids.	Silva-Queiroz	et	al.,	reported	challenges	in	the	production	of	custom-
made	mcl-PHA	polymers	from	complex	carbon	sources,	such	oils	and	fatty	acids	due	to	
complexity	of	the	metabolism	of	this	compound	(Silva	et	al.,	2009).		
In	this	work,	high	polymer	yield	(38%	dcw)	was	obtained	in	Pseudomonas	mendocina	
CH50	and	20g/L	of	waste	frying	oil	as	the	carbon	source.		The	mineral	salt	medium	was	
used	to	ensure	nitrogen	limitation.	Nutrient	limitation	is	one	of	the	major	factors	that	
stimulate	PHA	production.	In	addition,	excess	of	carbon	source	is	required	for	most	of	
the	bacterial	 strains	 (Rai	et	al.,	2011).	 In	 this	 study	nitrogen	 limiting	conditions	were	
provided	from	27	hours	of	the	fermentation,	when	ammonium	sulphate	was	completely	
consumed	by	bacteria.	 In	 this	 study,	 only	batch	 fermentation	was	 carried	out	 in	 the	
bioreactor.	 It	 is	well	known	from	the	 literature	 that	a	 fed-batch	 feeding	strategy	can	
enhance	mcl-PHA	production	to	obtain	polymer	yield	of	up	to	75.5%	dcw	(Jiang	et	al.,	
2013).	Also,	achieving	high	cell	densities	is	required	for	PHA	production,	because	those	
polymers	are	accumulated	as	inclusion	bodies	inside	the	cell	(Ienczak	et	al.,	2013).	For	
PHA	production,	high	cell	density	of	 the	culture	means	100g/L	total	concentration	of	
biomass	with	polymer	content	of	60-70%	dcw	(Ryu	et	al.,	1997).	Obtaining	large	amount	
of	biomass	and	polymer	yield	will	reduce	the	total	cost	of	PHA	production.	For	future	
work,	as	a	part	of	the	optimization	process	to	enhance	further	copolymer	production,	a	
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fed	batch	approach	with	different	feeding	strategies	or	high	cell	density	fermentation	
needs	to	be	explored.		
Polymer	 obtained	 by	 using	Pseudomonas	mendocina	CH50	 and	waste	 frying	 oil	 was	
confirmed	 as	mcl-PHA	and	 the	 chemical	 structure	 and	monomer	 composition	of	 the	
polymer	 showed	presence	of	FTIR	peaks	 characteristic	 for	medium	chain	 length	PHA	
(Simon-Colin	et	 al.,	 2008).	 The	 chemical	 structure	 of	 the	 obtained	 polymer	was	 also	
confirmed	by	GC-MS.	 Four	different	monomer	units,	 including:	 3HHx,	 3HO,	3HD	and	
3HDD	were	 identified.	Ashby	et	al.,	2004	has	reported	production	pf	mcl-PHA,	which	
contains	 3-hydroxyoctanoic,	 3-hydroxydecanoic	 and	 3-hydroxytetradecadienoic	 acid	
when	P.	corrugata	grown	on	various	concentrations	of	biodiesel	waste.	In	the	literature,	
different	mcl-PHA	copolymers	were	obtained,	when	waste-frying	oil	was	used	as	 the	
carbon	 source.	 Follonier	et	 al,	 2014,	 reported	 copolymer,	which	 contains	 5	different	
monomer	 units:	 3-hydroxyhexanoate,	 3-hydroxyoctanoate,	 3-hydroxydecanoate,	 3-
hydroxydodecanoate,	 and	 3-hydroxytetradecenoate	within	 the	 polymer	 chain.	 Hwan	
and	 co-workers,	 2008	 produced	 mcl-PHA	 copolymer,	 which	 contain	 5	 different	
monomer	 units,	 such	 as:	 3-hydroxyhexanoate,	 3-	 hydroxyoctanoate,	 3-
hydroxydecanoate,	3-hydroxytetradecanoate	and	3-hydroxyhexadecanoate.	Mcl-PHAs	
composition	depends	on	the	type	of	the	bacterial	strain	used	for	polymer	production.	
Mozejko	et	al.,	2011	used	two	different	strains	of	Pseudomonas	sp.	and	waste	rapeseed	
oil	as	a	carbon	source.	Obtained	polymer	 for	Pseudomonas	Gl01	contains	3	different	
monomer	 units:	 3-hydroxyoctanoate,	 3-hydroxydecanoate	 and	 3-dodecanoate,	
whereas	strain	Pseudomonas	Gl06	was	able	to	produced	mcl-PHA	copolymer,	containing	
3-hydroxyxehanoate,	 3-hydroxyoctanoate,	 3-hydroxydecanoate	 and	 3-dodecanoate	
within	 the	 polymer	 chain.	 This	 composition	 is	 similar	 to	 the	 mcl-PHA	 copolymer	
obtained	in	this	study.			
The	 P(3HHx-3HO-3HD-3HDD)	mcl-PHA	 copolymer	 was	 produced	 using	 cheap	 carbon	
sources,	such	as	waste	frying	oil,	to	overcome	the	main	problem	associated	with	large-
scale	production	of	PHAs	such	as	high	cost.	Different	approaches	towards	economical	
production	of	PHA	were	described	in	details	 in	the	section	1.8.8.	Using	cheap	carbon	
sources	 is	 one	 of	 the	main	 approaches,	which	were	 investigated.	 Each	 year,	 only	 in	
Europe,	24	million	tons	of	vegetable	oils	are	consumed.	Hence,	large	amounts	of	waste	
frying	oil	are	available	(OECD-FAO,	2017).	For	the	few	past	years	production	of	biodiesel	
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using	waste	frying	oil	or	biopolymers	gained	attention	from	many	research	projects.	This	
has	two	positive	effects,	such	as	reduction	of	the	cost	production	as	well	as	elimination	
of	waste	material	from	the	environment.	During	the	process	of	frying	oil	is	continuously	
or	 repeatedly	 treated	 at	 high	 temperature	 in	 the	presence	of	moisture	 and	 air.	 This	
causes	three	different	types	of	degradation	reactions,	such	as	hydrolysis,	oxidation	and	
polymerisation,	which	create	various	types	of	chemical	compounds,	such	as	free	fatty	
acids,	 ketones	and	aldehydes	as	well	 as	 aromatic	 triglycerides	 (Choe	and	Min,	 2007;	
Gertz,	2000).		
To	date,	there	are	no	published	results,	which	describe	mcl-PHA	production	using	waste	
frying	oil	and	Pseudomonas	mendocina	CH50.	In	this	study	production	of	mcl-PHA	was	
carried	out	as	a	 two-step	batch	cultivation	process	 in	a	5L	bioreactor.	The	maximum	
polymer	yield	obtained	was	38.0	%	dcw	at	48	hours.	Nutrient	 limitation	is	one	of	the	
factors	that	stimulate	PHA	production	in	the	presence	of	excess	carbon	for	most	of	the	
bacterial	 strains	 (Rai	 et	 al.,	 2011).	 In	 this	 study,	 nitrogen-limiting	 conditions	 were	
provided	from	27	hours	of	the	fermentation,	when	ammonium	sulphate	was	completely	
consumed	 by	 bacteria.	 In	 this	 study	 only	 batch	 fermentation	was	 carried	 out	 in	 the	
bioreactor.	For	the	future	work,	as	a	part	of	the	optimization	process	to	enhance	further	
copolymer	production,	a	fed	batch	approach	with	different	feeding	strategies	or	high	
cell	density	fermentation	(Chen,	2009)	should	be	considered.	It	is	well	known	from	the	
literature	 that	 fed-batch	 feeding	strategy	can	enhance	mcl-PHA	production	 to	obtain	
polymer	yields	up	to	75.5%	dcw	(Jiang	et	al.,	2013).	High	cell	densities	are	good	for	PHA	
production,	because	these	polymers	are	accumulated	as	inclusion	bodies	inside	the	cell	
(Ienczak	et	al.,	2013).	For	optimal	PHA	production,	high	cell	density	of	the	culture	with	
100g/L	total	concentration	of	biomass	and	polymer	content	of	60-70%	dcw	(Ryu	et	al.,	
1997)	is	required.	Obtaining	such	high	biomass	and	polymer	yield	will	reduce	the	total	
cost	of	PHA	production.	
It	 is	well	known	from	literature,	that	most	of	the	mcl-PHAs	have	properties	similar	to	
rubbers	and	both:	glass	transition	as	well	as	a	melting	event	have	been	observed.	The	
typical	thermal	properties	for	mcl-PHAs	are:	melting	temperature	in	a	range	between	
40	oC	to	60	oC	and	glass	transition	temperature	from	-50	oC	to	-25	oC	(Rai	et	al.,	2011).	
The	glass	transition	temperature	decreases	with	an	increasing	length	of	side	chains	or	
number	of	unsaturated	bonds	within	the	polymer	chain	(Haba	et	al.,	2007).	However,	
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Mozejko	and	Ciesielski,	2013,	reported	synthesis	of	different	mcl-PHAs,	which	showed	
glass	 transition	 temperature	 ranging	 from	 -14	oC	 to	 -55	oC	and	melting	 temperatures	
around	83-86	oC,	which	is	much	higher	than	usually	observed	in	mcl-PHAs.	The	mcl-PHA	
copolymer	 obtained	 in	 this	 study	 was	 amorphous	 in	 nature.	 Only	 glass	 transition	
temperature	was	detected	at	-32oC,	which	corresponded	with	the	values	presented	in	
the	 literature.	 Polymer	 thermal	 properties	 depend	 on	 the	 number	 of	 carbon	 atoms	
within	 the	 aliphatic	 chains	 of	 individual	 monomers.	 Longer	 chains	 and	 presence	 of	
unsaturated	groups	in	the	side	chains	increase	the	number	of	amorphous	regions	within	
polymer	chain,	which	might	cause	disturbance	 in	 the	crystallisation	process.	This	can	
explain	the	more	adhesive	nature	of	the	produced	polymer	rather	than	the	ability	to	
create	 films	 (Muangwong	et	al.,	 2016).	 There	are	 reports	 that	demonstrate	mcl-PHA	
production	which	are	amorphous	in	nature.	Follonier	and	co-workers,	2015	as	well	as	
Muangwong	et	al.,	2016	have	obtained	amorphous	mcl-PHA	copolymer	using	different	
carbon	sources	and	bacterial	strains.		
The	molecular	weight	of	the	obtained	copolymer	in	this	study	was	210.7	kDa.	There	are	
several	 factors	 which	 can	 influence	 the	 molecular	 weight	 of	 the	 PHAs,	 such	 as:		
concentration	 of	 the	 PHA	 synthase,	 PHA	 depolymerase	 activity,	 polymer	 recovery	
technique,	 bacterial	 strain	 as	well	 as	 culture	 conditions,	 such	 as	 temperature	 or	 pH	
might	affect	the	molecular	weight	of	the	final	polymer	(Tsuge,	2016;	Bugnicourt	et	al.,	
2014).	 Different	 researchers	 have	 reported	 production	 of	mcl-PHAs	 with	 a	 range	 of	
molecular	 weight	 values	 from	 60	 to	 330kDa.	 For	 example,	 Martelli	 and	 co-workers	
(2012)	produced	P(3HO-3HD-3HDD)	copolymer,	which	had	a	molecular	weight	140	kDa.	
Gumel	 et	 al.	 2012,	 reported	 the	 molecular	 weight	 of	 mcl-PHAs	 obtained	 from	
Pseudomonas	putida	Bet001	using	various	carbon	sources	to	be	between	55-77.7kDa.	
Mozejko	 and	 Ciesielski,	 2013	 observed	 production	 of	 mcl-PHA	 copolymers	 using	
Pseudomonas	sp.	Gl01	with	the	molecular	weight	range	from	60	to	110kDa.	On	the	other	
hand,	Preusting	et	al.,	1990	have	observed	production	of	mcl-PHAs	using	P.	oleovorans	
with	the	molecular	weight	of	over	300kDa.	Hence,	the	molecular	weight	of	the	polymer	
produced	in	this	project	was	within	the	range	of	values	demonstrated	by	other	labs.		
In	 conclusion,	 this	 study	 has	 demonstrated	 the	 ability	 of	 the	 selected	 strain,	
Pseudomonas	mendocina	CH50	to	produce	mcl-PHAs,	mainly	copolymers,	using	a	range	
of	different	carbon	sources,	including	cheap	carbon	sources	and	waste	materials.	PHA	
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yield	of	38.0%	dcw	was	obtained	using	waste	frying	oil	as	the	sole	carbon	source.	The	
obtained	 mcl-PHA	 copolymer	 contained	 four	 different	 monomer	 units	 within	 the	
repeatable	unit	in	the	polymer	chain.	This	study	confirmed	the	possibility	of	utilization	
of	vegetable	waste	frying	oil	as	the	carbon	source	by	Pseudomonas	mendocina	CH50	for	
economically	efficient	PHA	production.	
	
	
		
	
	
	
	
	
Chapter	5	
Development	of	Poly(3-
hydroxybutyrate)/oligo	-PHA	
blends	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER	5	
	
	 137	
5.	Introduction	
Polyhydroxyalkanoates	 (PHAs)	 are	 the	 natural	 biopolyesters,	 intensively	 studied	 for	
biomedical	 applications.	 PHAs	 are	 biocompatible,	 non-toxic,	 biodegradable	 and	have	
been	widely	studied	for	wound	management,	coronary	stents,	nerve	regeneration,	bone	
tissue	engineering,	drug	delivery	and	soft	tissue	engineering	(Hazer	et	al.,	2012).	P(3HB)	
is	well	known	representative	of	scl-PHAs	family.	Mechanical	properties	of	P(3HB),	such	
as	stiffness	and	brittleness	make	it	suitable	for	hard	tissue	engineering,	such	as	bone	
regeneration.	Neat	P(3HB)	and	its	copolymers	have	been	suggested	for	many	biomedical	
applications,	such	as:	bone	tissue	regeneration,	drug	delivery	systems,	nerve	conduits,	
sutures,	wound	management	and	soft	tissue	engineering	(Williams	and	Martin,	2005).		
Various	 approaches	 have	 been	 taken	 to	 improve	 the	 properties	 of	 the	 biomaterials.	
Physical	 blending	 is	 one	 of	 the	 approaches	 to	 obtain	 novel	 material	 with	 different	
properties,	superior	to	the	materials	already	existing	(Chen	and	Wu,	2005).	PHAs	have	
been	 blended	 with	 various	 types	 of	 materials,	 such	 as:	 polyhydroxyalkanoates	
(Lizarraga-Valdemarra	et	al.,	2015;	Nerkar	et	al.,	2014;	Basnett	et	al.,2013;	Zhao	et	al.,	
2003),	rubbers	(Bhatt	et	al.,	2008;	Calvão	et	al.,	2012),	starch	(Paruleka	and	Mohanty,	
2007;	Godbole	et	al.,	2003),	synthetic	polymers	(Zhao	et	al.,	2012;	Furukawa	et	al.,	2005;	
Cara	et	al.,	2003;	Koyama	and	Doi,	1997).		
However,	 the	 results	 obtained	 are	 still	 not	 satisfactory.	 The	 problem	 with	 blending	
between	two	different	types	of	polymers	is	poor	miscibility	of	the	system,	which	leads	
to	 a	 phase	 separation	 (Chen	 and	 Luo,	 2009).	 Addition	 of	 low	 molecular	 weight	
compounds,	 such	 as	 hydrolysed	polymers,	might	 have	 an	 improvement	 in	 the	blend	
miscibility	by	acting	as	the	plasticisers.	Poor	compatibility	in	P(3HB)	blends	with	other	
polymers	 is	 well	 documented	 including	 P(3HB)	 blends	 with	 other	 PHAs.	 Therefore	
P(3HB)	blends	are	multiphase	polymer	systems,	 the	properties	and	stability	of	which	
depend	on	their	processing	and	morphological	structure	(Larsson	et	al.,	2016;	Jacob	et	
al.,	2002;	Verhoogt	et	al.,	1994;	Scandola	et	al.,	1992).		
Plasticizers	 are	 small	 molecules	 incorporated	 into	 polymeric	 materials	 in	 order	 to	
enhance	their	flexibility	and	processability	(Platzer,	1982).	Plasticizers	are	mainly	added	
to	 hard	 and	 brittle	 polymers	 in	 order	 to	 decrease	 glass	 transition	 temperature	 (Tg),	
elastic	modulus	 and	 increase	 elastomeric	 properties	 of	 the	 blend	 (Sears	 and	 Darby,	
1982).	
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The	main	role	of	the	plasticizer	is	to	separate	neighbouring	polymer	chains	and	reduce	
interaction	between	them.	This	will	result	in	a	lower	Tg	and	influencing	the	final	material	
properties.	 In	 order	 to	 be	 used	 as	 a	 plasticiser	 every	 substance	 has	 to	meet	 certain	
criteria.	This	include:	low	volatility,	temperature	stability,	odourless,	compatibility	with	
the	 polymer,	 efficiency,	 permanence	 (Sachin	 et	 al.,	 2016).	 Selection	 of	 the	 right	
compound	requires	compromise,	since	none	of	the	known	plasticisers	can	meet	all	the	
criteria	at	that	time	(Edmund,	1965).		
Although	plasticisers	interact	with	polymer	chains,	they	are	not	chemically	bound	to	the	
polymer.	Hence,	they	can	leach	out	with	the	time	and	accumulate	in	the	environment	
(Erythropel	et	al.,	2014;	Staples	et	al.,	1997).	There	has	been	reports	regarding	health	
and	 safety	 concerns	 of	 the	 degradation	 products	 of	 various	 plasticisers	 (Horn	et	 al.,	
2004.).	 Therefore,	many	 research	 groups	 have	 been	working	 extensively	 in	 order	 to	
develop	safer	alternatives,	which	will	demonstrate	comparable	plasticising	effect,	faster	
biodegradation,	 lower	 toxicity	 and	 reduced	 leaching	 from	 the	 polymeric	 matrix	
(Erythropel	et	al.,	2016;	Wadey,	2003).	Plasticisers	can	be	used	with	short	chain	length	
polyhydroxyalkanoates,	like	P(3HB)	or	P(3HBV)	to	improve	their	elasticity.	Various	types	
of	ester-type	substances	have	been	tested	(Vieira	et	al.,	2011;	Mekonnena	et	al.,	2013).	
Different	 types	of	esters	of	 citric	acid,	 known	as	biocompatible	 compatibilisers,	have	
been	an	attractive	additive	for	PHAs	(Ghiya	et	al.,	1995;	Hull,	1990).	
Biomedical	 applications	 require	 from	 any	 biomaterials	 including	 various	 additives,	
plasticisers	and	 fillers	high	biocompatibility,	non-toxicity,	degradability,	processability	
and	 cost	 effectiveness.	 Although	 the	 issue	 of	 environmental	 impact	 of	 plastisizers	 is	
currently	widely	recognised	(Oehlmann	et	al.,	2009;	Beauchesne	et	al.,	2007;	Cadogan,	
1991),	the	current	literature	is	deficient	in	testing	cytotoxicity	of	implantable	plasticised	
polymer	materials.		
Additionally,	migration	of	low	molecular	weight	plasticisers	from	polymeric	matrix	into	
surrounding	 tissues	 may	 not	 only	 lead	 to	 toxicity	 effects	 but	 also	 drastically	 alter	
materials	properties	before	the	degradation	of	the	implanted	material	(Snejdrova	and	
Dittrich,	 2012).	 The	 smaller	 the	 plasticizer	 molecule,	 the	 greater	 its	 volatility	 and,	
therefore,	 the	 rate	 at	 which	 it	 is	 lost	 from	 the	 plasticised	 product	 (Li	 et	 al.,	 2008).	
Increase	 in	molecular	weight	of	plasticisers	 reduce	migration	 speed	or	 fully	prevents	
migration,	 which	 led	 to	 the	 development	 of	 oligomeric	 plastisizers.	 Oligomeric	
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analogues	of	a	polymer	could	be	an	ideal	approach	since	it	offers	good	affinity	between	
the	polymer	and	the	plasticiser.	Similar	chemical	structure	of	plasticiser	and	polymeric	
matrix	is	the	oldest	known	plasticizer-polymer	system	(Sachin	et	al.,	2016).	Oligomeric	
plasticisers	 have	 been	 studied	 already.	 Polyethylene	 glycol	 (PEG)	 and	 polypropylene	
glycol	have	been	used	as	plasticising	agents	 for	PLLA	(Laia	et	al.,	2004).	Oligomers	of	
lactic	acid	have	been	successfully	used	to	improve	flexibility	of	synthetic	biodegradable	
PLLA	(Burgos	et	al.,	2014)	or	PLLA/P(3HB)	blends	(Abdelwahaba	et	al.,	2012).	However,	
oligomers	of	PHAs	have	not	yet	been	widely	explored	as	additives	for	the	improvement	
of	P(3HB)	flexibility.	There	were	only	two	reports,	where	synthetic	atactic	P(3HB)	diols	
(El-Taweela	et	al.,	2004)	and	oligomeric	P(3HB)	(Meszynska	et	al.,	2016)	were	used	as	
additives	to	P(3HB).	Natural	plasticisers	are	very	attractive	group	of	additives	(Garcia-
Garcia	 et	 al.,	 2017).	 Hence,	 plasticisers	 based	 on	 PHAs	 can	 be	 very	 attractive	
compounds,	due	to	natural	origin,	biodegradability	and	non-toxicity.	They	can	be	very	
attractive	 alternative	 for	 petroleum	 based	 plasticisers	 and	 allow	 obtaining	 fully	
compostable	 materials.	 	 Oligomeric	 derivatives	 of	 PHAs	 can	 be	 produced	 by	 using	
various	 techniques,	 such	 as:	 alkaline	 or	 acidic	 hydrolysis,	 transesterification,	 thermal	
degradation	or	ester	reduction	(Crétois	et	al.,	2016).		
The	main	aim	of	this	part	of	the	work	was	to	develop	more	flexible	P(3HB)	based	blends	
using	oligomeric	form	of	mcl-PHA	copolymer	in	order	to	enable	the	application	of	P(3HB)	
in	coronary	artery	stents.	 In	 this	study,	 three	different	blends	of	P(3HB)/oligo-PHA	 in	
ratios:	95/5,	90/10	and	80/20	have	been	developed.	Materials	were	fully	characterized	
in	 order	 to	 obtain	 their	 thermal	 and	 mechanical	 properties.	 	 Evolution	 of	 various	
properties	 have	 been	 studied	 during	 material	 storage	 for	 7	 weeks.	 In	 vitro	
biocompatibility	of	the	blends	was	tested	with	human	dermal	microvascular	endothelial	
cells	HMEC-1	to	evaluate	the	potential	of	new	biodegradable	material	 in	applications	
such	 as	 coronary	 artery	 stent.	 Additionally,	 haemocompatibility	 studies,	 including	
haemolysis	 and	 blood	 clotting	 studies,	 as	 well	 as	 white	 cell	 activation	 studies	 were	
performed	 in	 order	 to	 study	 the	 blood	 cell	 behaviour	 after	 direct	 contact	with	 new	
material.	
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5.1.	Development	of	oligo-P(3HHx-3HO-3HD-3HDD)		
Mcl-PHA	copolymer	produced	by	Pseudomonas	mendocina	CH50	using	waste	frying	oils	
as	the	carbon	source	was	subjected	to	an	acidic	hydrolysis	for	20hrs	as	described	in	the	
section	2.8.1.	in	order	to	obtain	low	molecular	weight	oligomers	(oligo-PHA).	Samples	
were	 collected	 in	 3	 hours	 intervals.	 Polymer	 recovery	 of	 the	 hydrolysis	 reaction	 is	
presented	in	Table	16.		
Table	16:	Summary	of	hydrolysis	kinetics	of	P(3HHx-3HO-3HD-3HDD)	copolymer.	
Time	(hours)	
Polymer	
amount	(µg)	
Polymer	obtained	
(%	recovery)	
3	 		156	
	
21.2	
	
6	 166	 22.6	
9	 288	 39.2	
12	 346	 47.1	
15	 459	 62.5	
17	 464	 63.1	
19	 560	 76.7	
20	 1450	 92.0	
	
	
The	yield	of	the	reaction	increased	gradually	with	the	time	from	21.2%	after	3	hours	up	
to	 92%	 at	 the	 end	 of	 the	 reaction.	 The	 polymer	 obtained	 after	 20	 hours	 was	
characterised	further	by	FTIR,	DSC	and	GPC	analysis.	
5.1.2.		Oligo-PHA	characterisation	
	
The	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 was	 a	 waxy	 material.	 The	 material	 was	
characterised	 in	 order	 to	 investigate	 the	 influence	 of	 the	 acidic	 conditions	 on	 the	
chemical	and	thermal	properties	as	well	as	molecular	weight	of	the	polymer.			
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5.1.2.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	
(ATR/FT-IR)		
 
The	final	oligomeric	product	of	hydrolysis	obtained	after	20	hours	was	characterised	by	
ATR/FT-IR	spectroscopy.	The	absorption	peaks	corresponded	to	peaks	typical	for	mcl-
PHAs	 and	 the	 P(3HHx-3HO-3HD-3HDD)	 copolymer	 (Figure	 38)	 before	 hydrolysis	 as	
described	in	the	section	4.4.1.	
	
Figure	38:	ATR-FTIR	spectrum	of	the	oligo-PHA	obtained	from	Pseudomonas	mendocina	
CH50	and	waste	frying	oil	as	the	carbon	source	after	20	hours	of	hydrolysis	indicating	
peaks	characteristic	for	mcl-PHAs.		
Four	 main	 adsorption	 peaks	 were	 observed	 at:	 2926cm-1,	 2856cm-1,	 1726cm-1	 and	
1167.04cm-1,	 which	 correspond	 to	 C-H	 group,	 carbonyl	 group	 and	 -CO	 stretching	
respectively	(Figure	36).	There	was	no	difference	in	the	spectrum	between	hydrolysed	
and	non-hydrolysed	P(3HHx-3HO-3HD-3HDD).	
5.1.2.2.	Thermal	analysis	–	Differential	Scanning	Calorimetry	(DSC)	
 
The	 thermal	 properties	 of	 the	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	 copolymer	 were	
analysed	by	DSC.	The	thermogram	of	the	hydrolysed	polymer	is	shown	in	the	Figure	39.	
The	 summary	of	 the	 thermal	 properties	 of	 hydrolysed	polymer	 are	presented	 in	 the	
Table	17.		
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Figure	39:	Summary	of	thermal	properties	of	the	oligo-PHA	after	20	hours	of	hydrolysis.	
( )	first	heating	cycle,	( )	second	heating	cycle.	
Table	17:		Thermal	properties	of	the	hydrolysed	P(3HHx-3HO-3HD-3HDD)	after	20	hours	
of	 hydrolysis.	 Tm=	 melting	 temperature,	 Tg=	 glass	 transition	 temperature,	 Tc=	
crystallisation	temperature.		
Polymer	sample	 Tm	 Tg	 Tc	
Hydrolysed	P(3HHx-3HO-3HD-3HDD)	
28.6°C	
38.6°C	
-38.9°C	 -	
	
Oligomeric	mcl-PHA	demonstrated	presence	of	glass	transition	temperature	at	-38.9	°C	
and	two	different	melting	events	at	28.6°C	and	38.6°C.	Tc	was	not	detected,	which	is	a	
typical	characteristic	of	mcl-PHAs.	
5.1.2.3.	Molecular	weight	analysis	–	Gel	Permeation	Chromatography	(GPC)	
 
The	 summary	 of	 the	 results	 of	 the	 molecular	 weight	 analysis	 of	 the	 hydrolysed		
mcl-PHA	copolymer	obtained	using	P.	mendocina	CH50	and	waste	frying	oil	are	shown	
in	the	Table	18.	
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Table	 18:	 Summary	 of	 molecular	 weight	 analysis	 of	 the	 P(3HHx-3HO-3HD-3HDD)	
obtained	from	Pseudomonas	mendocina	CH50	and	waste	frying	oil	as	the	carbon	source	
after	2	hours	of	hydrolysis.	Mw=	weight	average	molecular	weight,	Mn=	number	average	
molecular	weight,	PDI=	polydispersity	index.	
 
Polymer	 Mw,	kDa	 Mn,	kDa	 PDI	
oligo-PHA	 10	 4.6	 2.2	
	
The	GPC	results	obtained	 (Table	17)	clearly	confirmed	that	hydrolysis	of	 the	P(3HHx-
3HO-3HD-3HDD)	 copolymer	 has	 occurred.	 The	 molecular	 weight	 of	 the	 hydrolysed	
polymer	was	 reduced	 significantly	 and	measured	 as	 10kDa.	 The	 polydispersity	 index	
obtained	 was	 2.2.	 The	molecular	 weight	 of	 the	 hydrolysed	 P(3HHx-3HO-3HD-3HDD)	
copolymer	was	over	20-fold	lower	than	the	original	copolymer	described	previously	in	
the	section	4.4.4.		
5.2.	Development	of	P(3HB)/oligo-PHA	blends	
P(3HB)	was	blended	with	oligo-PHA	in	ratios:	95/5,	90/10	and	80/20	(Figure	40)	to	obtain	
blends	for	coronary	stent	application	and	fully	characterised.	In	order	to	evaluate	the	
potential	of	the	oligomeric	mcl-PHA	derivative	as	a	plasticizer	for	P(3HB),	the	influence	
of	oligo-PHA	additives	on	thermal	and	mechanical	properties	of	P(3HB)	were	studied	
using	blend	films	prepared	by	solvent	casting	technique.	P(3HB)	embrittlement	during	
the	 storage	 is	 a	 well-known	 complex	 phenomenon	 which	 is	 mainly	 attributed	 to	 a	
secondary	 crystallisation	 and	 ageing	 of	 the	 amorphous	 phase	 (Barham	 et	 al.,	 1984).	
Therefore,	 the	 changes	of	 thermal	and	mechanical	properties	of	neat	P(3HB)	and	 its	
blends	with	oligo-PHAs	was	monitored	for	a	period	of	7	weeks	for	samples	stored	at	
room	temperature.		
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Figure	40:	Solvent	cast	films	of:	(A)	P(3HB)	neat	film,	(B)	P(3HB)/oligo-PHA	blend	film	in	
ratio	95/5,	(C)	P(3HB)/oligo-PHA	blend	film	in	ratio	90/10,	(D)	P(3HB)/oligo-PHA	blend	
film	in	ratio	80/20;	diameter:	60mm.	
5.2.1.	Blend	characterisation	
 
Blend	 films	 were	 characterised	 with	 respect	 to	 their	 thermal,	 mechanical	 and	
topographical	properties.	Additionally,	biocompatibility	and	haemocompatibility	studies	
were	perform	in	order	to	confirm	non-toxicity	and	safety	of	the	biomaterials.		
5.2.1.1.	Thermal	analysis	of	the	blend	films	after	7	weeks	of	storage	at	room	
temperature	-	ageing	experiments	
 
Thermal	properties	of	the	solvent	cast	films	were	studied	for	7	weeks,	in	order	to	check	
the	effect	of	ageing	on	the	material.	The	results	obtained	are	summarised	in	Table	19.	
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Table	 19:	 Summary	 of	 the	 thermal	 analysis	 of	 P(3HB)/hydrolysed	 P(3HHx-3HO-3HD-
3HDD)	blends	during	7	weeks	of	storage.	Tm=	melting	temperature,	DHapp=	enthalpy	of	
fusion,	DHnorm=	entalphy	of	fusion	normalised	to	P(3HB),	Xc=	crystallinity	degree.	
Week	 Sample	 Tm,	oC	 DHapp,	Jg-1	
DHnorm,	𝐉𝐠𝐏(𝟑𝐇𝐁)C𝟏 	 XC,	%*	
2	 P(3HB)	neat	 174.8	 82.5	 82.5	 56.5	
	 95/5	blend	 174.2	 66.9	 70.4	 48.2	
	 90/10	blend	 167.0	 67.5	 71.0	 48.6	
	 80/20	blend	 171.4	 -	 -	 -	
5	 P(3HB)	neat	 175.2	 84.4	 84.4	 57.8	
	 95/5	blend	 170.4	 62.6	 69.6	 47.7	
	 90/10	blend	 173.9	 65.1	 72.3	 49.5	
	 80/20	blend	 167.2	 43.1	 53.9	 36.9	
7	 P(3HB)	neat	 176.6	 85.9	 85.9	 58.8	
	 95/5	blend	 171.7	 -	 -	 -	
	 90/10	blend	 174.8	 56.5	 70.6	 48.4	
	 80/20	blend	 173.0	 43.3	 54.1	 37.1	
• Xc,	the	crystallinity	degree	of	P(3HB)	was	calculated	using	the	formula:		
Xc	=	DE	FGHI
DEJ x100,	H0=	146	J/g.	
The	enthalpy	of	fusion	of	P(3HB)	from	B.	subtilis	OK2	was	found	to	increase	during	the	
storage	 for	 7	 weeks	 (Table	 18),	 confirming	 the	 previously	 reported	 secondary	
crystallisation	of	P(3HB).	 Total	 enthalpy	of	 fusion	 (DHapp)	was	 lower	 for	 all	 blends	 as	
compared	with	neat	P(3HB).	Also,	addition	of	the	oligo-PHA	resulted	in	a	small	decrease	
of	melting	temperature	(Tm),	between	2	to	5	oC.	No	further	changes	in	the	enthalpy	of	
fusion	 and	 melting	 temperature	 were	 observed	 after	 7	 weeks	 of	 ageing	 indicating	
completion	of	P(3HB)	crystallisation	within	7	weeks.	Normalised	enthalpy	 (DHnorm)	of	
fusion	indicated	slower	rate	of	crystallisation	of	P(3HB)	in	blends	in	comparison	to	neat	
P(3HB).		
Crystallinity	degree	of	P(3HB)	(Xc)	in	blends	95/5	and	90/10	was	calculated	as	48%,	which	
is	20%	less	in	comparison	to	neat	P(3HB).	Addition	of	20%	wt	of	oligo-PHA	resulted	in	
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further	 drop	 in	 crystallinity	 degree	 up	 to	 37%	 after	 7	 weeks	 of	 storage	 at	 room	
temperature.		
	
Figure	41:	DSC	thermograms	of	first	cycle	of	P(3HB),	oligo-PHA	and	P(3HB)/oligo-PHA	
blends	(ratios:	95/5,	90/10,	80/20)	aged	for	7	weeks	at	room	temperature.	
DSC	 thermograms	 (Figure	 41)	 of	 blends	 did	 not	 show	 a	 thermal	 event	 in	 the	 range	
characteristic	 for	oligo-PHA	melting	 temperature	 in	 the	blends	 containing	20	wt%	of	
oligo-PHA.	Hence,	the	thermal	properties	indicated	that	obtained	blend	materials	were	
miscible	and	compatible	systems.		
5.2.1.2.	Mechanical	characterisation	of	the	blend	films	after	7	weeks	of	
storage	at	room	temperature	-	ageing	experiments	
 
Mechanical	properties	of	the	solvent	cast	films	were	measured	for	7	weeks,	in	order	to	
check	 the	 effect	 of	 storage	 for	 7	weeks	 at	 room	 temperature	 on	 the	 ageing	 on	 the	
material.	The	results	obtained	are	summarised	in	Table	20	and	Figure	42.		
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Table	20:	Summary	of	the	mechanical	properties	of	P(3HB)/oligo-PHA	blends	during	7	
weeks	of	storage	(n=3).	
Time	of	
storage	
(week)	
Blend	composition	
P(3HB)/P(3HHx-
3HO-3HD-3HDD)	
Tensile	test	
(MPa)	
Young’s	
Modulus	
(MPa)	
Elongation	at	
break	(%	
strain)	
0	
95/5	 16.9±0.2	 600±100	 45.9±1.3	
90/10	 15.1±0.5	 600±100	 47.0±0.4	
80/20	 11.4±0.05	 300±40	 52.8±2.4	
2	
95/5	 11.6±0.1	 900±100	 36.1±3.5	
90/10	 12.4±0.5	 900±20	 24.2±4.7	
80/20	 11.3±0.2	 890±5	 39.0±4.1	
5	
95/5	 12.8±0.4	 1000±100	 4.9±3.0	
90/10	 8.3±0.6	 660±40	 11.2±3.4	
80/20	 5.3±0.2	 420±40	 18.6±3.5	
7	
95/5	 12.9±0.8	 1040±90	 3.8±0.4	
90/10	 14.8±0.7	 1240±80	 6.2±0.8	
80/20	 6.4±0.4	 480±30	 13.3±3.8	
	
Material	ageing	has	 influenced	 the	mechanical	properties	of	 the	P(3HB)/oligo-PHA	blend	
films.	 For	 P(3HB)/oligo-PHA	 blend	 in	 ratio	 95/5	 the	 tensile	 strength	 decreased	 from	
16.9±0.2MPa	at	week	1	 to	12.9±0.8	MPa	after	7	weeks	of	 storage;	 the	Young’s	Modulus	
values	significantly	increased	from	600±100MPa	after	week	1	to	1040±90	MPa	after	week	7	
and	an	elongation	at	break	decreased	from	45.9±1.3%	after	week	1	to	3.8±0.4%	strain	after	
week	7.	Similar	trend	was	observed	for	P(3HB)/oligo-PHA	blend	in	ratio	90/10.	the	tensile	
strength	decreased	from	15.1±0.5MPa	at	week	1	to	14.8±0.7MPa	after	7	weeks	of	storage;	
the	 Young’s	 Modulus	 values	 significantly	 increased	 from	 600±100MPa	 after	 week	 1	 to	
1240±80MPa	after	week	7	and	an	elongation	at	break	decreased	from	47.0±0.4%	after	week	
1	 to	6.2±0.8%	strain	after	week	7.	 For	P(3HB)/oligo-PHA	blend	 in	 ratio	80/20	 the	 tensile	
strength	decreased	from	11.4±0.05MPa	at	week	1	to	6.4±0.4MPa	after	7	weeks	of	storage;	
the	 Young’s	 Modulus	 values	 significantly	 increased	 from	 300±40MPa	 after	 week	 1	 to	
480±30MPa	after	week	7	and	an	elongation	at	break	decreased	from	52.8±2.4%	after	week	
1	to	13.3±3.8%	strain	after	week	7.	
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Hence,	 ageing	of	 P(3HB)	 enhanced	 its	 strength	 and	 stiffness	but	 reduced	 its	 elastomeric	
properties.	The	material	became	more	brittle	with	time.	
	
	
	
Figure	42:	The	summary	of	tensile	strength	(A),	Young’s	modulus	(B)	and	elongation	at	
break	 (C),	during	aging	of	neat	P(3HB)	and	P(3HB)/oligo-PHA	blends	after	7	weeks	of	
storage	at	room	temperature.	( )	P(3HB),	( )	95/5	blend,	( )	90/10	blend,	( )	80/20	
blend.	 
The	embrittlement	behaviour	is	a	characteristic	material	property	of	P(3HB).	Addition	of	
oligo-PHA	 had	 a	 great	 impact	 on	 the	 mechanical	 properties	 of	 P(3HB).	 Increased	
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concentration	of	oligo-PHA	in	P(3HB)/oligo-PHA	blends	resulted	in	obtaining	materials	
with	lower	tensile	strength	and	Young’s	Modulus	values	than	neat	P(3HB).	Only	a	5	wt%	
addition	of	oligo-PHA	decreased	the	ultimate	tensile	strength	and	Young’s	modulus	by	
35%	and	28%,	respectively.	Elongation	at	break	demonstrated	an	opposite	trend.	Higher	
values	were	obtained	for	the	blend	composition	with	the	highest	concentration	(20	wt%)	
of	oligo-PHA.	After	7	weeks	of	storage	at	room	temperature,	elongation	at	break	of	the	
95/5	blend	was	similar	to	that	of	neat	P(3HB).	However,	when	the	content	of	oligo-PHA	
exceeded	10	wt%,	improvement	in	plasticity	was	observed	and	elongation	at	break	for	
the	80/20	blend	reached	almost	14%.		
In	 summary,	 an	 addition	 of	 oligo-PHA	 resulted	 in	 obtaining	 materials	 with	 novel	
properties	 in	 comparison	 to	 neat	 P(3HB),	 which	 can	 be	 suitable	 for	 biomedical	
applications,	such	as	coronary	stents.		
5.3.	Surface	topography	studies	
5.3.1.	Scanning	Electron	Microscopy	of	the	P(3HB)/oligo-PHA	blends	
SEM	was	used	to	examine	topography	of	neat	P(3HB)	and	P(3HB)/oligo-PHA	films.	As	
can	be	 seen	 from	SEM	 images	 shown	 in	Figure	43,	all	materials	had	 similar	 irregular	
surface	 topography.	 Few	 circular	 pores	 were	 observed	 on	 the	 surface	 of	 all	 tested	
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materials.																																																								
	
Figure	43:	Scanning	electron	micrographs	of	the	neat	P(3HB)	film	and	P(3HB)/oligo-PHA	
blends.	
The	 surface	of	both	 the	neat	and	 the	blend	 films	appeared	 to	have	a	 rough	surface.	
Surface	roughness	measurements	were	carried	out	to	confirm	the	SEM	data.	
	
5.3.2.	Surface	roughness	analysis	
	
	Generally,	surfaces	of	all	the	materials	appeared	to	be	rough.	Roughness	was	further	
characterised	 quantitatively	 as	 the	 root	 mean	 square	 roughness	 (Rq)	 using	 laser	
profilometry	 (Figure	 44).	 The	 mean	 square	 roughness	 of	 the	 P(3HB)	 neat	 film	 was	
0.64±0.04μm.	 With	 the	 increase	 of	 content	 of	 oligo-PHA	 in	 the	 blends	 the	 surface	
roughness	rose	from	0.8	±	0.02μm	for	95/5	blend	and	1.2	±	0.02μm	for	80/20	blend.	The	
roughness	of	the	blend	films	was	significantly	higher	in	comparison	to	neat	P(3HB).	
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Figure	44:	Surface	roughness	analysis	of	neat	P(3HB)	and	its	blends	with	oligo-PHA	(n=3;	
error	 bars=±SD).	 The	 data	 were	 compared	 with	 the	 neat	 P(3HB)	 using	 ANOVA.	 *	
indicates	p<	0.05	and	**	indicates	p<0.005.	
These	 results	 obtained	 from	 surface	 roughness	 measurements	 confirmed	 the	 SEM	
findings	 that	 surface	 of	 the	 all	 samples	 tested	 were	 rough.	 With	 an	 increase	 of	
concentration	of	oligo-PHA	higher	surface	roughness	was	observed.	The	difference	was	
significant	in	comparison	to	the	neat	P(3HB)	film.		
5.3.3.	Water	contact	angle	measurements	
Water	contact	angle	and	protein	absorption	represent	physiologically	relevant	surface	
properties	of	materials.	P(3HB)	is	a	hydrophobic	biopolymer	of	which	films	exhibited	a	
water	contact	angle	of	87.5±7.4o	(Figure	45).	There	was	a	steady	increase	in	values	of	
water	contact	angles	for	the	blends	with	the	increase	in	content	of	oligo-PHA	reaching	
118±7o	for	80/20	blends.	All	blend	films	had	significantly	higher	contact	angle	values	in	
comparison	to	that	of	neat	P(3HB).	The	longer	hydrophobic	aliphatic	chains	of	oligo-PHA	
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contribute	 to	 the	 increase	 of	 hydrophobicity	 of	 P(3HB)/oligo-PHA	 blends.	 However,	
increase	in	surface	roughness	of	the	blends	might	also	lead	to	the	higher	water	contact	
angle	values.				
											
	
Figure	45:	 Static	water	 contact	angle	measurements	 for	 the	neat	P(3HB)	 film	and	 its	
blends	with	oligo-PHA	(n=3;	error	bars=±SD).	The	data	were	compared	with	neat	P(3HB)	
using	ANOVA.		*	indicates	p-value	<	0.05.	
Materials,	 which	 have	 contact	 angle	 value	 higher	 than	 70°	 are	 considered	 as	
hydrophobic	 in	 nature.	 Bearing	 in	mind	 this	 definition,	 all	 tested	 film	 samples	were	
hydrophobic.	And	the	hydrophobicity	increased	with	the	increased	concentration	of	the	
hydrolysed	mcl-PHA	copolymer.	It	has	been	observed,	that	cells	prefer	to	attach	to	the	
weakly	hydrophilic	surfaces	(contact	angle	around	60o),	whereas	highly	hydrophilic	or	
hydrophobic	surfaces	have	been	used	to	inhibit	cell	adhesion	(Bacakova	et	al.,	2011).	
5.3.4.	Protein	adsorption	analysis	
The	affinity	of	the	materials	towards	proteins	were	evaluated	by	bicinchoninic	acid	assay	
with	 Foetal	 Bovine	 Serum	 (FBS)	 as	 a	model	 protein.	 	 It	was	 found	 that	 total	 protein	
adsorption	was	90±3,	105.6±15,	145±35	and	300±35	µg/cm2	for	the	neat	P(3HB)	film	
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and	 95/5,	 90/10	 and	 80/20	 blends	 respectively.	 There	 was	 no	 significant	 difference	
between	P(3HB)	and	95/5	blend.	There	was	significant	difference	between	the	90/10	and	
80/20	 blend	 in	 comparison	 to	 the	 neat	 P(3HB)	 film	 (**p=0.006	 and	 ***p=0.0001	
respectively)	(Figure	46).			
	
Figure	46:	Protein	adsorption	on	the	films	of	neat	P(3HB)	and	P(3HB)/oligo-PHA	blends	
(n=3;	 error	 bars=±SD).	 The	 data	were	 compared	with	 neat	 P(3HB)	 using	 ANOVA.	 **	
indicates	p<0.005	and	***	indicates	p<0.0005.	
The	amount	of	protein	adsorbed	on	the	film	samples	increased	with	the	addition	of	the	
oligo-PHA	and	was	almost	three	times	higher	for	the	80/20	blend	compared	with	neat	
P(3HB).	
5.4.	In	vitro	biocompatibility	studies	
The	carbon	source	used	for	P(3HHx-3HO-3HD-3HDD)	production	was	a	waste	material.	
Therefore,	it	was	crucial	to	evaluate	the	biocompatibility	of	the	developed	materials	in	
order	to	consider	them	for	any	biomedical	applications.	
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5.4.1	Cell	viability	studies	
	
Preliminary	 in	 vitro	 cell	 culture	 studies	 were	 carried	 out	 using	 a	 human	 dermal	
microvascular	cell	line.	Therefore	HMEC-1	was	chosen	to	investigate	 the	possibility	of	
using	softer	P(3HB)-based	materials	with	improved	plasticity	as	materials	for	scaffolds	
in	coronary	stent	applications.	The	 results	 of	biocompatibility	studies	are	presented	in	
Figure	47.	
		
Figure	 47:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)	 film	 and	
P(3HB)/oligo-PHA	blend	film	samples	at	day	1,	3	and	7	(n=3;	error	bars=±SD).	The	data	
were	 compared	 with	 standard	 tissue	 culture	 plastic	 (positive	 control),	 which	 was	
normalised	to	100%	using	ANOVA.	*	indicates	p<	0.05	and	**	indicates	p<0.005.	( )	TCP,	
( )	P(3HB),	( )	95/5	blend,	( )	90/10	blend,	( )	80/20	blend.		
Cell	proliferation	on	the	P(3HB)	film	samples	was	89.1±2.2%	on	day	1,	90.8±1.2%	on	day	
3	and	114.6±1.7%	on	day	7	compared	to	the	TCP.	The	differences	were	not	statistically	
significant	in	comparison	to	TCP.	Growth	of	HMEC-1	cells	on	the	P(3HB)	film	was	lower	
at	day	1	and	3	 in	 comparison	with	 the	TCP.	 The	 growth	of	 the	HMEC-1	 cells	 on	 the	
surface	of	the	95/5	blend	was	higher	than	TCP	on	day	1,	3	and	7.	The	differences	were	
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not	statistically	significant,	when	compared	with	standard	tissue	culture	plastic.	HMEC-
1	cell	viability	on	films	of	the	90/10	blend	was	also	higher	at	every	time	point	in	relation	
to	 TCP:	 152±0.5%,	 178.2±2.2%	 and	 192±1.6%	 at	 day	 1,	 3	 and	 7	 respectively.	 The	
differences	were	statistically	significant	in	comparison	to	TCP	at	day	1	(*p=0.019),	day	
3	 (*p=0.021)	 and	day	7	 (**p=0.0016).	 The	highest	 viability	 of	 the	HMEC-1	 cells	was	
achieved	on	the	surface	of	the	80/20	blend	which	supported	262.4±2.7%,	277.1±4.4%,	
291.7±2.1%	 of	 viable	 cells	 compared	 with	 TCP	 on	 day	 1,	 3	 and	 7	 respectively.	 The	
differences	were	statistically	significant	in	comparison	to	TCP	on	day	1	(**p=0.0048),	
day	3	(**p=0.0022)	and	day	7(**p=0.0031).	
Overall,	 the	 results	obtained	demonstrated	higher	biocompatibility	of	 all	 samples	 in	
comparison	to	TCP.	However,	the	highest	cell	adhesion	was	observed	for	P(3HB)/oligo-
PHA	80/20	blend	within	the	7-day	period.	Hence,	 in	conclusion,	P(3HB)	as	well	as	all	
blends	were	biocompatible.	Higher	adhesion	of	the	HMEC-1	cell	line	to	the	90/10	and	
80/20	P(3HB)/oligo-PHA	composition	in	comparison	to	the	TCP	indicated	the	possibility	
of	their	application	as	a	platform	material	in	coronary	stent	application.		
	
5.4.2.	Scanning	Electron	Microscopy			
	
Cell	 adhesion	 and	 proliferation	 was	 further	 characterised	 using	 SEM	 imaging.	
Micrographs	 presented	 in	 Figure	 46	 revealed	 that	 HMEC-1	 cells	 adhered	 and	
proliferated	evenly	 across	 the	 surface.	Cell	 density	evidently	 increased	with	a	higher	
concentration	of	oligo-PHA	within	the	blend,	which	is	in	agreement	with	the	results	of	
the	 MTT	 assay.	 This	 order	 of	 the	 materials	 ability	 to	 support	 cell	 proliferation	 also	
matched	 the	 order	 of	 increasing	 surface	 roughness,	 hydrophobicity	 and	 protein	
absorption.	Overall,	 all	 PHA-based	materials	 supported	HMEC-1	 cell	 attachment	 and	
proliferation	demonstrating	good	biocompatibility.	Addition	of	oligo-PHA	improved	cell	
proliferation	with	the	highest	cell	viability	achieved	for	90/10	and	80/20	blends	(Figure	
48).		
CHAPTER	5	
	
	 156	
	
Figure	 48:	 Scanning	 electron	 micrographs	 of	 the	 surfaces	 of	 (A)	 neat	 P(3HB)	 and	
P(3HB)/oligo-PHA	blends	in	ratios:	95/5	(B),	90/10	(C),	80/20	(D)	after	culturing	HMEC-1	
cells	for	7	days.	
HMEC-1	cells	adhered	to	the	surface	of	the	materials	had	spindle-shaped	morphology,	
typical	to	healthy	endothelial	cells.	With	respect	to	the	results	obtained,	neat	P(3HB)	as	
well	 as	all	blends	of	P(3HB/oligo-PHA	supported	 the	growth	of	 the	HMEC-1	 cell	 line.	
However,	blends	with	higher	amount	(over	10	wt%)	of	oligo-PHA	appeared	to	support	
better	cell	attachment	and	proliferation.	
	
5.4.3	Confocal	microscope	of	HMEC-1	cells	on	the	P(3HB)	neat	and	P(3HB)/oligo-
PHA	blends		
 
Confocal	imaging	was	performed	to	support	the	results	obtained	in	viability	studies	and	
SEM.	HMEC-1	cells	on	 the	P(3HB)	neat	 film	as	well	as	P(3HB)/oligo-PHA	blends	were	
stained	with	Calcein	AM	and	Ethidium	homodimer-1.	The	images	obtained	(Figure	49)	
demonstrated	high	cell	adhesion	and	growth	on	all	types	of	scaffolds	on	day	7.		
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Figure	49:	Representative	confocal	micrographs	of	live	HMEC-1	cells	(green)	and	dead	
HMEC-1	 cells	 (red)	 on	 different	 PHA	 materials	 at	 day	 7.	 (A)	 Neat	 P(3HB)	 film,	 (B)	
P(3HB)/oligo-PHA	 in	 ratio	95/5	blend	 film,	 (C)	P(3HB)/oligo-PHA	 in	 ratio	90/10	blend	
film,	(D)	P(3HB)/oligo-PHA	in	ratio	80/20	blend	film.	
HMEC-1	cells	attached	and	proliferated	on	the	surface	of	developed	biomaterials.	Green	
colour	of	the	cells	indicates	presence	of	alive	cells.	Confocal	images	further	confirmed	
results	obtained	by	MTT	assay	and	SEM	imaging,	indicating	high	biocompatibility	of	the	
neat	P(3HB)	and	P(3HB)/oligo-PHA	blends	to	the	HMEC-1	cell	line.		
	
	
	
	
	 		
	 	
A)																																																																																																																							
B)
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D)
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5.5.	Haemocompatibility	studies	
P(3HB)	neat	film	and	P(3HB)/oligo-PHA	blends	were	subjected	to	haemocompatibility	
studies,	which	included	haemolysis	studies,	whole	blood	clotting	as	well	as	monocyte	
and	neutrophils	activation.			
5.5.1.	Haemolysis	study	
Haemolysis	 study	 was	 performed	 on	 P(3HB)	 neat	 films	 as	 well	 as	 P(3HB)/oligo-PHA	
blends	to	check	if	the	materials	would	cause	haemolysis,	which	is	lysis	of	the	red	blood	
cells	after	direct	contact	with	 fresh	whole	blood.	Damaged	red	cells	will	 release	 free	
haemoglobin,	which	can	be	measured	spectrophotometrically.	The	results	obtained	are	
shown	in	Figure	50.	Distilled	water	was	used	as	positive	control.	0.9%	NaCl	solution	was	
used	as	a	negative	control.	
	
Figure	50:	Haemolysis	rates	of	the	P(3HB)	and	P(3HB)/oligo-PHA	blends	in	percent	after	
1h	of	incubation	at	37°C	(n=3).	All	 the	 film	 samples	were	 compared	with	the	control,	
(0.9%	NaCl)	calculated	as	0%	haemolysis	using	ANOVA.	No	significant	difference.		
Erythrocytes	underwent	haemolysis	after	direct	contact	with	distilled	water,	whereas	
0.9%	NaCl	solution	did	not	cause	lysis	of	red	blood	cells.	Among	the	PHAs	tested,	none	
of	the	materials	caused	haemolysis.	The	percent	of	haemolysis	observed	for	neat	P(3HB)	
and	95/5	P(3HB)/oligo-PHA	blend	was	1.5%	and	1.1%	respectively.	Additionally,	PL38	
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medical	grade	was	tested	in	order	to	compare	with	the	haemocompatibility	of	the	PHAs.	
The	percent	of	haemolysis	was	3.7%.	For	the	blends	with	an	addition	of	oligo-PHA	over	
10	w%,	the	percent	of	haemolysis	was	0%.	According	to	the	criteria,	described	by	van	
Oeveren,	2013,	a	material	can	be	classified	as	haemolytic,	when	%	haemolysis	is	higher	
than	 5%.	 The	 results	 obtained	 demonstrated	 that	 PHAs	 are	 non-haemolytic	 (%	
haemolysis	0-2%)	materials,	whereas	PL38	is	slightly	haemolytic	(%	haemolysis	2-5%).	
According	to	the	ISO	10993-4:2002	standard,	the	%	haemolysis	value	should	be	below	
5%.	 All	 tested	 materials	 demonstrated	 haemolysis	 at	 levels	 below	 5%.	 This	 result	
showed	that	all	tested	films	had	low	potential	to	destroy	red	blood	cells.	
5.5.2.	Whole	blood	clotting	
Whole	 blood	 clotting	 experiment	 was	 performed	 to	 investigate	 the	 potential	
procoagulant	 properties	 and	 thrombogenicity	 of	 the	 materials.	 Red	 blood	 cells	 not	
trapped	 in	 the	blood	clot	were	 lysed	by	addition	of	distilled	water	and	 released	 free	
haemoglobin,	which	was	measured	spectrophotometrically.	The	summary	of	the	results	
obtained	after	30	and	90	minutes	are	shown	in	Figure	51.		
 	
Figure	51:	Whole	blood	clotting	after	30	minutes	( )	and	90	minutes	( )	of	incubation	
on	 the	 neat	 P(3HB),	 P(3HB)/oligo-PHA	 blends	 and	 PL38	 medical	 grade	 (n=3;	 error	
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bars=±SD).	The	data	were	compared	with	standard	tissue	culture	plastic	using	ANOVA.	
*indicates	p<	0.05	and	***	indicates	p<0.0005.			
The	results	obtained	indicate	that	after	30	minutes	of	incubation,	the	P(3HB)	neat	film	
demonstrated	15.1±1.3%	blood	 clotting,	which	was	 significantly	 lower	blood	 clotting	
rate	 than	 the	positive	control,	 tissue	culture	plastic	 (TCP)	with	a	value	of	25.2±	0.2%	
(*p=0.0175).	 P(3HB)/oligo-PHA	 blend	 in	 the	 ratio	 80/20	 showed	 significantly	 higher	
blood	clotting	(36.1±0.3%)	rate	in	comparison	to	the	positive	control	(*p=0.0107)	after	
30	minutes.	All	other	materials,	after	30	minutes	resulted	in	higher	%	blood	clotting	than	
the	positive	control.	However,	the	differences	were	not	significant.	With	the	increase	of	
time,	the	%	blood	clot	increased	in	all	tested	materials	as	well	as	in	the	positive	control.	
After	90	minutes	the	control	blood	exhibited	82.9±3.3%	blood	clotting.	The	neat	P(3HB)	
film	exhibited	45.9±1.1%	blood	clotting,	P(3HB)-oligo-PHA	blends	had	%	blood	clotting	
over	 62.4-69.7%.	 PL38	 resulted	 in	 a	 decrease	 in	 blood	 clotting	 after	 90	 minutes	
(30.2±0.5%)	in	comparison	to	TCP.	This	difference	was	highly	significant	(***p=0.0008)	
in	comparison	to	the	standard	tissue	culture	plastic.	
	
5.5.3.	White	cell	activation	
	
White	cell	activation	was	performed	on	monocytes	and	neutrophils.	Fresh	whole	blood	
activated	with	LPS	(10ng/mL)	was	used	as	a	positive	control.	Non-activated	blood	was	
used	as	a	negative	control.	PL38,	commonly	used	for	medical	applications,	was	used	as	
a	 biomaterial	 control.	 The	 activation	was	 evaluated	by	 flow	 cytometry	 after	 staining	
whole	blood	with	specific	markers,	as	described	 in	the	section:	2.15.3.2.	CD11b	 is	an	
activation	marker	for	neutrophils	and	monocytes.		CD11b	regulates	leukocyte	adhesion	
and	migration	to	mediate	the	inflammatory	response.	Other	markers,	such	as	CD86-PE,	
CD45-PerCP	and	CD66b-FITC	were	used	in	this	study	were	to	select	the	right	fraction	of	
the	cells	during	flow	cytometry	analysis.	Obtained	results	are	expressed	as	the	Median	
Fluorescence	Intensity	(MFI).		
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5.5.3.1.	Whole	blood	staining	
Whole	blood	was	 incubated	at	37°C	overnight	and	stained	with	the	markers	 listed	 in	
Table1.	The	results	obtained	are	shown	in	Table	21	and	Figure	52.		
Table	21:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	whole	blood	incubated	with	neat	P(3HB),	P(3HB)/oligo-PHA	blends	in	ratios:	95/5,	
90/10,	 80/20	 PHAs	 and	 PL38	 and	 stained	with	 specific	markers	 in	 order	 to	 evaluate	
monocyte	and	neutrophil	activity.	Fresh	whole	blood	without	any	markers	were	used	as	
a	control.	
No.	 Sample	 Markers	
Monocyte	
activity	(MFI)	
Neutrophil	
activity	(MFI)	
1. 	 Fresh	whole	blood	 - 	 0	 0	
2. 	 Fresh	whole	blood	
CD86-PE	 114.9	 157.1	
CD45-PerCP	 109.4	 117.6	
3. 	 Fresh	whole	blood	
CD11b-PE	 135.9	 140.9	
CD66B-FITC	 202.6	 162.8	
Fresh	blood	without	any	antibodies	did	not	demonstrate	any	activity	as	expected.		
Fresh	blood	incubated	with	selective	and	activation	markers	demonstrated	low	level	of	
activity	for	monocytes	as	well	as	for	neutrophils.		
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Figure	52:	Flow	cytometry	histograms	of	stained	fresh	whole	blood	without	any	markers	
(A)	and	whole	blood	with	addition	of	markers	(B,	C).	Results	are	considered	as	significant	
when	more	than	500	events	were	recorded.	
5.5.3.2.	Blood	activation	with	LPS	
 
Whole	blood	was	incubated	with	LPS	(10ng/mL)	at	37°C	overnight	and	stained	with	the	
markers	listed	in	Table	2.	The	results	obtained	were	summarised	in	Table	22	and	Figure	
53.		
	
A
) 
B 
C 
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Table	22:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 activated	 with	 LPS	 and	 stained	 with	 specific	markers	 in	 order	 to	
evaluate	monocyte	and	neutrophil	activity.		
No.	 Sample	 Markers	
Monocytes	
activity	
(MFI)	
Percentage	
change	(%)	
Neutrophils	
activity	
(MFI)	
Percentage	
change	(%)	
1. 	
Fresh	
whole	
blood+LPS	
CD86-PE	 162.8	 41.7	 146.2	 -	
CD45-PerCP	 113.5	 3.7	 117.8	 0.17	
2. 	
Fresh	
whole	
blood+LPS	
CD11b-PE	 715.2	 426.3	 1104.6	 683.9	
CD66B-FITC	 175.1	 -	 225.9	 38.7	
	
LPS	 is	 present	 in	 the	 cell	 walls	 of	 Gram	 negative	 bacteria.	 It	 is	 also	 known	 as	 an	
endotoxin.		
	From	 the	 results	 obtained	 it	 is	 evident	 that	 LPS	 triggered	 an	 increased	 activity	 of	
monocytes	and	neutrophils.	CD11b-PE	 is	a	marker	of	activation	 for	both:	neutrophils	
and	monocytes.	 It	 is	an	adhesion	molecule	and	its	expression	increases	several	hours	
after	 cell	 activation.	 This	 blood	 samples	were	 incubated	overnight;	 therefore,	 higher	
activity	of	CD11b-PE	was	expected.	Other	markers	did	not	demonstrate	higher	activity	
in	presence	of	LPS.	 
Figure	53:	Flow	cytometry	histograms	of	stained	fresh	whole	blood	activated	with	LPS	
with	two	different	sets	of	markers	(A,	B).	
A
B
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	Fresh	whole	blood	activation	with	the	same	concentration	of	LPS	(10ng/mL)	tested	after	
16	hour	of	incubation	at	37°C	resulted	in	much	higher	values	of	CD11b-PE	for	monocytes	
as	well	as	neutrophils.	The	percentage	change	in	the	MFI	value	of	CD11b-PE	marker	in	
the	blood	activated	with	LPS	was	426.3%	and	683.9%	higher	in	comparison	to	the	fresh	
whole	blood.	In	conclusion,	addition	of	LPS	was	able	to	activate	both	fractions	of	white	
blood	cells.	This	aspect	needs	to	be	consider	during	purification	of	the	PHA	polymers	
obtained	from	Gram	negative	bacteria,	containing	LPS	within	the	cell	wall.	Traces	of	LPS	
present	 within	 the	 polymer	 can	 lead	 to	 accelerated	 white	 blood	 activation	 and	
inflammatory	 response	 from	 the	 body	 against	 the	 polymeric	 material.	 Therefore,	
maximum	 LPS	 levels,	 accepted	 in	 the	 biomaterial	 have	 been	 strictly	 regulated.	 For	
implants	which	will	be	in	contact	with	cardiovascular	system,	the	maximum	acceptable	
level	of	LPS	is	20	endotoxin	units	(20EU)	per	device	(FDA,	1987).			
5.5.3.3.	Monocyte	and	neutrophil	activity	with	neat	P(3HB)	and	P(3HB)/oligo-
PHA	blends		
P(3HB),	P(3HB)/oligo-PHA	blends	and	PL38	were	 incubated	with	whole	blood	at	37°C	
overnight	 and	 stained	 with	 the	 markers	 listed	 in	 Table	 2.	 Summary	 of	 the	 results	
obtained	are	shown	in	Table	23.		
Table	23:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	whole	blood	incubated	with	neat	P(3HB),	P(3HB)/oligo-PHA	blends	in	ratios:	95/5,	
90/10,	80/20	PHAs	and	PL38;	 and	 stained	with	 specific	markers	 in	order	 to	evaluate	
monocyte	and	neutrophil	activity.		
Sample	 Markers	
Monocytes	
Activity	(MFI)	
Percentage	
change	(%)	
Neutrophils	
Activity	
(MFI)	
Percentage	
change	(%)	
P(3HB)	
neat	
	
CD86-PE	 176.5	 53.6	 117.3	 -	
CD45-PerCP	 51.3	 -	 79.1	 -	
CD11b-PE	 464.2	 241.5	 955.3	 578.0	
CD66B-FITC	 -	 -	 -	 -	
95/5	
blend	
	
CD86-PE	 113.5	 -	 121.9	 -	
CD45-PerCP	 94.7	 -	 86.1	 -	
CD11b-PE	 665.1	 389.4	 742.32	 426.8	
CD66B-FITC	 117.6	 -	 113.5	 -	
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90/10	
blend	
	
CD86-PE	 217.4	 89.2	 162.6	 3.5	
CD45-PerCP	 135.9	 0.0	 117.8	 0.17	
CD11b-PE	 517.4	 280.7	 742.3	 426.8	
CD66B-FITC	 311.97	 53.9	 175.1	 7.5	
80/20	
blend	
CD86-PE	 126.4	 10.0	 136.9	 -	
CD45-PerCP	 121.9	 11.4	 94.7	 -	
CD11b-PE	 431.4	 217.4	 556.3	 294.8	
CD66B-FITC	 -	 -	 -	 -	
PL38	
CD86-PE	 106.6	 -	 101.6	 -	
CD45-PerCP	 113.5	 3.7	 101.8	 -	
CD11b-PE	 597.7	 339.8	 1584.1	 1024.3	
CD66B-FITC	 135.9	 -	 131.1	 -	
	
Results	 obtained	 after	 staining	 blood	 samples,	 exposed	 to	 various	 polymer	 samples	
demonstrated	different	levels	of	activity	of	monocytes	as	well	as	neutrophils.	The	neat	
P(3HB)	 film	 triggered	 higher	 activity	 of	 both	 fractions.	 An	 activation	marker:	 CD11b	
demonstrated	higher	activity	in	all	tested	comparison	to	the	non-activated	blood.	For	
nest	P(3HB)	film,	the	percentage	change	of	median	fluorescence	activity	was	241.5%	for	
monocytes	and	578%	for	neutrophils	higher	than	fresh	whole	blood.	P(3HB)/oligo-PHA	
blends	also	demonstrated	elevated	values	in	comparison	to	control.	Among	all	tested	
materials,	PL38	demonstrated	the	highest	percentage	changes	for	monocytes	(339.8%)	
and	neutrophils	(1024.3%)	activation	in	comparison	to	fresh	whole	blood.	Neutrophils	
activation	levels	were	34%	higher	in	comparison	to	blood	activated	by	LPS.		
5.6. Discussion	
	Embrittlement	of	P(3HB)	is	a	well-recognised	phenomenon	which	limits	applications	of	
P(3HB)	including	biomedical	applications.	Therefore,	addition	of	oligo-PHA	was	studied	
for	the	development	of	novel	materials	based	totally	on	PHAs.		
Oligomerisation	of	mcl-PHA	was	achieved	by	acidic	hydrolysis	which	resulted	in	an	mcl-
PHA	with	molecular	weight	around	10	kDa.	Presence	of	single	melting	peak	during	DSC	
analysis	 of	 P(3HB)/oligo-PHA	 blends	 (Figure	 41)	 confirmed	 good	 compatibility	 of	 the	
oligo-PHA	 with	 the	 P(3HB).	 It	 is	 worth	 noting	 that	 both	 thermal	 and	 mechanical	
properties	of	the	P(3HB)/oligo-PHA	blends	were	characterized	with	respect	to	material	
ageing	in	order	to	evaluate	embrittlement	of	P(3HB)-based	material.	The	P(3HHx-3HO-
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3HD-3HDD)	copolymer	after	hydrolysis	presented	different	thermal	properties	than	the	
same	 material	 before	 hydrolysis.	 The	 glass	 transition	 temperature	 for	 oligo-PHA	
copolymer	was	at	-39oC.	Two	melting	events	were	detected:	at	28.6°C	and	38.6°C.	The	
observed	 low	 value	 of	 Tg	 as	 typical	 to	 mcl-PHAs.	 Melting	 events	 observed	 in	 the	
thermograms	were	 at	 lower	 temperatures	 than	mcl-PHAs.	 Although	 the	 addition	 of	
oligo-PHA	to	P(3HB)	caused	only	a	small	decrease	 in	melting	temperature,	 it	 led	to	a	
significant	drop	in	the	crystallinity	of	P(3HB).	Meszynska	and	co-workers	(2015)	reported	
application	 of	 oligomeric	 compounds	 of	 P(3HB)	 as	 plasticiser	 into	 P(3HB-co-4HB)	
copolymer.	 However,	 oligo-PHB	 worked	 more	 like	 nucleating	 agent,	 rather	 than	
plasticiser.	Oligo-PHB	did	not	have	any	influence	on	the	glass	transition	temperature	or	
crystallisation	 temperature.	Melting	 temperature	of	 the	new	system	and	crystallinity	
degree	increased	significantly	in	comparison	to	neat	P(3HB-co-4HB)	copolymer.	Type	of	
plasticiser	can	have	detrimental	effect	on	the	material	properties.	The	same	polymer	
(P(3HB-co-4HB),	 mixed	 with	 monoglyceride	 acetate	 demonstrated	 totally	 different	
thermal	 properties	 than	 P(3HB-co-4HB)	 mixed	 with	 oligo-PHB.	 Glass	 transition	
temperature	and	crystallisation	temperature	decreased,	while	other	parameters	did	not	
change.	 Observed	 changes	 in	 glass	 transition	 temperature	 confirmed	 plasticisation	
effect	of	studied	additive	(Meszynska	et	al.,	2015).	Presence	of	plasticiser	results	in	an	
increase	 in	 free	volume	and	polymer	chains	mobility	between	polymer	chains,	which	
leads	to	decrease	in	glass	transition	in	the	materials	(D’Amico	et	al.,	2016).		
Addition	of	oligo-PHA	have	an	influence	on	the	mechanical	properties	of	the	material.	
Presence	of	plasticiser	resulted	in	decrease	of	Young’s	Modulus,	tensile	strength	and	an	
increase	of	an	elongation	at	break.	This	result	is	in	agreement	with	literature.		Ghiya	and	
co-workers	 studied	 addition	 of	 butyryltrihexyl	 citrate	 to	 P(3HB).	 Obtained	 material	
presented	lower	value	of	Young’s	Modulus	and	higher	elongation	at	break	in	comparison	
to	neat	P(3HB)	 (Ghiya	et	al.,	1995).	 In	another	study	reported	by	Meszynska	and	co-
workers	 (2015),	 an	 addition	 of	 monoglyceride	 acetate	 to	 P(3HB-co-4HB)	 confirmed	
results	obtained	in	this	study.	However,	an	addition	of	oligomeric	form	of	P(3HB)	to	the	
same	 copolymer	 resulted	 in	 different	 mechanical	 properties	 of	 the	 final	 material.	
Material	 became	 more	 stiff	 and	 strong,	 without	 loss	 of	 any	 elastomeric	 properties	
(Meszynska	 et	 al.,	 2015).	 Experiments	 performed	 by	 Garcia-Garcia	 and	 co-workers	
(2017)	 also	 demonstrated	 plasticising	 effect	 of	 vegetable	 oil	 derivatives,	 such	 as	
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maleinized	 linseed	 oil	 and	 an	 epoxidized	 fatty	 acid	 ester	 on	 P(3HB).	 Mechanical	
properties	of	new	material,	demonstrated	similar	trend	to	these	obtained	in	this	study	
(Garcia-Garcia	et	al.,	2017).	It	is	worth	mentioning	that	various	types	of	plasticisers	react	
differently	with	PHAs.	For	example,	in	another	study,	Requena	and	co-workers	studied	
effect	of	five	various	plasticisers,	such	as	three	different	molecular	weight	polyethylene	
glycols	 (PEG200,	 PEG1000	 and	 PEG4000),	 lauric	 and	 stearic	 acids	 on	 P(3HB-co-3HV)	
copolymer.	As	a	result,	among	all	tested	compounds,	only	addition	of	PEG1000	resulted	
in	 slight	 improvement	 of	 elastomeric	 properties	 in	 P(3HB-co-3HV)	 copolymers	 films	
(Requena	et	al.,	2016).	Another	very	important	aspect	was	related	to	the	concentration	
of	 the	 plasticiser.	 Panaitescu	 and	 co-workers	 (2016)	 reported	 that	 properties	 of	 the	
material	obtained	after	addition	of	plasticiser	depends	on	the	amount	of	the	compound	
added.	Higher	concentration	of	plasticisers	may	result	in	sudden	drop	in	the	properties	
of	 the	 material,	 which	 can	 be	 a	 consequence	 of	 phase	 separation	 and	 limited	
compatibility	 between	 polymer	 and	 an	 additive	 (Panaitescu	 et	 al.,	 2016).	 	 The	
mechanical	 properties	 of	 both	 neat	 P(3HB)	 and	 P(3HB)/oligo-PHA	 blends	 gradually	
changed	during	the	7-week	ageing.	Although	the	addition	of	oligo-PHA	did	not	eliminate	
the	 increase	 in	 stiffness	 of	 the	 P(3HB)-based	 materials	 attributed	 to	 the	 ageing	
processes,	oligo-PHAs	had	a	clear	plasticising	effect	on	the	P(3HB)	resulting	 in	softer,	
more	 elastomeric	 materials.	 The	 plasticising	 effect	 of	 the	 oligo-PHAs	 resulted	 in	
obtaining	P(3HB)-based	materials	with	a	wider	range	of	mechanical	properties	with	the	
potential	of	their	applications	as	coronary	stents.	
Addition	of	the	oligo-PHAs	also	resulted	in	changes	in	the	surface	topography.	With	an	
increase	of	the	amount	of	plasticizer,	the	surface	roughness,	static	contact	angle	as	well	
as	protein	adsorption	increased	significantly.	The	exact	mechanism	of	an	enhancement	
in	surface	roughness	by	addition	of	oligomeric	mcl-PHA	plasticiser	to	P(3HB)	is	not	fully	
understood	 due	 to	 shortage	 of	 relevant	 literature.	 Different	 approaches	 have	 been	
taken,	 in	 order	 to	 increase	 surface	 roughness	of	 PHAs.	 These	 include	mainly	 surface	
modifications,	such	as	plasma	treatment,	laser	micropatterning,	chemical	modifications	
(Slepicka	 et	 al.,	 2017).	 Surface	 roughness	 can	 be	 also	 affected	 by	 using	 different	
processing	techniques.	For	example,	Yu	and	co-workers,	2009	reported	that	solvent	cast	
PHA	 films	 had	 higher	 surface	 roughness	 than	 compression	moulded	 films	 (Yu	 et	 al.,	
2009).	An	increase	in	surface	roughness	after	addition	of	various	compounds,	such	as	
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cellulose,	organoclay,	carbon	nanotubes,	hydroxyapatite,	bioglass	into	PHAs,	have	been	
reported	previously	(Ma	et	al.,	2017;	Basnett	et	al.,	2013;	Bittmann	et	al.,	2013;	Francis	
et	al.,	2010).	
An	increase	of	surface	roughness	results	in	an	enlargement	of	surface	area,	which	might	
explain	an	increased	protein	adsorption	on	the	surface	of	the	blend	films	in	comparison	
to	neat	P(3HB).	It	is	known	from	literature,	that	protein	adsorption	is	higher	on	a	rough	
surface	compared	to	the	smooth,	flat	surface	(Chen	et	al.,	2009).	Inability	of	the	proteins	
to	attach	to	the	surface	of	the	implant	could	trigger	an	inflammatory	response	and	lead	
to	the	rejection	of	the	implant	(Das	et	al.,	2007).	Protein	adsorption	is	correlated	with	
surface	roughness	and	hydrophobicity	of	the	material.	The	more	hydrophilic	material,	
the	less	amount	of	protein	will	adsorb.	However,	they	will	remain	in	active	conformation	
(Baujard-Lamotte	et	al.,	2008).	However,	it	is	worth	mentioning,	that	various	proteins	
demonstrate	different	affinity	towards	materials.	For	example,	albumin	prefer	to	adsorb	
on	 the	 hydrophobic	 surfaces	 in	 comparison	 to	 fibronectin,	 which	 prefers	 more	
hydrophilic	 materials	 (Iuliano	 et	 al.,	 1993).	 Both	 proteins:	 albumin	 and	 fibronectin	
supports	each	other.	For	example,	adsorbed	albumin	inhibits	conformational	changes	in	
fibronectin	 and	 allows	 fibronectin	 RGD	 active	 sites	 to	 be	 more	 accessible	 to	 cells	
(Anselme	et	al.,	2010).	 	 In	general,	mcl-PHAs	have	higher	contact	angle	values	due	to	
increased	 hydrophobicity	 of	 the	material	 induced	 by	 the	 longer	 length	 of	monomer	
chains.	 Surface	 roughness	 is	 one	 of	 the	 crucial	 factors	 which	 is	 measured	 while	
evaluating	 any	 biomaterial	 for	 biomedical	 applications	 (Das	 et	 al.,	 2007).	 Numerous	
studies	 have	 revealed	 that	most	 of	 the	 cells	 prefer	 to	 attach	 on	 a	 rough	 surface	 as	
compared	to	the	smooth	surface.	An	uneven	or	a	rough	surface	provides	the	cells	with	
several	adhesion	points	that	allow	them	to	migrate	and	proliferate	(Hao	and	Lawrence,	
2004).	 Restrained	 hydrophilic	 and	 positively	 charged	 materials	 encourage	 cell	
attachment	 due	 to	 the	 adhesion	 of	 specific	 molecules,	 such	 as	 vitronectin	 and	
fibronectin,	 which	 make	 specific	 sites	 accessible	 for	 the	 cell	 adhesion	 receptors	
(Bacakova	et	al.,	2011).	
The	 human	 dermal	 microvascular	 cell	 line	 was	 used	 for	 in	 vitro	 assessment	 of	
attachment	 and	 proliferation	 of	 cells	 relevant	 to	 coronary	 stent	 application.	
Biocompatibility	studies	confirmed	that	P(3HB)/oligo-PHA	materials	were	not	cytotoxic.	
HMEC-1	 cells	 evenly	 colonised	 the	 surface	 of	 films	 and	 exhibited	 a	 typical	 healthy	
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morphology.	 All	 P(3HB)/oligo-PHA	 materials	 showed	 better	 ability	 to	 support	 cell	
growth	compared	with	control	standard	tissue	culture	plastic.	Cell	proliferation	on	the	
surface	 of	 blends	 improved	 compared	with	 the	 neat	 P(3HB)	 and	 increased	with	 the	
larger	content	of	oligo-PHA.	Protein	adsorption	occurs	as	a	first	step	before	cells	attach	
and	spread	over	the	surface	(Anselme	et	al.,	2010).	The	mechanism	of	cell	adhesion	to	
biomaterial	has	been	extensively	studied.	Immediately,	after	implantation,	biomaterial	
is	 covered	with	 proteins	 from	blood	 and	body	 fluids.	 Cells	 are	 able	 to	 sense	 foreign	
surfaces	by	this	adsorbed	protein	layer	and	respond	to	it	accordingly.	Process	of	cells	
adhesion	can	be	divided	 into	 few	phases:	at	early	 stage	physico-chemical	 interaction	
between	cells	and	material	occurs	by	Van	der	Waals	forces	and	ionic	forces.	Cells	attach	
to	the	surface,	spread,	express	cytoskeleton	proteins	and	integrins.		In	the	next	stage,	
clustering	of	integrin	receptors	occurs,	followed	by	cytoskeleton	reorganisation	and	cell	
spreading	on	the	surface	of	the	biomaterial	(Trepat	et	al.,	2008).	In	general,	cells	prefer	
to	 attach	 to	 rougher	 than	 smoother	 surfaces.	 However,	 the	 lever	 of	 roughness	 is	
individual	 for	 each	 cell	 type	 (Korovessis	 et	 al.,	 2002).	 For	 example,	 Kunzler	 and	 co-
workers	demonstrated	that	osteoblasts	more	favoured	rough	surfaces,	while	fibroblast	
definitely	 prefer	 smooth	 materials	 (Kunzler	 et	 al.,	 2007).	 Improved	 affinity	 of	
P(3HB)/oligo-PHA	blends	towards	proteins	could	contribute	to	the	materials	enhanced	
ability	to	support	cell	proliferation.	Also	by	variation	of	the	amount	of	plasticiser	varied	
the	 mechanical	 properties	 of	 the	 blend.	 There	 is	 growing	 research	 intrest	 in	
demonstrating	 the	 role	 of	 substrate	 mechanics	 in	 the	 behaviour	 and	 function	 of	
individual	 cells,	 in	 particular	material	 stiffness	 (Han	 et	 al.,	 2016).	 Pelham	 and	Wang	
(1997),	 demonstrated	 that	 rat	 kidney	 epithelial	 cells	 and	 3T3	 fibroblasts	 responded	
differently	 to	 varied	 flexibility	 of	 the	material	 (Pelham	 and	Wang,	 1997).	 In	 another	
study,	 Lo	 and	 co-workers	 (2000),	 demonstrated	 influence	of	material	 rigidity	 on	 3T3	
fibroblasts	cell	movement.	Cells	could	sense	stiffness	of	the	material	and	migrated	in	the	
direction	of	more	rigid	substrate	(Lo	et	al.,	2000).		
The	enhancement	of	HMEC-1	cell	proliferation	on	slightly	softer	blends	could	be	a	result	
of	the	fact	that	better	mimic	the	physiological	biomechanical	environment	of	these	cells.	
Bhattacharyya	and	co-workers	(2010),	reported	enhanced	adhesion	and	growth	rate	of	
human	aortic	endothelial	cells	(HAEC)	on	the	surfaces	containing	increased	number	of			
-COOH	 functional	 groups	 on	 the	 surface.	 It	 was	 possible	 to	 generate	 favourable	
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environment	 for	 increased	 endothelial	 cell	 adhesion	 and	 proliferation	 by	 adjusting	
surface	chemistry	as	well	as	polymer	film	thickness	(Bhattacharyya	et	al.,	2010).	
The	compatibility	of	P(3HB)	and	P(3HB)/oligo-PHA	blends	after	direct	contact	with	blood	
were	 investigated.	 All	 materials	 demonstrated	 a	 non-haemolytic	 effect	 on	 the	
erythrocytes.	 Addition	 of	 low	molecular	 weight	mcl-PHA	 resulted	 in	 deceleration	 of	
blood	clotting	after	90	minutes.		Haemocompatibility	is	a	crucial	factor	during	material	
evaluation,	especially	for	biomedical	applications.	There	is	only	one	publication,	where	
the	haemocompatibility	of	P(4HB)	was	analysed	 (Liu	et	al.,	2014).	The	blood-scaffold	
response	 is	 a	 very	 complex	 mechanism	 of	 several	 reactions,	 quite	 complicated	 to	
perform	in	one	study	(Ratner,	2007).	Many	different	experiments	need	to	be	carried	out	
to	evaluate	the	biomaterials	appropriately.	This	should	include	effect	on	haematology,	
coagulation,	 thrombosis	 as	well	 as	 the	 immunological	 response	 (Hanson	and	Ratner,	
2004).	Neutrophils	and	monocytes	were	found	to	be	major	factors	in	the	immunological	
response,	especially	with	cardiovascular	devices	(Gorbet	and	Sefton,	2004).	Indicators	
of	leucocyte	activation,	such	as	upregulation	of	CD11b	has	been	observed	 in	vivo,	for	
example	 after	 angioplasty	 (Takala	 et	 al.,	 1996;	 Serrano	 et	 al.,	 1997).	 Therefore,	
activation	of	both	fractions	was	studied	after	contact	with	PHA	films.	Although	the	life	
of	neutrophils	is	very	short	(8-20	hrs),	activation	triggered	by	LPS	can	prolong	this	time	
to	60hrs	(Cassatella,	2009).	Monocytes	circulate	between	36-104hrs	in	the	blood	stream	
and	 then	migrate	 into	 tissues	 and	 differentiate	 into	macrophages	 (Anderson,	 1993).	
Bacteria	and	their	metabolites	can	induce	activation	of	both:	neutrophils	and	monocytes	
(Gorbet	and	Sefton,	2004).	LPS	is	released	after	destruction	of	the	entire	cell	(Lynn	and	
Golenbock,	 1992).	 It	 can	 cause	 strong	 immunogenic	 response	 in	human	and	animals	
(Lemke,	1994).	FDA	approved	the	acceptable	level	of	endotoxin	in	medical	devices	to	be	
0.5EU/mL	 or	 20EU/device	 for	 products,	 which	 directly	 or	 indirectly	 contact	
cardiovascular	system	(FDA,	1987).	Leucocytes	can	be	activated	by	0.01	ng/ml	of	LPS,	an	
equivalent	of	0.05	EU/ml	(Weingarten	et	al.,	1993).	
P(3HB)	 was	 produced	 by	 Gram-positive	 bacteria,	 free	 from	 the	 presence	 of	 LPS.	
Therefore,	 it	was	worth	investigating	further,	the	reason	behind	obtaining	this	result.	
One	 of	 the	 hypothesis	might	 be	 an	 ability	 of	 some	 of	 the	Gram-positive	 bacteria	 to	
produce	 macroamphiphiles	 including	 lipoglycans	 and	 lipoteichoic	 acids	 (LTA),	 which	
have	highly	immunogenic	properties,	similar	to	LPS	(Ray	et	al.,	2013).	Surprisingly	PL38,	
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certified	 to	 be	 produced	 under	 GMP	 conditions	 and	 widely	 used	 for	 biomedical	
applications	also	induced	very	high	neutrophil	activation	(over	1500.MFI),	even	higher	
than	LPS	(1100.0MFI).	This	may	be	caused	by	some	chemical	impurities	in	the	material,	
which	react	with	the	blood	in	a	similar	way	like	LPS.	
In	 conclusion,	 addition	 of	 oligo-PHA	 resulted	 in	 an	 improved	 material	 properties	 in	
comparison	to	neat	P(3HB).	This	include	mechanical	properties,	surface	topography	and	
biological	 performance.	 P(3HB)/oligo-PHA	 blend	 90/10	 exhibited	 the	 most	 suitable	
characteristics	for	coronary	artery	stent	application.	Therefore,	this	composition	will	be	
selected	for	further	experiments.
	Chapter	6	
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6. Introduction	
Polyhydroxyalkanoates	are	natural	origin	biopolyesters,	produced	by	various	types	of	
bacteria.	They	have	been	widely	studied	in	order	to	be	used	in	various	fields,	such	as	
packaging,	food	industry,	photography,	medicine,	drug	delivery,	chemical	industry	and	
coatings	(Ali	and	Jamil,	2016;	Kushwah	et	al.,	2016;	Chen,	2012).	PHAs	represent	a	broad	
range	 of	 properties,	 which	 make	 them	 very	 attractive	 biomaterials	 for	 different	
applications.	They	can	be	mixed	with	other	components	to	create	blends,	described	in	
previous	chapter.	PHAs	can	be	also	used	to	produce	materials,	named	as	composites.	A	
composite	contains	a	matrix,	usually	polymeric	 in	nature	and	different	kind	of	 fillers,	
such	as	fibres,	 inorganic	salts,	bioglass	and	ceramics,	cellulose,	beer	spent	grains	and	
empty	fruit	bunches	from	oil	palm.	(Chiulan	et	al.,	2016;	Cunha	et	al.,	2015;	Khan	et	al.,	
2014;	Pardo-Ibanez	et	al.,	2014;	Misra	et	al.,	2006).	The	main	role	of	fillers	is	to	improve	
the	mechanical	properties,	such	as	tensile	strength	and	Young’s	modulus	of	the	base	
material	by	reinforcement	or	to	improve	functionality	of	the	material,	such	as	additional	
value	 to	 the	 compatibility	 or	 radiopaque	 properties,	 by	 acting	 as	 a	 contrast	 agent.	
Composites	 can	 be	 produced	 by	 various	 techniques,	 such	 as	 a	 solvent	 casting,	melt	
extrusion,	hot	pressing,	cross-linking	and	melt-blending	(De	Arenaza	et	al.,	2015).	
Radiopacity	is	a	property	exhibited	by	some	of	the	materials,	which	allows	them	to	be	
visible	 under	 X-ray.	 These	 materials	 are	 able	 to	 absorb	 X-rays	 and	 occur	 white	 on	
radiographs	 (Hunter	 and	Taljanovic,	 2003).	Chemical	 elements	with	high	density	 and	
high	atomic	number	exhibit	higher	radiopacity.	Hence,	those	materials	have	been	used	
as	markers	for	coronary	stents	made	form	Fe,	Cr,	Co,	Ni	and	their	alloys	(Dobranszky	et	
al.,	2014).	Several	markers	have	been	used	in	coronary	stents	in	order	to	improve	x-ray	
absorption	and	allow	surgeons	more	efficient	stent	deployment,	follow-up	monitoring	
or	stent	dislocation	(Kutryk	et	al.,	2000;	Fischell,	2000).	Markers	can	be	made	from	gold,	
platinum,	silver,	niobium,	tantalum,	zirconium,	tungsten	and	hafnium	(Fulkerson	et	al.,	
2004;	Lam	et	al.,	1998)	and	manufactured	using	various	techniques,	such	as	crimping,	
extrusion,	 laser	micro-welding	or	 braiding	 (Paszenda,	 2010).	 They	 can	have	different	
shapes,	such	as	rings	or	discs,	and	are	usually	located	on	the	proximal	and	distal	ends	of	
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the	 stent	 struts	 (Scott	 et	 al.,	 2004).	 Some	 of	 radiopaque	 markers,	 like	 for	 example	
tantalum	 have	 been	 studied	 as	 powder	 and	 be	 integrated	within	 stent	 (Nagy	 et	 al.,	
2014).	Several	studies	confirmed	significant	increase	of	visibility	of	the	stent	containing	
markers	 in	 comparison	 to	 neat	metallic	 stents	 (Nagy,	 2014;	Wiskirchen	 et	 al.,	 2004;	
Wiskirchen	 et	 al.,	 2003).	 Polymeric	 materials	 are	 not	 radiopaque	 in	 nature.	 Hence,	
addition	of	radiopaque	agents	is	required	in	order	to	be	able	to	be	implanted	within	the	
artery.	Commercially	 available,	polymeric	biodegradable	 stent,	named	Absorb	 (Abott	
Vascular,	US)	has	 four	platinum	beads	 incorporated:	 two	at	 the	proximal	and	 two	at	
distal	end	of	the	scaffold	(Rzeszutko,	2013).		
Barium	sulphate	is	one	of	the	radiopacifiers,	which	are	able	to	absorb	X-ray	and	has	been	
used	in	biomedical	applications.	Different	salts	or	oxides	of	heavy	metals	can	be	used,	
such	 as	 bismuth,	 barium,	 tantalum	or	 tungsten	 (Chen	et	 al.,	 2014).	However,	 at	 the	
moment,	barium	sulphate	is	a	commonly	used	for	biomedical	applications	(Meagher	et	
al.,	2013).	Application	of	BaSO4	allows	surgeons	correct	implant	insertion	and	monitoring	
over	time	(Ricker	et	al.,	2008).	Barium	sulphate	have	been	used	already	with	various	
materials	 such	 as	 polylactic	 acid,	 polyurethanes,	 polymethylmethacrylate	 and	
polypropylene	(Baleani	and	Viceconti,	2010;	Kurtz	et	al.,	2005).		
The	 main	 aim	 of	 this	 part	 of	 the	 project	 was	 to	 develop	 radiopaque	 P(3HB)-based	
materials	using	barium	sulphate	for	development	of	medical	devices,	such	as	coronary	
stents.	One	of	the	P(3HB)/oligo-PHAs	blend	in	ratio	90/10	was	selected	for	composites	
preparation.	Three	different	concentrations	of	barium	sulphate	were	investigated	as	an	
additive	to	create	radiopaque	composites.	Materials	were	fully	characterized	in	order	to	
evaluate	 the	 thermal	 and	 mechanical	 properties.	 In	 vitro	 biocompatibility	 of	 the	
composites	was	tested	with	human	dermal	microvascular	endothelial	cells	(HMEC-1)	to	
evaluate	the	potential	of	new	biodegradable	material	in	applications	such	as	coronary	
artery	stent.	Haemocompatibility	studies	were	carried	out	in	order	to	study	the	impact	
of	the	composite	materials	on	blood	cells.	Additionally,	microCT	measurements	were	
performed	to	study	the	potential	application	of	barium	sulphate	as	a	contrast	agent	for	
coronary	stents.		
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6.1.	 Development	 of	 Poly(3-hydroxybutyrate)/oligo-PHAs	 radiopaque	
composites	
Three	types	of	P(3HB)/oligo-PHA	in	ratio	90/10	composites	with	1	wt%,	3	wt%	and	5	wt%	
barium	 sulphate	 (Figure	 54)	 were	 prepared	 as	 described	 in	 section	 2.10.	 and	 fully	
characterised.	P(3HB)	was	blended	with	oligo-PHA	 in	the	ratio	90/10	and	mixed	with	
BaSO4	to	obtain	radiopacity	and	be	suitable	for	coronary	stent	application.	The	thermal	
and	mechanical	properties	of	P(3HB)/radiopaque	composites	were	studied	using	films	
prepared	by	 solvent	 casting	during	7	weeks	of	 storage	at	 ambient	 temperature.	 The	
mechanical	properties	of	the	composites,	such	as	the	tensile	strength,	Young’s	Modulus	
and	elongation	at	break	were	measured	at	four	time	points	(week	1,	3,	5,	7).		
 
Figure	54:	Composite	solvent	cast	films	of	P(3HB)/oligo-PHA	in	ratio	90/10	with	(A)	1	
wt%,	(B)	3	wt%,	(C)	5	wt%	of	barium	sulphate.	Film	diameter:	60mm.	
6.2.	P(3HB)/oligo-PHA	composite	characterisation	
Solvent	 cast	 composite	 films	 were	 characterised	 with	 respect	 to	 their	 thermal,	
mechanical	 and	 topographical	 properties.	 Additionally,	 biocompatibility	 and	
haemocompatibility	studies	were	perform	in	order	to	confirm	non-toxicity	and	safety	of	
the	biomaterials.		
6.2.1.	Attenuated	Total	Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
Preliminary	characterisation	of	the	P(3HB)/oligo-PHA	composites	with	barium	sulphate	
was	 carried	 out	 using	 ATR/FTIR.	 FTIR	 spectra	 (Figure	 55)	 revealed	 absorption	 bands	
centred	in	the	region	1131.4-1043.7	cm-1	with	a	shoulder	at	978.5cm-1,	corresponding	
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to	the	symmetrical	vibration	of	sulphate	group	(-SO42-).	Two	absorption	peaks	at:	625cm-
1	 and	 606cm-1,	 corresponded	 to	 the	 out	 of	 plane	 bending	 vibration	 of	 sulphate	
(Ramaswamy	et	al.,	2011;	Shen	et	al.,	2007).			
 
Figure	 55:	 ATR-FTIR	 spectrum	 of	 the	 P(3HB)/oligo-PHA	 composites	 with	 barium	
sulphate.	 ( )	 P(3HB)/oligo-mcl-PHA	 90/10	 blend	 without	 barium	 sulphate,	 ( )	
composite	 film	 containing	 1%	 barium	 sulphate,	 ( )	 composite	 film	 containing	 3%	
barium	 sulphate,	 ( )	 composite	 film	 containing	 5%	 barium	 sulphate	 indicating	
characteristic	peaks	for	PHAs	and	SO42-.		
FTIR-ATR	 analysis	 of	 the	 composites	 revealed	 absorption	 bonds	 at	 1720.5	 cm-1	 and	
1276.5	cm-1	corresponding	to	the	ester	carbonyl	group	and	the	-CH	group,	respectively.	
Obtained	 values	 are	 typical	 to	 scl-PHAs,	 as	 described	 in	 the	 section	 3.3.1.	 The	weak	
absorption	 bands	 at	 2938cm-1,	 2991cm-1	 and	 2939	 cm-1	 could	 be	 assigned	 to	 the	
aliphatic	C-H	group	of	the	pendant	alkyl	group	found	in	mcl-PHAs.	The	peak,	observed	
at	1182	cm-1	corresponded	to	the	-CO	stretching	group,	characteristic	of	mcl-PHAs	as	
described	in	the	section	4.4.1.	
FTIR	analysis	of	the	PHA	based	composites	with	barium	sulphate	confirmed	the	presence	
of	 chemical	 bonds,	 which	 belongs	 to	 scl-PHAs,	 mcl-PHAs	 and	 sulphate	 anions	 from	
BaSO4.	
CHAPTER	6	
	
	 177	
6.2.2.	Thermal	properties	of	the	composites	of	P(3HB)/oligo-PHA	blends	with	
barium	sulphate	after	7	weeks	of	storage	at	room	temperature	
The	thermal	properties	of	the	P(3HB)/oligo-PHA	composites	during	7	weeks	of	storage	
were	analysed	by	DSC.	The	summary	of	the	results	obtained	in	presented	in	Table	24	
and	Figure	56.	
Table	24:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	composites	with	
1,3	and	5	wt%	barium	sulphate	during	7	weeks	of	storage.	Tm=	melting	temperature,	Tg=	
glass	transition	temperature,	Tc=	crystallisation	temperature,	DHf=enthalpy	of	fusion.	
Time	of	
storage	
(week)	
Concentration	of	
Barium	sulphate	
Tg	(°C)	 Tm	(°C)	 ΔHf	(J/g)	 Tc	(°C)	
1	
1	wt%	 -11.6	 171.3±1.1	 88.1±8.5	 53	
3	wt%	 -4.2	 168.2±0.3	 74.3±1.9	 53.8	
5	wt%	 -8.4	 167.5±1.9	 75.5±3.5	 45.9	
3	
1	wt%	 -2.9	 169.2±1.6	 87.3±1.1	 52.5	
3	wt%	 -4.3	 168.8±2.0	 81.0±4.2	 53.9	
5	wt%	 -2.5	 170.4±1.5	 77.2±4.3	 52.9	
5	
1	wt%	 -2.2	 169.7±1.9	 82.7±2.1	 55.3	
3	wt%	 -2.1	 169.8±1.6	 83.9±0.9	 58.3	
5	wt%	 -2.6	 170±1.9	 78.9±0.8	 56.8	
7	
1	wt%	 -3.2	 169.1±1.5	 84.2±3.02	 53.8	
3	wt%	 -3.3	 169.1±2.1	 85.5±3.5	 55.2	
5	wt%	 -4.1	 168.3±1.6	 80.9±2.3	 51	
Addition	of	barium	sulphate	affects	the	thermal	properties	of	the	composites	(Table	24	
and	Figure	56).	With	the	increase	of	the	concentration	of	barium	sulphate,	Tm,	Tc	and	
ΔHf	values	decreased.		
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Figure	 56:	 DSC	 thermograms	 of	 P(3HB)/oligo-PHA	 blend	 in	 the	 ratio	 90/10	 and	
composite	films	with	addition	if	1%,	3%	and	5	wt%	of	BaSO4	stored	for	7	weeks	at	room	
temperature.	 ( )	0	wt%	barium	sulphate	film,	 ( )	1	wt%	barium	sulphate	composite	
film,	( )	3	wt%	barium	sulphate	composite	film,	( )	5	wt%	barium	sulphate	composite	
film	indicating	melting	peaks.		
The	glass	transition	temperature	for	all	compositions	of	P(3HB)/oligo-PHA	have	changed	
during	7	weeks	of	storage.	The	cold	crystallisation	temperature	remained	stable	for	1	
and	3	wt%	and	has	increased	(from	45.9	to	52.9°C)	for	5	wt%	concentrations	of	barium	
sulphate	within	3	weeks.	After	3	weeks,	no	changes	in	Tc	values	were	observed.	The	Tm	
value	 decreased	 for	 1	wt%	 barium	 sulphate	 concentration	 as	 compared	 to	 the	 neat	
blend	was	observed	at	similar	temperatures	for	3	wt%	barium	sulphate	and	increased	in	
the	sample	with	5	wt%.	ΔHf			decreased	for	composite	with	1	wt%,	remain	the	same	for	
3	wt%	of	barium	sulphate	and	increased	for	5	wt%	of	barium	sulphate	in	comparison	to	
P(3HB)/oligo-PHA	without	barium	sulphate.		
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6.2.3.	Mechanical	properties	of	 the	composites	of	P(3HB)/oligo-PHA	blend	 in	
ratio	 90/10	 with	 barium	 sulphate	 after	 7	 weeks	 of	 storage	 at	 room	
temperature	
Mechanical	properties	of	the	solvent	cast	composite	films	with	addition	of	1,	3,	5	wt%	
barium	sulphate	were	carried	out	for	7	weeks,	in	order	to	check	the	effect	of	the	addition	
of	 the	 radiopaque	 agent	 on	 the	 mechanical	 properties	 of	 the	 material.	 The	 results	
obtained	summarised	in	Table	25	and	Figure	57.		
Table	25:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	composites	
with	1,3	and	5	wt%	barium	sulphate	during	7	weeks	of	storage	at	room	temperature	
(n=3).	
Time	of	
storage	
(week)	
Concentration	of	
Barium	sulphate	
Tensile	test	
(MPa)	
Young’s	
Modulus	
(MPa)	
Elongation	
at	break	(%	
strain)	
1	
1	wt%	 12.9±1.3	 520±60	 14.2±0.2	
3	wt%	 11.2±0.4	 430±120	 9.1±0.3	
5	wt%	 13.1±1.9	 680±140	 7.9±1.1	
3	
1	wt%	 18.2±0.9	 1310±50	 8.4±0.4	
3	wt%	 18.1±0.9	 1250±30	 7.9±1.7	
5	wt%	 18.5±3.2	 1230±70	 4.7±0.1	
5	
1	wt%	 17.1±1.5	 1160±140	 4.3±0.7	
3	wt%	 17.1±0.8	 1250±7	 4.5±0.1	
5	wt%	 16.0±0.6	 1070±280	 4.3±0.1	
7	
1	wt%	 16.2±2.1	 1020±100	 4.4±0.8	
3	wt%	 14.6±1.3	 920±80	 4.9±0.6	
5	wt%	 14.1±0.3	 1110±70	 4.3±0.5	
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Figure	 57:	 Changes	 in	 the	 ultimate	 tensile	 strength	 (A),	 Young’s	 modulus	 (B)	 and	
elongation	 at	 break	 (C),	 during	 storage	 of	 neat	 P(3HB)/oligo-PHA	 blend	 and	 its	
composites	with	BaSO4	for	7	weeks	at	room	temperature.	( )		0%	barium	sulphate	film,	
( )	1%	barium	sulphate	composite	film,	( )	3%	barium	sulphate	composite	film,	( )	
5%	barium	sulphate	composite	film.	
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After	3	weeks	of	ageing,	the	mechanical	properties	of	the	P(3HB)/oligo-PHAs	composite	
films	with	 barium	 sulphate	 had	 changed.	 For	 the	 composite	with	 addition	 of	 1	wt%	
barium	 sulphate,	 elongation	 at	 break	 decreased	 after	 7	 weeks	 of	 storage	 from	
14.2±0.2%	to	4.3±0.2%.	Young’s	modulus	 increased	significantly	from	0.5±0.1	MPa	to	
1250±7MPa.	Tensile	strength	 increased	after	7	weeks	 from	12.9±1.3MPa	to	16.2±2.1	
MPa.	Addition	of	barium	sulphate	in	3	wt%	to	the	P(3HB)/oligo-PHAs	blend	in	the	ratio	
90/10	 resulted	 in	decrease	of	 the	elongation	at	break	after	7	weeks	of	 storage	 from	
9.9±6.1%	to	4.9±1.6%.	Young’s	modulus	 increased	from	0.4±0.1	MPa	to	0.9±0.1	GPa.	
The	tensile	strength	increased	after	7	weeks	from	11.2±0.4	MPa	to	14.6±1.3	MPa.	For	
the	 composition	 with	 the	 addition	 of	 5	 wt%	 barium	 sulphate,	 elongation	 at	 break	
decreased	after	3	weeks	of	storage	from	7.9±6.1%	to	4.3±0.5%.	Young’s	modulus	value	
increased	from	0.7±0.1	MPa	to	1.1±0.1	GPa.	Tensile	strength	increased	after	7	weeks	
from	 13.1±1.9	MPa	 to	 14.1±0.3	MPa.	 The	 results	 obtained	 suggest	 that	 addition	 of	
barium	sulphate	in	all	three	compositions	resulted	in	an	increase	of	the	tensile	strength	
and	Young’s	modulus	in	comparison	to	the	P(3HB)/oligo-PHAs	blend.	An	increase	of	the	
concentration	of	the	barium	sulphate	within	the	blend	improved	the	material	strength	
and	stiffness.	Addition	of	barium	sulphate	resulted	in	a	decrease	of	the	elongation	at	
break,	 hence,	 the	 material	 became	 more	 brittle.	 The	 minimum	 amount	 of	 barium	
sulphate	 required	 in	 order	 to	 obtain	 sufficient	 material	 radiopacity	 needs	 to	 be	
confirmed	in	future	work.	
6.3.	Surface	analysis	
6.3.1.	Scanning	Electron	Microscopy	(SEM)		
SEM	and	laser	profilometry	were	used	to	examine	the	topography	of	polymer	films.	As	
can	be	seen	from	SEM	images	presented	in	Figure	58,	P(3HB)/oligo-PHA	90/10	solvent	
cast	film	with	an	addition	of	BaSO4	had	similar	surface	topography	and	demonstrated	
visible	 irregularities	 with	 various	 protuberances	 in	 comparison	 to	 neat	 P(3HB)	 film,	
which	appeared	to	be	smoother	and	even.	
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Figure	 58:	 SEM	 micrographs	 of	 the	 surface	 of	 (A)	 P(3HB)/oligo-PHA	 blend	 without	
addition	of	barium	sulphate,	P(3HB)/oligo-PHA	composite	with	addition	of	(B)	1wt%,	(C)	
3wt%	and	(D)	5wt%	of	barium	sulphate.	
The	surface	of	composite	films	appeared	to	have	a	rougher	surface	than	P(3HB)/oligo-
PHA	blend.	The	surface	roughness	measurements	were	carried	out	to	confirm	the	SEM	
data.	
6.3.2.	Surface	roughness	analysis	
	
Composites	 roughness	 was	 characterised	 quantitatively	 as	 the	 root	 mean	 square	
roughness	(Rq)	using	laser	profilometry	(Figure	59).	The	roughness	of	the	P(3HB)/oligo-
PHA	in	the	ratio	90/10	was	0.9±0.04μm.	With	an	increase	in	the	content	of	BaSO4	in	the	
composites	the	surface	roughness	increased	from	1.1	±	0.02μm	for	1	wt%	BaSO4	to	1.6	
±	0.06μm	for	5	wt%	BaSO4	concentration.	Surface	roughness	value	of	composite	with	
the	 highest	 amount	 of	 BaSO4	 (5	 wt%)	 was	 significantly	 higher	 than	 the	 neat	
P(3HB)/oligo-PHA	blend.	
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Figure	59:	Surface	roughness	of	P(3HB)/oligo-PHA	blend	(90/10)	and	composites	with	
BaSO4	 (n=3;	 error	 bars=±SD).	 The	 data	were	 compared	with	 P(3HB)/oligo-PHA	90/10	
blend	film	without	addition	of	barium	sulphate	using	ANOVA.	*	indicates	p<	0.05.		
Results	 obtained	 from	 surface	 roughness	measurements	 confirmed	 further	 the	 SEM	
findings.	The	surface	of	the	all	composite	samples	resulted	with	root	mean	square	(Rq)	
value	greater	than	1.	SEM	images	of	the	surface	topography	for	P(3HB)/oligo-PHAs	with	
an	 addition	 of	 BaSO4	 composites	 demonstrated	 rough	 surfaces.	With	 an	 increase	 in	
surface	 roughness	with	 the	concentration	of	BaSO4	 the	difference	was	significant	 for	
composition	with	the	5	wt%	BaSO4	in	comparison	to	the	neat	P(3HB)/oligo-PHA	blend	
film.	Higher	 surface	 roughness	of	 the	P(3HB)/oligo-PHA	 composites	with	 an	 increase	
concentration	 of	 barium	 sulphate	 might	 have	 an	 impact	 on	 biocompatibility	 of	 the	
composite	materials.		
6.3.3.	Contact	angle	measurement	
Static	contact	angle	study	was	performed	to	measure	the	hydrophobicity	of	the	solvent	
cast	 P(3HB)/oligo-PHAs	 composites	 samples.	 The	 results	 of	 the	 water	 contact	 angle	
measurements	have	been	summarised	in	Figure	60.	
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Figure	60:	Static	water	contact	angle	measurements	of	 the	P(3HB)/oligo-PHA	 in	ratio	
90/10	 films	 (n=3)	 with	 different	 concentrations	 of	 barium	 sulphate	 (n=3;	 error	
bars=±SD).	The	data	were	compared	with	P(3HB)/oligo-PHA	90/10	blend	film	without	
addition	of	barium	sulphate	using	ANOVA.	*	indicates	p<	0.05.	
Obtained	results	demonstrated	that	the	water	contact	angle	was	higher	than	70	degrees	
in	 all	 tested	materials,	 therefore	materials	 were	 hydrophobic	 in	 nature.	 Addition	 of	
barium	 sulphate	 decreased	 the	 value	 of	 water	 contact	 angle,	 hence	 the	 related	
hydrophobicity.	Neat	blend	of	P(3HB)/oligo-PHAs	has	 contact	 angle	 value	112.5	±4.3	
degrees,	whereas	addition	of	5%	BaSO4	reduced	static	contact	angle	values	to	87.2±1.5	
degrees.	The	results	obtained	of	the	water	contact	angle	were	significantly	lower	for	the	
composites	 in	 comparison	 to	 the	 P(3HB)/oligo-PHAs	 blend	 in	 ratio	 90/10.	 Although,	
contact	 angle	 values	 for	 P(3HB)/oligo-PHA	 composites	 demonstrated	 lower	 values,	
materials	are	still	considered	as	hydrophobic.	However,	it	will	be	interesting	to	observe	
the	reaction	of	endothelial	cells	to	the	surface	of	P(3HB)/oligo-PHA	composite	materials	
during	biocompatibility	study.		
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6.3.4.	Protein	adsorption	on	the	surface	of	the	composites	containing	barium	
sulphate	
The	affinity	of	the	materials	towards	proteins	were	evaluated	by	using	the	bicinchoninic	
acid	assay	as	described	in	section	2.11.3.9.		It	was	found	that	total	protein	 adsorption	
was	145±3.5,	156.4±4.6,	173±14	and	175.4±4.6	µg/cm2	for	the	neat	P(3HB)/oligo-PHA	
90/10	blend	film	and	P(3HB)/oligo-PHA	composites	with	an	addition	of	1	wt%,	3	wt%,	5	
wt%	BaSO4	respectively	(Figure	61).	There	was	a	significant	difference	between	all	tested	
composites	 in	 comparison	 to	 the	 tissue	 culture	 plastic	 (*p=0.011,	 *p=0.0206	 and	
**p=0.0079	respectively)	(Figure	61).			
 
 
Figure	 61:	 Protein	 adsorption	 to	 the	 composites	measured	by	BCA	assay	 (n=3;	 error	
bars=±SD).	The	data	were	compared	with	standard	tissue	culture	plastic	using	ANOVA.	
*	indicates	p<	0.05	and	**	indicates	p<0.005.	
Composites	 with	 barium	 sulphate	 were	 characterized	 with	 higher	 concentration	 of	
proteins	adsorbed	on	the	surface	in	comparison	with	TCP	(positive	control).	The	amount	
of	proteins	adsorbed	on	the	TCP	was	114.7±11.7	µg/cm2.	All	the	composites	exhibited	
higher	protein	adsorption	than	the	control	and	the	P(3HB)/oligo-PHA		90/10	blend.		
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6.3.5.	XRD	analysis	
The	 effect	 of	 addition	 of	 barium	 sulphate	 on	 crystallinity	 of	 the	materials	 as	well	 as	
identification	 of	 presence	 of	 BaSO4	 was	 studied	 using	 X-ray	 diffraction,	 described	
previously	in	the	Chapter	2,	section	2.11.3.8.		Summary	of	XRD	patterns	for	P(3HB)/oligo-
PHA	blend	with	0%,	1%,	3%	and	5%	barium	sulphate	are	shown	in	the	Figure	62.	
	
Figure	62:	XRD	patterns	of	P(3HB)/oligo-PHA	90/10	blend	and	composites	with	1%,	3%	
and	 5	wt%	BaSO4.	 ( )	 P(3HB)/oligo-mcl-PHA	 90/10	 blend	without	 barium	 sulphate,										
( )	barium	sulphate	powder,	( )	composite	film	containing	1%	barium	sulphate,	( )	
composite	 film	 containing	 3%	 barium	 sulphate,	 ( )	 composite	 film	 containing	 5%	
barium	sulphate.	
In	the	composite	samples,	there	was	an	increased	in	the	peak	intensity	with	an	increase	
of	the	BaSO4	concentration.	The	intense	peaks,	such	as	25°,	26°,	28°,	33°,	42.5°	and	43°	
were	characteristic	of	BaSO4	and	present	in	all	concentrations	of	barium	sulphate.	The	
intensity	of	these	peaks	increased	with	increased	concentration	of	BaSO4.	Some	peaks,	
such	 as	 22.5°,	 31.5°,	 44°	 or	 49°	 were	 much	 less	 intense	 and	 detected	 only	 in	 the	
composite	sample	with	5	wt%	of	BaSO4.	None	of	these	peaks	were	observed	in	the	neat	
P(3HB)/oligo-PHA	in	90/10	blend.	
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	6.4.	In	vitro	biocompatibility	studies	
Biocompatibility	of	the	composite	samples	were	investigated	by	cell	viability	studies	
and	SEM	imaging	of	the	scaffolds.		
6.4.1.	MTT	assay	
MTT	 assay	 was	 used	 to	 evaluate	 cell	 adhesion	 and	 proliferation.	 Attachment	 and	
proliferation	of	the	HMEC-1	cells	on	the	film	samples	were	studied	over	a	period	of	1,	
3	and	7	days.	The	standard	tissue	culture	 plastic	was	 used	 as	 the	 positive	 control	 for	
these	experiments.	The	 results	 of	biocompatibility	studies	are	presented	in	Figure	63.	
 
 
Figure	 63:	 Cell	 proliferation	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composite	film	samples	on	day	1	( ),	day	3( )	and	day	7	( )		(n=3;	error	bars=±SD).	The	
results	were	compared	with	standard	tissue	culture	plastic,	which	was	normalised	to	
100%	 using	 ANOVA.	 *	 indicates	 p<	 0.05,	 **	 indicates	 p<0.005	 and	 ***	 indicates	
p<0.0005.	
Cell	proliferation	on	the	surface	of	composite	films	was	slightly	lower	than	TCP	at	day	1,	
but	higher	at	day	3	and	day	7.	The	observed	cell	viability	on	the	composite	film	samples	
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with	 1	 wt%	 barium	 sulphate	 was	 91.6±5.4%	 on	 day	 1,	 186.4±6.0%	 on	 day	 3	 and	
215.5±2.0%	 on	 day	 7	 as	 compared	 to	 that	 TCP.	 The	 differences	 were	 statistically	
significant	for	results	from	day	3	and	7	(***p=0.0005	and	**p=0.0013	respectively).	The	
growth	of	the	HMEC-1	cells	on	the	surface	of	3	wt%	BaSO4	composite	was	95.2±5.4%	
on	day	1	and	187.4±6.5%	and	203.5±8.0%	at	day	3	and	7	respectively.	The	differences	
were	statistically	significant	(**p=0.0088,	**p=0.0075)	in	comparison	to	TCP	on	day	3	
and	7.	Similarly,	HMEC-1	cell	viability	on	films	with	5	wt%	BaSO4	was	 lower	at	day	1	
(93.7±4.0%)	and	higher	on	day	3	and	7	in	relation	to	TCP:	182.2±9.0%	and	203.6±4.5%	
respectively.	The	differences	were	statistically	significant	in	comparison	to	TCP	at	day	
3	(*p=0.0182)	and	day	7	(***p=0.0009).		
The	 results	 obtained	 demonstrated	 higher	 biocompatibility	 of	 all	 tested	 composite	
samples	 in	comparison	to	TCP.	However,	the	highest	cell	adhesion	was	observed	for	
P(3HB)/oligo-PHA	 composite	 with	 1	 wt%	 BaSO4	 within	 7-day	 period.	 The	 results	
obtained	confirmed	that	all	composites	were	non-cytotoxic.		
6.4.2.	SEM		
 
Cell	 adhesion	 and	 proliferation	 was	 further	 characterised	 using	 SEM	 imaging.	 SEM	
images	presented	in	Figure	64	revealed	that	HMEC-1	cells	adhered	and	proliferated	
evenly	 across	 the	 surface.	 Cell	 density	 was	 comparable	 between	 the	 samples.	 The	
increase	 in	 cell	 adhesion	 and	 proliferation	 on	 the	 composites	 also	 matched	 the	
increasing	 surface	 roughness	 and	 protein	 absorption.	 All	 PHA-based	 materials	
supported	 HMEC-1	 cell	 attachment	 and	 proliferation,	 hence	 demonstrating	 good	
biocompatibility.	 Addition	 of	 barium	 sulphate	 improved	 cell	 proliferation	 with	 the	
highest	cell	viability	achieved	for	the	composite	with	1	wt%	BaSO4.	
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Figure	 64:	 SEM	 images	 of	 the	 surfaces	 of	 P(3HB)/oligo-PHA	 blend	 90/10	 (A)	 and	
P(3HB)/oligo-PHA	90/10	composites	with	1	wt%	BaSO4	(B),	3	wt%	BaSO4	(C)	and	5	wt%	
BaSO4	(D)	after	culturing	HMEC-1	cells	for	7	days.	
With	respect	to	the	results	obtained,	composites	of	barium	sulphate	with	P(3HB)/oligo-
PHAs	supported	the	growth	of	HMEC-1	cell	 line.	Addition	of	barium	sulphate	did	not	
inhibit	cell	attachment	or	proliferation.		
	
6.4.3.	Indirect	cytotoxicity		
	
The	 indirect	 cytotoxicity	 test	 was	 performed	 to	 investigate	 the	 influence	 of	 any	
substances	released	from	the	P(3HB)/oligo-PHA	composite	materials	on	the	HMEC-1	cell	
line.	Cells	without	an	extract	were	used	as	negative	control.	70%	methanol	instead	of	
media	or	extract	was	used	as	a	positive	control.		Endothelial	cells	were	selected	for	this	
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study	to	mimic	the	environment	present	in	the	human	body	after	stent	implantation.	
This	device	would	be	in	direct	contact	with	the	endothelium,	therefore	the	HMEC-1	cell	
line,	an	endothelial	cell	line	was	chosen.	The	summary	of	the	results	obtained	are	shown	
in	Figure	65.		
	
 
Figure	 65:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
composites	film	samples	at	day	1	( )	and	day	3	( ))	(n=3;	error	bars=±SD).	The	data	were	
compared	with	 standard	 tissue	 culture	 plastic,	which	was	 normalised	 to	 100%	using	
ANOVA.	*	indicates	p<	0.05	and	**	indicates	p<0.005.		
Cell	 proliferation	 on	 the	 composite	 film	 samples	 with	 1%	 barium	 sulphate	 was	
98.7±6.7%	on	day	1	and	101.4±8.4%	on	day	3	compared	to	the	TCP.	The	differences	
were	not	statistically	significant.	The	growth	of	HMEC-1	cells	on	the	composite	film	was	
similar	on	day	1	and	3	to	TCP.	The	growth	of	the	HMEC-1	cells	on	the	surface	of	3	wt%	
BaSO4	 composite	 was	 higher	 than	 TCP	 on	 day	 3	 (163±8.9).	 The	 difference	 was	
statistically	 significant	 (**p=0.0079).	HMEC-1	cell	 viability	on	composite	 films	with	5	
wt%	BaSO4	was	also	higher	on	day	3	in	relation	to	TCP:	142.6±4.8%.	The	difference	was	
statistically	significant	in	comparison	to	TCP	on	day	3	(*p=0.04).	The	highest	viability	of	
the	HMEC-1	cells	was	achieved	after	treatment	with	an	extract	from	composite	samples	
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with	3	wt%	barium	sulphate	in	comparison	to	TCP	after	3	days	of	incubation	(Figure	65).	
The	results	obtained	confirmed	an	absence	of	any	cytotoxic	substances	were	released	
from	 the	 composite.	 Moreover,	 extracts	 obtained	 after	 incubation	 of	 composites	
containing	3	wt%	and	5	wt	%	BaSO4	supported	the	cells	attachment	and	proliferation	
better	than	tissue	culture	plate.	Therefore,	PHA	based	composites	with	BaSO4	can	be	
strongly	considered	as	potential	materials	for	biomedical	applications,	such	as	coronary	
stents.		
6.4.4.	MicroCT	scan	of	the	composite	samples	
	
MicroCT	scans	were	performed	to	investigate	a	radiopacity	of	the	composites,	
containing	barium	sulphate.	The	images	are	presented	in	the	Figure	66.		
	
 
Figure	 66:	MicroCT	micrographs	 demonstrated	 x-ray	 absorption	 by	 barium	 sulphate,	
presented	in	the	concentrations	(from	the	left	to	right):	0	wt%,	1	wt%,	3	wt%	and	5	wt%	
in	the	PHAs	based	composites	in	comparison	with	a	neat	P(3HB)/oligo-PHA	blend	in	ratio	
90/10.	
From	the	micrographs	presented	in	the	Figure	66	it	is	evident	that	the	intensity	of	the	
signals	 is	 higher	 with	 an	 increased	 concentration	 of	 barium	 sulphate.	 The	 control	
sample,	such	as	neat	P(3HB)/oligo-PHAs	90/10	blend	did	not	exhibited	these	signals	as	
expected.		
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The	 results	 obtained	 suggest	 possibility	 of	 application	 of	 barium	 sulphate	 as	 a	
radiopaque	agent	for	coronary	stent	application.		
6.5.	In	vitro	haemocompatibility	studies	
P(3HB)	neat	film	and	P(3HB)/oligo-PHA	blends	were	subjected	to	haemocompatibility	
studies,	which	includes	haemolysis	studies,	whole	blood	clotting	as	well	as	monocytes	
and	neutrophils	activation.		
6.5.1.	Haemolysis	study	
Haemolysis	 study	 was	 performed	 on	 P(3HB)/oligo-PHAs	 composites	 with	 barium	
sulphate	to	check	an	effect	of	the	materials	on	the	erythrocytes	after	direct	contact	with	
fresh	 whole	 blood.	 The	 analysis	 was	 performed	 as	 described	 in	 section	 2.15.1.	 The	
results	obtained	are	shown	at	the	Figure	67.		
 
Figure	67:	Haemolysis	rates	of	the	P(3HB)/oligo-PHA	blend	and	composites	with	barium	
sulphate	after	1h	of	incubation	at	37°C	(n	=	3).	All	 the	 film	 samples	were	 compared	
to	the	control	with	0.9%	NaCl	using	ANOVA.	No	significant	difference.	
All	 tested	PHA	based	materials	confirmed	the	non-haemolytic	effect	on	erythrocytes.	
The	percent	of	haemolysis	1.3%,	0.7%	and	0.05%	was	obtained	for	composites	with	1	
wt%	BaSO4,	3	wt%	BaSO4	and	5	wt%	BaSO4	respectively.		
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6.5.2.	Whole	blood	clotting	
Whole	 blood	 clotting	 experiments	 were	 performed	 to	 investigate	 the	 potential	
thrombogenicity	of	the	materials	as	described	previously	in	section	2.15.2.	The	summary	
of	the	results	obtained	after	30	and	90	minutes	are	demonstrated	in	Figure	68.		
	
Figure	68:	Whole	blood	clotting	after	30	minutes	( )	and	90	minutes	( )		of	incubation	
on	the	neat	P(3HB)/oligo-PHA	blend	90/10,	composites	with	1	wt%,	3	wt%	and	5	wt%	
barium	sulphate	and	PL38	(n=3;	error	bars=±SD).	The	data	were	compared	with	standard	
tissue	culture	plastic	using	ANOVA.	*indicates	p<	0.05	and	***	indicates	p<0.0005.		
The	results	obtained	indicated	that	all	tested	materials	enhanced	the	activation	of	the	
coagulation	 cascade.	 After	 30	 minutes	 of	 incubation,	 composite	 with	 1%	 barium	
sulphate	 demonstrated	 29.2±2.6%	 blood	 clotting.	 Addition	 of	 BaSO4	 at	 level	 3	 wt%	
resulted	 in	 an	 increased	%	blood	 clotting	 after	 30	minutes	 to	 36.0±3.1%,	which	was	
significantly	 higher	 blood	 clotting	 rate	 than	 positive	 control	 25.2±	 0.2%	 (*p=0.014).	
P(3HB)/oligo-PHA	composite	with	5	wt%	barium	sulphate	showed	blood	clotting	rate	
35.5±2.3%	after	30	minutes.	With	the	increase	of	time,	the	%	blood	clot	increased	in	all	
tested	 materials	 as	 well	 as	 in	 positive	 control.	 After	 90	 minutes	 the	 blood	 control	
demonstrated	82.9±3.3%	blood	clotting.	P(3HB)/oligo-PHA	composites	with	1	wt%,	3	
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wt%	 and	 5	 wt%	 of	 barium	 sulphate	 resulted	 with	 blood	 clotting	 rate:	 69.9±4.4%,	
65.7±5.7%	and	75.7±3.7%	respectively.	The	results	obtained	for	composites	with	1	wt%	
and	3	wt%	barium	sulphate	were	considered	as	significantly	lower	than	positive	control	
(*p=0.026	and	*p=0.036).	There	was	no	difference	between	TCP	and	composite	sample	
with	5%	BaSO4.	Addition	of	barium	sulphate	resulted	in	higher	blood	clot	rate	formation	
than	neat	blend.	However,	 the	results	obtained	were	 lower	 than	positive	control.	To	
summarise,	composites	of	P(3HB)/oligo-PHA	with	barium	sulphate	did	not	demonstrate	
increased	 risk	 of	 thrombogenicity	 and	 can	 be	 consider	 as	 a	 biomaterial	 for	medical	
applications,	such	as	coronary	stent.	
	
6.5.3.	Monocytes	and	neutrophils	activity	in	the	P(3HB)/oligo-PHAs	composites	
	
P(3HB)/oligo-PHAs	 composites	 with	 different	 amounts	 of	 barium	 sulphate	 were	
incubated	with	whole	blood	at	37°C	overnight	and	stained	with	the	markers	listed	in	the	
section	2.15.3.1.	Summary	of	the	results	obtained	in	the	Table	26.	
Table	26:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 incubated	 with	 P(3HB)/oligo-PHA	 blend	 90/10,	 P(3HB)/oligo-PHA	
composites	 with	 1%	wt,	 3%	wt	 and	 5%	wt	 barium	 sulphate	 and	 PL38;	 stained	 with	
specific	markers	in	order	to	evaluate	monocyte	and	neutrophil	activity. 
Sample	 Markers	
Monocytes		
Activity	
(MFI)	
Percentage	
change		
(%)	
Neutrophils		
Activity	
(MFI)	
Percentage	
change		
(%)	
P(3HB)/oligo-
PHAs	90/10	
blend	
	
CD86-PE	 217.4	 89.2	 162.6	 3.5	
CD45-
PerCP	
135.9	 24.2	 117.8	 0.17	
CD11b-
PE	
576.4	 324.1	 797.9	 466.2	
CD66B-
FITC	
311.97	 53.9	 175.1	 7.5	
P(3HB)/oligo-
PHAs	90/10	
composite	
CD86-PE	 151.5	 31.8	 117.6	 -	
CD45-
PerCP	
86.5	 -	 88.1	 -	
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with	1	wt%	
BaSO4	
	
CD11b-
PE	
769.7	 466.4	 955.2	 577.9	
CD66B-
FITC	
117.6	 -	 113.5	 -	
P(3HB)/oligo-
PHAs	90/10	
composite	
with	3	wt%	
BaSO4	
CD86-PE	 135.9	 18.3	 116.7	 -	
CD45-
PerCP	
82.1	 -	 86.8	 -	
CD11b-
PE	
991.2	 629.3	 1187.7	 742.9	
CD66B-
FITC	
105.6	 -	 175.1	 7.5	
P(3HB)/oligo-
PHAs	90/10	
composite	
with	5	wt%	
BaSO4	
CD86-PE	 126.4	 10.0	 136.9	 -	
CD45-
PerCP	
121.9	 11.4	 94.7	 -	
CD11b-
PE	
991.2	 629.3	 1027.5	 629.2	
CD66B-
FITC	
121.9	 -	 157.2	 -	
	
Results	obtained	after	staining	blood	samples,	which	were	exposed	to	various	polymer	
samples	demonstrated	different	levels	of	activity	of	monocytes	as	well	as	neutrophils.	
All	tested	samples	containing	BaSO4	presented	elevated	activity	in	the	marker	CD11b-
PE.		The	percentage	change	of	MFI	in	the	composites	increased	with	larger	amounts	of	
barium	sulphate.	The	MFI	values	were	between	466.4-629.3%	for	monocytes	and	577.9-
742.9%	for	neutrophils	in	comparison	to	control	and	almost	2-fold	higher	in	comparison	
to	P(3HB)/oligo-PHA	blend	without	barium	sulphate.	The	results	obtained	suggest,	that	
addition	of	barium	sulphate	cause	an	increased	activation	of	neutrophils	and	monocytes	
with	an	increase	of	the	concentration	of	barium	sulphate.	
6.6.	Discussion	
Barium	sulphate	usually	occurs	as	a	white	powder,	used	as	x-ray	positive	contrast	agent	
for	imaging	or	diagnostics	purposes.	BaSO4	cannot	be	metabolized	or	absorbed	in	the	
physiological	 conditions.	 It	 is	 excreted	 from	 the	 body	 in	 unchanged	 form	 (Widmark,	
2007).	Barium	sulphate	has	been	used	as	a	contrast	agent	in	biomedical	applications,	
such	 as	 bone	 cement	 (Lewis,	 1997),	 microdamage	 detection	 (Wang	 et	 al.,	 2007)	 or	
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gastrointestinal	radiography	(Skucas,	1989).	It	exhibits	high	x-ray	attenuation	and	good	
biocompatibility	(Leng	et	al.,	2008).	
Barium	sulphate	has	been	used	as	one	of	the	compounds	in	bone	cements	or	contrast	
oral	 tablets.	 However,	 it	 has	 been	 reported	 that	 presence	 of	 BaSO4	 can	 facilitate	
macrophage	 differentiation	 to	 osteoclasts,	 which	 contribute	 to	 bone	 resorption	 and	
loosening	of	prosthesis	and	implants	(Lewis	et	al.,	2005;	Sabokbar	et	al.,	1997).		
In	this	study,	an	addition	of	barium	sulphate	changed	the	properties	of	the	composite	
materials.	The	differences	are	more	evident	in	the	mechanical	properties	of	composites.	
As	expected	the	most	affected	factor	was	the	elongation	at	break.	Addition	of	BaSO4	
resulted	in	an	increase	of	the	brittle	nature	of	the	material.	Elongation	at	break	in	all	
composites	 with	 addition	 of	 barium	 sulphate	 was	 significantly	 lower	 than	 without.	
During	 storage	changes	 in	 the	 tensile	 strength	and	Young’s	Modulus	were	observed.	
Both	factors	increased	after	3	weeks	of	storage	and	then	decreased	after	that.	In	the	
material	 without	 addition	 of	 filler	 the	 Young’s	 Modulus	 increased	 after	 7	 weeks	 of	
storage.	Composite	 stiffness	and	strength	were	 improved	significantly	after	3	weeks.	
However,	after	7	weeks	of	storage,	the	improvement	was	much	less	prominent.	Minari	
et	al.,	2000	reported	that	addition	of	BaSO4	resulted	in	decrease	of	the	strength	on	the	
material.	 De	 Arenaza	 et	 al.,	 2015,	 demonstrated	 an	 enhancing	 effect	 of	 addition	 of	
barium	sulphate	on	the	mechanical	properties	of	materials,	such	as	polylactic	acid	(De	
Arenaza	et	al.,	2015).	However,	an	addition	of	barium	sulphate	could	lead	to	negative	
effects	to	the	materials,	such	as:	fatigue	crack	 initiation	 in	methacrylic	bone	cements	
(Ricker	et	al.,	2008).	Barium	sulphate	used	as	a	filler	is	expected	to	enhance	the	material	
properties,	such	as	mechanical	properties,	optical	characteristics	and	flow	behaviour,	
which	 allows	 BaSO4	 application	 in	 pigments,	 printing	 inks,	 glasses,	 polymers	 and	
medicine	(Van	Leuween,	1998).	Additionally, BaSO4	particles	can	be	modified	in	order	
to	 improve	 reaction	 with	 polymer.	 Wang	 and	 co-workers	 demonstrated	 enhanced	
reinforcement	 effect	 of	 BaSO4	 particles	 on	 natural	 rubber	when	modified	 by	 5	wt%	
stearic	 acid.	 Achieved	 tensile	 strength	 was	 14.4MPa	 and	 elongation	 at	 break	 516%,	
which	was	240%	and	172%	higher	in	comparison	to	non-modified	BaSO4	(Wang	et	al.,	
2011).	 In	 another	 study,	 Wang	 and	 co-workers	 demonstrated	 increased	 Young’s	
Modulus	values	with	an	increase	amount	of	filler.	High	content	of	BaSO4	had	negative	
effect	on	the	yield	stress	of	the	composite	materials	(Wang	et	al.,	2003).	Presence	of	
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barium	 sulphate	 particle	 can	 result	 with	 different	 material	 properties.	 Yan	 and	 co-
workers	 (2016)	 reported	 that	 composites	made	 from	 polytetrafluoroethylene	 (PTFE)	
granular	 powder	 containing	 barium	 sulphate	 (BaSO4)	 demonstrated	 tensile	 strength	
19.4MPa	and	elongation	at	break	420%	in	comparison	to	16.4-17.3MPa	and	260-370%	
strain	for	PTEE	non-granular	powder	(Yan	et	al.,	2016).		
An	addition	of	barium	sulphate	also	resulted	in	changes	of	the	surface	topography	of	
the	materials.	A	significant	increase	of	surface	roughness	was	observed.	Especially	in	the	
composite	with	5	wt%	of	BaSO4	the	value	of	mean	root	square	was	87%	higher	than	
P(3HB)/oligo-PHA	blend	without	addition	of	barium	sulphate.	For	some	medical	devices,	
like	 for	example	catheters,	an	 increased	roughness	of	 the	surfaces	can	be	a	negative	
factor	 (Baleani	and	Viceconti,	2011).	Addition	of	5	wt%	of	BaSO4	have	decreased	the	
contact	angle	values	around	33%	in	comparison	to	neat	blend.	This	can	be	explained	by	
the	 hydrophilic	 nature	 of	 the	 barium	 sulphate	 surface,	 which	 can	 be	 wetted	 easily,	
although	is	insoluble	in	water	(Bala	et	al.,	2006).	Also,	addition	of	barium	sulphate	had	
an	 impact	on	protein	adsorption.	The	amount	of	proteins	attached	to	 the	composite	
materials	was	significantly	higher	in	comparison	to	TCP	or	the	neat	blend.	The	amount	
of	absorbed	proteins	on	the	surface	of	composite	with	5	wt%	BaSO4	was	47%	higher	as	
compared	to	tissue	culture	plastic	and	19%	higher	than	neat	PHA	blend.	
The	amounts	of	radiopacifier	used	 in	different	materials	varies	between	7	wt%	to	60	
wt%.	 	 However,	 Dios	 and	 co-workers	 observed	 that	 an	 addition	 of	 BaSO4	 at	
concentration	 5	wt%	 to	 the	 floating	 drug	 delivery	 system	was	 sufficient	 to	 obtain	 a	
radiopacity	 (Dios	et	al.,	 2016).	All	 tested	 composite	materials	with	 concentrations	of	
barium	sulphate	(1-5	wt%)	resulted	in	successful	absorbability	by	X-ray,	the	intensity	of	
the	signal	increased	with	higher	amount	of	barium	sulphate.		
Addition	 of	 barium	 sulphate	 also	 resulted	 in	 a	 significant	 increase	 of	 cell	 viability	 of	
HMEC-1	after	day	3	and	7.	In	the	indirect	cytotoxicity	analysis,	the	cell	viability	results	
were	 similar	 to	 those	 obtained	 in	 cell	 viability	 studies.	 The	 highest	 cell	 viability	was	
obtained	in	case	of	3	wt%	concentration	of	barium	sulphate.	This	experiment	confirmed	
non-toxic	effect	on	 the	HMEC-1	 cells.	Moreover,	higher	amounts	of	barium	sulphate	
supported	growth	and	proliferation	of	endothelial	cells.	High	adhesion	of	the	HMEC-1	
cell	 line	 to	 all	 types	 of	 tested	 composites	 in	 comparison	 to	 the	 TCP	 indicated	 the	
possibility	of	application	as	a	platform	material	in	coronary	stent.	However,	considering	
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the	other	factors,	such	as	mechanical	properties	as	well	as	radiopacity,	5	wt%	addition	
of	BaSO4	might	be	most	reasonable	choice.		
In	 this	 study,	 presence	 of	 barium	 sulphate	 in	 the	 composites	 did	 not	 affect	 the	
haemocompatibility	of	the	tested	materials.	According	to	ISO	10993-4:2002	standard,	
all	 tested	 films	 had	 low	 potential	 to	 destroy	 red	 blood	 cells.	 All	 composites	 did	 not	
present	any	haemolytic	properties	or	enhanced	blood	clot	 formation.	However,	 they	
presented	much	higher	activation	of	neutrophils	and	monocytes	as	shown	by	the	marker	
CD11b.	Similarly,	Lazarus	et	al.,	1994	reported	an	increased	secretion	of	inflammatory	
mediators	due	the	presence	of	BaSO4	particles	in	the	periprosthetic	tissue	(Lazarus	et	
al.,	1994).		
The	results	obtained	in	this	project	confirmed	the	non-toxic	effect	of	barium	sulphate	
on	the	endothelial	cells.	The	differences	 in	the	material	properties	between	different	
concentrations	 of	 barium	 sulphate	 were	 minor.	 The	 main	 aim	 of	 this	 study	 was	 to	
develop	 radiopaque	 material,	 suitable	 for	 coronary	 stent	 application	 using	 barium	
sulphate	as	a	radiopacifier.	Hence,	 in	conclusion,	the	composite	with	5	wt%	of	BaSO4	
would	be	the	most	reasonable	choice	for	stent	application	because	of	its	strong	X-ray	
absorption	 and	 improved	 surface	 topography	 which	 resulted	 in	 enhanced	
biocompatibility	with	human	endothelial	cells.		
	
	
		
	
	
	
Chapter	7	
Poly(3-hydroxybutyrate)/	
oligo-PHAs	tubes	manufacturing	
	
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER	7	
	
	 200	
7. Introduction	
Polymeric	materials	 can	be	processed	by	using	different	 techniques.	Selection	of	 the	
suitable	manufacturing	technique	depends	on	the	material	properties	as	well	as	final	
application.	Many	 techniques	 have	 been	 applied	 to	 the	 synthetic	 polymers,	 such	 as	
phase	 separation,	 gas	 foaming,	 freeze	 drying,	 solvent	 casting,	 particulate	 leaching,	
thermal	processing,	moulding,	 rapid	prototyping	or	electrospinning	 (Kim	et	al.,	2012;	
Chung	and	King,	2011;	Dhandayuthapani	et	al.,	2011).		
Polyhydroxyalkanoates	 represent	 a	 group	 of	 natural	 polymers	 with	 broad	 range	 of	
material	 properties.	 They	 can	 be	 processed	 by	 using	 different	 techniques,	 such	 as	
electrospinning,	solvent	casting,	spin	casting,	melt	extrusion,	to	form	films,	fibres,	3D	
structures,	tubes	and	foams	(Thellen	et	al.,	2012).	Solvent	casting	has	been	widely	used	
to	 study	 initial	 properties	 of	 the	 materials.	 Some	 of	 the	 applications	 required	 flat	
scaffolds,	 therefore	 this	 technique	 can	 be	 applied	 directly.	 The	main	 benefit	 of	 the	
solvent	 casting	 technology	 is	 obtaining	 materials	 by	 unique	 drying	 of	 the	 polymer	
solution	without	 additional	mechanical	 or	 thermal	 treatment	 (Siemann	et	 al.,	 2005).	
Fabrication	of	3D	structures	is	much	more	complicated.	There	are	few	factors,	which	can	
be	considered	during	material	processing,	such	as	solvents,	quantities	of	the	material,	
stability	 of	 the	 solution,	 processing	 conditions.	 Coronary	 stent	 applications,	 require	
tubular	 structures.	 Melt	 extrusion	 is	 a	 well-known	 technique,	 commonly	 used	 to	
produce	 tubes.	 However,	 this	method	 has	 some	 limitations,	 such	 as	 requirement	 of	
substantial	 quantities	 of	 the	 material,	 a	 large	 amount	 of	 waste	 material,	 not	 very	
suitable	for	sticky	polymers	(LaFountaine	et	al.,	2016).		
Dip	moulding	 is	a	 technique,	widely	used	 for	manufacturing	3D	structures	or	coating	
already	made	articles.	It	required	small	quantities	of	material	and	is	a	simple	piece	of	
equipment.	 The	 process	 is	 also	 cheaper	 than	melt	 extrusion.	 Important	 parameters	
which	require	an	optimisation,	include	the	right	choice	of	the	solvents,	stability	of	the	
solution,	correct	 temperature	and	time	of	drying.	Processing	of	 the	single	polymer	 is	
much	easier	than	mixture	of	two	different	types	of	the	materials,	therefore	preparation	
of	 blends	 or	 composites	 is	 much	 more	 challenging	 by	 using	 this	 method	
(Parameswaranpillai	et	al.,	2014).		
The	main	aim	of	 this	part	of	 the	project	 is	 to	develop	P(3HB)/oligo-PHA	based	 tubes	
using	the	dip	moulding	technique	for	development	of	medical	devices,	such	as	coronary	
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artery	 stents.	 Based	 on	 the	 results	 obtained	 for	 solvent	 cast	 films,	 one	 of	 the	
P(3HB)/oligo-PHA	 blends	 in	 ratio	 90/10	was	 selected	 for	 tube	manufacturing.	 Three	
different	types	of	tubes	were	prepared:	neat	P(3HB)/oligo-PHA	neat	tube,	P(3HB)/oligo-
PHA	 tube	 coated	 with	 PCL-PEG550	 and	 P(3HB)/oligo-PHA	 composite	 tube	 with	 an	
addition	of	5	wt%	barium	sulphate.		The	tubes	were	fully	characterized	with	respect	to	
their	 thermal	 and	mechanical	 properties.	 In	 vitro	 biocompatibility	 of	 the	 tubes	 was	
tested	 with	 human	 dermal	 microvascular	 endothelial	 cells	 HMEC-1	 to	 evaluate	 the	
potential	 of	 new	biodegradable	material	 in	 an	 application	 as	 coronary	 artery	 stents.	
Haemocompatibility	studies	were	carried	out	in	order	to	study	the	impact	of	the	tubular	
structures	 on	 blood	 cells.	 Additionally,	 microCT	 scanning	 was	 performed	 to	 study	
radiopacity	of	the	composite	tube,	containing	barium	sulphate	as	a	contrast	agent.		
7.1.	P(3HB)/oligo-PHA	tube	manufacturing	by	dip	moulding	technique	
The	P(3HB)/oligo-PHA	blend	in	ratio	90/10	was	selected	for	tube	manufacturing	by	the	
dip	moulding	technique.	The	P(3HB)/oligo-PHA	blend	90/10	was	dissolved	in	a	mixture	
of	solvents,	such	as	chloroform	and	1,1,2,2-tetrachloroethane	in	ratio	70:30	wt/wt	at	
room	temperature.	The	polymer	solution	was	clear	and	stable	at	 room	temperature.	
Metallic	moulds	(needles)	with	2.54mm	diameter	and	78mm	length	were	coated	with	
polymer	solution	in	order	to	create	tubes	(Figure	69).	Tubes	were	made	and	dried	at	50	
°C.	The	process	parameters	 included:	20	cycles,	2s	dwelling	time	and	30s	drying	time	
between	the	cycles.	After	every	5	cycles,	extended	drying	time	up	to	3	minutes	was	used.	
Coated	needles	were	dried	at	50	°C	 for	24	hours,	measured	with	Vernier	caliper	and	
removed	from	the	needles	after	being	cooled	down	to	the	room	temperature.		
                  
Figure	 69:	 Production	 of	 PHA	 tubes	 (needle	 2.54mm	 diameter,	 78mm	 length)	 A-B	
prepared	by	using	dip	coating	technique.	
A) B) 
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7.2.	Tube	characterization		
Obtained	 tubes	 were	 characterised	 with	 respect	 to	 their	 thermal	 and	 mechanical	
properties	 after	 7	 weeks	 of	 storage.	 Additionally,	 In	 vitro	 degradation	 studies	 for	 6	
months	were	performed.		
7.2.1.	Tube	dimensions	
Coated	moulds	were	measured	using	the	Vernier	caliper	in	3	places	and	recorded	as	the	
outer	diameter.	The	outer	diameter	of	the	tubes	was	measured	as	2.7±0.01mm.	Hence,	
the	obtained	P(3HB)/oligo-PHA	tubes	had	wall	thickness	146±3.2	µm.		
	
7.2.2.	Tubes	characterisation	after	7	weeks	of	storage	at	room	temperature	and	
incubation	in	DMEM	media	at	37°	C	
	
Tubes	were	 stored	 for	 7	weeks	 at	 room	 temperature	 (Figure	 70A)	 in	 order	 to	 study	
ageing	of	the	material.		Some	of	the	tubes	were	incubated	in	the	DMEM	media	at	37°C	
(Figure	70B)	in	order	to	mimic	an	environment,	which	is	similar	to	the	human	body.	The	
influence	 of	 the	 hydrophilic	 environment	 and	 body	 temperature	 on	 the	mechanical	
properties	of	the	material	was	investigated.	
	
																																		 	
Figure	70:	Tubes	stored	for	7	weeks	at	room	temperature,	dry	(Figure	A)	and	in	DMEM	
media	incubated	at	37°C	(Figure	B).	
A) 	B) 
CHAPTER	7	
	
	 203	
7.2.2.1.	Thermal	properties	of	the	tubes	stored	for	7	weeks	at	room	
temperature	
Thermal	properties	of	the	tubes	were	studied	by	using	Differential	Scanning	Calorimetry	
as	described	in	the	section	2.6.4.	The	results	obtained	were	listed	in	the	Table	27.	The	
thermograms	from	the	first	heating	cycle	of	the	tubes,	studied	at	week	1,	3,	5	and	7	of	
storage	are	shown	in	the	Figure	71.		
	
Table	27:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	during	7	
weeks	 of	 storage.	 Tm=	 melting	 temperature,	 Tg=	 glass	 transition	 temperature,	 Tc=	
crystallisation	temperature,	DHf=enthalpy	of	fusion.	
Time	of	storage	
(week)	
Tg	(°C)	 Tm	(°C)	 ΔHf	(J/G)	 Tc	(°C)	
1	 1.1	 166.00	 83.3	 58.6	
3	 2.7	 167.6	 69.1	 56.9	
5	 3.4	 171.4	 70.2	 54.1	
7	 2.5	 172.6	 79.3	 60.4	
	
The	thermal	properties	of	the	tubes	had	changed	during	7	weeks	of	storage.	The	glass	
transition	 temperature	 increased	 from	1.1°C	 to	2.5°C	after	 7	weeks.	 Temperature	of	
melting	 increased	 from	 166°C	 to	 172.6°C.	 Similarly,	 cold-crystallisation	 temperature	
increased	from	58.6°C	to	60.4°C.	The	value	of	enthalpy	of	fusion	decreased	from	83.3	
J/g	 to	79.3	 J/g.	However,	 significant	decrease	was	observed	after	week	3	and	5.	The	
values	of	ΔHf	have	dropped	down	about	16%	in	comparison	to	week	1.		
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Figure	 71:	 DSC	 thermograms	of	 P(3HB)/oligo-PHA	 tubes	 stored	 for	 7	weeks	 at	 room	
temperature	illustrating	melting	peaks.	( )	week	1,	( )	week3,	( )	week	5	and	( )	week	
7.	
The	DSC	thermograms	represent	the	first	heating	cycle	during	DSC	analysis.	This	part	of	
the	 analysis	 is	 very	 important	 during	 ageing	 experiments,	 which	main	 aim	 to	 study	
changes	in	thermal	properties	within	a	selected	period	of	time.	In	this	cycle	only	melting	
events	were	present	in	all	tested	samples.	The	temperature	of	melting	increased	slightly	
within	7	weeks	of	storage.	All	melting	peaks	obtained	were	double	peaks,	characteristic	
for	P(3HB)	and	described	in	previous	chapters.		
7.2.2.2.	Mechanical	properties	of	the	tubes	stored	for	7	weeks	at	room	
temperature		
 
The	analysis	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	stored	at	room	
temperature	were	carried	out	 for	7	weeks,	 in	order	 to	 study	 the	material	properties	
during	ageing.	The	results	obtained	are	summarised	in	Table	28.		
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Table	28:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	during	
7	weeks	of	storage	at	room	temperature.	
Week		 Tensile	strength	
(MPa)	
Elongation	at	
break	(%	strain)	
Young’s	Modulus	
(MPa)	
	1	 15.7±2.8	
	
14.6±1.9	 510±17	
3	 18.5±1.8	 9.9±0.9	 1280±170	
5	 20.5±4	.6	 8.6±1.3	 1230±50	
7	 21.6±2.6	 6.5±1.2	 1270±40	
	
As	expected	after	7	weeks	of	ageing	at	room	temperature,	the	mechanical	properties	of	
the	P(3HB)/oligo-PHA	tubes	changed.	The	tensile	strength	increased	from	15.7±2.8	MPa	
at	week	1	to	21.6±2.6	MPa	at	week	7.	Similarly,	Young’s	modulus	values	increased	from	
0.5±0.01GPa	to	1.27±0.04GPa.	The	material	became	stronger	and	stiffer	with	the	time.	
Elongation	 at	 break	 decreased	 from	14.6±1.9%	 to	 6.5±1.2%,	which	 confirmed	brittle	
nature	of	the	material.	The	material	behaviour	of	the	tubes	followed	the	trend	observed	
in	the	flat	P(3HB)	based	blend	films,	described	in	details	in	the	Chapter	5,	section	5.2.1.2.		
7.2.2.3.	Mechanical	properties	of	the	tubes	after	incubation	in	DMEM	media	
at	37°	C	for	7	weeks	
In	order	to	check	the	effect	of	the	hydrophilic	environment	and	body	temperature	on	
the	mechanical	properties	of	the	material,	the	analysis	of	the	mechanical	properties	of	
the	tubes	incubated	in	DMEM	media	at	37°	C	were	carried	out	for	7	weeks.	The	summary	
of	the	mechanical	properties	of	the	tubes	stored	at	room	temperature	and	at	37°C	for	7	
weeks	were	demonstrated	in	Table	29	and	Figure	72.		
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Table	29:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	during	
7	weeks	of	storage	in	DMEM	media	at	37°	C	for	7	weeks.	
Week		 Tensile	strength	
(MPa)	
Elongation	at	
break	(%	strain)	
Young’s	Modulus	
(MPa)	
	1	 10.9±3.9	
	
8.4±0.9	 360±40	
3	 17.1±1.9	 7.3±1.1	 690±90	
5	 17.8±0.1	 6.2±0.1	 690±10	
7	 19.5±1.6	 3.9±0.4	 740±30	
	
After	7	weeks	of	incubation	in	DMEM	media	at	37°C,	the	mechanical	properties	of	the	
P(3HB)/oligo-PHA	tubes	had	changed.	The	tensile	strength	increased	from	10.9±3.9	MPa	
at	week	1	to	19.5±1.6	MPa	at	week	7.	Similarly,	Young’s	modulus	values	increased	from	
0.36±0.04	GPa	to	0.74±0.03	GPa.	Material	became	stronger	and	stiffer	with	the	time.	
Elongation	at	break	decreased	from	8.4±0.9%	strain	to	3.9±0.4	MPa	after	week	7,	which	
is	53%	lower	than	value	obtained	at	week	1.	The	results	obtained	confirmed	the	relative	
brittle	 nature	 of	 the	material.	Material	 behaviour	 of	 the	 tubes	 followed	 the	 general	
trend	observed	in	the	flat	P(3HB)	based	blend	films,	described	previously	in	Chapter	5.		
	
CHAPTER	7	
	
	 207	
	
Figure	 72:	 The	 changes	 of	 ultimate	 tensile	 strength	 (A),	 Young’s	 modulus	 (B)	 and	
elongation	at	break	 (C),	during	aging	of	neat	P(3HB)/oligo-PHA	tubes	stored	at	 room	
temperature	( )	and	incubated	in	DMEM	media	at	37°C	( )for	7	weeks.	
 
The	 results	 obtained	 clearly	 suggest	 that	 tubes	 underwent	 the	 same	 embrittlement	
phenomenon	as	the	flat	films.	However,	it	is	worth	to	notice	that	the	storage	conditions	
played	crucial	role	in	order	to	shape	the	final	material	properties.	From	the	Figure	72	it	
is	clear	that	tubes	incubated	at	37°C	demonstrated	significant	differences	in	the	stiffness	
and	elongation	of	the	material.	On	the	other	hand,	the	differences	between	values	of	
tensile	strength	were	not	that	high.	Tubes	incubated	at	37°C	exhibited	Young’s	Modulus	
values	60%	lower	than	tubes	stored	at	room	temperature.	Elongation	at	break	was	40%	
lower	after	7	weeks	of	incubation	at	37°C	in	comparison	to	the	tubes	stored	at	room	
temperature.	 Overall,	 tubes	 stored	 in	 the	 DMEM	 media	 and	 body	 temperature	
environment	 became	 more	 brittle	 as	 well	 as	 less	 stiff	 than	 tubes	 storage	 at	 room	
temperature.	Hence,	in	future	we	need	to	investigate,	which	of	the	factors:	hydrophilic	
CHAPTER	7	
	
	 208	
environment,	 presence	 of	 different	 organic	 compounds	 such	 as	 proteins	 or	 higher	
temperature	is	a	determinant	factor	to	cause	changes	to	the	material.		
7.2.3.	Scanning	Electron	Microscopy	of	the	P(3HB)/oligo-PHA	tubes			
Microstructural	 studies	 of	 P(3HB)/oligo-PHA	 tubes	 were	 performed	 using	 Scanning	
Electron	Microscopy.	The	surface	of	the	cross-intersection	demonstrated	that	material	
is	uniform	(Figure	73A).	Very	small	irregular	pores	are	present	in	the	wall	of	the	tube	as	
an	effect	of	the	increased	chloroform	evaporation	at	50°C	during	dip	moulding	process.	
Surface	of	the	tube	was	smooth	and	even.	Pores	are	not	visible	on	the	outer	surface	of	
the	 tube	 (Figure	73C).	SEM	 imaging	allowed	measuring	 the	wall	 thickness.	Presented	
tube	 on	 the	 Figure	 73D	 has	 wall	 thickness	 145.6	 ±	 0.5μm,	 which	 confirmed	 results	
obtained,	measured	by	caliper.	Wall	thickness	on	the	studied	tube	was	quite	uniform	
and	 homogenous	 (Figure	 73B).	 Therefore,	 the	 chosen	 processing	 conditions	 were	
appropriate	to	formulate	tubular	structures	using	the	dip	moulding	technique.		
	
Figure	73:	SEM	images	of	the	P(3HB)/oligo-PHA	tubes:	cross	section	(A),	wall	topography	
(B)	surface	of	the	tube	(C),	wall	thickness	(D),	
A) B) 
C) D) 
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7.3.	In	vitro	degradation	studies	
In	vitro	degradation	study	was	carried	out	for	period	of	6	months	at	37°C	in	phosphate	
buffered	saline	solution	(PBS),	at	pH=7.4	to	mimic	In	vivo	environment	and	to	investigate	
the	degradation	behaviour	of	the	P(3HB)/oligo-PHA	neat	tubes.		
	
7.3.1.	Attenuated	Total	Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
FTIR	was	carried	out	on	the	tubes	to	investigate	the	changes	in	the	chemical	structure	
during	the	incubation	time.	Figure	74	illustrates	the	ATR/FTIR	spectra	obtained	for	the	
tubes	after	month	1,	3	and	6	of	degradation	studies.		
	
Figure	 74:	 ATR-FTIR	 spectrum	 of	 the	 P(3HB)/oligo-PHA	 tubes	 during	 6	 months	 of	
degradation	study.	( )	month	1,	( )	month	3,	( )month	6.		
There	were	no	differences	between	the	spectra	obtained	after	month	1	and	6.	All	the	
chemical	bonds,	which	have	been	detected	are	typical	to	P(3HB)/oligo-PHA	blends,	such	
as	peak	at	1720.5	cm-1	and	1276.5	cm-1	corresponding	to	the	ester	carbonyl	group	and	
the	 -CH	 group,	 respectively	 (scl-PHA)	 and	 the	 weak	 absorption	 bands	 at	 2938cm-1,	
2991cm-1	and	2939	cm-1	assigned	to	the	aliphatic	C-H	group	of	the	pendant	alkyl	group	
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found	 in	 mcl-PHAs	 and	 the	 peak,	 observed	 at	 1182	 cm-1	 corresponded	 to	 the	 -CO	
stretching	group,	characteristic	of	mcl-PHAs.	The	intensity	of	the	signals	obtained	for	C-
H	and	–CO	bonds	for	mcl-PHA	decreased	within	6	months	time.		
7.3.2.	Thermal	properties	–	Differential	Scanning	Calorimetry	
DSC	analysis	was	carried	out	in	order	to	study	changes	in	the	thermal	properties	in	the	
material	 caused	 by	 tubes	 degradation.	 A	 summary	 of	 the	 results	 obtained	 has	 been	
listed	in	Table	30.	First	heating	cycle	thermograms	are	illustrated	in	the	Figure	75.	
Table	30:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	during	6	
months	 of	 degradation	 study.	 Tm=	 melting	 temperature,	 Tg=	 glass	 transition	
temperature,	Tc=	crystallisation	temperature,	DHf=enthalpy	of	fusion.	
	 Month	1	 Month	2	 Month	3	 Month	4	 Month	5	 Month	6	
Tg	(°C)	 -3.1	 -4.5	 -4.7	 1.1	 -0.4	 -2.7	
Tm	(°C)	 175.5	 173.4	 174.8	 175.6	 173.7	 172.7	
Tc	(°C)	 53.9	 51.5	 50.1	 59.1	 59.3	 51.3	
ΔHf	(J/g)	 72.2	 71.6	 78.7	 72.3	 78.6	 79.3	
	
During	6	months	of	degradation	study,	the	thermal	properties	of	the	materials	changed.	
Glass	 transition	 temperature	 slightly	 increased	 from	 -3.1°C	 at	 month	 1	 to	 -2.7°C	 at	
month	6.	Melting	temperature	decreased	from	175.5°C	to	172.7°C	after	month	1	and	6	
respectively.	Similarly,	the	cold-crystallisation	temperature	decreased.	The	enthalpy	of	
fusion	values	had	 increased	 from	72.2	 J/g	 to	79.2	 J/g.	Hence,	 there	was	a	 significant	
change	in	the	thermal	behaviour	of	the	tubes	from	month	4	to	6.		
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Figure	75:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	during	6	months	of	degradation	
study	(first	heating	cycle)	illustrating	melting	peaks.	The	thermal	properties	of	the	tubes	
after	1	month	( ),	3	months	( )		and	6	months	( ).		
 
The	DSC	thermograms	 in	the	Figure	75	presents	the	first	heating	cycle	of	 tubes	after	
months	1,	3	and	6	of	degradation.	During	degradation	studies	and	ageing	experiments	
results	obtained	in	the	first	cycle	are	very	important.	DSC	analysis	of	the	tubes	during	
degradation	 study	 demonstrated	 presence	 only	 melting	 events	 during	 first	 heating	
cycle.	There	was	slight	decrease	in	the	temperature	of	melting,	observed	between	tubes	
after	month	1	and	6.	Glass	transition	was	not	observed	in	the	first	cycle	at	any	measured	
time	point.		
7.3.3.	 pH	measurements	 of	 the	 PBS	 during	 degradation	 studies	 of	 neat	 PHA	
tubes	
PBS,	in	which	the	tubes	were	incubated	were	studied	in	order	to	monitor	any	changes	
in	the	pH.	The	results	obtained	were	presented	in	the	Figure	76.		
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Figure	76:	pH	changes	of	PBS	after	incubation	with	P(3HB)/oligo-PHA	tubes	for	6	months	
(n=3;	error	bars±SD),	no	significant	difference	in	comparison	to	month	1,	ANOVA.	
The	pH	of	PBS	was	7.4	at	the	beginning	of	the	study.	After	6	months	of	incubation	at	
37°C	 the	 final	pH	was	6.9±0.05.	The	 results	obtained	 in	 this	 study	suggest	 release	of	
slightly	acidic	product	during	the	degradation	process,	which	cause	a	decrease	 in	pH.	
However,	the	pH	changes	were	not	significant.	
	
7.3.4.	Weight	loss	(%)	of	the	neat	tubes	during	degradation	studies	
	
Percentage	of	weight	 loss	was	measured	at	month	1,	2,	3,	4,	5	and	6	of	degradation	
study	as	described	previously	in	the	section	2.16.3.	The	summary	of	the	results	has	been	
illustrated	in	Figure	77.		
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Figure	77:	Weight	loss	(%WL)	by	the	P(3HB)/oligo-PHA	tubes	during	a	period	of	6	months	
(n=3).	Results	were	compared	to	%	weight	loss	after	month	1	using	ANOVA.	*	indicates	
p<0.05,	**	indicates	p<0.005.	
The	results	obtained	suggest	a	gradual	increase	in	the	weight	loss,	observed	in	the	tubes	
during	degradation	study.	Initial	weight	loss	at	month	1	and	2	was	below	3%.	The	most	
rapid	weight	loss	was	observed	after	month	4	of	degradation	study.	After	6	months,	the	
obtained	weight	loss	of	the	tubes	was	21.6±0.8%.			
	
7.3.5.	Water	uptake	(%)	of	the	neat	tubes	during	degradation	studies	
	
Percentage	 of	 water	 uptake	 (%WU),	 which	 is	 an	 amount	 of	 water	 absorbed	 by	 the	
material	during	incubation	was	measured	at	month	1,	2,	3,	4,	5	and	6	of	degradation	
study	as	described	previously	in	the	section	2.16.3.	the	summary	of	the	results	has	been	
illustrated	in	the	Figure	78.	
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Figure	78:	Water	absorption	 (%WU)	by	 the	P(3HB)/oligo-PHA	tubes	 for	a	period	of	6	
months	(n=3).	Results	were	compared	to	%	water	uptake	after	month	1	using	ANOVA.	*	
indicates	p<0.05,	**	indicates	p<0.005.	
The	results	obtained	 illustrated	the	amount	of	absorbed	water	by	the	tubes	during	6	
months	of	degradation	study.	The	water	uptake	increased	steadily	from	month	1	to	6.	
The	 final	 WU	 value	 obtained	 in	 this	 study	 after	 month	 6	 was	 58.1±2.2%.	 the	 most	
significant	increase	was	between	month	1	and	2	of	incubation.	
	
7.3.6.	Surface	studies	of	the	degraded	tubes	
	
After	each	time	point	during	degradation	studies	tubes	were	rinsed	with	distilled	water,	
dried	and	 imaged	using	Scanning	Electron	Microscope	as	described	 in	section	2.16.2.	
SEM	analyses	of	the	surface,	cross	section,	wall	thickness	of	the	tubes	was	carried	out	
to	analyse	any	 structural	 changes	 that	occur	due	 to	degradation.	 SEM	 images	of	 the	
tubes	obtained	after	6	months	of	degradation	studies	are	presented	in	the	Figure	79.	
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Figure	 79:	 SEM	 micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	 after	 6	 months	 of	
degradation	study.	(A)	tube	cross	section,	(B,	C,	D)	outer	surface	of	the	tube,	(E)	wall	
microstructure,	(F)	wall	thickness.	
SEM	 images	 confirmed	 the	 degradation	 process	 on	 the	 tubes	 after	 6	 months.	
Degradation	proceed	on	the	surface	of	the	tubes	along	with	decreasing	wall	thickness,	
which	decreased	30%	as	compared	to	that	before	the	incubation	(Figure	79F).	This	affect	
tube	 stability	 (Figure	 79A).	 Tubes	 became	 very	 fragile	 and	 brittle.	 Fractures	 were	
observed	 on	 the	 surface	 of	 the	 tubes	 (Figure	 B-D).	 The	 walls	 exhibited	 enhanced	
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porosity,	which	was	much	higher	in	the	outer	surface	of	the	tube	(Figure	79E),	i.e.	the	
increased	porosity	began	from	the	outer	part	of	the	tube	and	progressed	towards	the	
core.	 Increased	porosity	allowed	higher	water	penetration	through	the	material	wall.	
The	internal	surface	did	not	show	any	changes	in	topography	of	the	tubes.	The	results	
obtained	 in	 this	 study	 suggest	 that	 P(3HB)/oligo-PHA	 tubes	 undergo	 degradation	
process	by	surface	erosion.		
7.4.	 Manufacturing	 of	 the	 P(3HB)/oligo-PHA	 90/10	 tubes	 coated	 with	 PCL-
PEG550	
P(3HB)/oligo-PHA	tube	were	coated	with	a	monolayer	of	PCL-PEG550	as	described	 in	
the	section	2.11.1.	and	characterised	in	order	to	investigate	the	influence	of	the	coating	
on	the	properties	of	the	tube.		
7.4.1.		Thermal	analysis	of	PCL-PEG550		
PCL-PEG550	is	a	synthetic	block	polymer.	The	DSC	thermograms	are	presented	in	the	
Figure	80.		
	
Figure	80:	DSC	thermogram	of	PCL-PEG550	neat	polymer.	( )	first	heating	cycle,	( )	
second	heating	cycle.	
For	PCL-PEG550	only	one	melting	event	was	present	in	both	heating	cycles.	The	glass	
transition	temperature	as	well	as	cold-crystallisation	temperature	for	PCL-PEG550	were	
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not	detected.	The	melting	temperature	of	the	PCL-PEG550	is	60.8°C,	which	is	higher	than	
mcl-PHAs	and	lower	than	scl-PHAs.	
7.4.2.		P(3HB)/oligo-PHA	90/10	tubes	coated	with	PCL-PEG550	manufacturing		
	
Mandrels	with	a	 layer	of	P(3HB)/oligo-PHA	were	coated	with	PCL-PEG550	monolayer	
and	left	to	dry	at	room	temperature.	The	resulting	tubes	were	measured	with	a	caliper	
in	3	places	and	recorded	as	the	outer	diameter.	The	difference	between	outer	diameter	
of	the	mould	was	calculated	as	wall	thickness.	The	difference	between	outer	diameter	
of	neat	tube	and	coated	tube	was	used	to	obtain	the	thickness	of	the	coating.		
Obtained	tube	had	wall	thickness	187±3.1	µm.	the	size	of	the	PCL-PEG550	monolayer	
was	calculated	as	36±2.3	µm.		
7.4.3.	 Characterisation	 of	 P(3HB)/oligo-PHA	 tubes	 coated	with	monolayer	 of	
PCL-PEG550		
P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 were	 chemically	 characterised	 by	
using	FTIR.	Mechanical	and	thermal	properties	were	studied	during	7	weeks	of	storage	
at	room	temperature.	Microstructural	analysis	was	performed	using	Scanning	Electron	
Microscopy.		
7.4.3.1.	Attenuated	Total	Reflectance	Fourier	Transform	Infrared	Spectroscopy	
(ATR/FT-IR)	
	
ATR/FTIR	spectrum	of	coated	P(3HB)/oligo-PHA	tube	was	different	in	comparison	to	the	
neat	P(3HB)/oligo-PHA	tube	(Figure	81).	Chemical	bonds	from	PCL	and	PEG	were	present	
in	addition	to	PHAs,	described	previously	in	Chapter	5.	There	was	an	adsorption	peak	at	
2947cm-1	 and	 2872cm-1,	 which	 corresponded	 to	 the	 asymmetric	 stretching	 -CH2	 and	
symmetric	-CH2	respectively.	These	bonds	were	more	intense	in	the	coated	tubes,	which	
confirmed	the	presence	of	another	polymer,	such	as	PCL-PEG550.	The	carbonyl	bond	at	
1721cm-1	 is	 slightly	 shifted	 in	 comparison	 to	 the	 neat	 tube,	 due	 to	 the	 presence	 of	
additional	polymer.	Asymmetric	C-O-C-	stretching	bond	was	present	at	1239.8cm-1	and	
symmetric	-C-O-stretching	at	1166.8cm-1.	Additionally,	the	ether	bond	was	present	at	
CHAPTER	7	
	
	 218	
1045cm-1,	and	-C-H	bending	bond	at	1366.1	cm-1,	typical	for	the	PEG	part	of	the	coated	
layer.	
	
Figure	81:	ATR/FTIR	spectra	of	neat	P(3HB)/oligo-PHA	90/10	tube	( )	and	P(3HB)/oligo-
PHA	90/10	tube	coated	with	PCL-PEG550	( ).	
The	obtained	ATR/FTIR	spectra	of	the	tubes	confirmed	presence	of	the	PCL-PEG550	
unit	on	the	surface	of	the	tube	due	to	the	absorbance	observed	at	1045cm-1,	1366.1	
cm-1.	
7.4.3.2.	Thermal	properties	of	the	PCL-PEG550	coated	PHA	tube	
 
DSC	analysis	of	the	PCL-PEG550	coated	PHA	tube	was	carried	out	in	order	to	study	the	
thermal	 behaviour	 of	 the	 coated	 tube	 after	 week	 1	 and	 7	 of	 storage	 at	 room	
temperature.	The	summary	of	the	data	is	listed	in	the	Table	31.	The	DSC	thermograms	
from	first	heating	cycle	are	presented	in	the	Figure	82.		
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Table	31:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	with	
PCL-PEG550	 after	 1	 and	 7	 weeks	 of	 storage.	 Tm=	 melting	 temperature,	 Tg=	 glass	
transition	temperature,	Tc=	crystallisation	temperature,	DHf=enthalpy	of	fusion.	
Time	of	storage	
(week)	
Tg	(°C)	 Tm	(°C)	 ΔHf	(J/G)	 Tc	(°C)	
1	 1.1	
166.0	
64.0	
83.3	
2.6	
58.6	
7	 2.7	
167.6	
61.3	
69.1	
5.5	
56.9	
	
DSC	analysis	also	confirmed	the	presence	of	PCL-PEG550	compound	by	exhibiting	a	small	
melting	event	around	60°C,	which	is	melting	temperature	of	PCL-PEG550,	described	in	
section	7.4.1.	 	Two	melting	events	suggested	that	coated	tube	 is	a	separated	system	
with	the	bulk	polymer	being	the	P(3HB)/oligo-PHA	blend	and	PCL-PEG550	as	a	coating.	
There	was	only	one	glass	transition	temperature	detected.	After	7	weeks	of	storage	the	
glass	transition	temperature	as	well	as	melting	temperature	related	to	P(3HB)	increased.	
Temperature	of	melting	of	PCL-PEG550	decreased	from	64°C	at	week	1	to	61.3°C	at	week	
7.		On	the	other	hand,	the	cold-crystallisation	temperature	as	well	as	enthalpy	of	fusion	
presented	an	opposite	trend.	The	largest	change	for	ΔHf	values,	were	after	week	7,	the	
enthalpy	 of	 the	 PHAs	 decreased	 about	 17%	 in	 comparison	 to	 week	 1	 and	 enthalpy	
related	to	PCL-PEG550	increased	twice	in	comparison	to	week	1.		
	
Figure	82:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550	after	
1	( )	and	7	( )	weeks	of	storage	(first	heating	cycle)	indicating	melting	peaks.	
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The	first	heating	cycles	presented	in	the	Figure	82	showed	two	different	melting	events,	
related	to	two	different	compounds	in	the	tested	tube:	PHA-based	core	of	the	tube	and	
PCL-PEG550	coating,	which	forms	a	monolayer	on	the	outer	surface	of	the	tube.		
7.4.3.3.	Mechanical	properties	of	the	PCL-PEG550	coated	PHA	tube	
The	analysis	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	with	
PCL-PEG550	stored	at	room	temperature	were	carried	out	for	week	1	and	7,	in	order	to	
check	 the	properties	during	material	ageing.	The	results	obtained	are	summarised	 in	
Figure	83	and	Table	32.	
Table	32:	Summary	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	
with	PCL-PEG550	after	1	and	7	weeks	of	storage	(n=3).	
Week		 Tensile	strength	
(MPa)	
Elongation	at	
break	(%	strain)	
Young’s	Modulus	
(GPa)	
	1	 16.7±1.5	 9.3±1.3	 										0.7±0.1	
7	 29.2±1.0	 7.9±0.6	 1.4±0.1	
	
After	 7	 weeks	 of	 ageing	 at	 room	 temperature,	 the	 mechanical	 properties	 of	 the	
P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 had	 changed.	 The	 tensile	 strength	
increased	 significantly	 from	 16.7±1.5	 MPa	 at	 week	 1	 to	 29.2±1.0	 MPa	 at	 week	 7.	
Similarly,	Young’s	modulus	values	increased	from	0.7±0.1	GPa	to	1.4±0.1	GPa.	Material	
became	stronger	and	stiffer	with	the	time.	The	elongation	at	break	decreased	slightly	
from	9.3±1.2%	strain	to	7.9±0.6%.		
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Figure	83:	The	summary	of	(A)	the	ultimate	tensile	strength,	(B)	Young’s	modulus	and	
(C)	elongation	at	break	(C)	during	storage	of	neat	P(3HB)/oligo-PHA	neat	tubes	and	tubes	
with	 monolayer	 of	 PCL-PEG550	 for	 7	 weeks.	 ( )	 P(3HB)/oligo-PHA	 tube	 with	 PCL-
PEG550	coating,	( )	P(3HB)/oligo-PHA	neat	tube.		
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The	tubes	coated	with	PCL-PEG550	presented	slightly	different	mechanical	properties	in	
comparison	 to	 neat	 P(3HB)/oligo-PHA	 tubes.	 Initially,	 tensile	 strength	 values	 were	
similar.	However,	after	7	weeks	of	storage	the	PCL-PEG550	coated	tube	had	30%	higher	
tensile	 strength	 than	 neat	 P(3HB)/oligo-PHA	 tube.	 Coated	 tube	 had	 a	 slightly	 higher	
Young’s	Modulus.	At	first,	the	initial	elongation	at	break	of	the	coated	tube	is	30%	lower	
than	 the	 neat	 tube.	 However,	 after	 7	 weeks	 of	 storage	 PCL-PEG550	 coated	 tube	
demonstrated	stronger,	stiffer	and	more	elastomeric	properties	 in	comparison	to	the	
neat	tube.		
7.4.3.4.	SEM	
Microstructural	 studies	 of	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 were	
performed	 using	 Scanning	 Electron	 Microscopy.	 The	 surface	 of	 the	 tube	 cross-
intersection	(Figure	84A)	demonstrated	that	the	obtained	tube	had	uniform	structure.	
Presence	of	the	coating,	which	covered	surface	of	the	tube	was	confirmed.	The	thickness	
of	the	coating	evaluated	by	SEM	was	35.9±0.2	μm	(Figure	84B).	The	surface	of	the	tube	
is	smooth	and	even	as	presented	on	the	Figure	84C.	Pores	are	not	visible	from	the	outer	
surface	of	the	tube	(Figure	84D)	confirming	that	the	tube	was	well	formed.	Therefore,	
the	chosen	processing	conditions	were	appropriate	to	formulate	tubular	structures	by	
using	 the	 dip	 moulding	 technique	 coated	 with	 a	 monolayer	 of	 PCL-PEG550	 by	 dip	
coating.		
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Figure	84:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	a	monolayer	of	PCL-
PEG550:	(A)	cross-section,	(B)	tube	wall	with	coating	thickness	measurement,	(C)	inner	
surface	of	the	tube,	(D)	tube	outer	surface.	
7.5.	Manufacturing	 of	 P(3HB)/oligo-PHA	 composite	 tubes	with	 addition	 of	 5	
wt%	barium	sulphate	and	their	characterization	
The	composite	tube	manufacturing	was	performed	as	described	in	the	section	2.11.2.	
The	coated	mandrels	were	measured	using	a	caliper	at	3	places	and	recorded	as	outer	
diameter.	 The	 difference	 between	 outer	 diameter	 of	 the	 size	 of	 the	 mould	 was	
calculated	as	wall	thickness.	Obtained	P(3HB)/oligo-PHA	composite	tubes	containing	5	
wt%	BaSO4	had	wall	thickness	170±2.2	µm.	
A) B) 
C) D) 
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7.5.1.	Thermal	properties	
DSC	analysis	 of	 the	 composite	 tubes	were	 carried	out	 in	 order	 to	 study	 the	 thermal	
behaviour	of	the	coated	tube	after	week	1	and	7	of	storage	at	room	temperature.	The	
summary	of	the	data	is	listed	in	the	Table	33.	The	DSC	thermograms	from	first	heating	
cycle	after	week	1	and	7	are	presented	in	the	Figure	85.		
	
Table	33:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	composite	tubes	
with	5	wt%	barium	sulphate	after	1	and	7	weeks	of	storage.	Tm=	melting	temperature,	
Tg=	 glass	 transition	 temperature,	 Tc=	 crystallisation	 temperature,	 DHf=enthalpy	 of	
fusion.	
Time	of	storage	
(week)	
Tg	(°C)	 Tm	(°C)	 ΔHf	(J/G)	 Tc	(°C)	
1	 -1.7	 173.8	 79.1	 53.4	
7	 -4.7	 173.6	 71.7	 49.9	
	
DSC	analysis	confirmed	changes	in	the	thermal	behaviour	of	the	material.	After	7	weeks	
of	storage	the	glass	transition	temperature	has	decreased.	The	temperature	of	melting	
remained	stable	within	the	period	of	7	weeks.		The	cold-crystallisation	temperature	as	
well	 as	 the	 enthalpy	 of	 fusion	 presented	 similar	 trend.	 The	 largest	 changes	 were	
observed	 for	 the	 ΔHf	 values,	 where	 after	 week	 7,	 enthalpy	 of	 the	 composite	 tube	
decreased	by	about	10%	in	comparison	to	week	1.	The	Tc	value	decreased	from	53.4°C	
to	49.9°C.	
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Figure	 85:	 DSC	 thermograms	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	 with	 5	 wt%	
barium	sulphate	after	1	week	( )		and	7	weeks	( )	of	storage	illustrating	melting	peaks.	
 
The	first	heating	cycles	are	presented	in	the	Figure	85,	which	showed	only	melting	event,	
related	to	the	tested	composite	tubes.	The	temperature	of	the	melting	remained	the	
same	after	7	weeks	of	storage.	
7.5.2.	Mechanical	properties	
	
The	 analysis	 of	 the	mechanical	 properties	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	
stored	at	room	temperature	were	carried	out	for	7	weeks,	in	order	to	check	the	material	
properties	during	material	ageing.	The	results	obtained	are	summarised	in	Table	34.	
Table	34:	 Summary	of	 the	mechanical	properties	of	 the	P(3HB)/oligo-PHA	composite	
tubes	with	5	wt%	barium	sulphate	after	1	and	7	weeks	of	storage	(n=3).	
Week		 Tensile	strength	
(MPa)	
Elongation	at	
break	(%	strain)	
Young’s	Modulus	
(GPa)	
	1	 18.9±0.6	 7.9±1.2	 									1.2±0.1	
7	 20.7±1.4	 2.9±0.2	 1.4±0.1	
	
	
CHAPTER	7	
	
	 226	
After	 7	 weeks	 of	 ageing	 at	 room	 temperature,	 the	 mechanical	 properties	 of	 the	
P(3HB)/oligo-PHA	 tubes	had	 changed.	 The	 tensile	 strength	 increased	 from	18.9±0.56	
MPa	 at	 week	 1	 to	 20.7±1.4	 MPa	 at	 week	 7.	 Similarly,	 the	 Young’s	 modulus	 values	
increased	from	1.2±0.1	GPa	to	1.4±0.1	GPa.	The	material	became	stronger	and	stiffer	
with	the	time.	The	elongation	at	break	drastically	decreased	from	7.89±1.24%	strain	to	
2.9±0.2	MPa,	which	confirmed	the	brittleness	of	the	material.	Material	behaviour	of	the	
composite	tubes	observed	during	7	weeks	of	storage	at	room	temperature,	followed	the	
trend	observed	in	the	flat	P(3HB)	based	composite	films,	described	in	details	in	Chapter	
6.		
7.5.3.	SEM	
Microstructural	studies	of	P(3HB)/oligo-PHA	composite	tubes	with	5%	wt	BaSO4	were	
performed	using	Scanning	Electron	Microscopy.	The	surface	of	the	cross	section	of	the	
tube	 demonstrated	 that	 tubular	 structure	 of	 the	 stent	 was	 uniform	 (Figure	 86A).	
Porosity	of	the	material	was	not	visible	from	the	outer	surface	of	the	tube	as	well	as	
within	 the	 tube	 wall	 (Figure	 86B-D).	 The	 surface	 of	 the	 tube	 was	 even	 with	 some	
irregularities	due	to	the	presence	of	BaSO4	particles	(Figure	86D).	The	chosen	processing	
conditions	were	appropriate	to	formulate	tubular	composite	structures	by	using	the	dip	
moulding	technique.		
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Figure	 86:	 SEM	 micrographs	 of	 the	 P(3HB)/oligo-PHA	 composite	 tubes	 with	 5	 wt%	
barium	sulphate:	(A)	tube	cross-section,	(B)	wall	thickness,	(C)	wall	microstructure,	(D)	
tube	outer	surface.	
7.5.4.	MicroCT	
The	 composite	 tube	 was	 subjected	 to	 a	 microCT	 scan	 to	 observe	 barium	 sulphate	
particles,	which	has	the	characteristic	of	high	X-ray	attenuation	(Figure	87).	
	
	
	
	
	
	
A
)
B) 
C) D) 
A) 
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Figure	 87:	MicroCT	micrographs	 demonstrated	 x-ray	 absorption	 by	 barium	 sulphate,	
presented	in	the	P(3HB)/oligo-PHA	composite	tubes,	containing	5	wt%	BaSO4.	
From	the	micrographs	presented	in	the	Figure	87	it	is	evident	that	the	barium	sulphate	
was	distributed	uniformly	within	the	polymeric	matrix.	The	results	obtained	confirmed	
radiopacity	 of	 the	 composite	 tubes	 and	 possibility	 of	 using	 the	 composite	 for	 the	
application	in	the	development	of	coronary	stent	prototypes.		
7.6.	In	vitro	biocompatibility	studies	of	the	range	of	manufactured	PHA	tubes	
Neat	P(3HB)/oligo-PHA	tubes,	coated	tubes	and	composite	tubes	were	characterised	in	
order	to	evaluate	their	functionality	as	platform	materials	for	biomedical	applications.		
	
7.6.1.	Protein	adsorption	study	
Bicinchoninic	 acid	 assay	 was	 used	 to	 evaluate	 the	 affinity	 of	 the	 materials	 towards	
proteins	as	described	in	section	2.11.3.9.		It	was	found	that	total	protein	adsorption	was	
180.2±4.5,	225.6±5.6	and	170.7±7.1	µg/cm2	for	the	neat	P(3HB)/oligo-PHA	neat	tube,	
PCL-PEG550	 coated	 tube	 and	 P(3HB)/oligo-PHA	 composite	 tube	 with	 5	 wt%	 barium	
sulphate	respectively.	All	tested	materials	demonstrated	higher	protein	adsorption	than	
TCP.	However,	the	results	were	significant	only	for	tube	coated	with	monolayer	of	PCL-
PEG550	(*p=0.019).	There	was	no	significant	difference	between	tissue	control	plastic	
and	neat	P(3HB)/oligo-PHA	tube	or	PHA	based	composite	tube	with	5%	wt	BaSO4	(Figure	
88).			
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Figure	88:	Protein	adsorption	to	the	neat	P(3HB)/oligo-PHA,	coated	with	PCL-PEG550	
and	 composite	 tubes	measured	 by	 BCA	 assay	 (n=3;	 error	 bars=±SD).	 The	 data	were	
compared	with	standard	tissue	culture	plastic	using	ANOVA.	*	indicates	p<	0.05.	
P(3HB)/oligo-PHA	tubes	with	coating	layer	of	PCL-PEG550	adsorbed	significantly	higher	
concentration	of	proteins	on	the	surface	in	comparison	with	TCP	(positive	control).	The	
amount	of	proteins	adsorbed	to	the	TCP	was	137.5±7.8	µg/cm2.		
7.6.2.	MTT	assay	
	
The	MTT	assay	was	used	to	evaluate	cell	adhesion	and	proliferation.	Attachment	and	
proliferation	of	HMEC-1	cells	on	the	tube	samples	were	studied	over	a	period	of	1,	3	
and	7	days.	The	standard	tissue	culture	 plastic	was	 used	as	 the	positive	control	 for	
these	experiments.	The	 results	 of	biocompatibility	studies	are	presented	in	Figure	89	
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Figure	89:	Cell	proliferation	study	of	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	neat	tubes,	
coated	with	monolayer	of	PCL-PEG550	and	composite	tubes	with	5	wt%	barium	sulphate	
tube	samples	on	day	1	 ( ),	day	3	 ( )	and	7	 ( )	 (n=3;	error	bars=±SD).	The	data	were	
compared	with	 standard	 tissue	 culture	 plastic	 using	 ANOVA.	 *	 indicates	 p<	 0.05,	 **	
indicates	p<0.005	and	***	indicates	p<0.0005.	
Cell	proliferation	on	the	surface	of	neat	P(3HB)/oligo-PHA	tubes	was	similar	to	TCP	at	
day	1,	but	lower	at	day	3	and	day	7.	The	observed	cell	viability	on	the	tube	samples	was	
98.7.6±7.6%	at	day	1,	86.7±6.0%	at	day	3	and	88.2±2.0%	at	day	7	as	compared	to	the	
TCP.	The	differences	were	statistically	significant	for	results	from	day	3	and	7	(*p=0.014	
and	 *p=0.017	 respectively).	 The	 growth	 of	 the	HMEC-1	 cells	 on	 the	 surface	 of	 PCL-
PEG550	coated	tube	was	80.0±5.2%	at	day	1	and	79.4±4.5%	and	77.5±2.0%	at	day	3	and	
7	respectively.	The	differences	were	statistically	significant	for	day	3	and	7	(*p=0.013,	
*p=0.011)	 in	 comparison	 to	 TCP.	 On	 the	 other	 hand,	 HMEC-1	 cell	 viability	 on	 the	
composite	tubes	with	5	wt%	BaSO4	was	slightly	lower	on	day	1	(87.7±3.5.0%)	and	higher	
on	 day	 3	 and	 7	 in	 relation	 to	 TCP:	 140.5±6.5%	 and	 189.9±4.9%	 respectively.	 The	
differences	were	statistically	significant	in	comparison	to	TCP	at	day	3	(**p=0.0082)	and	
day	7	(***p=0.0001).		
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The	 results	 obtained	 demonstrated	 higher	 biocompatibility	 of	 the	 P(3HB)/oligo-PHA	
composite	 tube	 with	 5	 wt%	 BaSO4	 in	 comparison	 to	 TCP,	 whereas	 the	 neat	
P(3HB)/oligo-PHA	tube	and	PCL-PEG550	coated	tube	exhibited	lower	cell	attachment	
on	the	surface.	The	highest	cell	adhesion	was	observed	for	P(3HB)/oligo-PHA	composite	
tube	with	5	wt%	BaSO4	within	7	days.	The	higher	adhesion	of	the	HMEC-1	cell	line	to	
the	composite	tube	in	comparison	to	the	TCP	indicated	the	possibility	of	application	as	
a	platform	material	in	coronary	stent	application.		
7.6.3.	Indirect	cytotoxicity	study	
	
Indirect	cytotoxicity	test	was	performed	using	MTT	assay	to	investigate	the	influence	of	
any	leachable	substances	released	from	neat	P(3HB)/oligo-PHA	tube,	P(3HB)/oligo-PHA	
tube	with	PCL-PEG550	coating	and	P(3HB)/oligo-PHA	tube	with	5%	BaSO4	into	DMEM	
media	 on	 the	 HMEC-1	 cell	 line.	 Cells	 without	 an	 extract	 were	 used	 as	 the	 negative	
control.	 70%	 methanol	 instead	 of	 media	 or	 extract	 was	 used	 as	 a	 positive	 control.		
Results	obtained	were	summarised	in	the	Figure	90.	
 
	
Figure	90:	Indirect	cytotoxicity	study	of	the	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	neat	
tubes,	coated	with	monolayer	of	PCL-PEG550	and	P(3HB)/oligo-PHA	composite	tubes	
with	 5	 wt%	 barium	 sulphate	 tube	 samples	 on	 day	 1	 ( )	 and	 day	 3	 ( )	 (n=3;	 error	
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bars=±SD).	The	data	were	compared	with	standard	tissue	culture	plastic	using	ANOVA.	
*	indicates	p<	0.05,	**	indicates	p<0.005	and	***	indicates	p<0.0005.	
Cell	proliferation	on	the	neat	P(3HB)/oligo-PHA	tube	extract	was	106.0±3.5%	at	day	1	
and	91.4±4.4%	at	day	3	 compared	 to	 the	TCP.	The	differences	were	not	 statistically	
significant.	 The	 growth	 of	 HMEC-1	 cells	 treated	 with	 an	 extract	 from	 the	 neat	
P(3HB)/oligo-PHA	tube	was	similar	on	day	1	and	3	to	TCP.	The	growth	of	the	HMEC-1	
cells	 with	 extract	 from	 PCL-PEG550	 coated	 tube	 was	 higher	 than	 TCP	 on	 day	 1	
(113.9±4.3).	The	difference	was	statistically	significant	(*p=0.035).	HMEC-1	cell	viability	
in	the	extract	from	P(3HB)/oligo-PHA	composite	tube	with	5	wt%	BaSO4	was	also	higher	
on	day	1	and	3	in	relation	to	TCP:	108.06±4.8%	and	109.1±6.0%.	The	difference	was	not	
significant	in	comparison	to	TCP.	The	highest	viability	of	the	HMEC-1	cells	was	achieved	
after	treatment	with	an	extract	from	coated	tubes	in	comparison	to	TCP	after	1	day	of	
incubation.	 The	 results	 obtained	 confirmed	 an	 absence	 of	 any	 cytotoxic	 substances	
released	from	the	composite.	All	tested	extracts	supported	the	cells	attachment	and	
proliferation	similar	to	the	standard	tissue	culture	plastic.	Therefore,	PHAs	based	tubes	
can	be	considered	as	potential	materials	for	biomedical	applications,	such	as	coronary	
stent	prototype	production.		
7.6.4.	SEM	
	
Cell	adhesion	and	proliferation	was	further	characterised	using	SEM	microscopy.	SEM	
images	presented	in	Figure	91	revealed	that	HMEC-1	cells	adhered	and	proliferated	
on	the	surface	of	the	tubes.	Cell	density	was	much	higher	for	composite	tube	with	an	
addition	of	5	wt%	of	barium	sulphate.	All	PHA-based	materials	supported	HMEC-1	cell	
attachment	and	proliferation	demonstrating	good	biocompatibility.	Addition	of	barium	
sulphate	 improved	 cell	 proliferation	 with	 the	 highest	 cell	 viability	 was	 achieved	 for	
composite	tube.	
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Figure	91:	SEM	images	of	the	surfaces	of	P(3HB)/oligo-PHA	neat	tubes	(A),	PCL-PEG550	
coated	 tubes	 (B)	 and	 P(3HB)/oligo-PHA	 composite	 tubes	with	 5	wt%	BaSO4	 (C)	 after	
culturing	HMEC-1	cells	for	7	days.	
With	respect	to	the	results	obtained,	all	tested	materials	based	on	P(3HB)/oligo-PHAs	
supported	the	growth	of	HMEC-1	cell	 line.	However,	the	addition	of	barium	sulphate	
resulted	 in	much	higher	cell	attachment	after	7	days	of	 incubation.	Presence	of	PCL-
PEG550	in	the	coating	did	not	have	any	negative	impact	on	the	biocompatibility	of	the	
tested	materials	to	the	endothelial	cell	line.		
	
	
	
	
B) 
A) 
C) ) 
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7.7.	In	vitro	haemocompatibility	studies	
P(3HB)/oligo-PHA	 neat	 tubes,	 PCL-PEG550	 coated	 tubes	 and	 P(3HB)/oligo-PHA	
composite	 tubes	 with	 5	 wt%	 barium	 sulphate	 blends	 were	 subjected	 to	
haemocompatibility	studies,	which	includes	haemolysis	studies,	whole	blood	clotting	as	
well	as	monocytes	and	neutrophils	activation.		
7.7.1.	Haemolysis	study	
	
Haemolysis	 study	was	performed	on	PHAs	based	 tubular	 structures	 to	 investigate	an	
effect	of	the	materials	on	the	erythrocytes	after	direct	contact	with	fresh	whole	blood.	
The	analysis	was	performed	as	described	in	the	section	2.15.1.	The	results	obtained	are	
shown	at	the	Figure	92.		
	
Figure	92:	Haemolysis	rates	of	the	P(3HB)/oligo-PHA	neat	tubes,	tubes	coated	with	PCL-
PEG550	and	composite	tube	with	barium	sulphate	after	1h	of	incubation	at	37°C	(n=3).	
Results	were	compared	to	TCP	using	ANOVA.	No	significant	difference.		
All	tested	types	of	tubes	presented	non-haemolytic	effect	on	erythrocytes.	A	percent	
haemolysis	of	1.3%,	3.9%	and	2.3%	was	obtained	for	the	neat	tube,	coated	tube	and	
composite	 tube	 respectively.	 The	 results	 were	 not	 significant	 in	 comparison	 to	 TCP.	
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According	to	ISO	10993-4:2002	standard,	all	tested	tubes	demonstrated	low	potential	
to	destroy	red	blood	cells.	
7.7.2.	Whole	blood	clotting	
	
Whole	 blood	 clotting	 experiment	 was	 performed	 to	 investigate	 the	 potential	
thrombogenicity	of	the	different	types	of	tubes	as	described	previously	in	the	section	
2.15.2.	The	summary	of	the	results	obtained	after	30	and	90	minutes	are	shown	in	Figure	
93.		
	
Figure	93:	Whole	blood	clotting	after	30	minutes	( )	and	90	minutes	( )	of	incubation	
on	the	neat	P(3HB)/oligo-PHA	tubes,	coated	with	PCL-PEG550	and	composite	tubes	with	
5	 wt%	 barium	 sulphate.	 sulphate	 and	 PL38	 (n=3;	 error	 bars=±SD).	 The	 data	 were	
compared	with	standard	tissue	culture	plastic	using	ANOVA.	**indicates	p<	0.005	and	
***	indicates	p<0.0005.		
The	 results	 obtained	 indicate	 that	 P(3HB)/oligo-PHA	 neat	 tube	 and	 the	 PCL-PEG550	
coated	 tube	 enhanced	 the	 activation	 of	 the	 coagulation	 cascade,	 whereas,	 the	
composite	tube	containing	BaSO4	did	not	demonstrate	similar	effect.	After	30	minutes	
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of	incubation,	neat	PHA	tube	demonstrated	17.0±1.6%	blood	clotting.	Addition	of	PCL-
PEG550	 as	 a	 coating	 resulted	 in	 increased	 %	 blood	 clotting	 after	 30	 minutes	 to	
29.9±3.1%.	P(3HB)/oligo-PHA	composite	tube	with	5	wt%	barium	sulphate	exhibited	a	
blood	clotting	rate	of	4.5±0.2%	after	30	minutes.	With	the	increase	of	time,	the	%	blood	
clot	increased	in	all	tested	materials	as	well	as	in	the	control.	After	90	minutes	the	blood	
control	demonstrated	82.9±3.3%	blood	clotting.	P(3HB)/oligo-PHA	neat	tube	resulted	in	
slight	increase	in	the	blood	clotting	rate	up	to	84±5.7%.		PCL-PEG	coated	tube	presented	
decreased	blood	clotting	rate	(47.9±2.2%)	in	comparison	to	the	control	(82.9±3.3%).	The	
result	was	significant	(***p=0.0006).	The	results	obtained	for	the	composite	tubes	were	
considered	as	significantly	 lower	than	the	positive	control	(***p=0.0001).	Addition	of	
barium	sulphate	resulted	in	much	lower	blood	clotting	than	neat	P(3HB)/oligo-PHA	tube	
or	PCL-PEG550	coated	 tube.	To	 summarise,	all	 tested	materials	did	not	demonstrate	
increased	 risk	 of	 thrombogenicity	 and	 can	 be	 consider	 as	 a	 biomaterial	 for	medical	
applications,	such	as	coronary	stent.	
7.7.3.	Monocytes	and	neutrophils	activation	
	
Three	different	 types	of	 tubes:	 neat	 P(3HB)/oligo-PHA,	 PCL-PEG550	 coated	 tube	 and	
P(3HB)/oligo-PHA	composite	tube	with	5%	wt	BaSO4	were	incubated	with	whole	blood	
at	37°C	overnight	and	stained	with	the	markers	listed	in	the	section	2.15.3.1.	Summary	
of	the	results	obtained	was	demonstrated	in	Table	35.		
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Table	35:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 with	 P(3HB)/oligo-PHA	 90/10	 neat	 tube,	 P(3HB)/oligo-PHA	 90/10	
tube	 coated	with	PCL-PEG550,	P(3HB)/oligo-PHA	composite	 tube	with	5%	wt	barium	
sulphate	and	PL38;	and	stained	with	specific	markers	in	order	to	evaluate	monocyte	and	
neutrophil	activity. 
Sample	 Markers	
Monocytes	
Activity	
(MFI)	
Percentage	
change	(%)	
Neutrophils	
Activity	
(MFI)	
Percentage	
change	(%)	
P(3HB)/oligo-
PHA	90/10	
tube	
	
CD86-PE	 181.5	 57.9	 162.6	 3.5	
CD45-
PerCP	
225.4	 106.0	 121.9	 3.6	
CD11b-PE	 536.8	 294.9	 666.1	 372.7	
CD66B-
FITC	
188.2	 -	 279.9	 71.9	
P(3HB)/oligo-
PHA	90/10	
tube	coated	
with	PCL-
PEG550	
	
CD86-PE	 209.7	 82.5	 175.3	 11.6	
CD45-
PerCP	
135.9	 0.0	 76.3	 -	
CD11b-PE	 498.9	 267.1	 586.8	 316.5	
CD66B-
FITC	
168.8	 -	 279.8	
	
71.8	
P(3HB)/oligo-
PHA	90/10	
composite	
tube	with	5%	
BaSO4	
CD86-PE	 140.9	 22.6	 116.7	 -	
CD45-
PerCP	
94.7	 -	 86.8	 -	
CD11b-PE	 857.7	 531.1	 991.2	 603.5	
CD66B-
FITC	
105.6	 -	 117.6	 -	
	
Results	obtained	after	staining	blood	samples,	which	were	exposed	to	various	types	of	
tubes	demonstrated	different	levels	of	activity	of	monocytes	as	well	as	neutrophils.	All	
tested	samples	presented	higher	activity	of	the	activation	marker	CD11b-PE.		However,	
the	level	of	activity	was	lower	than	in	the	samples	activated	by	addition	of	LPS	(Chapter	
5,	 Table	 21).	 Among	 three	 types	 of	 tubes,	 P(3HB)/oligo-PHA	 tube	 coated	 with	 PCL-
PEG550	demonstrated	the	lowest	values	of	CD11b	marker:	267.1%	for	monocytes	and	
316.5%	for	neutrophils	activity	higher	than	control.	The	percentage	change	of	MFI	for	
P(3HB)/oligo-PHA	 tube	 was	 294.9%	 for	 monocytes	 and	 372.7%	 for	 monocytes	 and	
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neutrophils	 respectively	 in	comparison	 to	control.	 	P(3HB)/oligo-PHA	composite	 tube	
with	5	wt%	BaSO4	demonstrated	percentage	change	531.1%	for	monocytes	and	603.5%	
for	neutrophils	activation	marker	CD11b	in	comparison	to	control.	The	results	obtained	
further	confirmed,	that	addition	of	barium	sulphate	causes	an	increased	activation	of	
neutrophils	 and	monocytes,	which	was	 indicated	previously	 in	Chapter	6.	 It	 is	worth	
mentioning,	 that	 percentage	 change	 of	 MFI	 of	 composite	 tube	 was	 lower	 than	 flat	
composite	films	described	previously	in	the	Chapter	6.		
7.8.	Discussion	
In	this	study	three	types	of	tubes	were	prepared	using	the	dip	moulding	technique,	such	
as	neat	P(3HB)/oligo-PHA	tube	in	the	ratio	90/10,	P(3HB)/oligo-PHA	tube	coated	PCL-
PEG550	and	 composite	 tube,	prepared	by	addition	of	 5	wt%	barium	 sulphate	 to	 the	
P(3HB)/oligo-PHA	blend.	The	tubes	were	characterised	in	order	to	obtain	thermal	and	
mechanical	properties,	topography	studies	as	well	as	biocompatibility.	The	tubes	were	
subjected	to	ageing	for	7	weeks	in	order	to	obtain	final	material	properties.		
Storage	of	 fabricated	 tubes	 for	7	weeks	at	 room	 temperature	 resulted	 in	 changes	 in	
thermal	and	mechanical	properties	of	neat	P(3HB)/oligo-PHA	tubes.	After	7	weeks	of	
storage,	neat	tubes	stored	at	room	temperature	demonstrated	an	increase	in	the	glass	
transition	temperature,	cold-crystallisation	and	melting	temperature	within	the	time	of	
storage.	Tensile	strength	and	Young’s	Modulus	values	increased,	whereas	elongation	at	
break	decreased,	as	expected.	Material	behaviour	during	storage	time	is	closely	related	
to	 material	 ageing.	 Changes	 in	 the	 properties	 of	 P(3HB)	 and	 its	 copolymers	 during	
storage	time	at	room	temperature	has	been	already	recognised.	Elongation	at	break	is	
the	main	parameter,	which	change	within	the	time	of	storage	and	is	a	measurement	of	
material	 increased	brittleness.	 The	main	process,	which	 causes	P(3HB)	ageing	during	
storage	at	room	temperature	is	called	post-crystallisation	(Wen	et	al.,	2011;	Hong	et	al.,	
2011).	All	three	parameters,	which	determine	mechanical	properties	for	the	tubes	were	
similar	to	those	obtained	for	the	flat	films,	except	the	tensile	strength,	which	was	25%	
lower	 for	 the	 films	 in	 comparison	 to	 the	 tubes.	 This	might	 be	 explained	by	 applying	
completely	 different	 conditions	 during	 tube	 preparation,	 such	 as	 presence	 of	 an	
additional	 solvent	 (1,1,2,2-tetrachloroethane)	 and	 temperature	 of	 50°C	 during	 dip	
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coating	and	drying	time.	While	solvent	cast	films	were	prepared	by	dissolving	PHAs	in	
chloroform	only	at	room	temperature.	Dip	coating	allows	partial	solvents	evaporation	
from	each	 layer	 after	 each	dipping	 cycle,	whereas	 in	 solvent	 cast	 technique,	 solvent	
evaporation	rate	is	lower	and	chloroform	gradually	evaporates	from	the	surface	of	the	
polymer	 solution	 until	 thin	 film	 remains.	 	 It	 has	 been	 reported	 previously,	 that	
processing	technique	has	great	impact	on	the	material	properties	(Renstadt	et	al.,	1998).	
Interestingly,	 the	changes	 in	the	mechanical	properties	of	the	tubes	 incubated	 in	the	
DMEM	media	at	37°C	for	the	period	of	7	weeks	resulted	in	much	lower	values	for	all	
measured	 parameters	 in	 comparison	 to	 the	 tubes	 stored	 dry	 at	 room	 temperature.	
Tubes	 in	 DMEM	 medium	 became	 more	 brittle	 and	 less	 stiff	 in	 comparison	 to	 the	
materials	storage	at	room	temperature.	Results	obtained	were	 in	an	agreement	with	
literature,	that	temperature	and	hydrophilic	environment	has	a	crucial	 impact	on	the	
mechanical	properties	of	the	material	(Lyu	and	Untereker,	2009).	Coronary	stents	will	
be	placed	inside	the	artery	and	constantly	surrounded	by	blood	in	body,	hence	material	
properties	 obtained	 after	 incubation	 of	 tubes	 in	 DMEM	media	 at	 37°C	 can	 help	 to	
predict	the	material	behaviour	inside	the	human	body.		
Biodegradability	 of	 polyhydroxyalkanoates	 depends	 not	 only	 on	 their	 own	 material	
properties,	such	as	crystallinity,	presence	of	functional	groups,	but	also	on	the	surface	
area	 and	 the	 conditions	 in	 the	 surrounding	 environment,	 such	 as	 pH,	 temperature,	
moisture,	 presence	 of	 nutrients	 or	microbial	 activity	 (Sudesh	et	 al.,	 2000;	Doi	et	 al.,	
1989).	Highly	crystalline	materials	require	longer	time	to	degrade	in	comparison	to	semi-
crystalline	 or	 amorphous	materials	 (Miller	et	 al.,	 1977).	 Hydrolysis	 preferably	 occurs	
around	the	chain	ends,	which	are	usually	placed	in	the	amorphous	part	of	the	polymer	
(Yavuz	et	al.,	2002).	When	amorphous	regions	are	degraded,	hydrolytic	attack	progress	
within	crystalline	domains,	 leading	to	their	degradation.	Molecules	 in	the	amorphous	
regions	are	loosely	packed	and	more	susceptible	towards	reacting	species	or	solvents	
than	in	crystalline	region	(Yavuz	et	al.,	2002).	Also,	molecular	weight	seems	to	be	a	very	
important	 factor.	 It	 was	 found,	 that	 PHAs	 with	 low	 molecular	 weight	 are	 more	
susceptible	degradation.	The	thermal	properties	of	the	materials	have	an	influence	on	
the	 degradation	 rate.	 Generally,	 with	 an	 increase	 of	 melting	 temperature,	 the	
biodegradability	of	 the	material	decrease	 (Philip	et	al.,	2007).	Anjum	and	co-workers	
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reported	 that	 PHAs	 can	 degrade	 in	 aquatic	 environments	 within	 254	 days	 at	
temperature	below	60◦C	(Anjum	et	al.,	2016).	
In	general,	polymer	degradation	takes	place	mostly	through	scission	of	the	main	chains	
or	 the	 side-chains	of	 the	polymer	 structure.	 It	 can	be	 induced	by	 thermal	activation,	
photolysis,	 oxidation,	 radiolysis	 or	 hydrolysis	 (Doi	 and	 Fukuda,	 1994;	Benicewicz	 and	
Hopper,	1991).	The	degradation	process	via	hydrolysis	can	occur	with	or	without	the	
presence	 of	 enzymes;	 it	 can	 be	 catalysed	 by	 the	 presence	 of	 acid	 or	 base	 in	 the	
environment	(Rydz	et	al.,	2015;	Ikada	and	Tsuji,	2000).	Different	factors	can	trigger	the	
degradation	 process,	 like	 for	 example	 temperature.	 Therefore,	 one	 of	 the	 very	
important	 aspects	 to	 consider	 are	 processing	 conditions	 and	 chosen	 fabrication	
techniques.	 For	 example,	 melt	 extrusion	 and	 injection	 moulding	 require	 high	
temperature	and	 shear	 rate,	which	might	 lead	 to	 certain	 level	of	degradation	of	 the	
material.	 Injection	moulding	causes	partial	orientation,	usually	higher	 in	 the	external	
layer,	than	the	core	of	the	mould.	This	can	trigger	faster	degradation	of	the	material	in	
the	core	of	the	mould	rather	than	from	the	outer	layer.	Also,	various	additives,	such	as	
plasticizers,	stabilizers,	lubricants,	antioxidants,	salts	might	either	enhance	or	decelerate	
degradation	rate	of	the	materials	(Azevedo	and	Reis,	2004;	Yoshie	et	al.,	2000).	In	this	
study,	In	vitro	degradation	studies	demonstrated	high	percentage	of	water	adsorption	
and	 accelerated	weight	 loss	 after	 3	months	 of	 incubation.	Minor	 changes	 in	 the	 pH	
during	the	degradation	suggested	absence	of	the	highly	acidic	products	released	during	
polymer	degradation.	 It	 is	a	well-known	that	the	degradation	products	released	from	
synthetic	 polymers,	 such	 as	 PLLA	 are	 highly	 acidic,	 which	 can	 trigger	 an	 elevated	
immunogenic	 response	 in	 the	 body	 (Mani	 et	 al.,	 2007;	 Liu	 et	 al.,	 2006).	 Hydrolytic	
degradation	of	PHAs	is	a	slow	process,	which	can	take	up	to	several	months	(Marois	et	
al.,	 2000;	 Doi	 et	 al.,	 1990).	 Addition	 of	 polymers	 or	 plasticizers	 can	 increase	 the	
degradation	 rate	 of	 P(3HB).	 Addition	 of	 hydrophilic	 as	 well	 as	 amorphous	materials	
enlarge	water	adsorption	which	speeds	up	hydrolysis	(Freier	et	al.,	2002).	The	influence	
of	addition	of	PLA	and	PEG	to	PHAs	on	degradation	was	studied.	PLA	and	PEG	enhanced	
the	degradation	rate	only	in	PHBV,	without	any	effect	on	the	degradation	of	P(3HO)	due	
to	incompatibility	of	the	system	(Renart	et	al.,	2004).	In	this	study,	an	addition	of	oligo-
PHA	 accelerated	 the	 degradation	 rate	 of	 the	 PHA	 tubes.	 It	was	 already	 observed	by	
Zhang	and	co-workers,	that	addition	of	amorphous	polymers	or	plasticizers	can	lead	to	
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advanced	degradation	(Zhang	et	al.,	1996).	The	blend	of	P(3HB)	with	the	oligomer	of	
P(3HHx-3HO-3HD-3HDD)	 was	 a	 compatible	 system	 and	 plasticising	 effect	 occurred.	
Hence,	this	could	accelerate	degradation.	It	is	worth	mentioning,	that	PHA-based	tubes,	
studied	in	this	project	degraded	by	surface	erosion,	which	is	a	typical	property	of	PHAs.	
In	this	study,	an	increased	porosity	was	observed	in	the	external	layer	of	the	tube.	This	
can	 support	 the	 statement	mentioned	above.	Another	 reason	 for	enhanced	porosity	
might	 be	 possible	 migration	 of	 oligo-PHA	 form	 the	 polymeric	 matrix.	 Plasticiser	
migration	 is	 one	 of	 the	 most	 important	 problems	 associated	 with	 this	 process	
(Papakonstantinou	and	Papaspyrides,	1994).	Plasticisers	do	not	bond	to	the	polymeric	
chains.	They	penetrate	the	polymeric	matric,	increase	free	volume,	keep	near	chains	in	
the	distance	and	allow	increased	movement	of	polymer	chains	(Reinecke	et	al.,	2011).		
In	this	study,	after	3	months	of	degradation	studies,	tubes	became	fragile,	brittle	and	
very	difficult	to	handle	without	damaging	the	structure.	
In	the	second	part	of	study	P(3HB)/oligo-PHA	tubes	were	coated	by	a	monolayer	of	PCL-
PEG550.	FTIR	analysis	have	proven	the	presence	of	chemical	bonds	typical	to	PCL	and	
PEG	within	the	tube.	Thermal	analysis	of	the	coated	tubes	demonstrated	the	presence	
of	the	PCL-PEG	by	the	appearance	of	an	additional	melting	event,	observed	around	60°C,	
which	is	a	melting	temperature	of	PCL	(Sui	et	al.,	2015).	DSC	analysis	of	the	coated	tubes	
demonstrated	presence	 two	different	melting	points,	which	suggest	presence	of	 two	
different	types	of	polymers,	which	are	not	miscible	with	each	other.	One	peak	belongs	
to	PCL-PEG550	at	60°C	and	second	peak	at	167	°C	is	characteristic	for	P(3HB)/oligo-PHA	
blend	(Chapter	5,	Figure	41).	Storage	of	the	coated	tubes	resulted	in	changes	in	thermal	
and	mechanical	properties.	The	glass	transition	temperature	increased,	whereas,	cold-
crystallisation	 temperature	 and	 enthalpy	 of	 fusion,	 related	 to	 PHAs	 decreased.	 This	
behaviour	was	 similar	 to	 the	 neat	 tube.	With	 respect	 to	 the	mechanical	 properties,	
tensile	strength	of	the	material	as	well	as	stiffness	have	improved	significantly.	Initially,	
the	elongation	at	break	of	the	coated	tube	was	lower	than	the	neat	tube	and	decreased	
slightly	 within	 7	 weeks.	 The	 presence	 of	 PCL-PEG550	 has	 a	 positive	 impact	 on	 the	
mechanical	properties	of	the	tube,	such	as	strength,	stiffness	and	ductility,	which	makes	
this	material	very	attractive	for	coronary	stent	application.	Presence	of	synthetic	coating	
(PCL-PEG550)	reduced	the	deteriorating	effect	of	material	ageing	on	the	elongation	at	
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break	of	the	tubes.	Elongation	at	break	decreased	only	16%	in	the	PCL-PEG550	coated	
tubes	in	comparison	to	66%	reduction	in	case	of	the	neat	P(3HB)/oligo-PHA	tubes.		
The	 third	 type	 of	 tubes	 was	 prepared	 from	 P(3HB)/oligo-PHA	 90/10	 blend	 with	 an	
addition	 of	 5	 wt%	 barium	 sulphate.	 Within	 7	 weeks	 of	 storage	 the	 glass	 transition	
temperature,	enthalpy	of	fusion	and	cold-crystallisation	temperature	decreased.	There	
was	no	impact	on	melting	temperature	within	7	weeks	of	storage.	Addition	of	barium	
sulphate	 drastically	 influenced	 the	 elongation	 at	 break.	 The	 composite	 tube	became	
very	brittle	after	7	weeks	of	storage.	However,	the	material	became	much	stronger	and	
stiffer	after	week	7	in	comparison	to	week	1.	Addition	of	barium	sulphate	also	had	an	
impact	 on	 the	 topography	 and	 structure	 of	 the	 tubes.	 SEM	micrographs	 confirmed	
complete	absence	of	porosity	within	the	tube	wall	structure.	This	can	be	explained	by	
the	 fact,	 that	BaSO4	particles	could	act	as	 fillers	of	potential	 spaces	within	polymeric	
matrix.	The	surface	of	the	tube	was	rougher	due	to	the	presence	of	the	BaSO4	particles	
in	 comparison	 to	 the	 neat	 P(3HB)/oligo-PHA	 tube.	 This	 is	with	 agreement	with	 data	
obtained	earlier,	where	the	solvent	cast	film	composites	with	an	addition	of	5%	wt	BaSO4	
resulted	in	significant	increase	of	surface	roughness	(Chapter	6,	Figure	59).	Additionally,	
presence	of	barium	sulphate	lead	in	obtaining	intense	signals	by	high	x-ray	absorption,	
which	confirmed	the	radiopacity	of	the	tube.			
Protein	adsorption	studies	revealed	higher	protein	attachment	to	all	types	of	studied	
tubes	in	comparison	to	TCP.	Protein	adsorption	is	a	first	step	in	the	integration	between	
implanted	 material	 and	 tissue	 (Horbett,	 2004).	 However,	 the	 differences	 were	
significant	only	for	the	PCL-PEG550	coated	tube	in	comparison	to	standard	tissue	culture	
plastic.	This	might	be	explained	by	 the	wettability	of	 the	material.	PCL-PEG550	has	a	
contact	angle	of	around	61°,	whereas	PHAs	have	usually	much	higher	values	of	contact	
angle.	The	biocompatibility	study	resulted	in	much	higher	cell	viability	obtained	for	the	
composite	tube	in	comparison	to	TCP	and	other	tubes	tested.	Neat	and	coated	tube	had	
relatively	lower	cell	viability.	This	can	be	explained	by	different	surface	topography	of	
the	tube.	Neat	tube	and	coated	tube	had	very	smooth	and	even	surface,	which	might	
affect	 cell	 attachment.	 Presence	 of	 particles,	 allow	 obtaining	 rougher	 and	 enlarge	
surface	area,	which	creates	attachment	points	for	cells	 (Hao	and	Lawrence,	2004).	 It	
will	 be	 worth	 to	 investigate	 further	 an	 influence	 of	 barium	 ions	 on	 the	 functional	
behaviour	of	 the	endothelial	 cells.	 SEM	 images	 confirmed	 results	obtained	 from	 the	
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MTT	assay.	SEM	micrographs	clearly	demonstrated	increased	cell	density	on	the	tubes	
with	an	addition	of	barium	sulphate	in	comparison	to	neat	P(3HB)/oligo-PHA	tube	and	
PHA	 tube	coated	with	PCL-PEG550.	Obtained	 results	 suggest,	 that	 surface	 roughness	
was	 a	 crucial	 factor	 required	 for	 high	endothelial	 cell	 attachment.	 Considering	other	
factors,	important	for	cell	attachment	and	proliferation,	such	as	protein	adsorption	or	
wettability	of	the	material,	endothelial	cells	should	drive	more	towards	P(3HB)/oligo-
PHA	tube	coated	with	PCL-PEG550.	Material	stiffness	is	another	factor,	recently	gaining	
much	attention	in	correlation	to	cell	attachment	(Gu	et	al.,	2012).	However,	in	this	study	
there	was	no	difference	between	Young’s	Modulus	values	between	composite	and	PCL-
PEG550	coated	tube.	
Biodegradable	 polymers	 always	 release	 low	 molecular	 weight	 compounds	 into	 the	
surrounding	environment	as	a	result	of	degradation.	Those	foreign	compounds	might	
enter	the	cell	or	interact	with	the	surface,	leading	to	abnormal	functionality	(Ikada	and	
Tsuji,	2000).	Indirect	cytotoxicity	study	confirmed	non-toxic	effect	of	an	extract	released	
from	 the	 materials	 incubated	 in	 the	 media.	 Moreover,	 PCL-PEG550	 coated	 tube	
demonstrated	higher	cell	viability	after	day	1	as	compared	to	TCP.		
All	type	of	tested	tubes	did	not	have	any	haemolytic	effect	towards	red	blood	cells.	Neat	
P(3HB)/oligo-PHA	 tube	 demonstrated	 blood	 clotting	 rate	 similar	 to	 the	 control.	 PCL-
PEG550	 coated	 tube	 and	 the	 composite	 tube	 resulted	 in	 decelerated	 blood	 clot	
formation.	This	can	be	explained	by	the	presence	of	poly	(ethylene	glycol)	unit,	which	is	
a	well-known	anti-coagulant	due	to	presence	of	an	ether	oxygen	within	the	monomer	
units,	 which	 hinder	 proteins	 adsorption	 (Meyers	 and	 Grinstaff,	 2012).	 	 Moreover,	
barium	 ions	 seem	 to	 block	 an	 activation	 of	 the	 coagulation	 cascade,	 probably	 by	
displacement	of	Ca	ions,	which	are	required	to	trigger	blood	clotting	process.	All	tested	
tubes	demonstrated	elevated	monocytes	and	neutrophils	activity.	However,	the	values	
were	lower	than	that	obtained	for	the	solvent	cast	flat	films.	The	highest	activity	was	
obtained	for	the	composite	tube,	due	to	presence	of	barium	sulphate,	which	is	a	well-
known	trigger	for	white	cell	activation	(Lazarus	et	al.,	1994).	The	3D	tubular	structure	of	
studied	PHA	constructs	did	not	have	any	detrimental	effect	on	the	blood	cells.		
The	 results	 obtained	 confirmed	high	 biocompatibility	 of	 the	 P(3HB)/oligo-PHA	based	
tubes	 to	HMEC-1	cells.	Therefore,	all	 the	 tubes	 tested	can	be	suitable	candidates	 for	
coronary	stent	application.	The	composite	P(3HB)/oligo-PHA	tube	with	barium	sulphate	
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presented	 an	 additional	 advantage	 over	 the	 neat	 P(3HB)/oligo-PHA	 and	 PCL-PEG550	
coated	 P(3HB)/oligo-PHA	 tube,	 such	 as	 presence	 of	 radiopacity	 and	 higher	
biocompatibility.		
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8. Introduction	
Drug	eluting	stents	(DES)	were	discovered	as	a	second	generation	of	stent,	to	overcome	
the	limitations	accompanied	to	bare	metallic	stents,	such	as	restenosis.	The	drug	was	
released	locally	rather	than	in	a	systemic	manner.	DES	usually	contain	three	parts:	stent,	
coating	and	bioactive	agent	(Ako	et	al.,	2007).	Initially,	the	results	obtained	from	clinical	
trials	 were	 very	 promising.	 However,	 the	 long-term	 side	 effects	 appeared,	 such	 as	
thrombosis,	 which	 can	 lead	 to	 sudden	 death	 (Windecker	 and	 Meier,	 2007).	 As	 a	
polymeric	matrix,	non-biodegradable,	biodegradable	and	biological	polymers	have	been	
studied	 (Puskas	 et	 al.,	 2009).	 Four	 classes	 of	 drugs,	 such	 as:	 anti-inflammatory,	
antiproliferative,	 antithrombogenic	 and	 immunosuppressive	 have	 been	 taken	 into	
consideration	for	DES	(Grube	et	al.,	2002).	Several	different	drugs	have	been	tested	so	
far.	The	most	common	are	the	immunosuppressive	drugs,	which	belongs	to	the	“limus”	
family,	such	as:	sirolimus,	everolimus,	tacrolimus,	zotarolimus,	biolimus	A9,	as	well	as	
actinomycin	D,	dexamethasone	or	paclitaxel	(Khan	et	al.,	2012).,	described	previously	in	
the	 section	 1.5.	 Many	 research	 groups	 have	 been	 focusing	 on	 the	 development	 of	
appropriate	drug	delivery	 systems,	 to	allow	controlled	drug	delivery	of	 the	bioactive	
agent.	 Rapamycin,	 also	 referred	 as	 sirolimus	 is	 a	macrocyclic	 antibiotic	 produced	 by	
natural	fermentation	which	exhibits	potential	immunosuppressive	properties.	It	has	the	
ability	to	block	several	phases	 in	the	development	of	the	restenosis	cascade	(van	der	
Hoeven	 et	 al.,	 2005).	 Tacrolimus	 is	 an	 immunosuppressive	 agent,	 which	 has	 less	
inhibitory	 effect	on	 the	 cells	 attachment	 and	migration	 in	 comparison	 to	 rapamycin,	
therefore	can	be	considered	as	promising	agent	to	be	use	in	coronary	stents	(Matter	et	
al.,	2006).	Although	first	DES	were	based	on	metals,	a	lot	of	attention	was	put	towards	
bioresorbable	materials,	such	as	biodegradable	polymers	or	corrodible	metals.	None	of	
the	 materials	 have	 met	 all	 specific	 requirements,	 such	 as	 high	 biocompatibility,	
appropriate	mechanical	properties,	degradation	kinetics	and	inflammation.	There	is	still	
high	demand	for	the	development	of	novel	materials	(Ramcharitar	and	Serruys,	2008).	
Polyhydroxyalkanoates	 are	 biopolyesters,	 which	 were	 not	 studied	 extensively	 in	
coronary	 stents,	 but	 have	 been	 studied	 as	 drug	 delivery	 vehicles.	 They	 are	 very	
promising	 materials	 for	 drug	 delivery	 systems	 due	 to	 proven	 biodegradability,	 non-
toxicity	 and	 biocompatibility	 (Williams	 and	 Martin,	 2005).	 Mainly	 P(3HB)	 and	 its	
copolymers,	such	as:	P(3HB-co-3HV)	and	P(3HB-co-4HB)	were	explored	for	drug	delivery	
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applications.	 Microspheres,	 nanoparticles,	 rods,	 discs,	 biodegradable	 implants,	 films	
with	 different	 drugs,	 such	 as:	 gentamycin,	 aspirin,	 cefoperazone,	 doxorubicin,	
tetracycline	 and	 ampicillin	 have	 been	 developed	 (Nigmatullin	 et	 al.,	 2015).	
P(3HB)/P(3HO)	blends	were	proposed	as	a	matrix	for	drug	carrier	in	DES	(Basnett	et	al.,	
2013).	
Both	 drugs,	 rapamycin	 and	 tacrolimus	 are	 considered	 as	 the	 bioactive	 agents	 for	
coronary	 stents.	 Therefore,	 the	main	 aim	 of	 this	 part	 of	 the	 project	was	 to	 develop	
P(3HB)/oligo-PHA	 based	 tubes	 using	 the	 dip	 moulding	 technique	 with	 incorporated	
drugs,	such	as	rapamycin	or	tacrolimus	for	the	development	of	medical	devices,	such	as	
coronary	 stents.	 Each	 drug	 was	 dissolved	 in	 the	 PCL-PEG550	 polymeric	 matrix	 and	
applied	 on	 the	 surface	 of	 the	 tube	 as	 a	 monolayer.	 The	 materials	 were	 fully	
characterized.	 In	 vitro	 biocompatibility	 of	 the	 tubes	 was	 tested	 with	 human	 dermal	
microvascular	 endothelial	 cells	 (HMEC-1)	 in	 order	 to	 evaluate	 the	 potential	 of	 new	
biodegradable	 material	 in	 applications	 such	 as	 coronary	 artery	 stent.	
Haemocompatibility	studies	were	carried	out	in	order	to	study	the	impact	of	the	tubes	
with	incorporated	drugs	on	blood	cells.	Additionally,	drug	release	studies	were	carried	
out	in	order	to	investigate	the	rate	of	drug	elution	from	the	device.	In	vitro	degradation	
study	 was	 also	 performed	 on	 the	 PCL-PEG550	 coated	 P(3HB)/oligo-PHA	 tubes	 to	
investigate	the	degradation	rate	of	the	coated	PHA	tubes	with	incorporated	drugs.		
8.1.	Drugs	characterisation	
Analysis	of	 the	 chemical	nature	and	 thermal	properties	of	 rapamycin	and	 tacrolimus	
powders	 were	 carried	 out	 using	 Fourier	 Transform	 Infrared	 Spectroscopy	 and	
Differential	Scanning	Calorimetry	respectively.		
8.1.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
	
The	 ATR/FTIR	 spectrum	 of	 rapamycin	 (Figure	 94)	 present	 few	 chemical	 bonds,	
characteristic	of	rapamycin.	There	is	an	adsorption	peak	at	2947cm-1	which	corresponds	
to	asymmetric	stretching	-CH2.		The	carbonyl	bond	is	present	at	the	wavenumber	1716.3	
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cm-1.	Additionally,	 two	bonds,	typical	 to	 imines	are	present	at	1644.6	cm-1	 (C=N)	and	
1633.6	cm-1	(C-N)	respectively.		
	
Figure	 94:	 ATR/FTIR	 spectrum	 of	 rapamycin	 powder	 indicating	 characteristic	 peaks	
corresponding	to	chemical	bonds	observed	in	rapamycin.	
The	tacrolimus	powder	exhibited	various	peaks	related	to	the	functional	groups	present	
in	 the	 structure	 of	 tacrolimus	 (Figure	 95).	 There	 was	 a	 peak	 at	 3438	 cm-1,	 which	
corresponded	 to	 O-H	 stretching	 vibration.	 Carbonyl	 group	 C	 =	 O	 (ester	 and	 ketone)	
stretching	vibrations	were	present	at	1739.8	cm-1.	An	absorption	peak	at	1692.3	cm-1	
and	 1636.4	 cm-1	 corresponded	 to	 the	 keto-amide	 group	 C=O	 and	 C=C	 stretching	
vibration	respectively.	Additionally,	the	C–O	(ester)	stretching	vibration	was	present	at	
1191.2	cm-1	and	the	ether	group	C–O–C	(ether)	stretching	vibration	at	1087.2	cm-1.	
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Figure	 95:	 ATR/FTIR	 spectrum	 of	 tacrolimus	 indicating	 characteristic	 peaks	
corresponding	to	chemical	bonds	observed	in	tacrolimus	structure.	
Obtained	ATR/FTIR	spectra	of	the	rapamycin	and	tacrolimus	represent	chemical	bonds,	
typical	of	their	chemical	structures,	corresponded	with	literature	(Patel	et	al.,	2013).	
	
8.1.2.	Differential	Scanning	Calorimetry	
	
DSC	analysis	of	the	rapamycin	and	tacrolimus	powder	was	carried	out	in	order	to	study	
thermal	properties	of	the	drugs.	The	thermograms	are	shown	in	the	Figure	96	and	97	
for	rapamycin	and	tacrolimus	respectively.		
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Figure	96:	DSC	thermograms	of	rapamycin	registered	during	first	heating	cycle.	
One	heating	cycle	was	performed	during	DSC	analysis	 in	order	 to	obtain	 the	thermal	
properties	 of	 the	 drugs.	 The	 thermogram	 for	 rapamycin,	 presented	 in	 the	 Figure	 96	
demonstrated	the	presence	of	melting	event	at	189.4°C.	There	was	also	thermal	event,	
similar	 to	 a	 glass	 transition	 temperature	 at	 133.9°C.	 Obtained	 melting	 peak	 was	 a	
multiple	peak,	which	demonstrated	polymorphic	structure	and	maturity	of	crystals	of	
rapamycin.	
Figure	97:	DSC	thermograms	of	tacrolimus	registered	during	first	heating	cycle.	
The	DSC	thermogram	of	tacrolimus	powder	(Figure	97)	demonstrated	the	presence	only	
one	melting	event	at	147.4°C.	Glass	transition	as	well	as	cold-crystallization	were	not	
CHAPTER	8	
	
	 251	
detected	in	the	first	cycle,	as	expected.		The	observed	value	was	slightly	higher	than	that	
reported	by	Patel	and	co-workers,	i.e.	129.6°C	(Patel	et	al.,	2012;	Yamashita	et	al.,	2003).	
8.2.	 P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 and	 incorporated	 drug	
manufacturing	
Mandrels	with	 layers	 of	 P(3HB)/oligo-PHA	were	 coated	with	 PCL-PEG330	monolayer	
with	 incorporated	drugs:	rapamycin	or	tacrolimus	at	a	concentration	of	1.2µg/cm2	of	
the	material	as	described	in	the	section	2.11.1.		Prepared	tubes	were	measured	with	a	
calliper	in	3	places	and	this	was	recorded	as	the	outer	diameter.	The	difference	between	
the	outer	diameter	of	the	mould	was	calculated	as	wall	thickness	and	expressed	in	Table	
36	with	standard	deviation.	The	difference	between	the	outer	diameter	of	neat	tube	
and	coated	tube	was	calculated	to	be	the	thickness	of	the	coating.		
	
Table	36:	Dimensions	of	tubes	produced	using	P(3HB)/oligo-PHA	blend	coated	with	PCL-
PEG550	with	incorporated	drug.		
Material	
Outer	diameter	
(mm)	
Wall	thickness	
(µm)	
Coating	
thickness	(µm)	
Neat	P(3HB)/oligo-PHA	
90/10	tube	coated	with	PCL-
PEG-550	with	incorporated	
Rapamycin	
2.7±0.004	 183.5±4.3	 31.5±1.7	
Neat	P(3HB)/oligo-PHA	
90/10	tube	coated	with	PCL-
PEG-550	with	incorporated	
Tacrolimus	
2.7±0.002	 191.6±1.4	 34.2±2.2	
The	 obtained	 tube	 had	 a	 wall	 thickness	 183.5±4.3	 µm	 and	 coating	 thickness	 with	
rapamycin	 of	 31.5±1.7	 µm.	 The	 wall	 thickness	 of	 the	 tubes	 with	 tacrolimus	 was	
191.6±1.4	µm	and	monolayer	size	was	34.2±2.2	µm.	
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8.3.	 P(3HB)/oligo-PHA	 tubes	 coated	with	 PCL-PEG550	 and	 incorporated	 drug	
characterisation	
P(3HB)/oligo-PHA	tubes	with	incorporated	dugs	were	characterised	with	respect	to	their	
thermal,	mechanical	 and	 topographical	 properties.	 Additionally,	 biocompatibility	 and	
haemocompatibility	studies	were	perform	in	order	to	confirm	non-toxicity	and	safety	of	
the	biomaterials.		
8.3.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
	
FTIR	spectroscopy	was	performed	on	the	P(3HB)/oligo-PHA	90/10	blend	tubes	coated	
with	PCL-PEG550	and	rapamycin	or	tacrolimus	using	the	method	described	in	section.	
2.6.1.	This	was	done	to	confirm	presence	of	the	drugs	within	polymeric	matrix	placed	in	
the	external	layer	of	the	tube.		The	ATR/FTIR	spectrum	of	the	PHA	blend	tube	coated	
with	rapamycin	or	tacrolimus	in	comparison	with	neat	blend	coated	tubes	is	shown	in	
Figure	98A-B.	
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Figure	98:	(A)	ATR/FTIR	spectra	of	neat	P(3HB)/oligo-PHA	tube	with	monolayer	of	PCL-
PEG550	 ( )	 in	 comparison	 to	 P(3HB)/oligo-PHA	 tube	 with	 incorporated	 rapamycin	
within	 PCL-PEG550	 coating	 ( )	 indicating	 major	 peaks	 characteristic	 for	 PHA,	 PCL-
PEG550	 and	 rapamycin.	 (B)	 ATR/FTIR	 spectra	 of	 neat	 P(3HB)/oligo-PHA	 tube	 with	
monolayer	 of	 PCL-PEG550	 ( )	 in	 comparison	 to	 P(3HB)/oligo-PHA	 tube	 with	
incorporated	 tacrolimus	 within	 PCL-PEG550	 coating	 ( )	 Indicating	 major	 peaks	
characteristic	for	PHA,	PCL-PEG550	and	tacrolimus.	
The	spectrum	of	coated	PHA-tube	with	rapamycin	(Figure	98A)	demonstrated	presence	
of	weak	chemical	bonds	typical	of	rapamycin,	as	described	in	the	section	8.1.1.	in	Figure	
94.	Those	are	adsorption	peaks	at:	2947cm-1,	1644.6	cm-1	and	1633.6	cm-1.	Rapamycin	
have	 been	 loaded	 successfully	 into	 the	 polymeric	 matrix,	 which	 was	 coated	 on	 the	
P(3HB)/oligo-PHA	90/10	blend	tube.		
 
The	spectrum	of	coated	PHA-tube	with	tacrolimus	(Figure	98B)	demonstrated	presence	
of	weak	chemical	bonds	typical	to	tacrolimus,	as	described	in	the	section	8.1.1.	in	Figure	
95.	Those	were	adsorption	peaks	at:	3438cm-1,	1739.8	cm-1,	1692.3	cm-1	and	1636.4	cm-
1.	Drug	tacrolimus	had	been	successfully	loaded	into	the	polymeric	matrix,	which	was	
coated	on	the	P(3HB)/oligo-PHA	90/10	blend	tube.		
In	conclusion,	presence	of	both	drugs	was	detected	in	the	PHA	based	tubes	coated	with	
PCL-PEG550	with	drug.	
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8.3.2.	Scanning	Electron	Microscopy	
SEM	images	of	cross	section	of	the	P(3HB)/oligo-PHA	tubes	with	incorporated	rapamycin	
confirmed	that	the	material	was	uniform	(Figure	99A).	Presence	of	the	coating,	which	
covered	surface	of	 the	tube	was	detected.	The	thickness	of	 the	coating	evaluated	by	
SEM	was	36.0±0.6	μm	(Figure	99D).	The	surface	of	the	tube	is	smooth	and	even;	pores	
are	not	visible	from	the	outer	surface	of	the	tube	(Figure	99C).	Tube	wall	thickness	was	
measured	as	180.7±0.5	μm	(Figure	99B).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	99:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	monolayer	of	PCL-
PEG550	 with	 incorporated	 rapamycin.	 (A)	 tube	 cross-intersection,	 (B)	 tube	 wall	
structure,	(C)	tube	surface,	(D)	coating	thickness.		
SEM	images	of	cross	section	of	the	P(3HB)/oligo-PHA	tubes	with	incorporated	tacrolimus	
confirmed	that	the	material	was	uniform	(Figure	100).	The	thickness	of	the	coating	by	
SEM	was	36.1±0.8	μm	was	also	confirmed	(Figure	100D).	The	surface	of	the	tube	was	
smooth	and	even	as	 shown	 in	 the	 Figure	100C.	Pores	 are	not	 visible	 from	 the	outer	
A) B) 
C) D) 
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surface	of	the	tube	or	throughout	the	wall	thickness.	Obtained	tube	wall	thickness	was	
measured	as	180.7±0.5	μm	(Figure	100B).		
	
	
	
	
	
	
	
	
	 	 	 	
	
	
	
	
	
	
	
	
	
Figure	100:	SEM	micrographs	of	P(3HB)/oligo-PHA	tube	coated	with	monolayer	of	PCL-
PEG550	 with	 incorporated	 tacrolimus.	 (A)	 tube	 cross-intersection,	 (B)	 tube	 wall	
structure,	(C)	tube	surface,	(D)	coating	thickness.	
8.3.3.	Drug	release	studies		
	
The	 release	 of	 rapamycin	 from	 the	 P(3HB)/oligo-PHA	 90/10	 blend	 tube	 containing	
rapamycin	 incorporated	 within	 PCL-PEG550	 polymeric	 matrix	 was	 carried	 out	 as	
described	in	section	2.12.	for	a	period	of	90	days.	The	results	obtained	during	In	vitro	
release	study	were	summarised	in	Figure	101.		
A) B) 
C) D) 
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Figure	101:	In	vitro	release	profile	of	rapamycin	from	PCL-PEG550	polymeric	coating	of	
P(3HB)/oligo-PHA	90/10	blend	tube	for	a	period	of	90	days	(n=3).	
Rapamycin	was	 released	 slowly	 at	 a	 constant	 rate	 throughout	 the	period	of	 release.	
Burst	release	was	not	observed.	However,	slightly	faster	release	was	noticed	within	first	
24	hours.	This	might	be	due	to	the	release	of	drug	attached	to	the	surface	of	the	matrix.	
After	1	day	of	incubation	7.6±0.6%	of	rapamycin	was	released.	Within	12	days	almost	
30%	of	the	drug	was	released.	During	the	first	30	days	62.2±2.5%	was	released.	After	30	
days,	the	rate	of	release	slowed	down.	After	48	days	86.8%	of	rapamycin	was	released.	
After	 72	 days,	 no	 further	 release	was	 recorded.	 In	 this	 study,	 cumulative	 release	 of	
rapamycin	of	98.2%	occurred	within	a	period	of	90	days.		
	
The	 release	 of	 tacrolimus	 from	 the	 P(3HB)/oligo-PHA	 90/10	 blend	 tube	 containing	
monolayer	of	PCL-PEG550	with	tacrolimus	was	carried	out	as	described	in	section	2.13	
for	 a	 period	 of	 90	 days.	 	 The	 results	 obtained	 during	 In	 vitro	 release	 study	 were	
summarised	in	Figure	102.	
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Figure	102:	Cumulative	release	profile	of	tacrolimus	from	PCL-PEG550	polymeric	coating	
of	P(3HB)/oligo-PHA	90/10	blend	tube	for	a	period	of	90	days	(n=3).	
Tacrolimus	 was	 released	 slowly	 throughout	 the	 period	 of	 study.	 Burst	 release	 was	
observed	within	 first	 3	 days	 of	 incubation.	 This	might	 be	due	 to	 the	 release	of	 drug	
attached	to	the	surface	of	the	matrix.	After	1	day	of	incubation	12.6±0.4%	of	tacrolimus	
was	released.	Within	18	days	around	32%	of	the	drug	was	released.	During	the	first	30	
days	45.7±2%	was	released.	After	24	days,	the	rate	of	release	increased.	After	48	days	
60.0%	 of	 tacrolimus	was	 released.	 In	 this	 study,	 cumulative	 release	 of	 tacrolimus	 of	
69.2%	occurred	within	a	period	of	90	days.		
8.4.	In	vitro	biocompatibility	studies	
Neat	 P(3HB)/oligo-PHA	 90/10	 tubes	 coated	 with	 PCL-PEG550	monolayer,	 containing	
rapamycin	or	tacrolimus	were	characterised	in	order	to	evaluate	their	functionality	as	a	
platform	materials	for	biomedical	applications.		
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8.4.1.	Protein	adsorption	
Bicinchoninic	 acid	 assay	was	 used	 to	 evaluate	 the	potential	 of	 the	materials	 towards	
proteins	as	described	in	the	section	2.11.3.9.		It	was	found	that	total	protein	adsorption	
was	189.9±7.6	and	150.6±6.9	µg/cm2	for	the	P(3HB)/oligo-PHAs	blend	tube	containing	
tacrolimus	or	rapamycin	in	the	PCL-PEG550	matrix	respectively.	Both	tested	materials	
demonstrated	higher	protein	adsorption	than	TCP.	However,	the	results	were	significant	
only	 for	 tube	 containing	 tacrolimus	 (*p=0.033).	 There	 was	 no	 significant	 difference	
between	the	tissue	control	plastic	and	tube	with	incorporated	rapamycin	(Figure	103).			
	
 
Figure	103:	Protein	adsorption	to	the	P(3HB)/oligo-PHA	90/10	tubes	with	PCL-PEG550	
coating	with	 incorporated	drugs:	 rapamycin	or	 tacrolimus	 (n=3;	error	bars=±SD).	The	
data	were	compared	with	standard	tissue	culture	plastic	using	ANOVA.	*	indicates	p<	
0.05.		
The	tubes	with	tacrolimus	demonstrated	higher	concentration	of	proteins	adsorbed	on	
the	surface	in	comparison	with	TCP	(positive	control).	The	amount	of	proteins	adsorbed	
to	the	TCP	was	137.5±7.8	µg/cm2.	The	presence	of	drug	did	not	demonstrate	inhibiting	
effects	 on	 the	 amount	 of	 protein	 adsorbed	 on	 the	 surface	 of	 the	 tubes.	Moreover,	
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incorporated	 tacrolimus	 enhanced	 proteins	 affinity	 towards	 P(3HB)/oligo-PHA	 tube	
coated	with	PCL-PEG550.	
8.4.2.	Cell	viability	study	
 
MTT	 assay	 was	 used	 to	 evaluate	 cell	 adhesion	 and	 proliferation.	 Attachment	 and	
proliferation	of	HMEC-1	cells	on	the	tube	samples	were	studied	over	a	period	of	1,	3	
and	7	days.	The	standard	tissue	culture	 plastic	was	 used	 as	 the	 positive	 control	 for	
these	experiments.	The	 results	 of	biocompatibility	studies	are	presented	in	Figure	104.	
	 
	
Figure	104:	Cell	proliferation	study	of	the	HMEC-1	cells	on	the	P(3HB)/oligo-PHA	tubes	
coated	 with	 monolayer	 of	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	 tacrolimus	
samples	on	day	1,	3	and	7	(n=3;	error	bars=±SD).	The	data	were	compared	with	standard	
tissue	culture	plastic,	which	were	normalized	to	100%	using	ANOVA.	*	indicates	p<	0.05	
and	**	indicates	p<0.005.	( )	standard	tissue	culture	plastic,	( )	tube	with	incorporated	
rapamycin,	( )	tube	with	incorporated	tacrolimus.	
Cell	 proliferation	 on	 the	 surface	 of	 P(3HB)/oligo-PHA	 90/10	 blend	 tubes	 with	
incorporated	tacrolimus	within	PCL-PEG550	matrix	was	slightly	lower	in	comparison	to	
TCP	on	day	1,	3	and	7.	The	cell	viability	obtained	on	the	tube	samples	was	89.6±5.4%	on	
day	 1;	 94.4±3.7%	 on	 day	 3	 and	 90.9±2.5%	 on	 day	 7	 as	 compared	 to	 the	 TCP.	 The	
differences	were	not	statistically	significant	for	all	the	results	obtained.	The	growth	of	
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the	HMEC-1	cells	on	the	surface	of	tube	with	rapamycin	was	lower	in	comparison	to	
the	control.	The	cell	 viability	observed	was:	81.5±2.4%	on	day	1	and	66.6±4.9%	and	
62.9±4.0%	on	day	3	and	7	respectively.	The	differences	were	statistically	significant	for	
day	3	and	7	(*p=0.022,	*p=0.012)	 in	comparison	to	TCP	on	day	3	and	7.	Presence	of	
rapamycin	within	 the	polymeric	matrix	had	a	negative	 impact	on	the	viability	of	 the	
HMEC-1	cells.		
The	 results	 obtained	 demonstrated	 higher	 biocompatibility	 of	 the	 tube	 with	
incorporated	tacrolimus	 in	comparison	to	rapamycin.	Therefore,	 this	drug	should	be	
considered	for	application	in	coronary	stents.		
8.4.3.	Scanning	Electron	Microscopy	
Cell	attachment	and	morphology	was	further	characterised	using	SEM	imaging.	SEM	
images	 presented	 in	 Figure	 105	 revealed	 that	 HMEC-1	 cells	 adhered	 to	 and	
proliferated	on	the	surface	of	the	tubes.	However,	much	higher	cell	density	for	the	tube	
containing	tacrolimus	in	comparison	to	rapamycin	was	observed.	The	cell	morphology	
was	similar	in	both	tested	materials.	HMEC-1	cells	exhibited	spindle-shape	morphology,	
typical	for	this	cell	line.	Additionally,	cell-to–cell	interactions	were	observed.		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 105:	 SEM	 micrographs	 of	 the	 HMEC-1	 cells	 attached	 to	 the	 surfaces	 of	
P(3HB)/oligo-PHA	 tubes	 containing	 rapamycin	 (A),	 and	 tacrolimus	 (B)	 after	 7	 days	of	
culturing.	
A) 
B) 
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With	 respect	 to	 the	 results	obtained,	not	all	 tested	materials	based	on	P(3HB)/oligo-
PHAs	 supported	 the	 growth	 of	 HMEC-1	 cell	 line.	 Addition	 of	 tacrolimus	 into	
P(3HB)/oligo-PHA	tube	demonstrated	much	higher	biocompatibility	to	the	endothelial	
cell	line	in	comparison	to	rapamycin,	which	distinctly	inhibited	growth	of	the	HMEC-1	
cells.		
	
8.4.4.	Indirect	cytotoxicity	study	
	
Indirect	cytotoxicity	test	was	performed	to	investigate	the	influence	of	the	substances	
released	from	the	tubes	with	incorporated	drugs,	such	as	rapamycin	or	tacrolimus	on	
the	HMEC-1	cell	 line.	Cells	with	 fresh	DMEM	medium	were	used	as	negative	control.	
70%	methanol	instead	of	media	or	extract	was	used	as	the	control.			
	 
Figure	 106:	 Indirect	 cytotoxicity	 study	 of	 the	 HMEC-1	 cells	 on	 the	 P(3HB)/oligo-PHA	
tubes	coated	with	monolayer	of	PCL-PEG550	with	incorporated	rapamycin	or	tacrolimus	
samples	on	day	1,	3	(n=3;	error	bars=±SD).	The	data	were	compared	with	standard	tissue	
culture	 plastic	 containing	 DMEM	 medium,	 which	 were	 normalised	 to	 100%	 using	
ANOVA.	 *	 indicates	 p<	 0.05.	 ( )	 fresh	 DMEM	 medium,	 ( )	 extract	 from	 the	 tube	
containing	rapamycin	( )	extract	from	the	tube	containing	tacrolimus.		
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Cell	proliferation	on	the	P(3HB)/oligo-PHA	tube	with	tacrolimus	was	119.9±4.3%	on	day	
1	 and	 94.4±3.8%	 on	 day	 3	 compared	 to	 TCP.	 The	 differences	 were	 not	 statistically	
significant.	The	growth	of	HMEC-1	cells	on	the	extract	from	tube	containing	tacrolimus	
was	similar	on	day	1	and	3	to	TCP.	The	growth	of	the	HMEC-1	cells	with	an	extract	from	
P(3HB)/oligo-PHA	tube	with	rapamycin	was	lower	than	TCP	on	day	1	(79.2±2.3	and	day	
3	 (45.1±0.5).	 The	 difference	 was	 statistically	 significant	 (**p=0.0033)	 for	 the	 result	
obtained	 after	 day	 3.	 The	 highest	 viability	 of	 the	 HMEC-1	 cells	 was	 achieved	 after	
treatment	with	an	extract	from	tube	with	incorporated	tacrolimus	in	comparison	to	TCP	
after	1	day	of	 incubation.	The	results	obtained	suggest	 that	no	cytotoxic	substances	
were	released	from	the	tube	containing	tacrolimus.	This	drug	did	not	inhibit	the	growth	
of	HMEC-1	cells.		An	opposite	effect	was	observed	with	rapamycin.	This	drug	definitely	
interfered	 with	 endothelial	 cells	 and	 inhibited	 their	 attachment	 and	 proliferation.	
Therefore,	 PHAs	 tubes	 with	 tacrolimus	 can	 be	 strongly	 considered	 as	 potential	
materials	for	biomedical	applications,	such	as	coronary	stents.		
8.5.		Haemocompatibility	studies	
P(3HB)/oligo-PHA	tubes	with	incorporated	drugs,	such	as	rapamycin	or	tacrolimus	were	
subjected	 to	 haemocompatibility	 studies,	 which	 includes	 haemolysis	 studies,	 whole	
blood	clotting	as	well	as	monocytes	and	neutrophils	activation.		
	
8.5.1.	Haemolysis	study	
	
Haemolysis	 study	 was	 performed	 on	 P(3HB)/oligo-PHA	 tubes	 with	 tacrolimus	 and	
rapamycin	in	order	to	investigate	an	effect	of	the	materials	on	erythrocytes	after	direct	
contact	with	fresh	whole	blood.	The	analysis	was	performed	as	described	in	the	section	
2.15.1.	The	results	obtained	are	shown	at	the	Figure	107.		
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Figure	107:	Haemolysis	 rates	of	 the	P(3HB)/oligo-PHA	 tubes	 coated	with	PCl-PEG550	
with	 incorporated	 rapamycin	 or	 tacrolimus	 after	 1h	 of	 incubation	 at	 37°C	 (n=3).	 *	
indicates	p<0.05	compared	to	blood	control	sample	containing	0.9%	NaCl	using	ANOVA;	
no	significant	difference.	
All	tubes	exhibited	non-haemolytic	effect	on	erythrocytes.	The	percent	of	haemolysis	
3.7%,	 and	 0%	 was	 obtained	 for	 tube	 with	 rapamycin	 and	 tacrolimus	 respectively.	
According	to	ISO	10993-4:2002	standard,	all	tested	tubes	had	low	potential	to	destroy	
red	blood	cells.	
8.5.2.	Whole	blood	clotting	study	
	
Whole	 blood	 clotting	 experiment	 was	 performed	 to	 investigate	 the	 potential	
thrombogenicity	 of	 P(3HB)/oligo-PHA	 tubes	 containing	 different	 types	 of	 drugs	
incorporated	in	the	polymeric	matrix	as	described	previously	in	the	section	2.15.2.	The	
summary	of	the	results	obtained	after	30	and	90	minutes	are	demonstrated	in	Figure	
108.	
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Figure	 108:	 Summary	 of	 whole	 blood	 clotting	 results	 after	 30	 minutes	 ( )	 	 and	 90	
minutes	 ( )	 of	 incubation	 on	 the	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	
containing	rapamycin	or	tacrolimus.	Tissue	culture	plastic	was	used	as	the	control	(n=3;	
error	 bars=±SD).	 The	 data	were	 compared	with	 standard	 tissue	 culture	 plastic	 using	
ANOVA.	*	indicates	p<	0.05,	**	indicates	p<0.005.	 
The	results	obtained	indicate	that	P(3HB)/oligo-PHA	coated	tube	containing	rapamycin	
or	tacrolimus	enhanced	the	activation	of	the	coagulation	cascade.	After	30	minutes	of	
incubation,	 P(3HB)/oligo-PHA	 tube	 with	 rapamycin	 demonstrated	 24.2±1.6%	 blood	
clotting.	Addition	of	tacrolimus	within	the	coating	resulted	in	increased	%	blood	clotting	
after	30	minutes	by	21.9±3.1%.	The	results	were	not	significant	 in	comparison	to	the	
control.	With	the	increase	of	time,	the	%	blood	clot	increased	in	all	tested	materials	as	
well	as	in	positive	control.	After	90	minutes	the	blood	control	demonstrated	82.9±3.3%	
blood	clotting.	P(3HB)/oligo-PHA	tube	with	rapamycin	resulted	in	decrease	in	the	blood	
clotting	rate	to	31.5±1.2%.	The	difference	was	significant	(**p=0.0022).	P(3HB)/oligo-
PHA	coated	tube	with	tacrolimus	presented	decreased	blood	clotting	rate	(48.4±1.5%)	
in	comparison	to	the	control	(82.9±3.3%).	The	result	was	significant	(*p=0.011).	Addition	
of	drugs	resulted	in	much	lower	blood	clot	rate	formation	than	control.	To	summarise,	
all	tested	materials	did	not	demonstrate	increased	risk	of	thrombogenicity	and	can	be	
considered	as	a	biomaterial	for	medical	applications,	such	as	coronary	stents.	
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8.5.3.	Monocytes	and	neutrophil	activation	
	
Three	different	types	of	tubes:	neat	P(3HB)/oligo-PHA,	coated	tube	and	composite	tube	
were	incubated	with	the	whole	blood	at	37°C	overnight	and	stained	with	the	markers	
listed	in	section	2.15.3.1.	Summary	of	the	results	obtained	was	demonstrated	in	Table	
37.		
Table	37:	Summary	of	median	fluorescence	intensity	(MFI)	obtained	after	incubation	of	
fresh	 whole	 blood	 with	 P(3HB)/oligo-PHA	 90/10	 tube	 coated	 with	 PCL-PEG550,	
P(3HB)/oligo-PHA	 tube	 coated	 with	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	
tacrolimus	and	PL38	stained	with	specific	markers	in	order	to	evaluate	monocyte	and	
neutrophil	activity.	
Sample	 Markers	
Monocytes	
Activity	
(MFI)	
Percentage	
change	(%)	
Neutrophils	
Activity	
(MFI)	
Percentage	
change	(%)	
P(3HB)/oligo-
PHA	90/10	
tube	coated	
with	PCL-
PEG550	
CD86-PE	 209.7	 82.5	 175.3	 11.6	
CD45-
PerCP	
135.9	 24.2	 76.3	 -	
CD11b-PE	 498.9	 267.1	 586.8	 316.4	
CD66B-
FITC	
168.8	 -	 279.8	 71.8	
P(3HB)/oligo-
PHA	90/10	
tube	coated	
with	PCL-
PEG550	and	
rapamycin	
CD86-PE	 188.9	 64.4	 109.3	 -	
CD45-
PerCP	
66.9	 -	 98.4	 -	
CD11b-PE	 642.3	 372.6	 1104.2	 683.6	
CD66B-
FITC	
131.1	 -	 168.8	 3.7	
P(3HB)/oligo-
PHA	90/10	
tube	coated	
with	PCL-
PEG550	and	
tacrolimus	
CD86-PE	 140.9	 22.6	 116.7	 -	
CD45-
PerCP	
131.5	 20.2	 109.4	 0	
CD11b-PE	 436.7	 321.4	 546.2	 287.6	
CD66B-
FITC	
249.6	 23.2	 163.8	 0.61	
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The	results	obtained	after	staining	blood	samples,	which	were	exposed	to	various	types	
of	drugs	incorporated	within	the	tubes	demonstrated	different	levels	of	activity	of	the	
monocytes	 and	 neutrophils.	 All	 tested	 samples	 presented	 higher	 activity	 in	 the	
activation	 marker	 CD11b-PE.	 The	 percentage	 change	 of	 MFI	 for	 tube	 containing	
tacrolimus	was	 321.4%	 for	monocytes	 and	 287.6%	 for	 neutrophils	 in	 comparison	 to	
control.	 The	 tube	 with	 rapamycin	 demonstrated	 1.5-2.0-fold	 higher	 white	 cells	
activation	 than	 the	 neat	 tube	 PCL-PEG550	 coated	 tube	 without	 any	 drug.	 The	
percentage	 change	 of	 MFI	 for	 P(3HB)/oligo-PHA	 tube	 containing	 rapamycin	 was	
recorded	as	372.6%	for	monocytes	and	683.6%	for	neutrophils	in	comparison	to	control.	
The	results	obtained	suggested,	that	addition	of	rapamycin	caused	an	increased	higher	
activation	of	neutrophils	and	monocytes	in	comparison	to	tube	containing	tacrolimus	or	
tube	without	any	drug.	
8.6.	In	vitro	degradation	study	
 
A	degradation	 study	was	 carried	out	 for	 a	 period	of	 3	months	 at	 37°C	 in	 phosphate	
buffered	 saline	 solution	 (PBS)	 to	 investigate	 the	 degradation	 behaviour	 of	 the	
P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-PEG550	 with	 incorporated	 rapamycin	 or	
tacrolimus.		
	
8.6.1.	Attenuated	Total	 Reflectance	 Fourier	 Transform	 Infrared	 Spectroscopy	
(ATR/FT-IR)	
	
FTIR	was	carried	out	on	the	tubes	to	investigate	the	changes	in	the	chemical	structure	
during	 incubation	 time.	 Figure	 109	 illustrates	 the	 ATR/FTIR	 spectra	 obtained	 for	 the	
tubes	after	month	1	and	3	of	degradation	studies.		
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Figure	109:	ATR-FTIR	spectrum	of	the	P(3HB)/oligo-PHA	tubes	with	rapamycin	(A)	and	
tacrolimus	 (B)	 after	 3	 months	 incubation	 in	 PBS	 indicating	 characteristic	 peaks.	 ( )	
month	1	of	degradation	study,	( )	month	3	of	degradation	study.	
There	 were	 no	 differences	 between	 all	 spectra	 obtained	 after	 month	 1	 and	 3	 for	
P(3HB)/oligo-PHA	tubes	with	 rapamycin	or	 tacrolimus.	All	 the	chemical	bonds,	which	
were	 detected	 are	 typical	 of	 P(3HB)/oligo-PHA	 blends	 and	 PCL-PEG550	 coating	
described	previously	in	Chapter	7.	
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8.6.2.	Thermal	properties	–	Differential	Scanning	Calorimetry	
	
DSC	analysis	was	carried	out	in	order	to	study	changes	in	the	thermal	properties	in	the	
material	containing	drugs,	caused	by	degradation	of	the	tubes.	A	summary	of	the	results	
obtained	has	been	listed	in	Table	38.	The	first	heating	cycle	thermograms	are	shown	in	
Figure	110.	
	
Table	38:	Summary	of	the	thermal	properties	of	the	P(3HB)/oligo-PHA	tubes	containing	
rapamycin	or	tacrolimus	after	3	months	of	degradation	study.	Tm=	melting	temperature,	
Tg=	 glass	 transition	 temperature,	 Tc=	 crystallisation	 temperature,	 DHf=enthalpy	 of	
fusion.	
Type	of	drug	 Tube	with	incorporated	Rapamycin	 Tube	with	incorporated	Tacrolimus	
Time	 Month	1	 Month	2	 Month	3	 Month	1	 Month	2	 Month	3	
Tg	(°C)	 0.4	 -0.4	 -0.1	 -3.4	 2.3	 -1.3	
Tm	(°C)	
64.4	
173.1	
64.9	
176.8	
79.2	
176.6	
62.7	
176.3	
62.5	
175.9	
176.3	
Tc	(°C)	 58.9	 60.5	 58.3	 52.2	 58.4	 55.0	
ΔHf	(J/g)	
10.38	
65.5	
6.85	
65.0	
5.6	
66.2	
3.4	
82.43	
6.12	
88.15	
83.9	
	
During	3	months	of	degradation	 study,	 the	 thermal	properties	of	 the	materials	have	
changed.	In	the	tube	with	rapamycin,	the	glass	transition	temperature	slightly	decreased	
from	 0.4°C	 at	 month	 1	 to	 -0.1°C	 at	 month	 3.	 There	 were	 2	 melting	 temperatures	
detected:	one	related	to	PCL-PEG550,	present	in	the	coating	and	one	related	to	PHAs.	
Tm	 for	PCL-PEG550	 increased	 significantly	 from	64.4°C	 to	79.2°C	after	3	months.	The	
melting	temperature	for	the	PHAs	also	increased	from	173.1°C	to	176.6°C	after	month	
1	 and	 3	 respectively.	 The	 cold-crystallisation	 temperature	 increased	 at	month	 2	 and	
decreased	back	to	58.3°C	in	month	3.	The	enthalpy	of	fusion	values	increased	slightly	
from	65.5J/g	to	66.2J/g	for	PHAs	and	decreased	from	10.38	J/g	to	5.6	J/g	for	PCL-PEG550	
after	3	months.		
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Figure	110:	DSC	thermograms	of	P(3HB)/oligo-PHA	tubes	with	incorporated	rapamycin	
(A)	and	tacrolimus	(B)	during	3	months	of	degradation	study.	( )	month	1	of	degradation	
study,	( )	month	3	of	degradation	study.	
In	the	tube	with	tacrolimus	the	glass	transition	temperature	increased	from	-3.4°C	to	-
1.3°C	after	3	months.	Cold-crystallisation	temperature	increased	from	52.5°C	to	55.5°C	
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after	3	months.	There	was	significant	change	in	the	melting	temperature.	There	was	one	
melting	event	observed	after	3	months	of	study.	This	can	be	explained	by	degradation	
of	the	external	layer	of	the	tube.	As	a	result,	mostly	PHA	polymers	were	left.	Degradation	
study	 did	 not	 affect	 the	 melting	 temperature	 and	 was	 stable	 around	 176.3°C	 for	 3	
months	in	the	case	of	PHAs	and	62.5°C	for	PCL-PEG550	for	2	months.	The	enthalpy	of	
fusion	increased	for	2	months	from	82.4	J/g	to	88.15	after	month	2	and	decreased	back	
after	month	3	to	the	level	83.9	J/g.		
The	DSC	thermograms	in	the	Figure	110	presents	the	first	heating	cycle	of	tubes	with	
rapamycin	(Figure	A)	and	tacrolimus	(Figure	B)	after	months	1	and	3	of	degradation.	In	
the	thermogram	obtained	from	tube	with	tacrolimus,	there	was	lack	of	melting	event	
for	 PCL-PEG550	 after	 month	 3,	 whereas	 this	 peak	 was	 still	 present	 in	 tube	 with	
rapamycin.	No	other	thermal	events	were	observed.	Both	types	of	tubes	demonstrated	
different	 behaviour	 with	 respect	 to	 their	 thermal	 properties	 during	 3	 months	
degradation	study.		
8.6.3.	Mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	coated	with	PCL-
PEG550	with	incorporated	drugs		
	
The	analysis	of	the	mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	with	rapamycin	
or	tacrolimus	incorporated	within	PCL-PEG	550	polymeric	matrices	were	incubated	with	
PBS	at	37°C	for	3	months,	in	order	to	check	the	material	properties	during	degradation.	
The	results	obtained	are	summarised	in	Table	39.		
Table	39:	Summary	of	the	mechanical	properties	of	 the	P(3HB)/oligo-PHA	tubes	with	
rapamycin	or	tacrolimus	during	month	1,	2	and	3	of	the	degradation	study.	
Month	
Type	of	drug	
incorporated	
Tensile	
strength	(MPa)	
Elongation	at	
break	(%	strain)	
Young’s	
Modulus	(GPa)	
1	
Rapamycin	 20.8±1.6	 7.8±1.5	 0.8±0.1	
Tacrolimus	 19.7±1.8	 7.4±1.2	 0.9±0.06	
2	
Rapamycin	 21.7±0.9	 4.4±0.7	 1.4±0.15	
Tacrolimus	 22.3±0.8	 4.1±0.4	 1.6±0.04	
3	
Rapamycin	 16.1±2.1	 1.7±0.3	 1.1±0.05	
Tacrolimus	 18.8±0.75	 2.6±0.5	 1.0±0.12	
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Mechanical	properties	of	the	P(3HB)/oligo-PHA	tubes	with	incorporated	rapamycin	or	
tacrolimus	after	3	months	of	incubation	in	PBS	at	37°C	had	changed.	There	was	a	similar	
trend	 in	 the	behaviour	of	both	 types	of	 the	 tubes	with	 rapamycin	and	 tacrolimus.	 In	
general,	the	tensile	strength	and	Young’s	modulus	values	increased	after	2	months	and	
decreased	after	month	3	of	 the	degradation	study.	On	the	other	hand,	elongation	at	
break	values	decreased	significantly.	The	results	obtained	confirmed	brittleness	of	the	
material,	 which	 might	 be	 caused	 by	 degradation	 and	 weight	 loss	 of	 the	 tubes.	
Mechanical	properties	of	the	tubes	incubated	with	PBS	were	different	than	tubes	stored	
at	 room	 temperature	 as	 described	 in	 the	 section	 7.4.3.3.	 Tubes	 stored	 at	 room	
temperature	for	7	weeks	demonstrated	higher	tensile	strength	values	and	elongation	at	
break	in	comparison	to	tubes	incubated	at	37°C	in	PBS.	Young’s	Modulus	after	7	weeks	
was	similar	to	the	incubated	tubes	after	2	months	of	degradation	study.	The	hydrolytic	
environment	 had	 a	 negative	 effect	 on	 the	 mechanical	 properties,	 i.e.	 decrease	 in	
stiffness	of	the	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550.	
8.6.4.	 pH	measurements	 of	 the	 PBS	 during	 degradation	 studies	 of	 neat	 PHA	
tubes	
	
The	 PBS	 in	 which	 the	 tubes	 were	 incubated	 were	 studied	 in	 order	 to	 monitor	 any	
changes	in	the	pH	during	the	degradation	study.	The	results	obtained	were	presented	in	
the	Figure	111.		
	
Figure	 111:	 pH	 changes	 of	 PBS	 after	 incubation	 of	 P(3HB)/oligo-PHA	 tubes	 with	
incorporated	 rapamycin	 ( )	 or	 tacrolimus	 ( )	 	 for	 3	 months	 (n=3).	 no	 significant	
difference	in	comparison	to	month	1.	
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The	pH	of	PBS	was	7.4	in	the	beginning	of	the	study.	After	3	months	of	incubation	at	
37°C	the	final	pH	was	6.8±0.02	for	tubes	with	rapamycin	and	6.8±0.05	for	tubes	with	
tacrolimus.	These	results	obtained	during	this	study	suggested	release	of	slightly	acidic	
products	during	degradation	process,	which	resulted	in	a	decrease	in	pH.	However,	the	
pH	changes	are	inconsiderable.	
	
8.6.5.	Weight	loss	(%)	of	the	neat	tubes	during	degradation	studies	
	
Percentage	of	weight	loss	was	measured	at	month	1,	2	and	3	of	degradation	study	as	
described	 previously	 in	 the	 section	 2.16.3.	 The	 summary	 of	 the	 results	 has	 been	
illustrated	in	the	Figure	112.	
	
Figure	 112:	 Weight	 loss	 (%WL)	 of	 the	 P(3HB)/oligo-PHA	 tubes	 with	 incorporated	
rapamycin	( )	or	tacrolimus	( )	for	a	period	of	3	months	(n=3).	Results	were	compared	
to	%	weight	loss	after	month	1	using	ANOVA.	*	indicates	p<0.05.	
The	results	obtained	suggest	slow	increase	in	weight	loss,	observed	in	the	tubes	during	
the	degradation	 study.	 For	 the	 tubes	 containing	 rapamycin,	 the	 initial	weight	 loss	 at	
month	1	was	slightly	above	4%.	After	3	months,	the	%	weight	loss	observed	was	5.5%.	
Similarly,	in	the	tube	with	tacrolimus	weight	loss	increased	from	4.4%	after	month	1	to	
6.4%	after	month	3.		
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8.6.6.	Water	uptake	(%)	of	the	neat	tubes	during	degradation	studies	
	
Percentage	 of	 water	 uptake	 (%WU),	 which	 is	 an	 amount	 of	 water	 absorbed	 by	 the	
material	during	incubation	was	measured	at	month	1,	2	and	3	of	degradation	study	as	
described	 previously	 in	 the	 section	 2.16.3.	 the	 summary	 of	 the	 results	 has	 been	
illustrated	in	the	Figure	113.	
 
Figure	113:	Water	absorption	(%WU)	by	the	P(3HB)/oligo-PHA	tubes	with	incorporated	
rapamycin	( )	or	tacrolimus	( )	for	a	period	of	3	months	(n=3).	Results	were	compared	
to	%	water	uptake	after	month.	*	indicates	p=0.04	and	**	indicates	p=0.005.	
The	results	obtained	illustrated	the	amount	of	water	absorbed	by	the	tubes.	In	the	tubes	
with	rapamycin	the	water	absorption	level	decreased	slightly	from	13.8%	at	month	1	to	
12.4%	after	month	3.	For	the	tube	with	tacrolimus	the	water	uptake	increased	steadily	
from	 month	 1	 to	 3.	 The	 final	 WU	 value	 obtained	 in	 this	 study	 after	 month	 3	 was	
19.3±1.4%.		
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8.6.7.	Surface	studies	of	the	degraded	tubes	
	
After	each	time	point	during	degradation	studies	tubes	were	rinsed	with	distilled	water,	
dried	and	imaged	using	the	Scanning	Electron	Microscope	as	described	in	section	2.16.2.	
SEM	analyses	of	the	surface,	cross	section,	wall	thickness	of	the	tubes	was	carried	out	
to	analyse	any	changes	on	the	surface	due	to	degradation.	SEM	images	of	the	tubes	with	
incorporated	drugs,	obtained	after	3	months	of	degradation	studies	are	presented	in	the	
Figure	114	and	115.		
	
	
	
	
	
	
	
	
	
	
	
	
	 	 	
	
	
	
	
	
	
Figure	 114:	 SEM	micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	with	 rapamycin	 after	 3	
months	of	degradation	study.	(A)	tube	wall	structure,	(B)	tube	surface,	(C)	tube	coating	
thickness,	(D)	inner	surface	of	the	tube.		
A) B) 
C) D) 
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SEM	 images	 of	 the	 P(3HB)/oligo-PHA	 tube	with	 incorpotayed	 rapamycin	within	 PCL-
PEG550	polymeric	coating	have	confirmed	that	the	degradation	process	occurred	after	
3	months.	 The	 degradation	mechanism	 seemed	 to	 involve	 the	 surface	 erosion	 from	
external	 layer.	Therefore,	within	3	months	only	the	coating	layer	was	affected	by	the	
degradation	process.	The	 loss	of	 the	coating	thickness	was	16%	(Figure	114C).	 In	 the	
Figure	114B	it	 is	clearly	visible,	how	hydrolytic	degradation	eroded	the	surface	of	the	
tube.	 The	 internal	 layer	 of	 the	 tube	 (Figure	 114D)	was	 however	 not	 affected	 by	 the	
hydrolytic	 environment	 during	 the	 3	 months	 study.	 Slightly	 increased	 porosity	 was	
observed	in	the	wall	of	the	tube	(Figure	114A).	The	monolayer	of	PCL-PEG550	protected	
the	inner	core	of	the	tube	before	degradation.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 115:	 SEM	micrographs	 of	 the	 P(3HB)/oligo-PHA	 tubes	with	 tacrolimus	 after	 3	
months	of	degradation	study.	(A)	tube	wall	structure,	(B)	tube	surface,	(C)	thickness	of	
the	coating,	(D)	tube	wall	structure.	
A) B) 
C) D
)
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SEM	 images	 of	 the	 tubes	 with	 incorporated	 tacrolimus	 confirmed	 the	 degradation	
process	has	started	within	3	months	(Figure	115A-D).	The	degradation	had	happened	by	
surface	 erosion	 from	 external	 layer.	 Separation	 between	 coating	 layer	 and	 the	
P(3HB)/oligo-PHA	tube	core	have	been	observed.	After	3	months	time	of	degradation	
study	mainly	coating	layer	was	affected	by	degradation	process.	The	loss	of	the	coating	
thickness	was	67%	(Figure	115C)	in	comparison	to	the	fresh	tube	as	described	previously	
in	Chapter	7.	Figure	115B	demonstrated	outer	surface	of	the	tube,	which	belongs	mainly	
to	 the	 PCL-PEG550	 coating.	 Hydrolytic	 degradation	 obtained	 after	 3	 months	 of	
incubation	of	tubes	in	PBS	at	37°C	damaged	the	coating	layer	on	the	surface	of	the	tube.	
PCL-PEG550	polymeric	matrix	 layer	 is	hardly	 visible;	 a	 lot	of	polymeric	debris	on	 the	
surface	 of	 the	 tube	 (Figure	 115B).	 Internal	 layer	 of	 the	 tube	 presented	 increased	
porosity,	 caused	 by	 hydrolytic	 environment	 within	 3	 months	 time	 (Figure	 115D).	
Monolayer	 of	 PCL-PEG550	 protected	 core	 of	 the	 tube	 before	 degradation.	 After	 3	
months	the	tubes	were	still	stable	in	the	structure	and	easy	to	handle,	whereas	the	neat	
tubes	were	quite	fragile	and	brittle.		
The	 results	 obtained	 in	 this	 study	 suggest	 that	 P(3HB)/oligo-PHA	 tubes	 with	 a	 PCL-
PEG550	coating	undergo	a	degradation	process	by	surface	erosion.	P(3HB)/oligo-PHA	
tubes	 with	 incorporated	 tacrolimus	 underwent	 slightly	 more	 intense	 degradation	
process	in	comparison	to	the	P(3HB)/oligo-PHA	tubes	containing	rapamycin.	However,	
in	both	cases,	after	3	months	of	degradation	study,	mainly	outer	 layers	 (PCL-PEG550	
coating)	of	the	tubes	were	affected	by	hydrolytic	environment.		
8.7.	Discussion	
One	of	the	main	properties	of	an	ideal	stent,	require	the	ability	to	deliver	drugs	at	the	
site	 of	 injury	 to	 allow	 ordinary	 healing	 of	 the	 artery	wall	 and	 to	 prevent	 neointimal	
proliferation,	which	lead	to	restenosis	(Ako	et	al.,	2007).	In	this	study,	P(3HB)/oligo-PHA	
90/10	 blend	 tubes	 were	 investigated	 for	 their	 ability	 to	 deliver	 immunosuppressive	
drugs,	such	as	rapamycin	or	tacrolimus	in	a	controlled	manner.	The	P(3HB)/oligo-PHA	
90/10	blend	tube	coated	with	polymeric	layer	of	PCL-PEG550	with	incorporated	drugs	
were	successfully	prepared	by	using	the	dip	moulding	and	dip	coating	techniques.	The	
effect	 of	 rapamycin	 or	 tacrolimus	 loading	 on	 the	 surface,	 degradation	 properties,	
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biocompatibility	and	haemocompatibility	study	of	these	tubes	were	performed.	In	vitro	
drug	release	studies	were	carried	out.	 	Drug	powders	were	characterised	 in	order	 to	
check	 the	 thermal	 properties	 and	 the	 presence	 of	 typical	 chemical	 bonds.	 In	 vitro	
degradation	study	was	performed	for	3	months	to	test	the	influence	of	the	hydrolytic	
environment	along	with	higher	temperature	on	the	tubes.	
The	 presence	 of	 both	 drugs	 was	 confirmed	 by	 FTIR	 analysis.	 Coated	 tubes	 with	
incorporated	 drugs	 showed	 weak	 chemical	 bonds	 characteristic	 of	 rapamycin	 and	
tacrolimus	in	comparison	to	tubes	without	loaded	drugs	(Patel	et	al.,	2013).		
SEM	was	carried	out	to	investigate	the	effect	of	drug	loading	on	the	surface	topography	
of	 the	 blend	 films	 using	 SEM.	 A	 uniform	 surface	 of	 the	 tubes	 with	 rapamycin	 or	
tacrolimus	was	observed,	similar	to	the	neat	tubes	coated	only	with	a	polymeric	layer.	
Drugs	were	dissolved	completely	in	a	uniform	polymeric	matrix.	Rapamycin	have	been	
used	previously	in	coronary	stents.	The	concentration	used	in	this	study	(1.2µg/mm2)	
within	the	range	used	in	coronary	stents,	which	is	1-1.5µg/mm2	(Serruys	et	al.,	2002).		
The	total	protein	adsorption	test	was	also	carried	out	on	the	P(3HB)/oligo-PHA	tubes	
coated	with	PCL-PEG550	containing	rapamycin	or	tacrolimus	to	assess	the	effect	of	the	
presence	of	the	drugs	on	proteins	adsorption	to	the	surface.	As	mentioned	previously,	
protein	adsorption	is	generally	found	to	be	higher	on	the	hydrophilic	surface	(Hao	and	
Lawrence,	2006).	PCL-PEG550	is	more	hydrophilic	than	PHAs.	Rapamycin	and	tacrolimus	
are	hydrophobic	drugs.	Therefore,	the	total	amount	of	proteins	attached	to	the	material	
with	incorporated	drugs	should	be	higher	in	comparison	to	neat	tubes	but	lower	than	
coated	 tubes	 without	 drugs	 (neat	 PHA	 tube<PCL-PEG550	 coated	 PHA	 tube	 with	
incorporated	drugs<PCL-PEG550	coated	PHA	tube).	This	was	exactly	in	agreement	with	
the	results	obtained	in	this	study.	Hence,	the	higher	protein	adsorption	observed	on	the	
coated	 tube	 with	 rapamycin	 or	 tacrolimus	 is	 most	 likely	 due	 to	 the	 increase	 in	 the	
hydrophobicity	of	the	surface	gained	as	a	result	of	the	presence	of	hydrophobic	drugs	
within	the	matrix.		
In	vitro	release	profile	of	rapamycin	confirmed	local	presence	of	the	drug	up	to	72	days.	
On	the	other	hand,	only	69.2%	of	tacrolimus	was	released	within	90	days.	Park	and	co-
workers	reported	release	of	tacrolimus	as	well	as	sirolimus	from	the	polymeric	matrix,	
used	to	coat	bare	metallic	stent,	within	32	days.	(Park	et	al.,	2015).	Khan	et	al.,	2013	
reported	 controlled	 release	 of	 crystallised	 rapamycin	 from	 stents	 within	 80	 days.	
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Addition	of	polyethylene	glycol	(PEG)	as	a	plasticizer	further	improved	the	release	rate	
of	the	drug	by	acceleration	of	the	degradation	of	the	polymer	(Wang	et	al.,	2006).		Han	
and	 co-workers	 reported	 complete	 release	 of	 rapamycin	 from	 vascular	 grafts	within	
77days	(Han	et	al.,	2013).	In	conclusion,	the	drug	release	kinetics,	obtained	in	this	study	
demonstrated	controlled	release	of	rapamycin	and	tacrolimus	throughout	the	release	
period.	This	suggested	that	the	P(3HB)/oligo-PHA	90/10	blend	tube	with	rapamycin	or	
tacrolimus	would	be	suitable	for	the	drug	delivery	applications.		
Another	important	aspect,	that	was	addressed	in	these	blend	tubes	with	rapamycin	or	
tacrolimus	was	the	 in	vitro	degradation	study.	Polymer	hydrolytic	degradation	can	be	
defined	 as	 the	 scission	 of	 chemical	 bonds	 in	 the	 polymer	 backbone	 by	molecules	 of	
water	to	form	oligomers	and	finally	monomers.	After	immersing	the	material	in	the	PBS	
or	other	media,	the	biomaterial	absorbs	water	and	swells,	and	degradation	will	progress	
from	 the	 external	 part	 of	 the	material	 toward	 its	 internal	 site	 (Williams	 and	 Zhong,	
1994).	It	is	well-known	fact,	that	the	nature	of	the	materials	influences	their	degradation	
rate.	 All	 biodegradable	 materials	 contain	 hydrolysable	 bonds	 within	 their	 chemical	
structures.	As	first,	hydrophilic	materials	with	hydrolysable	bonds	will	degrade	followed	
by	hydrophobic	materials	with	hydrolysable	bonds.	Than	hydrophilic	and	hydrophobic	
materials	with	non-hydrolysable	bonds	respectively	(Azevedo	and	Reis,	2004).	However,	
presence	 of	 strong	 covalent	 bonds	 in	 the	 backbone	 (like	 C-C)	 and	 non-hydrolysable	
groups	 require	 longer	 time	 for	 degradation.	 This	 is	 in	 agreement	 with	 the	 results	
obtained	in	this	study.	In	vitro	degradation	studies	demonstrated	lower	percentage	of	
water	 adsorption	 and	 lower	 rates	 of	 weight	 loss	 after	 3	 months	 of	 incubation	 in	
comparison	 to	neat	 tubes.	Minor	changes	 in	 the	pH	suggested	absence	of	 the	highly	
acidic	products	released	during	polymer	degradation.	Homopolymer	PCL	required	over	
110	weeks	to	degrade	in	phosphate	buffer	(Dai	et	al.,	2009).		PCL	is	well	known	synthetic	
polymer,	 which	 degrades	 slowly	 (up	 to	 4	 years)	 (Woodruff	 and	 Hutmacher,	 2010;	
Gunatillake	and	Adhikari,	2003).	However,	addition	of	Poly(ethylene-glycol)	(PEG)	 is	a	
stablished	method	for	accelerating	the	degradation	rate	of	homo-polycaprolactone	(Bei	
et	al.,	1997;	Pitt,	1990).	Degradation	of	polymers	is	highly	dependent	on	the	molecular	
weight.	The	higher	the	molecular	weight	of	the	polymer,	the	longer	degradation	time	
required,	which	is	in	agreement	with	the	results	obtained	in	this	study	(Pitt	et	al.,	1981).	
Presence	of	an	additional	polymeric	layer	placed	on	the	surface	of	the	PHA	tube	as	a	
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coating	monolayer	demonstrated	a	protective	role	for	the	inner	PHA	tube	structure.	In	
this	case,	the	degradation	of	the	tube	might	take	longer	time	in	vivo	in	comparison	to	
the		neat	PHA	tube	without	coating.		
Presence	of	PEG550	block	to	the	PCL	enhanced	hydrolytic	degradation	of	the	coating.	
However,	addition	of	an	external	layer	of	PCL-PEG550	polymer	into	P(3HB)/oligo-PHA	
neat	 tube	 resulted	 in	 the	 initiation	of	 the	degradation	process	on	 the	 surface	of	 the	
tubes.	After	3	months,	the	coating	was	mainly	present	as	debris	on	the	surface	of	the	
tube.	In	this	study,	the	addition	of	PCL-PEG550	layer	slowed	down	the	degradation	rate	
of	 the	 PHA	 tubes.	 DSC	 data	 of	 the	 tube	 coated	 with	 PCL-PEG	 with	 incorporated	
tacrolimus	 confirmed	 the	 absence	 of	 the	 melting	 peak,	 characteristic	 for	 the	 PCL-
PEG550	from	the	coating.	An	 increased	porosity	was	observed	across	 the	wall	of	 the	
tube.	The	mechanical	characterisation	of	the	blend	tubes	coated	with	PCL-PEG550	with	
rapamycin	 or	 tacrolimus	 was	 carried	 out	 to	 investigate	 the	 effect	 of	 the	 hydrolytic	
degradation	on	 their	mechanical	properties.	The	Young’s	modulus	values	and	 tensile	
strength	of	the	degrading	samples	were	lower	than	the	non-degraded	samples.	Tubes	
became	more	brittle	and	material	strength	were	affected	by	the	degradation.		
Another	test	 that	was	done	on	these	tubes	with	 incorporated	drugs	was	the	 indirect	
cytotoxicity	 study.	 This	 experiment	 was	 performed	 to	 determine	 the	 effect	 of	 the	
rapamycin	 or	 tacrolimus	 on	 the	 growth	 of	 HMEC-1	 cells.	 Considering	 the	 potential	
application	 of	 these	 P(3HB)/oligo-PHA	 90/10	 blend	 tubes	 coated	 with	 PCL-PEG550	
containing	rapamycin	or	tacrolimus	as	the	platform	material	for	the	drug	eluting	stent	
application,	it	is	very	crucial	to	investigate	compatibility	of	the	tubes	with	the	endothelial	
cells.	Indirect	cytotoxicity	study	confirmed	inhibiting	effect	on	the	growth	of	endothelial	
cells	 incubated	 with	 the	 extract	 from	 the	 tubes,	 containing	 rapamycin.	 This	 was	
confirmed	with	the	results	from	the	literature	(Liu	et	al.,	2010).	On	one	side,	rapamycin	
inhibits	 smooth	muscle	cells	migration,	which	has	a	positive	effect	 inhibiting	 in-stent	
restenosis.	 On	 the	 other	 hand,	 presence	 of	 rapamycin	 leads	 to	 undermined	
endothelialisation,	 which	 can	 cause	 late	 stent	 thrombosis	 and	 therefore	 requires	
prolonged	 antiplatelet	 therapy	 (Moss	 et	 al.,	 2010).	 	 This	 has	weakened	 the	 positive	
effect	of	 rapamycin	on	 the	 inhibition	of	 the	neointimal	growth	 in	drug	eluting	stents	
(Holmes	et	al.,	2004).	Indirect	cytotoxicity	study	confirmed	non-toxic	effect	of	an	extract	
released	from	the	tubes	with	tacrolimus	incubated	in	the	media.	Moreover,	those	tubes	
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demonstrated	higher	cell	viability	after	day	1	than	TCP.	The	results	obtained	established	
the	potential	of	these	tubes	with	tacrolimus	in	the	area	of	drug	eluting	biodegradable	
stents.		
The	biocompatibility	studies	resulted	in	similar	or	slightly	 lower	cell	viability	obtained	
for	tube	with	significantly	inhibited	cell	attachment,	proliferation	and	survival	of	HMEC-
1	cell	 line.	Obtained	results	were	 in	an	agreement	with	results	reported	 in	 literature.	
Gao	and	co-workers	 reported	 significant	decrease	 in	 the	number	of	endothelial	 cells	
after	72	hours	incubation	in	the	media	with	three	different	concentrations	of	rapamycin:	
0.001,	0.01	and	1µg/mL	respectively	(Gao	et	al.,	2011).	The	results	obtained	in	this	study	
were	in	agreement	with	the	literature.	It	is	a	well-known	phenomenon,	that	rapamycin	
inhibits	 endothelial	 cell	 migration	 and	 proliferation	 as	 well	 as	 smooth	 muscle	 cells,	
whereas,	 tacrolimus	does	not	present	 such	effects.	 	Although	 the	 inhibiting	effect	of	
tacrolimus	on	the	migration	of	smooth	muscle	cells	is	lower	in	comparison	to	rapamycin,	
the	antiproliferative	effect	of	tacrolimus	towards	endothelial	cells	 is	significantly	 less,	
which	is	a	positive	result.	This	make	tacrolimus	a	more	promising	drug	for	application	in	
drug-eluting	stents	(Matter	et	al.,	2006).	SEM	micrographs	confirmed	these	results.	Cell	
attachment	 and	 proliferation	was	much	 less	 on	 the	 surface	 of	 the	 tubes	 containing	
rapamycin.	All	of	the	tested	tubes	did	not	have	any	haemolytic	effect	towards	red	blood	
cells.	Both	types	of	tubes	demonstrated	blood	clotting	rate	lower	than	the	control.	The	
presence	 of	 immunosuppressive	 drugs,	 such	 as	 sirolimus	 and	 tacrolimus	 resulted	 in	
decelerated	blood	clot	formation.	Secondly,	both	drugs	seem	to	have	the	same	effect	
on	the	blood	clot	 formation	rate.	All	 tested	tubes	demonstrated	elevated	monocytes	
and	neutrophils	activity.	Surprisingly	presence	of	rapamycin	lead	to	a	higher	white	cells	
activation,	 although	 it	 is	 a	 well-known	 inhibitor	 of	 inflammatory	 response.		
Haemocompatibility	 study	was	performed	after	24hrs,	hence	only	acute	mechanisms	
could	 be	 observed.	 Extended	 time	 of	 this	 experiment	 could	 possibly	 bring	 more	
understanding	 about	 mechanisms	 of	 reaction	 of	 white	 blood	 cells	 with	 rapamycin	
incorporated	within	PHA	based	tubes	and	result	in	different	outcome.		
In	conclusion,	P(3HB)/oligo-PHA	tubes	coated	with	PCL-PEG550	layer	with	incorporated	
rapamycin	or	tacrolimus	were	successfully	produced	and	characterised.	Controlled	local	
release	of	both	drugs	was	achieved.	However,	an	incorporation	of	rapamycin	resulted	
in	 inhibition	 of	 endothelial	 cells	 attachment	 and	 had	 toxic	 effect	 on	 the	 viability	 of	
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HMEC-1.	Presence	of	rapamycin	had	affected	the	biocompatibility	of	the	tested	material	
significantly.	The	results	obtained	confirmed	high	biocompatibility	of	HMEC-1	cells	to	
the	material	with	incorporated	tacrolimus.	Therefore,	this	drug	can	be	considered	for	
coronary	stent	application.	By	demonstrating	good	cell	growth	and	proliferation,	tubes	
containing	 tacrolimus	 are	more	 suitable	 for	medical	 devices,	 such	 as	 coronary	 stent	
application.	
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9.1.	Conclusions		
Polyhydroxyalkanoates	are	a	very	attractive	group	of	biomaterials	with	great	potential	
for	biomedical	applications	(Hazer	et	al.,	2012).	They	present	a	broad	range	of	properties	
and	can	be	processed	by	using	various	techniques.	Moreover,	they	are	biodegradable	
and	biocompatible	(Philip	et	al.,	2007).	Varied	types	of	modifications	can	be	applied	to	
PHAs	in	order	to	further	improve	their	properties.	They	can	be	used	to	produce	blends,	
composites	and	grafts.	PHAs	can	be	processed	into	2D	flat	films	as	well	as	3D	structures,	
such	as	fibers,	tubes,	patches,	spheres,	films	and	foams	(Williams	et	al.,	1999).	There	is	
a	 high	 interest	 in	 the	 large-scale	 production	 and	 commercial	 exploitation	 of	 these	
materials.	However,	one	of	the	major	limitations	in	the	commercialization	of	PHAs	is	its	
high	cost	of	production,	which	significantly	reflects	in	their	market	price.	Much	attention	
has	been	devoted	to	an	efficient	reduction	of	these	costs,	for	example	by	using	cheaper	
carbon	sources,	solvent-free	polymer	recovery	techniques,	genetically	modified	strains,	
more	productive	fermentations	strategies	(Koller	et	al.,	2017;	Anjum	et	al.,	2016;	Choi	
and	Lee,	1999).		
This	research	project	can	be	divided	into	six	main	parts,	which	include:	scl-PHA	and	mcl-
PHA	 production	 and	 characterisation,	 development	 of	 P(3HB)/oligo-PHA	 blends,	
development	of	radiopaque	composites,	fabrication	of	tubes	and	incorporation	of	drugs	
into	the	polymeric	matrix.		
The	 first	 part	 of	 the	 project	 focused	 on	 scl-PHA	 production,	 using	 various	 types	 of	
bacterial	 strains	 and	 a	 range	 of	 carbon	 sources.	 All	 tested	 types	 of	 bacteria,	 which	
included	Bacillus	sp.,	Pseudomonas	sp.	and	Cupriavidus	necator	were	able	to	produce	
P(3HB).	It	is	a	well-known	fact,	that	bacteria	from	Bacillus	and	Cupriavidus	genera	are	
able	to	produce	P(3HB)	from	a	variety	of	carbon	sources,	following	specific	metabolic	
pathways.	In	this	study,	P(3HB)	was	also	produced	by	P.	mendocina,	when	mixed	carbon	
sources	were	used.	It	is	worth	highlighting	the	fact,	that	the	highest	polymer	yield	was	
obtained	 from	B.	 subtilis	OK2,	when	grown	on	glucose	as	 the	 sole	 carbon	 source.	B.	
subtilis	is	a	Gram-positive	bacterium,	which	does	not	contain	lipopolysaccharides	within	
the	cell	wall,	hence	do	not	trigger	enhanced	immunogenic	response.	B.	subtilis	has	been	
classified	 by	 FDA	 as	 GRAS	 bacteria,	 which	 means:	 “Generally	 Recognised	 as	 Safe”	
(Morimoto	 et	 al.,	 2008).	 This	 strain	 has	 been	 used	 in	 the	 industry	 for	 a	 large-scale	
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production	of	enzymes,	proteins	and	fine	chemicals	(Zweers	et	al.,	2009).	Until	today,	
there	is	only	one	report	about	P(3HB)	production	from	B.	subtilis	OK2.	In	this	study,	a	
batch	fermentation	mode	has	been	explored.	Therefore,	further	optimisation	study	is	
required	in	order	to	enhance	the	polymer	productivity	and	make	it	competitive	in	the	
market.	The	P(3HB)	obtained	has	been	identified	and	fully	characterised.	It	has	similar	
properties	to	those,	obtained	from	different	bacterial	strains.	The	final	properties	of	the	
material	can	be	achieved	after	few	weeks,	due	to	organisation	of	chains	at	a	molecular	
level.		
The	second	part	of	this	project	involved	the	economical	production	of	mcl-PHAs	using	
renewable	and	cheap	carbon	sources	such	as	sugarcane	molasses,	biodiesel	waste	and	
vegetable	oils.	Pseudomonas	sp.	have	been	known	to	produce	mainly	mcl-PHAs.	They	
utilize	both	structurally	related	and	unrelated	carbon	sources	and	accumulate	diverse	
mcl-PHA	monomer	units.	Homopolymers	as	well	as	copolymers	with	different	numbers	
of	monomers	within	 the	 recurrent	monomer	unit	were	produced.	P.	mendocina	was	
able	to	produce	mcl-PHAs	from	different	carbon	sources.		Utilisation	of	biodiesel	waste	
as	a	carbon	source,	resulted	in	a	PHA	yield	of	38.9%	dcw.	The	polymer	was	identified	
using	FTIR	and	GC-MS.	It	was	found	to	be	a	tetramer,	which	contains:	3HHx,	3HO,	3HD	
and	3HDD	monomer	units.	From	sugarcane	molasses,	an	mcl-PHA	copolymer,	containing	
3HO	and	3HD	units	were	obtained	and	 the	polymer	yield	was	14%	dcw.	When	using	
vegetable	oils,	various	mcl-PHA	copolymers	were	produced.	Among	all	tested	oils,	waste	
frying	 oil	 resulted	 in	 the	 highest	 polymer	 accumulation,	 which	 was	 38%	 dcw.	 The	
chemical	 structure	 of	 the	 material	 was	 confirmed	 by	 FTIR	 and	 GC-MS.	 The	 results	
demonstrated	 that	 waste	 frying	 oil	 was	 a	 promising	 carbon	 source	 for	 mcl-PHAs	
production.	 P(3HHx-3HO-3HD-3HDD)	 copolymer	 obtained	 was	 very	 sticky	 and	
amorphous	in	nature.	Moreover,	a	lack	of	solubility	in	organic	solvents	was	observed.	
These	 results	 demonstrated	 that	 P.	 mendocina	 was	 capable	 of	 utilising	 sugarcane	
molasses,	biodiesel	waste,	various	types	of	vegetable	oils,	waste	frying	oil	and	mixed	
carbon	 sources	 as	 the	 feedstock	 for	 the	 production	 of	 PHAs.	 The	 use	 of	 these	
inexpensive	 carbon	 sources	 could	 not	 only	 effectively	 reduce	 the	 total	 cost	 of	 the	
production	of	PHAs	but	also	enhance	its	competitiveness	in	various	fields	(Nor	Aslan	et	
al.,	2016).	
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The	main	objective	of	 this	 research	project	was	 to	develop	 a	 novel	 PHA	 for	medical	
devices,	such	as	coronary	stents.	To	meet	this	objective,	novel	blends	of	P(3HB)	with	an	
addition	 of	 low	 molecular	 weight	 mcl-PHA	 copolymer	 (oligo-PHA)	 were	 developed	
focusing	on	the	potential	use	of	these	2D	blend	films	as	a	platform	material	for	coronary	
stents.	 Physical	 blending	 is	 one	 of	 the	 most	 economic	 and	 comprehensive	 way	 of	
producing	novel	materials	by	combining	the	desired	properties	of	different	polymers.	
This	will	allow	wider	range	of	application	of	these	biopolymers	(Ke	et	al.,	2017).	Neat	
P(3HB)	and	three	different	types	of	blends:	 	P(3HB)/5	wt%	oligo-PHA,	P(3HB)/10	wt%	
oligo-PHA	and	P(3HB)/20	wt%	oligo-PHA	blend	films	were	prepared	by	solvent	casting	
technique.	 The	 blend	 films	were	 characterised	 in	 order	 to	 evaluate	 the	 effect	 of	 an	
addition	of	oligomers,	acting	as	plasticising	agents	on	the	properties	of	the	polymer.	The	
results	obtained	emphasized	the	role	of	 these	additives	 in	enhancing	the	mechanical	
properties	 of	 these	 blend	 films.	 Especially	 elongation	 at	 break	 was	 improved	 in	
comparison	 to	 neat	 P(3HB).	 Thermal	 analysis	 confirmed	 miscibility	 of	 the	 obtained	
system.	According	to	the	wettability	studies,	there	was	an	increase	in	the	water	contact	
angle	of	the	blend	films	compared	to	the	neat	P(3HB)	films,	due	to	the	addition	of	the	
longer	 chains,	 indicating	 an	 increase	 in	 the	 hydrophobicity	 of	 the	 blend	 film.	
Biocompatibility	is	a	crucial	requirement	from	biomaterials	considered	for	biomedical	
applications.	It	depends	on	several	factors,	such	as:	chemical	structure,	hydrophilicity,	
shape,	porosity,	microenvironment	and	degradation	products	(Wang	et	al.,	2004).	Cell	
proliferation	studies	were	carried	out	using	the	HMEC-1	cells	over	a	period	of	1,	3	and	7	
days,	which	demonstrated	the	biocompatibility	of	the	P(3HB)/oligo-PHA	blends	and	neat	
P(3HB)	films.	The	cell	growth	and	proliferation	on	the	blend	films	with	addition	of	10	
wt%	and	20	wt%	oligo-PHA	was	higher	compared	to	the	neat	P(3HB)	film	during	7	days	
of	incubation.	P(3HB)/oligo-PHA	in	ratio	80/20	had	the	most	promising	biocompatibility,	
the	highest	protein	adsorption	and	surface	roughness.	However,	the	material	presented	
the	weakest	mechanical	 properties,	 such	 as	 stiffness	 and	 strength.	 Therefore	 blend,	
which	contains	10%	addition	of	oligo-PHA	was	selected	for	further	study.	In	these	blend,	
the	mechanical	 properties	were	 similar	 to	neat	P(3HB),	 but	 the	biocompatibility	 and	
surface	 characteristic	were	 improved	 significantly.	 These	 results	 indicated	 that	 these	
novel	 P(3HB)/oligo-PHA	 blends	 would	 be	 well	 qualified	 for	 tissue	 engineering	
applications.	Excellent	biocompatibility	 is	one	of	the	most	 important	requirements	of	
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any	tissue	engineering	scaffold	(O’Brien,	2011).	The	cell	culture	data	obtained	from	this	
study	revealed	promising	results	by	demonstrating	high	cell	growth	and	proliferation	on	
the	blend	films.	Tested	blends	were	non-haemolytic	in	direct	contact	with	fresh	whole	
blood.	All	tested	materials	demonstrated	low	thrombogenic	properties.	Neat	P(3HB)	as	
well	 as	 P(3HB)/oligo-PHA	 blends	 showed	 slightly	 higher	 activity	 of	 monocytes	 and	
neutrophils	in	comparison	to	the	non-activated	whole	blood	Interestingly,	similar	trend	
was	observed	in	PL38,	a	GMP	class	material.	The	results	obtained	make	these	blends	
promising	biomaterials	for	a	biomedical	application	in	coronary	stent	application.	
In	the	next	part	of	the	study,	P(3HB)/oligo-PHA	blend	90/10	was	produced	selected	for	
development	 of	 radiopaque	 composites.	 Radiopacity	 is	 one	 of	 the	 characteristics,	
essential	for	biodegradable	stents,	which	would	allow	surgeons	to	monitor	the	device	
during	deployment	and	after	the	procedure.	Barium	sulphate	was	selected	as	a	contrast	
agent	in	concentration	1	wt%,	3	wt%	and	5	wt%.	Composites	were	prepared	by	solvent	
casting	technique.	These	materials	obtained	were	characterised	with	respect	 to	their	
mechanical,	 thermal	 and	 surface	 properties.	 They	 were	 also	 characterised	 for	 their	
bioactivity	 using	 HMEC-1	 cells.	 The	 results	 highlighted	 that	 the	 addition	 of	 barium	
sulphate	within	the	P(3HB)/oligo-PHA	matrix	reduced	the	elastomeric	properties	of	the	
blends.	Materials	obtained	were	much	more	brittle.	There	was	slight	improvement	in	
the	tensile	strength	of	the	material.	Addition	of	BaSO4	affected	significantly	the	surface	
topography	of	 the	 composite	materials.	 Composites	with	barium	sulphate	presented	
higher	surface	roughness	and	protein	adsorption	in	comparison	to	neat	blend.	With	an	
increased	concentration	of	barium	sulphate	the	contact	angle	values	decreased,	hence	
material	 became	 less	 hydrophobic.	 Indirect	 cytotoxicity	 results	 showed	 that	 these	
composite	films	were	not	toxic	to	the	HMEC-1	cells.	Moreover,	addition	of	3	wt%	and	5	
wt%	of	barium	sulphate	resulted	in	significant	improvement	in	cell	viability	after	day	1	
and	3	of	incubation.	The	%	cell	viability	on	the	composite	films	was	higher	compared	to	
the	neat	P(3HB)/oligo-PHA	blend	film.	The	results	of	the	cytocompatibility	assessment	
demonstrated	 increased	biocompatibility	of	 these	composites	with	the	HMEC-1	cells.	
Additionally,	 radiopacity	 of	 the	 materials	 was	 achieved	 and	 the	 x-ray	 adsorption	
increased	 with	 greater	 amount	 of	 BaSO4.	 Composites	 did	 not	 demonstrate	 any	
haemolytic	effect	towards	red	blood	cells.	The	materials	had	decelerating	effect	on	the	
blood	 clot	 formation.	 However,	 presence	 of	 barium	 sulphate	 resulted	 in	 significant	
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increase	in	neutrophils	and	monocytes	activity.	The	results	obtained	such	as	improved	
surface	topography	and	biocompatibility	along	with	radiopacity	make	these	composites	
an	attractive	biomaterial	for	a	biomedical	application	in	coronary	stent	application.		
Next	 part	 of	 the	 project	 was	 focused	 on	 tubes	 manufactured	 by	 the	 dip	 moulding	
technique	using	P(3HB)/oligo-PHA	blend	in	the	ratio	90:10,	obtained	in	the	previous	part	
of	study.	P(3HB)/oligo-PHA	neat	tubes,	composite	tubes	with	addition	of	5	wt%	barium	
sulphate	and	P(3HB)/oligo-PHA	tube	coated	with	PCL-PEG550	were	fabricated.	Tubes	
were	 fully	 characterised	 in	 order	 to	 investigate	 mechanical,	 thermal	 properties,	
conditions	of	storage,	surface	topography	and	biocompatibility.	Neat	P(3HB)/oligo-PHA	
90/10	 blend	 tubes	 demonstrated	 promising	 thermal	 and	 mechanical	 properties.	
However,	 the	 material	 underwent	 embrittlement	 phenomenon	 within	 7	 weeks	 of	
storage.	 Incubation	 of	 tubes	 in	 DMEM	 media	 at	 37°C	 influenced	 the	 mechanical	
properties	of	the	tubes	in	comparison	to	tubes	stored	at	room	temperature	without	any	
media.	 Incubated	 tubes	 became	 more	 brittle,	 had	 much	 lower	 values	 of	 Young’s	
modulus	and	slightly	lower	tensile	strength.	Mechanical	properties	of	the	tubes	storage	
at	room	temperature	were	higher	than	tubes	incubated	in	DMEM	media	at	37°C.	Tubes	
underwent	process	called	“material	aging”	within	the	time	and	followed	similar	pathway	
to	this	demonstrated	by	blend	films.	Overall,	material	based	on	P(3HB)	became	more	
brittle	and	stiff.	 	 In	vitro	degradation	study	was	carried	out	for	6	months	on	the	neat	
tubes.	P(3HB)/oligo-PHA	90/10	tubes	after	6-month	incubation	in	PBS	at	37°C	resulted	
in	a	weight	loss	of	30%.	P(3HB)/oligo-PHA	tubes	were	characterised	with	high	level	of	
water	absorption.	The	degradation	products	that	leached	to	the	media	slightly	lowered	
the	pH.	 	After	3-month	 incubation	time	the	tubes	became	fragile	and	brittle.	Surface	
characterisation	confirmed	the	degradation	process	as	well	as	over	30%	loss	within	the	
wall	thickness.	An	increased	porosity	was	observed	within	the	tube	walls.	The	coated	
tubes	by	covering	the	blend	tube	with	a	monolayer	of	PCL-PEG550	were	prepared	to	
investigate	 the	 potential	 of	 PHAs	 as	 drug	 delivery	 vehicles	 for	 drug	 eluting	 coronary	
stents.	 The	 FTIR	 and	DSC	 analysis	 clearly	 confirmed	 presence	 of	 additional	 polymer,	
which	 demonstrated	 different	 propertied	 than	 PHAs.	 Presence	 of	 an	 additional	
polymeric	 layer	had	a	positive	effect	on	 the	mechanical	properties	of	 the	 tubes.	The	
strength	as	well	as	stiffness	of	the	material	had	improved.	The	PCL-PEG550	layer	had	a	
protective	 function	 on	 the	 tube	 and	 slowed	 down	 the	 embrittlement	 process	 after	
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storage	at	room	temperature	for	7	weeks	in	comparison	to	the	neat	tubes.	Addition	of	
the	hydrophilic	polymer	in	the	external	layer	resulted	in	enhanced	protein	adsorption	
to	the	coated	surface	in	comparison	to	the	neat	tubes.	Barium	sulphate	was	added	as	a	
contrast	agent	in	order	to	obtain	radiopacity	required	for	the	monitoring	of	the	device	
inside	 the	 body.	 Addition	 of	 barium	 sulphate	 to	 the	 blend	 resulted	 in	 enhanced	
brittleness	of	the	tubes.	Also,	it	did	affect	the	microstructure	of	the	tubes.	Composite	
tubes	did	not	have	any	porosity.	A	MicroCT	scan	confirmed	the	potential	radiopaque	
effect,	 caused	 by	 the	 presence	 of	 BaSO4.	 PCL-PEG550	 coated	 tube	 demonstrated	
significantly	 higher	 protein	 adsorption,	 which	 can	 be	 explained	 by	 increased	
hydrophobicity	of	the	material	by	addition	of	PCL-PEG550.	Biocompatibility	study	was	
carried	out	for	7	days.	Composite	tubes	demonstrated	the	highest	cell	attachment	and	
proliferation,	 which	 might	 be	 the	 enhanced	 roughness	 of	 the	 material,	 due	 to	 the	
addition	 of	 BaSO4	 particles	 resulted	 in	 a	 rougher	 surface	with	 anchor	 points	 for	 the	
endothelial	cells.	Indirect	cytotoxicity	studies	confirmed	the	non-toxic	effect	of	extracts	
from	all	kinds	of	tested	tubes	on	the	HMEC-1	cell	line.	The	tubes	did	not	demonstrate	
any	 haemolytic	 effect	 on	 the	 erythrocytes.	 PCL-PEG550	 coated	 tube	 significantly	
decelerated	blood	clot	formation	rate.	The	coagulation	cascade	was	not	activated	in	the	
presence	of	composite	tube.	Presence	of	barium	sulphate	led	to	higher	neutrophils	and	
monocytes	 activity,	 as	 described	 previously.	 Further	 surface	 modifications	 of	 the	
external	layer	of	the	tubes,	in	order	to	achieve	higher	surface	roughness,	might	enhance	
the	cell	attachment	and	proliferation	on	the	neat	blend	and	coated	tubes.	Additionally,	
an	appropriate	stent	design,	might	help	to	solve	the	 issues	raised	due	to	the	smooth	
surface	topography.		
	Finally,	 an	 investigation	 of	 the	 P(3HB)/oligo-PHA	 blend	 tube	with	 PCL-PEG550	 layer	
containing,	as	the	base	material	for	the	development	of	a	drug	eluting	biodegradable	
stent	was	carried	out	by	incorporation	of	immunosuppressive	drugs,	such	as	rapamycin	
or	 tacrolimus.	 Influence	 of	 the	 tubes	 on	 surface	 topography,	 biocompatibility,	
haemocompatibility	and	the	degradation	rate	were	investigated.	A	drug	release	study	
was	 carried	 out	 by	 using	 UV-VIS	 Spectrophotometry	 and	 High	 Performance	 Liquid	
Chromatography	 (HPLC)	 for	 rapamycin	 and	 tacrolimus	 respectively.	 Microstructural	
study	demonstrated	no	 influence	on	 the	 surface	 topography	of	 the	 tubes.	However,	
presence	 of	 hydrophobic	 drugs	 influenced	 the	 amount	 of	 proteins	 attached	 to	 the	
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surface,	which	was	lower	than	P(3HB)/oligo-PHA	tube	with	coating	without	any	drugs.	
In	vitro	biocompatibility	study	demonstrated	high	cell	viability	on	the	tubes	containing	
tacrolimus.	 Rapamycin	 had	 an	 inhibiting	 effect	 on	 cell	 viability,	 attachment	 and	
proliferation.	Presence	of	drugs	lead	to	the	reduction	of	side	effects,	such	as	restenosis,	
which	was	the	main	limitation	of	bare	metallic	stent	(Alfonso	et	al.,	2014).	One	of	the	
most	 important	 features	 of	 the	 drug	 eluting	 biodegradable	 stent	 is	 the	 local	 and	
controlled	release	of	the	drugs.	Drug	release	studies	showed	that	there	was	a	controlled	
release	of	rapamycin	as	well	as	tacrolimus	from	the	coating	on	the	tubes,	throughout	
the	release	period.	After	72	days,	over	95%	of	rapamycin	was	released.	The	amount	of	
released	tacrolimus	after	90	days	was	around	70%.		In	vitro	degradation	study,	carried	
out	 for	 3	 months	 confirmed	 an	 initiation	 of	 hydrolytic	 degradation	 process,	 which	
progressed	from	the	surface	of	the	tube	and	result	in	gradual	disappearance	of	the	most	
external	layer,	which	was	PCL-PEG550	coating	with	incorporated	drugs.	DSC	analysis	of	
tubes	with	tacrolimus	confirmed	the	disappearance	of	the	melting	peak	related	to	the	
presence	of	PCL-PEG550.	Mechanical	properties	of	the	tubes	changed	within	the	time	
of	incubation.	The	tensile	strength	values	decreased	slightly,	whereas	Young’s	Modulus	
values	increased.	Parameter	that	was	the	most	affected	was	elongation	at	break,	with	
tubes	becoming	much	more	brittle.	The	achieved	weight	loss	was	5.5%-6.4%	for	tubes	
with	 rapamycin	 and	 tacrolimus	 respectively.	 The	 tube	 containing	 tacrolimus	 had	 a	
higher	water	absorption	in	comparison	to	the	tubes	with	rapamycin.	Tubes	with	drugs	
were	identified	to	be	non-haemolytic	with	very	low	risk	of	thrombogenicity.	Addition	of	
drugs	 resulted	 in	 higher	 activation	 of	 neutrophils	 and	 monocytes,	 especially	 in	 the	
presence	of	rapamycin.		
In	 summary,	 a	 drug	 delivery	 system	 for	 the	 controlled	 delivery	 of	 rapamycin	 and	
tacrolimus	 was	 successfully	 developed.	 P(3HB)/oligo-PHA	 tubes	 coated	 with	 PCL-
PEG550	 with	 and	 without	 drugs	 were	 prepared	 using	 the	 dip	 coating	 technique	 to	
investigate	 their	 potential	 as	 a	 drug	 delivery	 system	 for	 the	 controlled	 release	 of	
rapamycin	or	 tacrolimus.	From	the	drug	 release	pattern,	we	could	conclude	 that	 the	
P(3HB)/oligo-PHA	based	tubes	could	be	used	for	the	sustained	long	term	drug	release.	
Tacrolimus	emerged	to	be	the	more	promising	drug	for	coronary	stents	due	to	its	higher	
biocompatibility.		
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9.2.	Future	work		
	
Results	obtained	in	this	study	demonstrated	possibility	of	production	of	P(3HB)	by	using	
B.	 subtilis	 OK2	 and	 to	 use	 it	 along	 with	 low	molecular	 weight	 mcl-PHA	 for	 medical	
devices,	such	as	coronary	stents.	Base	on	the	data,	following	areas	can	be	explored	in	
order	to	improve	further	achieved	outcomes.	
	
Optimisation	studies	of	P(3HB)	production	using	B.	subtilis	OK2	
	
	P(3HB)	 was	 successfully	 produced	 and	 identified	 during	 this	 study.	 However,	 the	
polymer	yield	needs	 improvement	to	 lower	the	total	cost	of	production	and	become	
competitive	with	other	plastics	in	the	market.	In	the	first	step,	the	media	composition,	
which	will	contain	the	list	of	all	nutrients	required	for	growth	and	polymer	production	
in	optimal	concentration	needs	to	be	identified.	Secondly,	various	carbon	sources	as	well	
as	 different	 fermentation	 strategies	 can	 be	 investigated.	 Additionally,	 design	 of	
experiments	can	be	applied	to	optimise	further	the	production	of	P(3HB).		
	
Surface	modifications	of	the	material	
	
	Various	 types	 of	 surface	 modifications	 of	 these	 blend	 tubes	 can	 be	 explored.	 For	
example:	 laser	 micropatterning	 (physical	 method),	 plasma	 treatment	 (biochemical	
method),	chemical	modifications	of	the	PHAs.	This	will	create	a	more	attractive	surface	
for	 endothelial	 cells	 attachment	 and	 proliferation	 and	 improve	 further	 material	
biocompatibility.			
	
Optimisation	of	coating	matrix	
	
Selection	of	appropriate	material	for	coating	is	crucial	in	drug-eluting	stents	in	order	to	
ensure	 controlled	 local	 drug	 delivery	 from	 the	 device.	 Also,	 the	 degradation	 profile	
needs	to	fulfil	those	requirements.	Therefore,	exploration	of	various	types	of	materials	
for	coating	along	with	drug	release	studies	will	be	a	great	interest.		
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In	vitro	degradation	study	
	
PHAs	require	several	months	to	degrade.	Therefore,	intensive	degradation	study,	both:	
enzymatic	and	non-enzymatic	will	be	an	interesting	field	of	research.	This	will	help	to	
improve	further	the	material	properties,	if	required.		
	
	Drug	selection	
	
In	 this	 study,	only	 two	antiproliferative	drugs	were	 tested.	 It	will	be	worth	exploring	
another	possible	bioactive	agent,	in	order	to	reduce	risk	of	restenosis,	but	with	minimal	
reduction	 of	 biocompatibility	 of	 the	 construct.	 Additionally,	 different	 types	 of	 drug	
carriers	 can	be	 explored,	 such	 as	 bioactive	 glasses,	microspheres,	 fibres	 loaded	with	
drugs.	
	
Haemocompatibility	study	
	
Haemocompatibility	studies	are	required	to	know	the	reaction	of	blood	cells	after	direct	
contact	 of	 developed	 biomaterial	 with	 blood.	 Special	 attention	 needs	 to	 be	 paid	 to	
platelet	 adhesion	 and	 white	 cell	 activation.	 Parallel	 studies	 of	 degradation	 and	
haemocompatibility	would	be	interesting	in	order	to	evaluate	the	effect	of	degradation	
products,	such	as	low	molecular	weight	compounds	on	whole	blood	cells.		
	
Stent	prototype	fabrication	and	characterisation	
	
In	this	study,	3D	tubular	structures	were	successfully	developed.	However,	due	to	lack	
of	time	it	could	not	be	fully	fabricated	to	a	stent	prototype.	Development	of	a	complete	
stent	prototype	with	a	novel	stent	design	and	its	complete	characterisation	would	be	
very	relevant.	Incorporation	of	antiproliferative	drugs	or	different	bioactive	agents,	such	
as	 antibodies	 within	 the	 stent	 prototype	 and	monitoring	 their	 drug	 release	 kinetics	
would	be	 the	next	 step	 forward.	 Cell	 culture	 and	degradation	 studies	of	 these	 stent	
prototypes	 under	 dynamic	 conditions,	 mimicking	 the	 surroundings	 of	 blood	 vessel	
would	be	worth	exploring.		
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In	vivo	stent	prototype	evaluation		
	
In	 this	 study,	 P(3HB)/oligo-PHA	 blend	 tubes	 were	 fabricated	 for	 their	 use	 in	 the	
development	 of	 biodegradable	 stents.	 In	 the	 future,	 in	 vivo	 evaluation	 of	 stent	
prototypes	in	small	and	large	animals	would	be	a	great	addition.	In	vivo	study	can	also	
be	 used	 to	 evaluate	 prototype	 in	 order	 to	 evaluate	 an	 appropriate	 sterilisation	
techniques,	stent	deployment,	radiopacity,	degradation	within	the	body	and	biological	
functionality.		
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